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over PAR1. Lastly, spinal astrocytic and endothelial expression of the intermediate filament, vimentin, are
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ABSTRACT 
 
DEFINING THE ROLE OF BLOOD-SPINAL CORD BARRIER BREAKDOWN AND 
SPINAL THROMBIN SIGNALING IN THE DEVELOPMENT OF PAIN 
FOLLOWING NEURAL TRAUMA 
 
Jenell R. Smith 
 
Beth A. Winkelstein 
 
 Peripheral neural trauma is known to induce blood-spinal cord barrier (BSCB) 
breakdown, but if and how BSCB breakdown contributes to pain is unknown. The studies 
in this thesis use rat models of cervical nerve root insults (compressive and 
inflammatory) to investigate which components of injury contribute to BSCB disruption 
and if BSCB disruption controls the pain responses. Further, whether serum-derived 
thrombin extravasates into the spinal parenchyma during BSCB breakdown and 
contributes to the associated spinal astrocyte activation and pain through its activation of 
PAR1 is investigated. BSCB breakdown occurs transiently early after root compression 
exclusively when pain develops; blocking BSCB breakdown with activated protein C 
prevents pain. During increased BSCB permeability, thrombin acts enzymatically in the 
spinal cord. By inhibiting spinal thrombin with intrathecal hirudin before a painful 
compression, and separately by administering exogenous rat thrombin intrathecally to 
naïve rats, spinal thrombin is found to contribute to BSCB breakdown, spinal astrocyte 
activation and pain. Additionally, spinal thrombin initiates spinal neuroinflammation and 
pain through its activation of PAR1, which is determined using pharmacological 
v 
 
inhibition of spinal PAR1 with SCH79797. In contrast to mammalian thrombin, studies 
using the same painful in vivo model and complementary endothelial and astrocytic in 
vitro experiments also demonstrate that salmon thrombin exerts opposite effects on 
vascular permeability, astrocytic inflammation, and pain. Using synthetic fluorogenic 
peptides and in silico protein models, the vascular protection and anti-inflammatory 
effects of salmon thrombin are hypothesized to be controlled by its unique affinity for 
protein C over PAR1. Lastly, spinal astrocytic and endothelial expression of the 
intermediate filament, vimentin, are shown to undergo a delayed increase at day 7 after a 
painful compression, suggesting that spinal cells may modulate their cellular mechanics 
in response to a painful neural injury. These studies identify how one pathological 
response, BSCB breakdown, that occurs in the spinal cord early after painful injury 
initiates a host of immediate and delayed biochemical and biomechanical responses that 
contribute to pain development. Findings further establish the powerful, yet diverse, role 
of spinal thrombin and its ability to initiate pathological or protective effects based on the 
signaling cascades it activates.    
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Chapter 1 
Introduction & Background 
 
 
1.1 Introduction & Motivation 
In a recent report by the Institute of Medicine of the National Academies, the 
annual incidence of chronic pain in America is over 100 million adults (Institute of 
Medicine (US) Committee on Advancing Pain Research 2011). Pain, defined by the 
International Association for the Study of Pain (IASP), is “an unpleasant sensory and 
emotional experience associated with actual or potential tissue damage” (Radu et al. 
2013). The ability to detect a harmful, or potentially harmful, stimulus is essential for 
survival; however, when pain persists beyond the potential threat of tissue damage, it 
becomes problematic. Noxious stimuli, or those that have the potential to cause tissue 
damage, are encoded through the neural process of nociception (Merksey and Bogduk 
1994).  Clinically, “acute” pain is pain that resolves within three months; pain is 
classified as “chronic” when it lasts for longer than three months (Fishbain et al. 2014, 
Melloh et al. 2011, Wall and Melzack 1994). Depending on the severity of the symptoms, 
pain can be a debilitating disorder substantially impacting quality of life (Breivik et al. 
2006, Merksey and Bogduk 1994, Ramirez-Maestre and Esteve 2013). Each year in the 
United States, chronic pain accounts for expenditures exceeding $600 billion, which 
includes the costs associated with both health care and loss of productivity (Institute of 
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Medicine (US) Committee on Advancing Pain Research 2011). Over 20% of chronic pain 
cases are reported to have neuropathic characteristics (Bouhassira et al. 2008). According 
to the IASP, neuropathic pain “arises as a direct consequence of a lesion or diseases 
affecting the somatosensory system” (Jensen et al. 2011). 
Nearly 10% of the general population and 20% of the adult population are 
burdened by chronic pain with neuropathic symptoms (Torrance et al. 2006, van Hecke et 
al. 2014). Individuals experiencing pain with neuropathic characteristics report that their 
pain is generally more severe than that of non-neuropathic origin and that their health-
related quality of life can be as low as that reported with depression, coronary heart 
disease or a recent myocardial infarction (Torrance et al. 2014). Neuropathic pain is not 
itself a disease, but rather it is a complex syndrome that can arise from a wide range of 
disorders in the central or peripheral nervous system (Haanpää and Treede 2010, Jensen 
et al. 2011). Neuropathic pain arising in the central nervous system (CNS) can result from 
stroke, spinal cord injury, multiple sclerosis, and other neurological disorders. Painful 
peripheral neuropathy is most commonly due to lumbar or cervical radiculopathy, 
postherpetic neuralgia, diabetic neuropathy, human immunodeficiency virus (HIV) 
related neuropathy, and chronic postsurgical pain (Haanpää and Treede 2010, Jensen et 
al. 2011).  
Radiculopathy is a pathology of the spinal nerve roots with clinical symptoms of 
pain and numbness that radiate into the extremities (Abbed and Coumans 2007, Caridi et 
al. 2011). The specific location of the presenting symptoms after root injury depends on 
which nerve root is affected. The areas of skin that are innervated by a single nerve root 
exhibit dermatomes mapping to each nerve root’s innervation. Injuries to the C7 nerve 
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root, for example, produce sensitivity and numbness in the arm, forearm, and middle 
finger (Abbed and Coumans 2007). Injury to the nerve roots can be produced by non-
physiological mechanical loading or exposure to chemical and/or inflammatory stimuli 
(Abbed and Coumans 2007, Garfin et al. 1991, Krivickas and Wilbourn 2000, Olmarker 
and Myers 1998, Panjabi et al. 2006). The nerve roots are susceptible to mechanical 
loading from disc herniation or spinal spondylosis, both of which typically apply 
sustained loads to the roots. In addition to nerve root impingement from disc herniation, 
there is also often an inflammatory component applied to the nerve root; the nucleus 
pulposus is secreted from the disc and introduces pro-inflammatory stimuli to the nerve 
root (Hou et al. 2003, Olmarker et al. 1993). Transient loading the nerve roots via trauma 
from sports- or automotive-related injury also has the potential to induce long-term 
radicular pain depending on the profile of the mechanical loading to the root, which 
depends on the overall kinematics of the spine (Krivickas and Wilbourn 2000, Panjabi et 
al. 2006, Tominaga et al. 2006).  
Quantifiable measures have been developed to assess evoked pain and which 
provide clinicians and researchers with objective measures of pain (DeLeo and 
Winkelstein 2002, Loeser and Treede 2008, Merksey and Bogduk 1994). Two types of 
hypersensitivity are distinguished, allodynia and hyperalgesia. Allodynia is defined as 
pain in response to a stimulus that is usually not painful, whereas hyperalgesia is the 
increased response to a stimulus which is normally painful, and includes all conditions of 
increased pain sensitivity (Baron et al. 2010, Merksey and Bogduk 1994, Winkelstein 
2011, Woolf and Mannion 1999). At least 20% of patients with general neuropathic pain 
have mechanical allodynia and nearly 30% have mechanical hyperalgesia (Baron et al. 
  4 
2010, Maier et al. 2010). Those behavioral symptoms of sensitivity are perceived on the 
skin local to the source of pain (primary), as well as in nearby unaffected areas of skin 
(secondary) (Baron et al. 2010, Maier et al. 2010).  
Despite the high prevalence and debilitating nature of neuropathic pain, 
treatments that effectively eliminate symptoms are still lacking (Baron et al. 2010, 
O'Connor and Dworkin 2009, Vranken 2009). Less than 50% of patients in neuropathic 
pain trials achieve satisfactory pain relief with the currently available treatments 
(O'Connor and Dworkin 2009). The standard set of pharmacologic treatments most 
commonly recommended for neuropathic pain include tricyclic antidepressants, 
anticonvulsants, and the 5% lidocaine patch (Dworkin et al. 2003, Finnerup et al. 2010, 
O'Connor and Dworkin 2009). Each of those treatments only target the neuronal 
contributions to nociception (Argoff 2000, Gilron 2007, O'Connor and Dworkin 2009, 
Sindrup et al. 2005). However, it has become widely recognized and accepted that many 
other cell types within the CNS contribute to the development and maintence of chronic 
neuropathic pain (Baron et al. 2010, Milligan and Watkins 2009, Scholz and Woolf 2007, 
Vallejo et al. 2010, Watkins et al. 2001, Woolf and Mannion 1999). Identifying the 
contributions of non-neuronal cell types and their pathological processes that contribute 
to pain can provide important and relevant insight for the design and development of 
effective treatments for neuropathic pain.  
Rat models of painful radiculopathy have defined a host of neuronal and non-
neuronal mechanisms that contribute to the development of neuropathic pain (Garfin et 
al. 1991, Hubbard and Winkelstein 2005, Kawakami et al. 1994). Injury to the nerve root 
can produce secondary behavioral sensitivity that can be quantified in the forepaw where 
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the injured afferents innervate (Olmarker and Myers 1998, Olmarker et al. 1993, 
Rothman and Winkelstein 2007, Winkelstein and DeLeo 2002). Our lab has developed a 
transient compressive nerve root injury that can produce customizable pain profiles and 
cellular responses at the location of injury and in the spinal cord where the injured 
afferents synapse depending on the loading profile, i.e. magnitude and duration of the 
compression. For example, a root compression that is greater than 38.16mN held for 15 
minutes induces mechanical allodynia for up to 7 days (Hubbard et al. 2008a); but a 
compression greater than that magnitude threshold (98mN) held for only 3 minutes does 
not induce allodynia (Nicholson et al. 2011, Rothman et al. 2010). In fact, mechanical 
allodynia lasts for up to 4 weeks after nerve root compression (Rothman et al. 2007). 
Inflammatory root insults, applied separate or in combination with a mechanical insult, 
have also been shown to produce mechanical allodynia and hyperalgesia for up to 14 
days (Chang and Winkelstein 2011, Rothman et al. 2009, Rothman and Winkelstein 
2007, Zhang et al. 2013). These customizable injury scenarios allow for the investigation 
of, and differentiation between, cellular responses that are specific to pain and those that 
are produced simply as a result of trauma. Peripheral mechanically-induce neuropathic 
injuries have been shown to disrupt the blood-spinal cord barrier (BSCB) (Beggs et al. 
2010, Cahill et al. 2014, Echeverry et al. 2011, Gordh et al. 2006). However, the 
components of those injuries that contribute to BSCB breakdown and whether that 
breakdown contributes to the associated pain is not known. 
The studies in this thesis investigate if, and how, BSCB breakdown contributes to 
the development of pain after a nerve root injury. BSCB breakdown is measured over 
time after a variety of painful and non-painful insults to the cervical nerve root that are 
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both mechanical and chemical. In a separate study, BSCB breakdown is 
pharmacologically blocked with activated protein C (APC) after a painful nerve root 
compression to define if BSCB breakdown contributes to the onset of pain. Studies then 
identify whether the serum-derived enzyme, thrombin, enters the spinal parenchyma as a 
result of BSCB breakdown. The contribution of spinal thrombin and its downstream 
signaling cascades to the development of pain are then investigated by: (1) blocking 
spinal thrombin activity prior to a painful nerve root compression, (2) administering rat 
thrombin to the spinal cord of non-injured naïve rats, and (3) antagonizing the thrombin 
receptor protease-activated receptor-1 (PAR1) in conjunction with painful root 
compression or rat thrombin administration. Hirudin is administered intrathecally before 
a painful compression in order to selectively inhibit thrombin activity in the spinal cord 
(Narita et al. 2005, Rydel et al. 1990). Lastly, the small molecule, SCH79797, which is a 
PAR1 antagonist, was given intrathecally before a compression or painful stimulus 
(Manaenko et al. 2013, Yan et al. 2013), in order to test whether spinal thrombin acts 
through PAR1 to induce BSCB breakdown, spinal astrocyte activation and pain. 
Mechanical hyperalgesia, BSCB breakdown and spinal astrocytic activation are 
quantified in order to identify the role that thrombin and its activation of PAR1 have in 
pain and spinal endothelial and astrocytic pathology.  
In a separate study, the effects of salmon thrombin on mediating pain, vascular 
permeability, and astrocyte-induced inflammation was measured and compared to human 
thrombin utilizing complementary in vivo and in vitro studies. The activity of salmon and 
human thrombin towards different thrombin-activated substrates is also investigated 
because thrombin mediates cell signaling cascades based on the cell-bound substrate it 
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activates (Bouwens et al. 2013, Di Cera 2008, Griffin 1995, Komarova et al. 2007, Lane 
et al. 2005). Lastly, studies establish whether activated spinal astrocytes modulate their 
cellular mechanics via changes in their expression of vimentin in response to a painful 
nerve root compression alone or with analgesic treatments of hirudin or salmon thrombin.  
The four specific aims of this thesis, the rationale supporting them, and their 
governing hypotheses are summarized in Chapter 2, which also includes the outline and 
organization of the other chapters in this thesis. More detailed background information 
for each study is separately provided within each chapter. The background information in 
this chapter is intended to provide relevant information about neural anatomy, the cellular 
populations within the relevant neural tissue and various cellular functions and 
dysfunctions in response to neuropathic injury that induces pain. In addition, a brief 
overview of the mechanistic differences between mammalian thrombin and salmon 
thrombin is introduced. 
 
1.2 Relevant Background 
2 
1.2.1. The Cervical Spine & Neural Anatomy 
 The cervical spine is comprised of seven bony vertebrae (C1-C7) that are 
connected and stabilized by spinal ligaments and muscles (Figure 1.1) (Antonacci et al. 
1998, Crosby et al. 2015). Each pair of bony vertebrae in the cervical spine is separated 
by the intervertebral disc anteriorly and a pair of bilateral facet joints posteriorly that 
restricts the motion of the spinal segments (Figure 1.1). The space running longitudinally 
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through each cervical vertebrae is the spinal canal, which surrounds and protects the 
spinal cord (Figure 1.1).  
 
 
Extending from the spinal cord bilaterally at each spinal level are the dorsal and 
ventral nerve roots, which exit the spinal column through the intervertebral foramen. The 
dorsal root carries the afferent axons and the ventral root houses the efferent axons. The 
efferent axons within the ventral nerve root relay information from the ventral spinal 
cord, where the efferent somata are housed, to the periphery. In contrast, the afferent 
axons within the dorsal nerve root originate in the periphery and relay sensory 
Figure 1.1. Anatomy of the bony structures and soft tissues of a cervical spinal joint. An axial view 
of the cervical spine in between spinal levels. Adjacent spinal laminae are connected via the articulating 
intervertebral disc and the bilateral facet joints, which limit motion and transmit loads. The spinal cord 
is housed within the spinal canal and protected by meninges. The spinal nerve roots exit the cord at the 
spinal dorsal horn and join distally to the dorsal root ganglion (DRG), which houses the cell bodies of 
the afferent neurons. The nerve roots exit the spinal canal through the intervertebral foramen and 
continue to form the peripheral spinal nerves. This figure is adapted from Crosby et al. 2015. 
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information in to the spinal cord and CNS (Almeida et al. 2004). The cells bodies of the 
afferent neurons are clustered together within the bilateral dorsal root ganglia (DRG) at 
each spinal level (Figure 1.1). Afferent axons synapse in the dorsal horn of the spinal 
cord with second order neurons that project to the brainstem. In addition to axons, the 
nerve roots contain blood vessels, which are necessary for supplying adequate amounts of 
oxygen to the nerve fibers (Rydevik et al. 1984). 
Each set of dorsal and ventral nerve roots extend from the spinal cord towards the 
periphery where they couple together to form the peripheral nerve outside of the spinal 
column (Figure 1.1) (Martini et al. 2003). Despite there being only seven vertebrae, there 
are eight levels of the cervical spinal cord and the nerve root that exits the spinal column 
between the C7 and T1 vertebrae is, by convention, termed the C8 nerve root (Martini et 
al. 2003). In this thesis, studies focus on insults to the C7 nerve root because clinical 
studies have found that the C7 nerve root is the most commonly affected cervical root in 
patients diagnosed with cervical radiculopathy, with a reported incidence rate of around 
50% (Carette and Fehlings 2005, Wainner and Gill 2000). 
The spinal cord is enclosed by the meninges (Figure 1.1), which are a system of 
three collagenous membranes (pia mater, arachnoid mater, and dura mater) that separate 
and protect the spinal cord within the surrounding vertebral column. The dura mater, in 
particular, resists mechanical tension and provides support to the neural structures that it 
surrounds (Maikos et al. 2008). The meninges also encase the cerebrospinal fluid (CSF) 
which serves as a mechanical buffer for the nervous tissue within the CNS. In addition to 
providing mechanical protection, the meninges of the spinal cord form the first line of 
defense of the BSCB and protect the CNS from fluctuations in ions, hormones, and other 
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signaling molecules in the periphery (Abbott et al. 2010, Ballabh et al. 2004). The dorsal 
and ventral spinal nerve roots are also encased within CSF, the dura mater, and the 
arachnoid membrane as they exit the intervertebral foramen and join together to form the 
peripheral nerves outside of the spinal column (Figure 1.1). This is true in both in the 
human and in the rat.   
In contrast to many other tissues in the body, the brain and spinal cord lack a 
highly organized extracellular matrix (Gaudet and Popovich 2014, Hynes and Naba 2012, 
Zimmermann and Dours-Zimmermann 2008). The extracellular space of the CNS 
encompasses roughly 15-30% of the total CNS volume and is primarily comprised of 
proteoglycans, hyaluronan and tenascins (Barros et al. 2011, Gaudet and Popovich 2014, 
Wong et al. 2013, Zimmermann and Dours-Zimmermann 2008). The other 70-85% of the 
CNS is made up of neurons, glial cells, and endothelial cells. Although arguably the most 
important cells within the CNS, neurons are outnumbered by astrocytes. Astrocytes 
comprise the main mechanical support system for neurons and also regulate normal 
neural functions; astrocytes transport oxygen and nutrients from microvessels to neurons, 
regulate synaptic transmission, and signal to endothelial cells to maintain the blood-brain 
barrier (BBB) structure (Abbott et al. 2006, Volterra and Meldolesi 2005, Wong et al. 
2013). Microvascular endothelial cells also make up a significant proportion of the cells 
in the CNS. Each neuronal cell body is typically within 8-20µm of the closest capillary 
and every neuron in the brain is estimated to have its own capillary (Abbott et al. 2006, 
Schlageter et al. 1999, Wong et al. 2013, Zlokovic 2008). Other cells within the CNS 
include microglia, which act as the resident immune cells responding to injury and 
foreign pathogens (Kreutzberg 1996, Stollg and Jander 1999), and pericytes, which 
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surround the microvessels helping to regulate vascular tone and to maintain tight 
junctions (Balabanov and Dore-Duffy 1998, Krueger and Bechmann 2010). 
The microvessels in the spinal cord are unique from peripheral blood vessels 
because they form the BSCB. Endothelial cells that comprise the BSCB face the luminal 
side of the blood vessels and are bound tightly together by tight junctions (Abbott et al. 
2010). Tight junctions are the key feature of the BSCB since they prevent paracellular 
diffusion of ions and polar solutes between the endothelial cell fenestrations (Abbott et al. 
2010). Tight junctions are comprised of adherin junctions, occludins, claudins and 
junctional adhesion molecules that span the intracellular cleft. Pericytes completely 
encase the microvascular endothelial cells followed by astrocytic end-feet, both of which 
contribute to BSCB function and act as a second line of defense to the endothelial 
structure of the barrier (Balabanov and Dore-Duffy 1998, Wolburg et al. 2009).  
 
1.2.2. Mechanisms of Neuropathic Pain 
 A number of peripheral and central pathological cellular responses occur after 
neuropathic injury that contribute to the establishment and maintenance of pain. Altered 
sensitivity that accompanies neuropathic pain is ultimately controlled by a change in the 
normal signaling of neurons (Crosby et al. 2015, Vranken 2009). In response to a 
stimulus, whether mechanical, chemical, or thermal, that is above the nociceptive 
threshold, the primary afferent neurons transmit nociceptive signals to the spinal dorsal 
horn (Figure 1.2). Primary afferent neurons can become sensitized and can exhibit a 
lowered threshold for evoking firing in response to stimuli or an increased rate of firing 
once activated (Vranken 2009). Sensitization of the primary afferents is induced local to 
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the injury site by the release of chemicals from the injured axons and vasculature and by 
a local inflammatory response. Afferent injury produces localized increases in 
neuropeptides and neurothrophins, such as nerve growth factor (NGF), glial cell line-
derived neurotrophic factor (GDNF), calcitonin gene-related peptide (CGRP), substance 
P, bradykinin, as well as nitrous oxide (NO), adenosine triphosphate (ATP) and other 
molecules that themselves also stimulate the primary afferents (Scholz and Woolf 2007). 
Macrophages respond almost immediately to peripheral neuropathic injury by migrating 
to the location of neural trauma and initiating a local inflammatory cascade (Scholz and 
Woolf 2007). Those macrophages produce cytokines and chemokines that also directly 
stimulate the afferents and attract additional immune cells to the location of injury 
(Scholz and Woolf 2007). This peripheral neuroinflammation continuously stimulates 
afferents which thereby increases their release of excitatory neurotransmitters in the 
spinal cord where they synapse (Figure 1.2). 
Injured afferents synapse in the dorsal horn of the spinal cord and trigger a host of 
cellular and molecular responses centrally that contribute to central sensitization in 
response to trauma (Figure 1.2). Central sensitization is a major contributor to 
dysfunctional pain states and results from changes in neuronal properties such that 
neurons respond abnormally to non-noxious stimuli or respond with an increased gain to 
typically noxious stimuli (Latremoliere and Woolf 2009). Although neurons ultimately 
control aberrant nociceptive signaling in the CNS (Latremoliere and Woolf 2009), the 
other resident cells within the CNS also have roles in enhancing nociception and 
contribute to the continued neuronal dysfunction that leads to central sensitization (Inoue 
2006, Vallejo et al. 2010, Vranken 2009). As such, the classical view of synaptic 
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transmission between two neurons has been adapted to include astrocytes; that “tripartite 
synapse” consists of the pre-synaptic neuron, the post-synaptic neuron, and the astrocytic 
encasement of the synapse and controls synaptic transmission (Halassa et al. 2007). With 
increased information about the physical and trophic interaction between neurons, glia 
and vasculature in the CNS (Abbott et al. 2006, Hawkins and Davis 2005, Wong et al. 
2013), synaptic transmission has also been further expanded to include the microvascular 
endothelial cells since they contribute to maintaining neuronal function and dysfunction. 
The functional coupling between synaptic neurons, astrocytes, and endothelial cells 
makes up the neurovascular unit (Figure 1.3) (Hawkins and Davis 2005, Radu et al. 
2013, Zlokovic 2008, Zlokovic 2010).  
 
 
 
Figure 1.2. Peripheral and central responses initiated after neuropathic injury.  Injury to primary 
afferents induces many cascades in peripheral neural tissue including local nociceptor release of 
excessive neurotransmitters and neuropeptides and initiation of a complex inflammatory response. 
Afferents transport excitatory molecules to the spinal dorsal horn, inducing spinal glial activation, 
immune cell transmigration into the spinal parenchyma, and pro-inflammatory cytokine and chemokine 
release.  
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1.2.3. The Neurovascular Unit 
Microvascular endothelial cells comprise the primary cellular structure of the 
BBB. The presence of tight junctions distinguishes endothelial cells of the BBB or BSCB 
from those comprising the blood vessels in the periphery. With the help of pericytes, 
endothelial cells regulate, and in healthy conditions prevent, the transport of ions and 
other blood-borne proteins into the CNS parenchyma. Astrocytes act as a physical and a 
trophic bridge between endothelial cells and nearby neurons. Physically, astrocytic end-
feet appose blood vessels and the body of the astrocyte interfaces with the nearby 
neuronal synapses (Figure 1.3) (Abbott et al. 2006).  
 
 
Figure 1.3. The neurovascular unit in healthy and pathological states. In healthy states, the 
microvascular endothelial cells are tightly bound together by tight junctions permitting the entrance of 
serum-derived proteins into the CNS. Astrocytic end-feet appose endothelial cells and provide trophic 
support maintaining the BBB integrity. Astrocytes also provide essential nutrients to nearby neurons 
and regulate synaptic concentrations of neurotransmitters. During pathological states of BBB or BSCB 
breakdown, serum cytokines and proteins extravasate into the CNS along with peripheral immune cells. 
Astrocytes become activated, release inflammatory molecules, and dysregulate synaptic concentrations.  
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Under healthy conditions, astrocytes transport essential nutrients from the blood 
vessels to the neurons, clear neurotransmitters from the synapses, and maintain the 
BBB/BSCB integrity by secreting molecules, such as transforming growth factor (TGF-
β), GDNF, basic fibroblast growth factor (bFGF), and angiopoetin 1, back to the 
endothelial cells (Abbott et al. 2006, Wong et al. 2013). The neurovascular unit responds 
to pathological conditions in the CNS. Neurons increase their release of excitatory 
neurotransmitters, astrocytes become activated, and endothelial junctions are disrupted 
(Figure 1.3) (Zlokovic 2008). A hallmark of astrocyte activation is the increased 
astrocytic expression of the intermediate filament, glial fibrillary acidic protein (GFAP) 
(Haydon and Carmignoto 2006, Pekny and Pekna 2004). Activated astrocytes release 
pro-inflammatory cytokines, alter their expression of neurotransmitter receptors, and 
downregulate their production and release of BBB-protecting molecules (Abbott et al. 
2006, McMahon et al. 2005, Milligan and Watkins 2009, Watkins et al. 2001, Wolburg et 
al. 2009). Together, this reactive response exacerbates inflammation within the CNS, 
leads to even higher synaptic concentrations of excitatory molecules, and exacerbates 
BBB breakdown. BBB breakdown is caused by a decrease in functional transendothelial 
tight junctions, which permits the influx of serum molecules that are typically excluded 
from the CNS. Pro-inflammatory cytokines have been shown to extravasate from the 
serum into the parenchyma (Echeverry et al. 2011, Pan and Kastin 2007, Sharief and 
Thompson 1992, Szelenyi 2001), but the extent of protein extravasation has not been 
fully explored. Additionally, whether those serum-derived molecules potentiate astrocytic 
activation and contribute to the development of pain is not known.  
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1.2.4. Compressive & Inflammatory Nerve Root Insults 
 Nerve root injury models in the rat provide growing insight into the peripheral 
and central cellular cascades that contribute to the development and maintence of pain 
following different types of nerve root insults (Chang and Winkelstein 2011, Cornefjord 
et al. 2004, Hubbard and Winkelstein 2005, Kawakami et al. 1994, Nicholson et al. 2011, 
Olmarker et al. 1993, Rothman et al. 2011). Many of the clinical causes of nerve root-
mediated pain are due to a compression of the root, either transiently or chronically. 
Animal models of injury have shown that the resulting pain responses depend on the 
mechanics of compression, e.g. the duration, magnitude, and rate of the compression 
(Garfin et al. 1995, Hubbard et al. 2008a, Igarashi et al. 2005, Rothman et al. 2010, 
Rydevik et al. 1981). The magnitude and duration of compression also control the extent 
of cellular dysfunction both within the injured root and centrally in the spinal cord 
(Hubbard et al. 2008a, Hubbard and Winkelstein 2008, Nicholson et al. 2011, Nicholson 
et al. 2012, Rothman et al. 2010).  
A transient compression of the C7 nerve root that is applied for only 15 minutes 
induces mechanical behavioral sensitivity that lasts for at least 14 days after injury 
(Chang and Winkelstein 2011). In contrast, when a compressive load of the same 
magnitude is applied for only 30 seconds or 3 minutes, mechanical allodynia does not 
develop (Nicholson et al. 2012, Rothman et al. 2010, Zhang et al. 2013). Nerve root 
tissue responds differently both mechanically and biologically to a compressive insult 
depending on the duration of compression (Nicholson et al. 2011, Rothman et al. 2010). 
A compressive load applied to a nerve root relaxes with increasing time of compression 
due to the viscoelasticity of neural tissue. By 3 minutes into a compression of 
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approximately 110mN, the load applied to the root decreases to 84% of the maximum 
load, but by 15 minutes into the compression the load relaxes to 64% of the peak applied 
load (Rothman et al. 2010). The nerve root exhibits structural deformation immediately 
after the removal of the compression only when the compression is applied for 15 
minutes, and not 3 minutes (Rothman et al. 2010). The compressed afferent neurons in 
the root also respond electrophysiologically with increasing time of compression. Evoked 
neuronal firing in the spinal cord where those compressed neurons synapse is maximally 
decreased at 6.6±3.0 minutes into a compression of 98mN (Nicholson et al. 2011). 
Compressing nerve or nerve root tissue also has been shown to disrupt blood flow 
through the vasculature depending on the magnitude and time of compression (Garfin et 
al. 1995, Igarashi et al. 2005, Olmarker et al. 1989, Yoshizawa et al. 1989). In the rabbit, 
30mmHg of compression applied to the nerve root is sufficient to block blood flow 
through the venules, but blood flow through the arterioles is not compromised until 
pressures reach 60-70mmHg (Garfin et al. 1995, Rydevik et al. 1981, Rydevik et al. 
1984). Compressing the cauda equina in pigs with pressures above 40mmHg has been 
shown to disrupt blood flow in the capillaries of the root (Olmarker et al. 1989). In 
addition to blocking flow at the location of the compression, a lumbar nerve root 
compression also induces an immediate drop in blood flow to the spinal cord for the 
entire time of the 60-minute compression (Igarashi et al. 2005). That study shows that 
after removal of the 45gf compressive load in dogs, blood flow is restored to baseline 
values within 1 hour (Igarashi et al. 2005). However, in a rat model, compressing the L5 
lumbar nerve root with 45gf for even 2 seconds disrupts blood flow in the DRG that lasts 
for up to 3 hours after the compression is released (Yoshizawa et al. 1989). Taken 
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together, these studies demonstrate that nerve root compression introduces ischemia in 
the compressed tissue, as well as within the surrounding neural tissue, to an extent that 
depends on the magnitude and duration of compression, as well as the species in which 
the compression is being administered. 
Immediate macroscopic deformation of the nerve root has been shown to be 
associated with a longer-term disruption in axonal integrity, as well as the pain that 
develops and is maintained. A 15-minute nerve root compression produces an immediate 
reduction in the width of the root to 72.4±12.6% of the original geometry (Rothman et al. 
2010). By day 7 after that 15-minute compression, expression of neurofilament-200 
(NF200) in myelinated axons is decreased and unmyelinated axons exhibit swelling 
(Hubbard and Winkelstein 2008, Nicholson et al. 2011). Axonal degeneration is 
hypothesized to disrupt the transport of neuropeptides to the spinal dorsal horn. In fact, 
the spinal expression of substance P and CGRP is decreased after a 15-minute 
compression (Hubbard et al. 2008a, Hubbard et al. 2008b). Mechanical allodynia 
develops by day 1 after the 15-minute compression that induces immediate structural 
deformation in the root and sustained axonal dysfunction. In contrast, a compression 
applied for only 3 minutes does not cause immediate macroscopic deformation of the root 
tissue, nor does it induce axonal degeneration at day 7 after injury or produce mechanical 
allodynia (Nicholson et al. 2011, Rothman et al. 2010). These studies support the severity 
of compressive root injury being associated with the presence of nerve root degeneration 
and development of pain. 
The magnitude and duration of a nerve root compression also control the degree 
of extended glial activation in the spinal cord. A painful 15-minute nerve root 
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compression induces robust microglial activation in the spinal cord at day 7 after injury; 
however, non-painful compressions, applied for either 30 seconds or 3 minutes, do not 
induce microglial activation. Spinal astrocytic activation exhibits a more graded response 
to compression duration; a 3-minute compression induces an increase in astrocytic 
activation over normal levels, but a 15-minute compression increases spinal astrocytic 
activation to levels that are higher than produced by that 3-minute compression. These 
studies support the further association between compression-induced pain and spinal glial 
activation following compression.  
 In addition to compressive insults, inflammatory insults to the spinal nerve roots 
also induce behavioral sensitivity (Chang and Winkelstein 2011, Cornefjord et al. 2004, 
Rothman et al. 2009, Rothman and Winkelstein 2007). Our lab has adapted an 
inflammatory model of nerve injury by applying chromic gut suture to the C7 nerve root 
(Chang and Winkelstein 2011, Rothman and Winkelstein 2007). Although both a 15-
minute compression and an inflammatory insult induce behavioral sensitivity lasting for 
up to 14 days (Chang and Winkelstein 2011), they have been shown to induce a host of 
different spinal and nerve root pathologies. For example, within 1 hour, transcription of 
tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and IL-6 is increased 
after a 15-minute painful compression, but only IL-6 transcription is elevated at this time 
after a painful chromic inflammatory insult (Rothman et al. 2011). Spinal astrocyte and 
microglia expression are also increased only after a compressive insult, but not an 
inflammatory insult (Rothman and Winkelstein 2007). Those studies suggest that a 
painful compression induces more robust immediate and sustained neuroinflammation in 
the spinal cord compared to the inflammatory insult. Additionally, at day 14, after an 
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inflammatory insult axonal myelination is not disrupted nor is there robust phagocytotic 
macrophage infiltration in the nerve root (Chang and Winkelstein 2011).  Together, these 
studies demonstrate that the cellular mechanisms that contribute to nerve root-mediated 
pain induced by an inflammatory stimulus may be different than those that contribute to 
pain from a compressive insult.  
 
1.2.5. Thrombin’s Induction of Cell Signaling Cascades 
Thrombin is a serine protease that enzymatically activates a vast array of 
substrates within biological systems, influencing a wide range of biological processes. 
Thrombin cleaves fibrinogen into fibrin, the main polymeric structure of blood clots, 
thereby having a crucial role in coagulation (Boon 1993). In addition to activating 
fibrinogen and other substrates involved in the clotting cascade, thrombin also cleaves 
and activates, cell-bound receptors to initiate cell signaling cascades (Di Cera 2008, 
Komarova et al. 2007). Interestingly, in many of those signaling cascades thrombin is 
capable of activating opposing pathways, including platelet activation, endothelial 
permeability, and inflammation (Coughlin 2000, Griffin 1995, Komarova et al. 2007). 
Since thrombin can activate many substrates, and many of which themselves initiate 
distinct cellular responses, its structure is comprised of regions that interact with co-
factors to guide thrombin to activate certain substrates; those regions are known as 
exosites (Di Cera 2008, Gandhi et al. 2011, Lane et al. 2005). Thrombin activates three 
separate G-protein coupled receptors (GPCRs) known as the protease-activated receptors 
(PARs): PAR1, PAR3, and PAR4 (Coughlin 2000, Jacques et al. 2000). Of those, 
thrombin has the highest affinity for PAR1 due to exosite I of thrombin interacting 
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closely with an amino acid sequence contained within an extracellular loop of PAR1 
(Coughlin 2000). This sequence of amino acids is known as the hirudin-like domain of 
PAR1, due to its remarkable similarity to hirudin; hirudin is a protein derived from 
leeches and is often used to inhibit thrombin activity because of thrombin’s strong 
affinity towards it (Jacques et al. 2000, Rydel et al. 1990).  
In vascular systems, freely-circulating thrombin primarily activates PAR1 
expressed on the endothelial surface, which induces endothelial barrier disruption, cell 
contraction, and production of pro-inflammatory factors (Figure 1.4) (Bernard et al. 2001, 
Bouwens et al. 2013, Di Cera 2008, Esmon 1993). However, thrombin can also bind to 
thrombomodulin, which enables it to activate protein C, bound to the endothelial protein 
C receptor (EPCR). Thrombin’s activation of endothelial-bound protein C leads to 
endothelial barrier stability, cytoprotection, and anti-inflammatory events (Bouwens et al. 
2013, Esmon 1993). Under normal physiological conditions, thrombin circulates at 
relatively low concentrations, activating PAR1 and protein C to maintain vasculature 
stability (Figure 1.4) (Bouwens et al. 2013, Riewald and Ruf 2005). However, under 
traumatic conditions, thrombin concentration is elevated and thrombin primarily activates 
PAR1 to disrupt vasculature (Figure 1.4) (Bouwens et al. 2013, Mosnier et al. 2012). 
Interestingly, APC is an enzyme and produces its vascular protective effects also by 
activating PAR1 (Bouwens et al. 2013, Esmon 1993, Mosnier et al. 2012). However, 
APC cleaves the extracellular domain of PAR1 at a different residue than thrombin 
activates (Mosnier et al. 2012). The ability of PAR1 to induce opposite signaling 
cascades when activated by different agonists is common among many GPCRs and is 
known as biased agonism (Mosnier et al. 2012, Zhao et al. 2014). 
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In addition to endothelial cells, PAR1 is expressed on a variety of cells within the 
CNS, including neurons, astrocytes, and microglia (Luo et al. 2007, Shavit et al. 2011, 
Suo et al. 2002, Vellani et al. 2010, Wang et al. 2002). Under healthy conditions, 
thrombin is not present in the adult CNS, but the exogenous administration of thrombin 
into the CNS induces local inflammation (Boven et al. 2003, Fan et al. 2005, Niego et al. 
2011, Nishino et al. 1993). For example, thrombin infused into the rat midbrain over 7 
days, induces astrocytic upregulation of GFAP and another astrocytic intermediate 
filament, vimentin, which are both markers of astrocyte activation (Nishino et al. 1993). 
Thrombin’s activation of astrocytes has also been observed in vitro in mixed 
hippocampal cultures (Niego et al. 2011). Thrombin induces astrocyte activation and 
production of pro-inflammatory mediators through PAR1 (Boven et al. 2003, Fan et al. 
2005, Nicole et al. 2005, Niego et al. 2011, Nishino et al. 1993, Simmons et al. 2013). 
Figure 1.4. Thrombin’s dual regulation of endothelial barrier stability. Thrombin preferentially 
activates endothelial PAR1, but is also capable of activating protein C into APC. Activation of 
endothelial-bound protein C induces endothelial barrier stability, whereas PAR1 activation leads to 
barrier disruption. Under physiological conditions, such as low blood concentration of thrombin, these 
processes are balanced and vasculature integrity remains intact. During trauma, thrombin concentration 
is elevated and thrombin preferentially activates PAR1 to disrupt barriers allowing for the passage of 
serum molecules into the interstitial fluid of nearby tissues. 
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The role of PAR1 in astrocyte activation is supported by PAR1 null mice exhibiting less 
astrocyte activation after a cortical stab wound than seen in wild-type mice (Nicole et al. 
2005). Thrombin has also been shown to induce mechanical allodynia when injected 
directly into the spinal cord in mice (Narita et al. 2005). However, the mechanism of 
thrombin’s entrance into, or production within, the CNS after painful neuropathic injury 
and whether thrombin contributes to pain have not yet been investigated.  
 
Section 1.2.6. Salmon Thrombin 
In contrast to mammalian thrombin, salmon thrombin has been shown to exert 
distinct effects from human thrombin on certain biological processes. Salmon and human 
thrombin both retain the same level of activity towards a fibrinogen substrate over a 
range of concentrations and temperatures (Michaud et al. 2002, Smith et al. 2013). 
Despite exhibiting indistinguishable enzymatic activity for fibrinogen, salmon thrombin 
activity is inhibited less effectively by hirudin than is human thrombin (Smith et al. 
2013), demonstrating that not all molecular interactions are the same between these two 
species of thrombin. Salmon thrombin’s lower affinity for hirudin is also suggestive of it 
having a lower affinity for PAR1, since the hirudin-like sequence on the extracellular 
domain of PAR1 controls thrombin’s interaction with it (Jacques et al. 2000, Lane et al. 
2005). Differences in thrombin’s affinity for PAR1 are hypothesized to manifest as 
differences in the resulting cell signaling. In fact, salmon thrombin does not activate 
platelets as strongly as its mammalian counterpart; it takes approximately 10 times as 
much salmon thrombin to induce platelet aggregation to the same degree as human 
thrombin in vitro (Michaud et al. 2002). Platelet aggregation is mainly controlled by 
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thrombin’s activation of platelet-expressed PAR1. Since salmon thrombin has a lower 
affinity for hirudin and also activates less PAR1-controlled platelet activation than human 
thrombin, salmon thrombin is hypothesized to have a lower affinity for PAR1.  
In neural tissue, salmon coagulation factors have also been shown to induce more 
favorable effects on neurons and glia compared to mammalian thrombin. Salmon fibrin 
gels, which are comprised of thrombin and fibrinogen both derived from salmon, have 
been shown to promote more neurite extension and branching in vitro compared to fibrin 
gels derived from mammals (Ju et al. 2007). Salmon fibrin applied to the injury site of 
hemisection of the spinal cord improves locomotor function and bladder control to a 
greater degree than human thrombin (Sharp et al. 2012). Most importantly, when salmon 
fibrin or salmon thrombin is applied to the nerve root after a painful 15-minute 
compression, it inhibits the development of mechanical allodynia for at least 7 days after 
injury (Weisshaar et al. 2011). That single treatment of salmon thrombin also reduces the 
infiltration of phagocytotic macrophages into the compressed root at day 7 whereas 
human thrombin does not (Smith et al. 2013, Weisshaar et al. 2011), implying that 
salmon thrombin might even exhibit anti-inflammatory properties. Due to the suggested 
neuroprotective and anti-inflammatory properties of salmon thrombin in neural tissue, as 
well as its anti-nociceptive effects, studies in this thesis further investigate its role in pain 
and neuroinflammation following painful nerve root compression. 
 
1.2.7. Cytoskeletal Control of Cellular Mechanics 
Many cells respond mechanically to environmental cues and/or respond to the 
mechanical properties, including stiffness, of their environment (Fletcher and Mullins 
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2010, Janmey 1998, Janmey and McCulloch 2007). The ability of a cell to resist 
deformation to applied loads, to transport organelles intracellularly, to change shape, and 
undergo movements each depends on the integrated organization and movements of the 
cytoskeleton (Fletcher and Mullins 2010, Janmey 1998, Janmey and McCulloch 2007). 
The cytoskeleton is comprised of three classes of filaments: microtubules, actin 
filaments, and intermediate filaments. Actin filaments are crosslinked by the molecular 
motor, myosin, which displaces those filaments relative to each other. Since actin 
filaments are also connected to the cell cortex through focal adhesions, their intracellular 
movements relative to one another translate to extracellular movements of the cell cortex. 
Focal adhesions physically connect a cell to its surrounding matrix or substrate. The 
actomyosin/focal adhesion complex enables cells to contract, and detect the stiffness of 
their matrix and respond accordingly (Fletcher and Mullins 2010). Although actin plays 
an important role in cell mechanics, microtubules and intermediate filaments play 
distinct, yet important, roles within a cell as well. 
Cytoskeletal filaments are polymeric structures and the three classes of filaments 
are of different sizes and exhibit different mechanical properties. Microtubules are the 
largest (25nm) and stiffest of the three filaments, but buckle under compressive loading 
(Fletcher and Mullins 2010). Because of their inability to resist compressive loads, 
microtubules do not contribute to the stiffness of a cell. Microtubules form long 
structures within the cell (up to 5mm) which facilitate trafficking of organelles and 
molecules along the length of a cell. Actin filaments are the thinnest (8nm) of the three 
classes of cytoskeletal filaments and undergo rapid polymerization and depolymerization 
depending as a product of a variety of intracellular signaling cascades (Fletcher and 
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Mullins 2010). Because of their dynamic nature, actin filaments play a major role in cell 
movement as they contribute to the propagation of the leading edge of a migrating cell. 
The size of intermediate filaments is between microtubules and actin filaments (10nm) 
and only recently have the functions of intermediate filaments begun to be elucidated 
(Buehler 2013, Fletcher and Mullins 2010, Herrmann et al. 2007). Intermediate filaments 
are the most stable of the three cytoskeletal components. They resist high tensile loads 
and therefore have the highest influence on the mechanical integrity of a cell (Buehler 
2013, Herrmann et al. 2007).  
Vimentin filaments are the most widely expressed intermediate filament in 
eukaryotic cells and have been shown to control cytoplasmic stiffness (Guo et al. 2013, 
Janmey et al. 1991, Wang and Stamenovic 2002). Vimentin is expressed in both 
astrocytes and endothelial cells and plays distinct roles within each cell type. Astrocytes 
upregulate their expression of vimentin, along with another intermediate filament GFAP, 
upon their activation (Pekny and Pekna 2004). In vitro, elevated astrocytic expression of 
vimentin correlates to an increase in cytoplasmic stiffness in vitro (Lu et al. 2011). 
Although increased expression of astrocytic vimentin is related to their activation and 
pathology, decreased expression of vimentin in endothelial cells contributes to their 
dysfunction. In endothelial cells, decreased stability and/or expression of vimentin 
corresponds to increased vascular endothelial barrier permeability (Buehler 2013, Guo et 
al. 2013, Liu et al. 2010, Liu et al. 2014). Although vimentin expression plays relevant 
roles in astrocyte activation and vascular disruption, it is not known if the astrocytic and 
endothelial expression of vimentin in the spinal cord is modulated after painful nerve root 
injury. 
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Cells respond to the mechanics of their substrate in various ways. Neurons, in 
particular, exhibit increased extension of neurites and more neurite branching on 
substrates with a softer stiffness (Flanagan et al. 2002, Lamoureux et al. 1998). Certain 
neuronal functions have also been shown to depend on applied tension and compression, 
including synaptic vesicle transport along axons and clustering at synapses (Ahmed et al. 
2012, Flanagan et al. 2002, Georges et al. 2006, Koch et al. 2012). In the CNS, astrocytes 
are the main mechanical substrate for neurons (Volterra and Meldolesi 2005). However, 
it is not known if spinal astrocytes modify their expression of cytoskeletal filaments, such 
as vimentin, that control their stiffness when they become activated following painful 
nerve root injury or if changes in their mechanics may contribute to the neuronal 
dysfunction that maintains nociception.  
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Chapter 2 
Rationale, Context, Hypotheses & Aims 
 
 
2.1 Rationale & Context 
 Despite the high prevalence of chronic pain among the adult population, the 
physiological mechanisms that initiate pain are not completely understood which 
prevents the development of effective treatments. Inflammation within the central 
nervous system (CNS) is initiated via the upregulation of pro-inflammatory cytokines and 
is maintained by activated glial cells long after an initial insult occurs (Inoue 2006, 
McMahon et al. 2005, Milligan and Watkins 2009, Rothman et al. 2009, Rothman and 
Winkelstein 2007, Vallejo et al. 2010, Watkins et al. 2001). Painful nerve root injury 
initiates a host of pro-inflammatory cascades in the spinal cord in parallel with the 
development of long-term radicular pain (Chew et al. 2011, Hashizume et al. 2000, 
Nicholson et al. 2014, Norimoto et al. 2014, Rothman et al. 2009, Rothman et al. 2011, 
Rothman and Winkelstein 2007). Blocking the actions of just one pro-inflammatory 
cytokine, tumor necrosis factor-alpha (TNF-α), in the spinal cord prior to a typically 
painful nerve root compression attenuates behavioral sensitivity for at least a week (de 
Souza Grava et al. 2012, Olmarker et al. 2003, Rothman et al. 2009, Rothman and 
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Winkelstein 2010), highlighting the influence of early spinal inflammation in the 
development of chronic neuropathic pain.  
Spinal glial cells are at least partially responsible for the almost immediate (within 
1 hour) upregulation of pro-inflammatory cytokines in the spinal cord after painful nerve 
root compression (Rothman and Winkelstein 2010). Serum-derived cytokines, along with 
blood-borne immune cells, can infiltrate into the spinal parenchyma from the periphery 
and also amplify the spinal neuroinflammatory response induced by neuropathic injury 
(DeLeo et al. 2004, Echeverry et al. 2011, Radu et al. 2013, Rutkowski et al. 2002, 
Sweitzer et al. 2002). Under healthy conditions the blood-spinal cord barrier (BSCB), 
which is made up of fenestrated endothelial cells sealed together by tight junctions, 
prevents cytotoxic serum components from interacting with spinal neurons (Abbott et al. 
2010, Ballabh et al. 2004, Zlokovic 2008). Breakdown of the BSCB occurs in a wide 
range of neuroinflammatory pathological states (Beggs et al. 2010, Echeverry et al. 2011, 
Gordh et al. 2006, Hawkins and Davis 2005, Sandoval and Witt 2008, Zlokovic 2010, 
Zlokovic 2011). Blood-brain barrier (BBB) and BSCB permeability is often identified in 
animal models by measuring the expression levels of serum proteins, including 
immunoglobulin G (IgG) and albumin  in the CNS parenchyma since they are absent in a 
healthy state (Beggs et al. 2010, Echeverry et al. 2011, Gordh et al. 2006, Poduslo et al. 
1994). Although increased BSCB permeability contributes to inflammation within the 
spinal cord (Echeverry et al. 2011, Hawkins and Davis 2005, Webb and Muir 2000, 
Zlokovic 2008), it is not known whether BSCB breakdown is induced after various types 
of nerve root injuries and if that breakdown facilitates the subsequent pain that develops 
after neural trauma and induces neuroinflammation. Studies outlined in this thesis 
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characterize the spatiotemporal distribution of BSCB breakdown after separate painful 
compressive or inflammatory nerve root insults and establishes the contribution of that 
breakdown to the spinal and systemic inflammation, as well as pain, that develop after 
injury.  
Although serum-derived inflammatory cytokines can penetrate a compromised 
BSCB after neuropathic injury (Banks et al. 1995, Echeverry et al. 2011), it is not clear 
whether other bioactive molecules, such as thrombin, also enter the spinal parenchyma in 
regions of BSCB breakdown. Thrombin has a crucial role in coagulation by 
enzymatically cleaving fibrinogen into fibrin which polymerizes to form the main 
structural component of blood clots (Boon 1993, Di Cera 2008, Griffin 1995). However, 
thrombin also exerts potent enzymatic effects on a variety of cell types through its 
catalytic activation of cell receptors, including protease-activated receptors 1, 3 and 4 
(PAR1, PAR3 and PAR4), and other cell-bound proteins (Coughlin 2000, Di Cera 2008). 
Although not typically present in the brain or spinal cord under healthy conditions, 
mammalian thrombin activates glial cells when injected directly into the midbrain or 
administered to astrocyte cultures (Niego et al. 2011, Nishino et al. 1993). Thrombin also 
stimulates astrocytic production of pro-inflammatory cytokines in vitro (Fan et al. 2005, 
Simmons et al. 2013). Blocking thrombin’s activation of astrocytic PAR1 inhibits 
thrombin-induced astrocytic inflammation in vitro (Choi et al. 2008), suggesting that 
thrombin activates astrocytes through PAR1. Further, intrathecal thrombin (1x10-12mol) 
also induces mechanical behavioral hypersensitivity in naïve mice which persists for up 
to one week (Narita et al. 2005). Although PAR1 mediates thrombin-induced glial 
inflammation (Choi et al. 2008, Fan et al. 2005, Nicole et al. 2005, Niego et al. 2011, 
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Nishino et al. 1993), it not known if spinal thrombin also initiates pain through spinal 
PAR1. Studies in this thesis test the hypothesis that thrombin extravasates into the spinal 
parenchyma in regions of BSCB breakdown contributing to spinal glial activation and 
pain through its activation of spinal PAR1. 
Thrombin also regulates vascular permeability. Depending on the substrate to 
which thrombin is bound it can activate various endothelial cell receptors and cell bound 
proteins which induce opposing cellular effects (Bouwens et al. 2013, Komarova et al. 
2007, Riewald and Ruf 2005). Freely circulating mammalian thrombin preferentially 
activates endothelial PAR1, which induces vascular leakiness (Coughlin 2000, Griffin 
1995, Jacques et al. 2000). However, at low serum concentrations it can also bind to 
thrombomodulin and activate endothelial-bound protein C into activated protein C 
(APC), which stabilizes vasculature (Esmon 1993, Griffin 1995, Komarova et al. 2007, 
Riewald and Ruf 2005). Although the biased agonism of PAR1 is apparent for 
mammalian thrombin, thrombin that is derived from salmon has unique and opposite 
effects on a variety of biological processes in mammals while exhibiting an 
indistinguishable ability to form clots (Laidmae et al. 2006, Wang et al. 2000). Of note, 
salmon thrombin administered at the nerve root after its transient compression in the rat 
has prolonged effects on preventing the development of pain, which corresponds to 
preserving axonal integrity and diminishing the extent of immune cell infiltration within 
the injured root (Weisshaar et al. 2011). However, the mechanism by which salmon 
thrombin activates analgesic pathways is unknown and it is also not known if its 
analgesic effects are unique to salmon thrombin as compared to other species. Several 
studies in this thesis test whether salmon thrombin exhibits unique specificity for various 
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thrombin-activated substrates controlling its distinct effects on vascular breakdown and 
astrocytic inflammation, both of which contribute to pain after neural trauma, in 
comparison to human thrombin. 
CNS tissue, in contrast to many other biological tissues, lacks a prominent fibrous 
extracellular matrix (ECM) and exhibits a microstructure that is mainly comprised of a 
well-organized scaffold of cells (Shreiber et al. 2009). Astrocytes make up nearly 2/3 of 
the cells within the CNS and are the main matrix for the resident neurons (Vallejo et al. 
2010). In addition to the biochemical effects that thrombin exerts on a variety of cell 
types, it also mediates cellular mechanics, also through cell receptor activation. 
Mammalian thrombin activates endothelial PAR1 which leads to phosphorylation of 
intracellular myosin light chain and induces cell contraction (Nobe et al. 2005, Satpathy 
et al. 2004). Endothelial cells increase their cytoskeletal density of actin stress fibers, 
form larger focal adhesions and increase their cortical stiffness upon contraction (Blum et 
al. 2008, Cuerrier et al. 2009). In astrocytes, thrombin increases the expression of the 
intermediate filaments glial fibrillary acidic protein (GFAP) and vimentin, induces cell 
spreading and initiates focal adhesion formation (Niego et al. 2011, Suidan et al. 1997), 
all of which suggest that thrombin also can modify astrocytic mechanics. Since neuronal 
function depends on substrate stiffness (Flanagan et al. 2002, Georges et al. 2006, Koch 
et al. 2012), astrocytes that become activated after nerve root compression might modify 
their stiffness and contribute to sustained neuronal dysfunction and chronic pain. 
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2.2 Overall Hypothesis & Specific Aims 
 The objective of the work in this thesis is to use complementary in vivo and in 
vitro models to elucidate the role of BSCB breakdown and spinal thrombin activity in 
spinal neuroinflammation and chronic pain. The overall hypothesis of this thesis is that 
compressive nerve root injury disrupts the integrity of the blood-spinal cord barrier 
allowing for serum molecules, including thrombin, to extravasate into the spinal 
parenchyma and induce a host of cascades, including spinal PAR1 activation, mechanical 
modifications in activated spinal glia, and pain. Blocking BSCB breakdown with 
molecules, such as activated protein C, that stabilize the vascular integrity is 
hypothesized to prevent nerve root-induced pain; this action is mimicked by salmon 
thrombin through its unique substrate specificity profile which is distinct from 
mammalian thrombin. These hypotheses are tested through the following specific 
hypotheses and specific aims: 
 
Hypothesis 1. Painful nerve root compression induces BSCB breakdown, which 
facilitates the accumulation of serum molecules in the spinal parenchyma in regions of 
vascular breakdown. The development of nerve root-induced pain is inhibited when that 
BSCB breakdown is blocked. 
 
Aim 1: Characterize BSCB permeability and define its role in pain following different 
types of injury to the nerve root including, painful compression, non-painful 
compression, and painful inflammatory insult, separately.  
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1a. Characterize the time course of BSCB permeability by measuring spinal IgG 
immunolabeling in the bilateral dorsal horns at the same spinal level as injury at 
days 1 and 7 after separate painful compression, non-painful compression, and 
painful inflammatory insults. 
1b. Measure serum inflammatory cytokine and chemokine concentrations at time 
points corresponding to when BSCB breakdown is evident (determined in Aim 
1a) following painful and non-painful root injuries. 
1c. Block endothelial barrier disruption with APC after painful nerve root injury that 
induces BSCB leakiness (determined in Aim 1a) and measure behavioral 
sensitivity. 
 
Hypothesis 2. Thrombin acts enzymatically in the spinal parenchyma in regions that 
undergo BSCB breakdown after painful nerve root compression. Spinal thrombin 
activates PAR1 leading to nerve root-induced spinal astrocyte activation and pain. 
 
Aim 2. Define the role of thrombin-induced spinal PAR1 activation in nerve root-
mediated pain, spinal glial activation, and BSCB integrity. 
2a. Measure spinal fibrin accumulation in areas of BSCB breakdown by co-
immunolabeling for fibrin and fibrinogen, as well as IgG, in the ipsilateral dorsal 
horn at days 1 and 7 after painful and non-painful nerve root compressions, 
separately.  
2b. Inhibit enzymatic activity of spinal thrombin using hirudin administered 
intrathecally before painful nerve root injury that induces BSCB leakiness and 
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evaluate behavioral sensitivity over 7 days. Measure ipsilateral spinal IgG at day 
1 and spinal GFAP at day 7 after injury in order to investigate the effects of spinal 
thrombin on the early BSCB breakdown and sustained spinal glial activation that 
occurs after painful root compression. 
2c. Administer rat thrombin intrathecally to naïve rats, with and without the PAR1 
inhibitor SCH79797, and evaluate behavioral sensitivity for 7 days to determine 
whether spinal thrombin acts through PAR1 to induce pain. Measure spinal IgG 
and GFAP at days corresponding to maximal rat thrombin-induced behavioral 
sensitivity.  
2d. Block spinal PAR1 activation with SCH79797 before the BSCB-disrupting 
painful nerve root injury determined in Aim 1a and evaluate behavioral sensitivity 
over 7 days. Also measure the ipsilateral spinal expression of IgG at day 1 and 
GFAP at day 7, in order to determine if spinal PAR1 activation contributes to 
compression-induced early BSCB breakdown and sustained spinal astrocyte 
activation. 
2e. Quantify and compare astrocytic PAR1 expression in the ipsilateral spinal dorsal 
horn at days 1 and 7 after painful and non-painful root compression. 
 
Hypothesis 3. Salmon thrombin, which initiates cellular signaling cascades distinct from 
mammalian thrombin, exhibits different rates of activating thrombin-activated substrates. 
Salmon thrombin’s distinctive substrate affinity translates into unique effects on 
inflammation and vascular permeability, both of which contribute to its analgesic 
capabilities after painful nerve root compression.  
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Aim 3. Define differences between salmon and mammalian thrombin on nerve root-
mediated pain and BSCB breakdown in vivo, and astrocytic secretion of inflammatory 
cytokines and endothelial vessel permeability in vitro. Measure and compare the 
molecular activation rates of thrombin-activated receptors between those two species of 
thrombin. 
3a. Evaluate and compare behavioral sensitivity and ipsilateral spinal IgG expression 
at day 1 after painful nerve root compression treated immediately with salmon 
and human thrombin, in separate groups. 
3b. Measure and compare the effects of salmon and human thrombin on cytokine-
induced endothelial barrier permeability, with and without protein C, using an in 
vitro endothelial cell model. 
3c. Define how astrocytic inflammatory cytokine production is modulated in response 
to stimulation by salmon and human thrombin, using in vitro astrocytic cell 
culture preparations. 
3d. Measure and compare the cleavage rate of the thrombin enzymatic substrates, 
PAR1, PAR3, PAR4 and protein C, by salmon and human thrombin. 
 
Hypothesis 4. Painful nerve root compression activates spinal astrocytes and modifies 
their expression of intermediate filaments that have a role in cellular mechanical 
integrity. 
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Aim 4. Measure changes in astrocytic vimentin expression in the spinal dorsal horn after 
separate painful and non-painful nerve root compressions at times (days 1 and 7) when 
astrocytes are activated after root compression. 
 
Rat models of painful nerve root injuries previously developed in our lab (Chang 
and Winkelstein 2011, Rothman et al. 2010, Rothman and Winkelstein 2007) were used 
to test the hypotheses guiding each of the Aims in this thesis and were supplemented by 
complementary in vitro and in silico studies. By quantifying the temporal bilateral spinal 
expression of IgG immunolabeling after compressive and inflammatory nerve root insults 
(Aim 1a), BSCB breakdown was determined to occur transiently by day 1 and only after 
a compression injury that also induces pain. That painful longer 15-minute nerve root 
compression that induced BSCB breakdown, only exhibited increases in IgG in the 
ipsilateral spinal dorsal horn, corresponding to the exclusive development of mechanical 
hyperalgesia in the ipsilateral forepaw after this injury. Together, those findings from the 
work in Aim 1a were was used to guide the subsequent studies. Specifically, since a 15-
minute nerve root compression was the only injury to induce ipsilateral BSCB 
breakdown, and that response peaked at one day after compression, that injury was used 
in the treatment studies for Aim 1c, as well as studies in Aims 2-4. Inflammatory 
cytokines and chemokines were profiled at day 1 when BSCB breakdown is a maximum; 
serum concentrations of the inflammatory analytes were linearly fit to elevations in 
mechanical hyperalgesia following compressive and inflammatory root injuries (Aim 1b) 
because systemic inflammation influences both BSCB permeability and pain (Echeverry 
et al. 2011, Huber et al. 2001, Kraychete et al. 2010, Pedersen et al. 2015, Sharief and 
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Thompson 1992, Szelenyi 2001). Since APC stabilizes vascular integrity in various 
neuropathic models (Andreou et al. 2015, Bernard et al. 2001, Zlokovic and Griffin 
2011), it was administered intrathecally after painful nerve root compression, but prior to 
BSCB breakdown, in order to test whether the development of nerve root compression-
induced mechanical hyperalgesia depends on the breakdown of the BSCB. Ipsilateral 
spinal IgG expression was measured at day 1 when applicable throughout the rest of the 
studies in this thesis since the findings from Aim 1 highlight the importance of early 
BSCB breakdown in pain induced by nerve root compression. 
Studies in Aim 2 were designed to investigate the role of rat thrombin activity in 
the spinal cord in the development of pain and spinal astrocytic activation. The work in 
Aim 2a tested whether thrombin extravasates across the BSCB during its breakdown after 
painful root compression and then exerts enzymatic activity in the spinal parenchyma. As 
such, fibrin(ogen) was used as a proxy for thrombin activity and co-labeled with IgG in 
the ipsilateral spinal cord after painful and non-painful root compressions. Results from 
the studies in Aim 2a suggested that spinal fibrin(ogen) is present only after a 15-minute 
compression and localizes with spinal regions that also undergo BSCB breakdown. 
Therefore, the specific thrombin inhibitor, hirudin, used in Aim 2b was administered 
intrathecally (Narita et al. 2005) prior to a painful 15-minute nerve root compression in 
order to test whether spinal thrombin activity contributes to pain onset. To further define 
the role of spinal thrombin in pain, rat thrombin was intrathecally administered to naïve 
rats to test whether thrombin in the CNS alone is potent enough to induce mechanical 
hyperalgesia (Aim 2c). In order to determine whether thrombin acts through PAR1 in the 
spinal cord to induce glial activation and pain, the PAR1 antagonist, SCH79797, was 
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delivered prior to intrathecal administration of rat thrombin (Aim 2c) or a painful nerve 
root compression (Aim 2d); mechanical hyperalgesia was monitored for up to 7 days. 
Studies in Aim 2e measured the temporal expression of astrocytic GFAP and PAR1 using 
the nerve root injury groups outlined in Aim 1a (painful compression, non-painful 
compression, inflammatory insult) in order to define whether those common indicators of 
glial activation are specific to pain or are a result of the type of nerve root insult. 
 Studies have identified key biological differences between mammalian and salmon 
thrombin (Michaud et al. 2002, Uibo et al. 2009, Weisshaar et al. 2011). The effects of 
salmon thrombin on nerve root-mediated BSCB breakdown and pain were measured and 
compared to those induced by human thrombin (Aim 3a) in order to further define the 
physiological differences of this enzyme between the two species. Since endothelial cells, 
and the tight junctions binding them together, control vascular and BBB permeability, 
studies in Aim 3b investigated whether salmon and human thrombin differentially 
regulate inflammation-induced endothelial permeability using an in vitro microchannel 
setup. Sustained glial activation has been shown to be associated with persistent pain 
after nerve root compression injury (Nicholson et al. 2014, Rothman et al. 2010, 
Rothman and Winkelstein 2007). Therefore, Aim 3c measured levels of cytokine 
transcription produced by astrocyte cultures in response to stimulation by both species of 
thrombin. Since multiple thrombin receptors control the cellular effects elicited by 
thrombin, the activation rates of PAR1, PAR3, PAR4 and protein C induced by both 
species of thrombin were measured (in Aim 3d) and supporting in silico studies 
comparing the protein structures of the two species of thrombin were performed to 
provide structural support for differences in substrate affinity.  
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 The relationship between glial cell mechanics and nerve root-mediated pain was 
investigated in studies under Aim 4. The intermediate filament vimentin is expressed in a 
variety of cell types, including astrocytes and endothelial cells, and levels in its 
expression within the cytoskeleton partially controls its mechanics and stiffness (Buehler 
2013, Guo et al. 2013, Wang and Stamenovic 2002). Vimentin is also upregulated by 
astrocytes upon their activation, in parallel with GFAP, highlighting the influence of 
astrocytic vimentin expression not only as a possible indicator of changes in cellular 
mechanics, but a marker for their activation. Therefore, studies in Aim 4 measured the 
spinal expression of astrocytic and endothelial vimentin at days 1 and 7 following painful 
and non-painful nerve root compressions in order to investigate whether painful root 
compression modulates the cellular mechanics of contractile cells within the CNS.  
 In summary, the studies presented in this thesis define how nerve root compression-
induced modifications in spinal vasculature contribute to persistent spinal 
neuroinflammation and pain after injury. Studies outlined in the above Aims are 
presented in separate chapters. Chapter 3 summarizes the in vivo findings that temporally 
characterize nerve root injury-induced BSCB breakdown, systemic inflammation and 
pain and establish that their modifications depend on the type of painful mechanical 
insult. That work highlights the strong influence of increased BSCB permeability on pain 
development using a pharmacologic strengthener of endothelial junctions. Studies 
outlined in Aim 2 manipulate the spinal thrombin/PAR1 signaling pathway by 
administering a variety of biologic and small molecule agents in our models of painful 
nerve root compression; those findings define how spinal thrombin contributes to nerve 
root compression-induced spinal glial activation and pain and are presented in Chapter 4. 
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Studies from Aim 3 are summarized in Chapter 5 and determine that, unlike human 
thrombin, an analgesic dose of salmon thrombin prevents injury- and inflammation-
induced vascular breakdown and does not initiate astrocytic inflammation. Studies in 
Chapter 5 further define that those contrasting cellular outcomes induced by salmon and 
human thrombin depend on their distinct substrate specificity profiles. These findings 
promote the use of salmon thrombin as an effective biologic to treat neuropathic injuries, 
as well as other BBB-disruptive disorders. The studies under Aim 4 measure painful root 
compression-induced modifications of spinal vimentin expressed by astrocytes and 
endothelial cells in order to relate changes in spinal glial cell stiffness to pain after nerve 
root injury. Those findings are presented in Chapter 6. Lastly, Chapter 7 integrates across 
the studies in this thesis, the existing literature on spinal thrombin and pain, and the 
broader implications of those findings in relation to the development of novel biologics to 
prevent chronic pain. 
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Chapter 3 
Defining Relationships between Painful 
Compressive & Inflammatory Nerve Root Insults, 
BSCB Breakdown & Serum Cytokine Expression 
 
Part of this chapter has been adapted from a submitted manuscript: 
 
Smith JR, Galie PA, Slochower DR, Weisshaar CL, Janmey PA, Winkelstein BA. 
Salmon-derived thrombin inhibits development of chronic pain through an endothelial 
barrier protective mechanism dependent on APC. Biomaterials, accepted. 
 
3.1. Overview 
Cervical radiculopathy is a neuropathic condition that induces long-term pain that 
radiates from an injured or irritated cervical nerve root to the shoulders and arms (Abbed 
and Coumans 2007, Wall and Melzack 1994). Cervical disc herniation is a common 
cause of radicular pain in the cervical spine and often involves both compressive and 
inflammatory insults to the cervical nerve roots; a bulging disc can physically impinge on 
the nerve root and also release materials from its nucleus pulposus, which is 
inflammatory to the root (Abbed and Coumans 2007, Caridi et al. 2011, Wall and 
Melzack 1994). Rat models imposing compressive or inflammatory nerve root insults 
separately have established that while both components of injury can individually induce 
sustained mechanical behavioral sensitivity, these stimuli differentially modulate 
pathological responses at the site of injury and within the spinal cord (Chang and 
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Winkelstein 2011, Colburn et al. 1999, Hashizume et al. 2000, Hou et al. 2003, 
Kawakami et al. 1994, Kawakami et al. 1994, Rothman and Winkelstein 2007). For 
example, a transient C7 nerve root compression for 15 minutes in the rat upregulates the 
transcription of interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) in the 
spinal cord at 1 hour after compression and activates spinal glia for at least 7 days 
(Hubbard and Winkelstein 2005, Rothman et al. 2009, Rothman et al. 2010, Winkelstein 
and DeLeo 2002). An inflammatory insult imposed by chromic gut suture does not 
induce the same early spinal transcription of IL-1β and TNF-α nor does it lead to the 
persistent glial activation that is induced after a root compression (Rothman et al. 2009, 
Rothman and Winkelstein 2007, Rothman and Winkelstein 2010). This same nerve root 
compression disrupts axonal myelination and promotes phagocytotic macrophage 
infiltration at the injured root by two weeks after injury, while an inflammatory insult 
only induces macrophage infiltration and to a much less degree than compression (Chang 
and Winkelstein 2011). Since both compressive and inflammatory insults to the nerve 
root produce indistinguishable mechanical hypersensitivity in the ipsilateral forepaw for 
up to 2 weeks (Chang and Winkelstein 2011, Rothman and Winkelstein 2007), but a 
compressive insult induces more robust spinal and nerve root pathologies (Chang and 
Winkelstein 2011, Rothman and Winkelstein 2007), it is hypothesized that different 
cellular cascades are induced by compressive and inflammatory stimuli to produce and 
maintain the associated pain responses.  
The blood-brain barrier (BBB) and blood-spinal cord barrier (BSCB) are 
comprised of endothelial cells and act as physical obstacles between the circulatory 
system and the central nervous (CNS) to inhibit the entrance of blood-borne pro-
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inflammatory molecules and cells under healthy conditions (Abbott et al. 2010, Ballabh 
et al. 2004). Despite being remote from the CNS, chronic nerve ligation injury, which 
induces sustained pain, disrupts the BSCB for up to 30 days in spinal regions where the 
injured afferents synapse in both rats and mice (Beggs et al. 2010, Echeverry et al. 2011, 
Gordh et al. 2006). This increased BSCB permeability facilitates the transmission 
radioiodine-labeled IL-1β and green fluorescent protein positive (GFP+) bone marrow-
derived monocytes into the spinal cord (Echeverry et al. 2011); both the presence of pro-
inflammatory cytokines and peripheral immune cells centrally can exacerbate 
neuroinflammation. Different types of neural injuries can increase spinal microglial 
activation through either resident spinal microglial division or through facilitated 
infiltration of peripheral monocytes that express markers of microglia activation once 
they are in the spinal cord (DeLeo et al. 2004, Rothman et al. 2009, Rutkowski et al. 
2002, Stollg and Jander 1999, Sweitzer et al. 2002). A compressive, but not an 
inflammatory, insult to the nerve root increases microglia populations in the spinal cord 
both early (day 1) and at later times (day 7) after injury (Rothman and Winkelstein 2007). 
It is possible that the lack of spinal microglial activation induced by an inflammatory root 
insult might be due to its lack of induction of BSCB breakdown preventing peripheral 
immune cell transmigration into the spinal cord. Studies in this chapter evaluate whether 
compressive or inflammatory insults to the nerve root induce different extents of BSCB 
breakdown and whether such barrier breakdown directly mediates pain.  
Systemic concentrations of pro- and anti-inflammatory cytokines and chemokines 
are upregulated in a variety of neuropathic and autoimmune disorders and influence the 
permeability of the BSCB and BBB (Choi et al. 2008, Kraychete et al. 2010, Pan and 
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Kastin 2007, Pedersen et al. 2015, Sharief and Thompson 1992). Intravenous pro-
inflammatory IL-1β, TNF-α or monocyte chemotactic protein-1 (MCP-1), independently, 
increase BSCB permeability in normal naïve rats, which also has been shown to permit 
the extravasation of serum proteins into the spinal parenchyma where the BSCB is 
compromised (Echeverry et al. 2011, Pan and Kastin 2007, Sharief and Thompson 1992). 
In contrast, anti-inflammatory transforming growth factor-beta (TGF-β) and IL-10 rescue 
the BSCB breakdown that is induced after painful sciatic nerve ligation (Echeverry et al. 
2011); this increased BSCB integrity is also achieved by anti-MCP-1 given intrathecally 
over 3 days after ligation (Echeverry et al. 2011). Increased serum levels of some of these 
BBB-disrupting cytokines are also increased in patients with painful disc herniation 
(Kraychete et al. 2010, Pedersen et al. 2015); in particular, serum concentrations of IL-6, 
IL-8 and TNF-α are elevated in those patients experiencing more intense chronic pain 
compared to those with “mild” or no pain (Kraychete et al. 2010, Pedersen et al. 2015). 
Despite a strong implication of peripheral inflammation in both BSCB breakdown and 
pain, the relationship between systemic inflammation at times of increased BSCB 
permeability after compressive and/or inflammatory nerve root insults and pain has not 
yet been studied.  
This chapter summarizes a multi-part study that tests two separate hypotheses. 
The first two studies (Section 3.3 & Section 3.4) summarize a subset of the experiments 
under Aim 1 and test the hypothesis that painful nerve root injury induces BSCB 
breakdown and systemic inflammation facilitating the accumulation of serum molecules 
in the spinal parenchyma where the BSCB is compromised (Aim 1a). To test this 
hypothesis, a nerve root compression model in the rat was used characterize the extent of 
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BSCB breakdown over time after painful and non-painful nerve root compressions 
separately (Section 3.3). The comparative effects of compressive and inflammatory nerve 
root insults on BSCB breakdown and pain were also investigated (Section 3.4). BSCB 
breakdown was measured in the bilateral spinal cord by immunolabeling for the serum 
protein, immunoglobulin G (IgG), which is not typically present in the CNS (Echeverry 
et al. 2011, Poduslo et al. 1994), at times early and later after the neural insults (Aim 1a). 
To define the relationship between expression of inflammatory serum molecules and pain 
at times of BSCB breakdown, the concentration of 23 pro- and anti-inflammatory serum 
cytokines and chemokines was correlated to pain severity after a compressive injury 
(Section 3.3) or an inflammatory insult (Section 3.4) to the nerve root (Aim 1b). Of the 
cytokines found to correlate to pain intensity after a nerve root compression, TNF-α 
expression was immunolabeled in the spinal dorsal horn at the time point when BSCB 
reaches a maximum after painful and non-painful compression injuries.  
The last set of studies in this chapter (Section 3.5) investigates the role of BSCB 
breakdown in pain development after a nerve root compression and was designed to test 
the hypothesis that blocking BSCB breakdown can inhibit the development of nerve root 
compression-induced pain. Activated protein C (APC), a serum protease that strengthens 
endothelial tight junctions and effectively reduces vascular leakiness in studies of sepsis 
and ischemic stroke (Bernard et al. 2001, Petraglia et al. 2010, Zlokovic and Griffin 
2011), was administered intravenously at 1 hour after a painful nerve root injury that 
induces BSCB breakdown. The inhibition of BSCB breakdown by APC was confirmed 
by labeling spinal IgG at day 1; behavioral hypersensitivity also was measured at that 
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time to determine if BSCB breakdown contributes to the development of nerve root-
induced pain (Aim 1c).  
 
3.2. Relevant Background 
BBB disruption is characteristic of many neurological disorders, including 
ischemic stroke, Parkinson’s disease and amyotrophic lateral sclerosis (ALS), and 
contributes to the associated neuroinflammation and neurodegeneration within the central 
nervous system (Sandoval and Witt 2008, Winkler et al. 2014, Zlokovic 2011). The 
neurovasculature of the BBB is comprised of endothelial cells that are trophically 
coupled to nearby neurons via glial cells, which together, make up the ‘neurovascular 
unit’ and interact closely to maintain inflammatory dysfunction in disease states (Abbott 
et al. 2010, Abbott et al. 2006, Hawkins and Davis 2005). The healthy BBB endothelium 
is bound together by tight junctions, which inhibit the transmission of serum components 
and blood-borne cells into the CNS (Abbott et al. 2010, Ballabh et al. 2004). Disruption 
of the BBB permits entrance of neurotoxic factors into the CNS that impair normal 
neuronal function and exacerbate inflammation (Webb and Muir 2000, Zlokovic 2008). 
Peripheral nerve injuries themselves have also been shown to increase the permeability of 
the BSCB at the same spinal level as the injury where the injured afferents synapse 
(Beggs et al. 2010, Echeverry et al. 2011, Radu et al. 2013). Nerve injuries also induce 
chronic neuropathic pain which is, at least partially, maintained by spinal 
neuroinflammation (Echeverry et al. 2011, Rothman and Winkelstein 2007, Watkins et 
al. 2001). However, it is unclear whether BSCB disruption itself contributes to pain. 
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Further, if BSCB breakdown is related to development of chronic pain, therapeutics 
targeting and preventing vascular permeability would be ideal candidates for pain 
prevention after neuropathic injury. 
Systemic inflammation contributes to spinal neuroinflammation both indirectly 
and directly. Pro-inflammatory molecules indirectly influence spinal homeostasis by 
stimulating peripheral neuronal receptors (Szelenyi 2001). These primary afferents 
synapse centrally in the spinal dorsal horn and become hyperexcitable due to constant 
peripheral activation (Szelenyi 2001). Circulating pro-inflammatory cytokines, such as 
TNF-α and IL-1β, also activate endothelial cells leading to increased vascular 
permeability, which promotes their own entrance into the CNS via a compromised BBB 
(Echeverry et al. 2011, Hoffmann et al. 2004, Huber et al. 2001, Pan and Kastin 2007, 
Sharief and Thompson 1992). Once in the CNS, pro-inflammatory cytokines and 
chemokines can directly interact with and stimulate neurons and glia, which further 
accentuate nociceptive pathways by increasing synaptic concentration of excitatory 
neurotransmitters and cytokines (DeLeo and Yezierski 2001, Milligan and Watkins 
2009). Of note, independently blocking the actions of either spinal TNF-α or IL-1β 
attenuates pain after compressive nerve root injury (Rothman et al. 2009), highlighting 
the strong influence of these pro-inflammatory cytokines in pain signaling. Systemic and 
central inflammation play important roles in pain and are integrated through BBB 
permeability (Ballabh et al. 2004, Hawkins and Davis 2005, Huber et al. 2001, Sharief 
and Thompson 1992, Szelenyi 2001, Webb and Muir 2000). Yet, it is not known whether 
there is a relationship between nerve root-induced pain and systemic levels of 
inflammatory cytokines or chemokines at times of BSCB breakdown. 
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Vascular permeability, including that of the BBB and BSCB, is controlled 
through various endothelial pathways. The serine protease, thrombin, most notably 
recognized for its role in coagulation, also regulates a variety of endothelial processes 
including permeability via its enzymatic activation of cell-bound receptors (Coughlin 
2000, Di Cera 2008). Thrombin initiates distinct cellular signaling cascades depending on 
the cofactor it binds, and therefore the substrate it activates (Coughlin 2000, Di Cera 
2008, Jacques et al. 2000, Komarova et al. 2007, Riewald and Ruf 2005, Xu et al. 2005). 
In its unbound state, mammalian thrombin increases vascular permeability by directly 
cleaving protease-activated receptor-1 (PAR1) on the endothelial surface (Gandhi et al. 
2011, Jacques et al. 2000, Komarova et al. 2007). In contrast, when bound to 
thrombomodulin, thrombin activates endothelial-bound protein C into APC, which 
stabilizes vascular integrity (Esmon 1993, Fuentes-Prior et al. 2000, Komarova et al. 
2007, Xu et al. 2005). Both clinical trials and animal studies have tested APC for its 
enhancement of endothelial barriers in sepsis and ischemic stroke (Zlokovic and Griffin 
2011); but, its strong anticoagulant effects hamper its clinical safety (Bernard et al. 2001, 
Finfer et al. 2008, Marti-Carvajal et al. 2012). For this reason, a major effort in thrombin 
mutagenesis and protein engineering has identified peptide domains in thrombin’s 
structure that control protein C activation which they can manipulate in order to increase 
thrombin’s innate affinity for protein C instead of PAR1 (Dang et al. 1997, Gibbs et al. 
1995, Marino et al. 2010). Although APC is not a clinically relevant treatment option for 
neural trauma, administering APC after painful nerve root injury to fortify the BSCB 
enables testing the dependence of nerve root-induced pain on BSCB disruption. 
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This three-part study was used to test the hypotheses that a painful nerve root 
compression induces BSCB breakdown, which facilitates the accumulation of serum 
molecules in the spinal parenchyma in regions of breakdown and that the formation of 
nerve root-induced pain is inhibited when BSCB breakdown is blocked. Section 3.3 
details the methods and results of a characterization study measuring BSCB breakdown 
after painful and non-painful nerve root compression by immunolabeling IgG, a serum 
protein that is not expressed in the CNS under normal conditions (Poduslo et al. 1994). In 
that study, behavioral responses were induced using two previously defined durations of 
nerve root compression: 15-minutes to induce sustained pain and 3-minutes to serve as a 
loading control in which the nerve root undergoes injury, but pain does not develop 
(Nicholson et al. 2012, Rothman et al. 2010). Forepaw mechanical hyperalgesia and 
spinal IgG were assessed on days 1 and 7 as time points corresponding to the 
development and maintenance of pain, respectively. Expression of serum cytokines and 
chemokines were assayed at the time point (day 1) corresponding to BSCB breakdown 
using a multiplex assay in order to characterize systemic inflammation and its 
relationship to pain.  
The second part of this chapter investigates the influence of the type of pain-
inducing nerve root insult (i.e. compressive versus inflammatory) on BSCB breakdown 
and behavioral hypersensitivity (Section 3.4). A painful inflammatory insult was imposed 
using a rat model of chromic gut suture application to the nerve root (Chang and 
Winkelstein 2011, Rothman et al. 2011). Following the same procedures as from the 
characterization study (Section 3.3), ipsilateral forepaw mechanical hyperalgesia and 
spinal IgG expression were assessed on days 1 and 7 after an inflammatory root insult to 
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investigate the comparative effects of compressive and inflammatory nerve root insults 
on BSCB breakdown (Section 3.4).  
The third part of the study defined the role of BSCB breakdown in the 
development of pain by blocking BSCB after painful root compression injury (Section 
3.5). APC was administered after painful nerve root compression to block BSCB 
breakdown, based on its clinical and pre-clinical effectiveness at reducing vascular 
disruption (Bernard et al. 2001, Marti-Carvajal et al. 2012). Spinal IgG levels were 
measured at day 1 after injury with treatment to confirm its effectiveness and then 
behavioral responses were measured at this early time point. The goal of the studies in 
this chapter was to identify if BSCB breakdown is induced, and if so, to what 
spatiotemporal extent within the spinal cord, after both compressive and inflammatory 
nerve root insults. Further, the influence of nerve-root induced BSCB breakdown on pain 
development and/or maintenance was investigated. The relationship between serum 
inflammatory markers and pain severity was also defined at times of increased BSCB 
permeability.  
 
3.3. Characterization of BSCB Breakdown after Nerve Root 
Compression 
3.3.1. Methods 
3.3.1.1. Surgical Procedures for Nerve Root Compression 
For all animal studies, male Holtzman rats (Harlan Sprague-Dawley; Indianapolis, 
IN) were housed under conditions approved by the United State Department of 
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Agriculture (USDA) and the Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC) with free access to water and food. All experimental 
procedures were approved by the University of Pennsylvania Institutional Animal Care 
and Use Committee (IACUC) and carried out under the guidelines of the Committee for 
Research and Ethical Issues of the International Association for the Study of Pain (IASP) 
(Zimmermann 1983).  
Surgical procedures were performed under inhalation isoflurane anesthesia (4% 
for induction, 3% for maintenance). Previously defined protocols were used for nerve 
root compression injury (Rothman et al. 2010). Briefly, rats were placed in a prone 
position; a midline incision was made along the back of the neck and the paraspinal 
muscles were removed to expose the C6 and C7 vertebrae. A C6/C7 hemilaminectomy 
and facetectomy was performed on the right side to expose the right C7 dorsal nerve root. 
A small incision was made in the dura over the C7 nerve root and a 10gf microvascular 
clip was applied to the exposed root (Figure 3.1).  
 
 
 
Figure 3.1. Nerve root compression injury. Cross-section schematic (A) and dorsal image (B) of 
nerve root compression applied unilaterally to the right C7 dorsal nerve root in the rat. A microvascular 
clip (10g force) is applied transiently to the root, between the DRG and spinal cord, for 3 or 15 minutes. 
Shaded boxes indicate the dorsal horns where the compressed axons synapse. 
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Compression was applied to the C7 dorsal nerve root via the clip for 3 minutes 
(3min, n=12) or 15 minutes (15min, n=10) after which the wound was closed using 3-0 
polyester suture and surgical staples. Rats were allowed to recover in room air with 
continual free access to food and water. Sham operated rats (sham, n=9) underwent 
identical surgical procedures except they did not undergo nerve root compression. Spinal 
cord tissue from rats was harvested on day 1 (15min, n=5; 3min, n=7; sham n=5) or day 7 
(15min, n=5; 3min, n=5; sham n=4) in order to measure temporal responses of BSCB 
permeability.  
Spinal cord tissue was harvested from rats either on day 1 or day 7 after surgery. 
Rats received an overdose of sodium pentobarbital (65mg/kg), administered 
intraperitoneally. Once unconscious, rats were transcardially perfused with 1% 
phosphate-buffered saline (PBS; Mediatech, Inc.; Manassas, VA) until blood ran clear 
and were subsequently perfused by 300ml of 4% paraformaldehyde (Sigma; St. Louis, 
MO). The C7 bilateral spinal cord was exposed via a bilateral C5-T1 laminectomy and 
facetectomy and harvested en bloc. Spinal tissue was post-fixed overnight in 4% 
paraformaldehyde, transferred to 30% sucrose for one week at 4°C and then embedded in 
optical cutting temperature (OCT) compound (Sakura Finetek USA, Inc.; Torrance, CA) 
for cryosectioning. Fixed spinal cord tissue was sectioned at 14µm along the long-axis of 
the spinal cord to create cross-sections that were mounted directly onto slides for 
immunolabeling. Spinal cord tissue at C7 also was harvested from naïve rats (n=2) and 
included in tissue processing for comparison of expression of IgG in tissue from rats that 
underwent root compression. 
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3.3.1.2. Assessment of Mechanical Hyperalgesia 
In this study, mechanical hyperalgesia was measured as the response threshold, in 
grams, of the forepaw to a mechanical stimulus. Mechanical thresholds were measured in 
the bilateral forepaws for 7 days post-surgery. Prior to each testing round, rats were 
acclimated for 15 minutes to the testing apparatus, which consisted of an elevated mesh-
floored cage with walls providing a separate testing chamber for each rat. A series of 
calibrated von Frey filaments (1.4g-26g) (Stoelting; Wood Dale, IL) was applied in 
ascending order to the plantar surface of the forepaw until a filament induced a positive 
response (Chang and Winkelstein 2011, Chaplan et al. 1994, Lee and Winkelstein 2009). 
A positive response was defined as a withdrawal of the stimulated forepaw and was often 
accompanied with a shaking or licking of the paw. Each filament was applied for five 
consecutive stimulations and the filament strength that elicited a positive response was 
recorded as the withdrawal threshold if the next consecutive filament also elicited a 
positive response. If no response was evoked by a filament, then the highest magnitude 
filament (26g) was recorded as the threshold. Each series of stimulations was repeated 
three times for each testing round with at least 10 minutes between series; the withdrawal 
threshold of each forepaw was taken as the average of the three series.  
Mechanical hyperalgesia in the bilateral forepaws was assessed prior to surgery 
on day 0 (baseline) and every other day for 7 days (day 1, 3, 5 and 7) after surgery. 
Behaviors from rats that were terminated on day 7 were compared over time between a 
15-minute compression (15min, n=5), a 3-minute compression (3min, n=5) and sham 
(n=4). The mechanical threshold of each paw was normalized by the corresponding 
baseline (day 0) thresholds for each rat on each testing day. Differences between groups 
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over time in forepaw mechanical hyperalgesia were determined separately for the 
ipsilateral and contralateral forepaws using two-way repeated measures ANOVAs (group 
x day) with Tukey’s Honestly Significant Difference (HSD) test. 
 
3.3.1.3. Spinal Immunohistochemistry of IgG Expression 
Spinal cord sections at C7 were fluorescently immunolabeled for rat IgG as a 
proxy for BSCB breakdown since this serum-derived protein is not present in the CNS 
under normal conditions (Poduslo et al. 1994). Briefly, slide-mounted tissue sections 
were blocked in 5% normal goat serum (Vector Laboratories; Burlingame, CA) with 
0.3% Triton-X100 (Bio-Rad Laboratories; Hercules, CA) for 1 hour at room temperature. 
Slides were then incubated with goat anti-rat IgG Alexa Fluor 568 (1:200; Life 
Technologies; Carlsbad, CA) for two hours at room temperature and then washed with 
PBS and cover slipped with fluoro-gel with TRIS buffer (Electron Microscopy Sciences; 
Hatfield, PA). The ipsilateral and contralateral spinal dorsal horns were digitally imaged 
at 10x in 2-6 spinal sections for each rat.  
Spinal IgG labeling was quantified in uniformly cropped images of the dorsal 
horn using a custom densitometry MATLAB script (Nicholson et al. 2012, Rothman et al. 
2010, Rothman and Winkelstein 2007). The densitometry script quantified the percent of 
the total tissue pixels that were above a pre-defined threshold; that threshold was chosen 
using normal naïve spinal tissue to include pixels that represented positive IgG labeling 
and was kept constant to analyze all images (Nicholson et al. 2012, Rothman et al. 2010, 
Rothman and Winkelstein 2007). Levels of spinal IgG were then normalized to labeling 
in the same region from naïve rats and the percent positive IgG in injury groups was 
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represented as expression relative to normal levels. Differences in normalized percent 
positive IgG between 15-minute compression, 3-minute compression and sham were 
tested on day 1 (15min, n=5; 3min, n=7; sham n=5) and day 7 (15min, n=5; 3min, n=5; 
sham n=4), using two-way repeated measures ANOVA (group x day) with Tukey’s test.  
 
3.3.1.4. Serum Collection & Cytokine Multiplex Assay  
Rats were anesthetized with 4% isoflurane anesthesia by inhalation for blood 
collection procedures. Blood samples were taken from a subset of rats undergoing either 
a 15-minute (n=6), 3-minute (n=4) or 0-minute (sham, n=3) nerve root compression. 
Blood was collected (~0.5ml) via a 25G needle syringe from the tail vein on day 0 
(baseline) before, and on day 1, after surgery. Whole blood was allowed to clot at room 
temperature and serum was separated using consecutive spins at 4°C, the first at 1000rcf 
for 15 minutes and the second at 10,000rcf for 10 minutes. Serum samples were assayed 
in duplicate for a panel of 23 pro- and anti-inflammatory cytokines and chemokines using 
a multiplex bead-based Luminex assay kit (#L80-01V11S5; Bio-Rad; Hercules, CA). The 
analytes measured within this pre-made kit are: IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, 
IL-10, IL-12, IL-13, IL-17, IL-18, MCP-1, TNF-α, erythropoietin (EPO), granulocyte 
colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor 
(GM-CSF), keratinocyte-derived chemokines/growth-related oncogene (GRO/KC), 
interferon-gamma (IFN-γ), macrophage colony-stimulating factor (M-CSF), macrophage 
inflammatory protein-3 alpha (MIP-3α), regulated on activation, normal T cell expressed 
and secreted (RANTES) and vascular endothelial growth factor (VEGF). For each rat, the 
serum concentration of each analyte on day 1 was normalized to baseline levels and 
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correlated to the normalized paw withdrawal threshold at day 1. Each pair of bivariate 
data – the normalized withdrawal threshold and the normalized cytokine concentration – 
was fit with a linear regression and analyzed to identify those cytokines that strongly 
(R2>0.5) and significantly (p<0.05) correlate to paw withdrawal threshold (Cohen 1988). 
 
3.3.1.5. Spinal Immunohistochemistry for TNF-α 
TNF-α was chosen from the four cytokines that were found to strongly correlate 
to forepaw withdrawal thresholds (IL-7, IL-12, IL-1α, TNF-α) and was co-
immunolabeled with IgG in the ipsilateral spinal cord. The IgG protocol described in 
Section 3.3.1.3 was adapted to include TNF-α in order to visually assess whether its 
spinal expression co-localizes to spinal regions where there is also BSCB breakdown. 
Tissue sections harvested from two rats in each of the compressive insult and 
corresponding control groups (15-minute compression, 3-minute compression, sham) at 
day 1 were blocked in 5% goat serum in 0.3% TX-100 and incubated over night with 
rabbit anti-TNF-α (1:200; Cell Signaling; Danvers, MA). Those slides were then 
fluorescently labeled with goat anti-rabbit Alexa Fluor 488 (1:1000; Invitrogen; Carlsbad, 
CA) and goat anti-rat IgG Alexa Fluor 568 (1:200; Invitrogen; Carlsbad, CA). The 
ipsilateral dorsal horn was digitally imaged at 10x and visually inspected for the presence 
of TNF-α and its co-localization with IgG. 
 
3.3.2. Results 
A 15-minute nerve root compression induces a significant decrease (p=0.0002) in 
the withdrawal threshold in the ipsilateral forepaw, corresponding to an increase in pain, 
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compared to sham procedures at all 7 days after injury (Figure 3.2A). That decrease in 
the withdrawal threshold in the ipsilateral forepaw after a 15-minute compression is also 
significant (p=0.0002) when compared to the threshold generated after a 3-minute 
compression, which is not different from sham responses (Figure 3.2A). The withdrawal 
thresholds in the contralateral forepaw are not different between any of the groups over 
time or compared to the respective baseline (day 0) withdrawal thresholds (Figure 3.2A). 
The individual paw withdrawal threshold data for each rat in each group are provided in 
Appendix A. 
Robust spinal IgG labeling is evident on day 1 after the painful 15-minute 
compression in the ipsilateral, but not contralateral, spinal dorsal horn (Figure 3.2B). IgG 
expression is also minimal, or not present, in the bilateral spinal cord at this time point for 
either of the non-painful 3-minute root compression or the sham surgery (Figure 3.2B). 
Quantification of spinal IgG reveals that a 15-minute nerve root compression induces a 
significant increase in IgG labeling compared to the labeling after both of a 3-minute 
compression (p<0.0001) and sham (p<0.0001) at day 1 (Figure 3.2C). The elevation in 
spinal IgG induced by a 15-minute compression returns to sham levels by day 7, when 
IgG labeling is also significantly lower (p<0.0001) than levels at day 1 (Figure 3.2C). 
This early and transient increase in IgG occurs only after painful neural injury. A detailed 
summary of the quantification of IgG expression in the bilateral spinal cord for each rat 
in this study is provided in Appendix B. 
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At the same time when BSCB breakdown peaks (day 1) after the painful 15-
minute nerve root compression, the withdrawal threshold of the ipsilateral forepaw 
positively correlates to the serum concentration of four cytokines: IL-7 (R2=0.617; 
p=0.0015), IL-12 (R2=0.572; p=0.0028), IL-1α (R2=0.558; p=0.0033) and TNF-α 
(R2=0.523; p=0.0052) (Table 3.1; Figure 3.2D). All of these are pro-inflammatory 
Figure 3.2. Peripheral neural injury causes early BSCB breakdown and spinal TNF-α expression 
corresponding to pain onset. (A) A dorsal root compression for 15 minutes (15min) significantly 
decreases the ipsilateral forepaw withdrawal threshold over 7 days compared to both a 3-minute (3min, 
*p=0.0002) and 0-minute (sham, **p=0.0002) compression. Contralateral thresholds are not different 
between groups or from baseline. Data are shown as mean±SD. (B) Representative images show 
intense IgG labeling only in the ipsilateral dorsal horn on day 1 in 15min. Minimal bilateral IgG 
labeling is evident on day 1 for 3min and sham. (C) The percent spinal IgG labeling significantly 
increases (***p<0.0001) at day 1 after 15min compared to 3min and sham. By day 7, ipsilateral IgG 
significantly decreases (^p<0.0001) from levels at day 1. Data are mean±SD. (D) On day 1, the paw 
withdrawal thresholds normalized to baseline values positively correlates to the serum concentration of 
four pro-inflammatory cytokines: IL-7, IL-12, IL-1α and TNF-α. Ipsilateral spinal TNF-α 
immunoreactivity also increases in areas of BSCB breakdown on day 1 only for the 15min group. 
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mediators and have a coefficient of determination greater than 0.5 (Table 3.1). A 15-
minute compression increases TNF-α immunolabeling in the ipsilateral spinal cord at day 
1 in regions that are also positively labeled for IgG (Figure 3.2D). Spinal TNF-α is not 
evident after either the 3-minute compression injury or the sham procedure (Figure 3.2D), 
both of which do not induce BSCB breakdown or mechanical hyperalgesia at this time 
either (Figure 3.2). The co-localization of TNF-α with IgG suggests that increased serum 
concentrations of TNF-α may diffuse into the spinal cord from the circulation during 
BSCB breakdown. Cytokine and chemokine expression in the serum for all groups is 
outlined in Appendix C. 
Table 3.1. Serum levels of pro- and anti-inflammatory cytokines and chemokines (x) and equations 
describing their correlation to ipsilateral forepaw withdrawal threshold (y) on day 1 after root compression. 
cytokine correlation R2 p-value 
pro-inflammatory 
IL-7 y=0.74x+0.77  0.617 0.0015 
IL-12 y=0.73x+1.78  0.572 0.0028 
IL-1α  y=0.57x+1.07  0.558 0.0033 
TNF-α y=0.72x+1.18  0.523 0.0052 
VEGF y=0.43x+1.04  0.485 0.0082 
IL-17 y=0.43x+0.98  0.479 0.0087 
G-CSF y=0.66x+1.14  0.456 0.0113 
IL-1β y=0.72x+1.04  0.446 0.0126 
MIP-3α y=0.37x+1.03  0.422 0.0162 
IFN-γ y=0.56x+1.09  0.376 0.0258 
IL-2 y=0.41x+1.02  0.345 0.0348 
IL-18 y=0.58x+1.01  0.283 0.0613 
MCP-1 y=0.21x+1.01  0.182 0.1459 
GM-CSF y=0.89x+1.25  0.173 0.1574 
GRO/KC y=0.71x+1.13  0.163 0.1707 
RANTES y=0.12x+0.98  0.042 0.5031 
anti-inflammatory 
IL-13 y=0.68x+1.04  0.496 0.0072 
IL-10 y=0.42x+0.94  0.439 0.0137 
IL-5 y=0.27x+0.99  0.415 0.0175 
IL-4 y=0.50x+1.02  0.383 0.0241 
EPO y=0.56x+1.00  0.344 0.0352 
pro- and anti-inflammatory 
IL-6 y=0.56x+1.09  0.356 0.0315 
M-CSF y=0.21x+1.01  0.321 0.0434 
Note: Shaded cells indicate R2 greater than 0.5. Bolded values represent coefficients of variation 
greater than 0.5 and p-values <0.05. 
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3.4. Comparative Effects of Painful Compressive & Inflammatory 
Nerve Root Insults on BSCB Breakdown 
3.4.1. Methods 
3.4.1.1. Surgical Procedures for Inflammatory Insult 
In order to examine whether BSCB breakdown is altered after an inflammatory 
insult, a separate group of rats underwent a painful inflammatory insult to the nerve root 
(chromic, n=11) using previously developed and characterized procedures (Chang and 
Winkelstein 2011, Rothman and Winkelstein 2007). Identical surgical procedures were 
followed as those described in Section 3.3.1.1 to expose the right C7 dorsal nerve root in 
the rat. Following root exposure, four 1mm pieces of 3-0 chromic gut suture (Surgical 
Specialties; Reading, PA) were placed directly on top the nerve root. Chromic gut suture 
pieces were kept in contact with the root and the wound was closed using 3-0 polyester 
suture and surgical staples. On day 1 (n=7) or day 7 (n=4) after surgery, fixed C7 spinal 
cord tissue was harvested and processed for immunolabeling as described in Sections 
3.3.1.1 and 3.3.1.3.   
 
3.4.1.2. Assessment of Mechanical Hyperalgesia 
For this study, ipsilateral mechanical hyperalgesia was assessed only on days 0, 1 
and 7 after the inflammatory nerve root insult, since those time points correspond to the 
development and maintence of nerve root-induced pain in this model. Using behavioral 
hypersensitivity methods described previously (Section 3.3.1.2), mechanical hyperalgesia 
was measured in the ipsilateral forepaw as measured by the paw withdrawal threshold 
  62 
normalized to baseline (day 0) levels. The paw withdrawal threshold in rats treated with 
chromic gut suture were compared to thresholds of rats that received a 15-minute 
compression or sham operation (see Section 3.3.1). Ipsilateral paw withdrawal thresholds 
at day 1 (chromic, n=11; 15min, n=11; sham, n=10) and day 7 (chromic, n=4; 15min, 
n=5; sham, n=4) were normalized to baseline (day 0) thresholds. Differences in the 
normalized paw withdrawal threshold between groups over time were determined using a 
repeated measures two-way ANOVA (group x time) with Tukey’s test. This two-way 
ANOVA also tests for differences between the 15-minute compression group and sham 
over time, which is also analyzed in the characterization of BSCB breakdown after nerve 
root compression (Section 3.3). 
 
3.4.1.3. Spinal Immunohistochemistry for IgG 
IgG expression was labeled using methods described in Section 3.3.1.3 in the 
bilateral spinal cord from a subset of rats that underwent inflammatory nerve root injury. 
In order to assess the influences of injury type on BSCB permeability, spinal IgG 
expression in tissue from rats receiving an inflammatory insult via chromic gut suture 
application to the root was compared to IgG expression in the spinal cord from 15-minute 
compression and sham at day 1 (chromic, n=3; 15min, n=5; sham, n=5) and day 7 
(chromic, n=4; 15min, n=5; sham, n=4). A two-way ANOVA (group x day) with Tukey’s 
test was used to test differences in spinal IgG expression between painful compression 
and inflammatory injuries. This two-way ANOVA compares IgG expression for the 15-
minute compression group and sham over time, which is also analyzed in the 
characterization of BSCB breakdown after nerve root compression (Section 3.3) 
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3.4.1.4. Serum Collection & Cytokine Multiplex Assay  
 Procedures for blood draw and elution of serum from whole blood samples were 
performed according to the methods described in Section 3.3.1.4. For analysis of cytokine 
levels after an inflammatory nerve root insult, blood was collected from rats on day 1 
after exposure to chromic gut suture (chromic, n=7) and assayed. Concentrations of 23 
cytokines and chemokines on day 1 were normalized to the corresponding baseline levels 
and were correlated to the normalized ipsilateral paw withdrawal threshold at day 1 for 
each rat. Each set of bivariate data (normalized threshold versus normalized cytokine 
concentration) was fit using a linear regression as described in Section 3.3.1.4. 
 
3.4.2. Results 
Overall, an inflammatory nerve root insult induces a significant decrease in paw 
withdrawal threshold compared to sham (p=0.0148), as well as on day 1 compared to 
sham (p=0.0435) and its own baseline (day 0) levels (p=0.0307) (Figure 3.3A). Similarly, 
the 15-minute root compression significantly reduces withdrawal threshold in the 
ipsilateral forepaw compared to sham on days 1 (p<0.0001) and 7 (p=0.0021) and overall 
(p<0.0001), as well as compared to its own baseline levels (p<0.0001) (Figures 3.2A & 
3.3A). The inflammatory and compressive insults do not induce different withdrawal 
thresholds on any individual day probed (Figure 3.3A); yet, a 15-minute compression 
does induce a significant drop in withdrawal threshold compared to an inflammatory 
chromic insult overall (p=0.0159) (Figure 3.3A). The paw withdrawal thresholds for each 
rat in each group at each day probed are provided in Appendix A. 
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A painful inflammatory nerve root insult does not induce a substantial increase in 
spinal IgG labeling and its expression is not different from sham levels (Figures 3.3B & 
3.3C). A painful 15-minute compression significantly increases (p<0.0001) ipsilateral 
spinal IgG expression compared to sham and IgG expression after an inflammatory insult 
on day 1 (Figures 3.3B & 3.3C). Taken together, both inflammatory and compressive 
nerve root insults induce behavioral sensitivity (Figure 3.3A), but only the compressive 
injury also induces BSCB breakdown (Figures 3.3B & 3.3C). A summary of the 
quantified spinal IgG expression for each rat in this study is detailed in Appendix B. 
 
Figure 3.3. A painful inflammatory nerve root insult does not induce BSCB breakdown at day 1. 
(A) The normalized paw withdrawal threshold is significantly decreased at 1 day after an inflammatory 
root insult induced by chromic gut (chromic) compared to sham (**p=0.0435) and baseline (day 0, 
#p<0.0307). A 15-minute root compression (15min) significantly decreases the withdrawal threshold at 
days 1 and 7 compared to sham (*p<0.0021) and day 0 (#p<0.0307). (B) Spinal IgG labeling is 
relatively low at day 1 in the ipsilateral dorsal horn for both sham and a chromic root insult in contrast 
to the 15min group, which exhibits robust IgG labeling. (C) The percent of IgG labeling normalized to 
expression in naïve rats in the ipsilateral spinal cord is significantly elevated (*p<0.0001) at day 1 after 
a 15min compression compared to both sham procedures and a chromic insult. Data are mean±SD. 
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 Serum levels of pro- and anti-inflammatory cytokines and chemokines were 
assayed at day 1 after an inflammatory nerve root injury in order to determine if 
inflammatory components also modulate systemic inflammation similarly to a 
compressive insult. Unlike nerve root compression (Table 3.1), an inflammation-induced 
nerve root insult does not significantly alter any of the serum factors probed in a manner 
that correlates to mechanical hyperalgesia (Table 3.2). Serum analyte expression for all 
rats in each group can be found in Appendix C. 
 
Table 3.2. Serum levels of pro- and anti-inflammatory cytokines and chemokines (x) and equations of their 
correlation to ipsilateral forepaw withdrawal threshold (y) on day 1 after inflammatory root insult. 
cytokine correlation R2 p-value 
pro-inflammatory 
GM-CSF y=-0.06x+0.73 0.186 0.5690 
MCP-1 y=0.30x+0.08  0.176 0.3487 
IL-17 y=-0.24x+0.84  0.164 0.3673 
MIP-3α y=0.15x+0.36  0.042 0.6569 
IL-2 y=0.11x+0.41 0.040 0.6675 
TNF-α y=0.04x+0.46  0.037 0.6782 
GRO/KC y=-0.12x+0.67 0.034 0.6914 
RANTES y=-0.13x+0.66  0.016 0.7890 
IL-1β y=0.03x+0.49  0.014 0.7982 
IL-7 y=-0.05x+0.59 0.011 0.8269 
VEGF y=0.04x+0.48  0.009 0.8382 
IL-12 y=0.03x+0.50  0.006 0.8645 
G-CSF y=0.02x+0.50  0.006 0.8648 
IL-18 y=-0.03x+0.57  0.004 0.8898 
IL-1α  y=-0.01x+0.55 0.001 0.9443 
IFN-γ y=-0.01x+0.55  0.001 0.9375 
anti-inflammatory 
EPO y=0.11x+0.40 0.048 0.6361 
IL-13 y=0.02x+0.50  0.006 0.8655 
IL-10 y=0.04x+0.49  0.005 0.8821 
IL-5 y=-0.06x+0.59  0.002 0.9223 
IL-4 y=-0.00x+0.54  0.000 0.9772 
pro- and anti-inflammatory 
M-CSF y=-0.07x+0.63  0.011 0.8197 
IL-6 y=-0.00x+0.54  0.001 0.9618 
Note: Shaded cells indicate R2 greater than 0.5. Bolded values represent coefficients of variation greater 
than 0.5 and p-values <0.05. 
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3.5. The Role of BSCB Breakdown in Pain after Nerve Root 
Compression 
3.5.1. Methods 
 3.5.1.1. APC Treatment  
In order to assess the effects of blocking BSCB breakdown on mechanical 
hypersensitivity, another group of rats underwent a 15-minute nerve root compression 
with treatment of the vascular protecting agent APC (Bouwens et al. 2013, Riewald et al. 
2002, Zlokovic and Griffin 2011). Human APC (Haematologic Technologies Inc.; Essex 
Junction, VT) was administered intravenously (0.2mg/kg rat) as a single bolus injection 
(5ml/kg) given 1 hour after the nerve root compression (15min+APC, n=6). This dosing 
paradigm was previously optimized in other rat models of sepsis and shown to reduce 
vascular permeability (Keller et al. 2011, Teke et al. 2008). Since maximal BSCB 
breakdown was observed at day 1 after painful nerve root compression (Figure 3.2), fixed 
C7 spinal cord tissue was harvested only on day 1 after APC treatment and a 15-minute 
compression rats.  
 
3.5.1.2. Spinal IgG Immunolabeling 
Methods described above (Section 3.3.1.3) were used for immunolabeling of IgG 
expression in the bilateral spinal cord of rats that received a 15-minute nerve root 
compression with APC treatment. To confirm that the APC dose was sufficient to block 
BSCB breakdown, spinal IgG expression quantified at day 1 was compared between the 
APC treated 15-minute compression (15min+APC; n=6) and matching tissue from rats 
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from the study in Section 3.3 that underwent a 15-minute compression alone (15min; 
n=5). A two-way ANOVA (group x side) with Tukey’s test was used to determine 
significant differences in spinal IgG expression between groups. 
 
3.5.1.3. Assessment of Mechanical Hyperalgesia 
Behavioral sensitivity after APC-treated compression was measured in the 
ipsilateral forepaw only on days 0 and 1 since pain develops at day 1 after a 15-minute 
nerve root compression (Figure 3.2A) and BSCB breakdown reaches a maximum at this 
time as well (Figure 3.2B & 3.2C). Using methods described in Section 3.3.1.2, the 
normalized paw withdrawal thresholds measured after the APC-treated 15-minute 
compression (15min+APC, n=6) was compared to thresholds for the 15-minute 
compression (15min, n=5) and sham (n=4) groups (Section 3.3). Statistical differences in 
mechanical hyperalgesia were determined between groups using a two-way repeated 
measures ANOVA with Tukey’s test. 
 
3.5.2. Results 
A painful 15-minute nerve root compression induces a significant increase 
(p=0.028) in IgG expression in the ipsilateral spinal cord compared to the contralateral 
spinal cord (Figure 3.4). A single intravenous injection of APC (0.2mg/kg) administered 
1 hour after a 15-minute root compression significantly reduces (p<0.0001) IgG 
expression at 1 day compared to IgG expression for a 15-minute compression alone 
(Figure 3.4). A detailed summary of the quantification of IgG labeling in the ipsilateral 
spinal cord for each rat in this study is provided in Appendix B. 
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In addition, treating a painful nerve root compression with APC prevents the 
compression-induced decrease in paw withdrawal threshold; rats receiving an APC-
treated compression exhibit a significantly higher (p=0.034) threshold at day 1 compared 
to the untreated compression (Figure 3.4C), suggesting the absence of mechanical 
hyperalgesia. The individual paw withdrawal thresholds for each rat in each group can be 
found in Appendix A. 
 
 
 
 
 
Figure 3.4. Blocking BSCB breakdown with intravenous APC inhibits mechanical hyperalgesia 
development after neural injury. (A) Spinal IgG is reduced after APC treated 15-minute compression 
(15min+APC) compared to compression alone (15min). (B) A 15min compression significantly 
increases (**p=0.028) spinal IgG in the ipsilateral dorsal horn compared to the contralateral dorsal horn 
on day 1. The IgG in the ipsilateral spinal cord for the 15min+APC group is significantly lower 
(*p<0.0001) than after the 15min compression on day 1 and is not different from respective 
contralateral values. (C) The Forepaw withdrawal threshold at day 1 is significantly reduced 
(*p=0.028) by a 15min compression compared to sham, whereas the 15min+APC group exhibits a 
significantly higher (**p=0.034) withdrawal threshold than 15min, which is not different sham. All data 
are represented as mean±SD. 
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3.6. Discussion 
The immunohistochemical and behavioral studies in this chapter demonstrate that 
the development of pain after a nerve root compression depends on the breakdown of the 
BSCB that occurs transiently, and early, after injury (Figures 3.2 & 3.4). Behavioral 
sensitivity and BSCB breakdown are induced in parallel within 1 day of a 15-minute 
nerve root compression (Figure 3.2), and are both evident only after that longer 
compressive injury and only in the ipsilateral spinal cord, supporting their association. 
Since pain is still present on day 7 after that compression, when BSCB permeability has 
returned to normal (Figure 3.2), BSCB breakdown may be associated with the onset, 
rather than the maintenance, of nerve root compression-induced pain. Early breakdown in 
the BSCB is unique to compression-mediated pain and not pain in general, since the 
inflammatory nerve root insult does not increase BSCB permeability at any of the time 
points probed, despite inducing pain (Figure 3.3). The 15-minute nerve root compression 
utilized in these studies has been shown to deform the macroscopic nerve root structure 
immediately after compression and to decrease the structural integrity of the compressed 
axons within the root for up to 2 weeks (Chang and Winkelstein 2011, Hubbard et al. 
2008b, Nicholson et al. 2011). Neither a 3-minute compression nor an inflammatory 
insult to the root induces the axonal disruption that is typically observed at later times 
after the painful compression (Chang and Winkelstein 2011, Nicholson et al. 2011, 
Rothman et al. 2010). The lack of BSCB breakdown induced by both a non-painful 
compression and an inflammatory insult suggests that BSCB breakdown might be 
controlled by the mechanical components of neural injury. Further, blocking the early 
  70 
compression-induced BSCB breakdown with APC completely prevents pain from 
developing (Figure 3.4C), suggesting that the rapid targeting of the APC pathway after 
neural injury might eliminate the need for chronic use of analgesics later. 
 The treatment window for blocking BSCB is expected to be on the order of hours 
to a day after the initial injury since increased BSCB permeability is observed by day 1 
after painful nerve root compression (Figure 3.2). In agreement, a painful chronic sciatic 
nerve ligation induces BSCB breakdown in the lumbar spinal cord between 6 and 24 
hours (Beggs et al. 2010, Echeverry et al. 2011). However, that nerve ligation induces 
breakdown for up to 30 days in some cases (Echeverry et al. 2011), whereas spinal IgG 
levels return to normal by day 7 after a transient root compression (Figure 3.2). This 
discrepancy in the duration of BSCB breakdown after a nerve root compression and a 
sciatic nerve ligation is most likely due to duration of local mechanical injury; the nerve 
root compression is only applied transiently (for 15 minutes) in contrast to a nerve 
ligation, which imposes a sustained neural compression.  
Deforming neural tissue compromises both neuronal and vascular integrity 
transiently during the applied compression (Igarashi et al. 2005, Rothman et al. 2010, 
Rydevik et al. 1981, Yoshizawa et al. 1989). Compression of the nerve root blocks blood 
flow through the root inducing a transient state of ischemia (Igarashi et al. 2005, 
Olmarker et al. 1989, Rydevik et al. 1981). Although blood flow is restored within hours 
after the compression is removed (Igarashi et al. 2005, Yoshizawa et al. 1989), evidence 
of decreased axonal integrity is still present for up to 2 weeks (Chang and Winkelstein 
2011). Since neural compression-induced ischemia occurs transiently (Yoshizawa et al. 
1989), but axonal degeneration persists for much longer (Chang and Winkelstein 2011, 
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Hubbard et al. 2008b), it is possible that the transient disruption in the BSCB is due to the 
ischemic, rather than neuronally-mediated effects. A nerve root compression applied for a 
longer duration, which may be more clinically relevant due to a bulging disc or spinal 
stenosis, might induce BSCB breakdown that lasts longer, and, therefore, may offer a 
longer treatment window after compression. It is also possible that chronic compression 
of the nerve root may induce BSCB breakdown that is so robust that a single treatment or 
even repeat treatments with APC would not adequately fortify the vasculature. 
Administering APC or some other vascular protecting drug repeatedly would provide 
more information about the regulatory mechanism of root-induced BSCB disruption. 
A limitation of the current study is that the mechanism by which a painful nerve 
root compression, which is remote from the spinal cord, is capable of disrupting spinal 
vasculature was not investigated. The nerve root, where the compression is applied, is 
physically connected to the spinal cord through afferent axons and the vasculature, 
suggesting that injury to, and therefore dysfunction of, axons or vasculature might 
mediate the breakdown. The effect of the neural compression duration on spinal 
pathology is important. By day 7, a painful 15-minute compression induces axonal 
degeneration in the nerve root, whereas a 3-minute compression does not induce any 
nerve root pathology (Nicholson et al. 2011, Rothman et al. 2010). In the current study, 
BSCB breakdown occurs only after the longer 15-minute, and not the shorter 3-minute, 
compression (Figure 3.2). Electrophysiological activity in the ipsilateral dorsal horn is 
maximally reduced at 6.6±3.0 minutes after the start of root compression (Nicholson et 
al. 2011). That threshold of altered spinal neuronal signaling falls between the two 
durations of compression examined in the current study (3-minutes and 15-minutes). 
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Since spinal IgG expression increases exclusively after a compression that is held for 
longer than that threshold required to immediately disrupt spinal neuronal firing (Figure 
3.2), it is possible that BSCB breakdown may also be influenced by early changes in 
neuronal signaling. Yet, neuronal hyperexcitability in the spinal cord and axonal 
degeneration in the nerve root remain at day 7 after a 15-minute compression (Zhang et 
al. 2013) when BSCB integrity has recovered (Figure 3.2), suggesting that the breakdown 
is not entirely controlled by neuronal signaling.  
 Compression applied to the nerve root, and the vasculature within, disrupts blood 
flow to the spinal cord and dorsal root ganglia (Igarashi et al. 2005, Kobayashi et al. 
2008, Olmarker et al. 1989, Yoshizawa et al. 1989), which may also influence BSCB 
breakdown experienced after a compressive injury. This study shows that only the 15-
minute compression induces changes in permeability of the spinal vasculature (Figure 
3.2). Previous studies have reported that compression of the lumbar nerve roots or cauda 
equina also induce duration-dependent changes in blood flow. Blood flow within the root 
is reduced within 10 minutes of compression and continuously decreases as the duration 
of compression increases (Igarashi et al. 2005, Olmarker et al. 1989), suggesting that only 
the 15-minute compression might disrupt blood flow to the spinal cord. The compression-
induced blockage of blood flow in the nerve root is similar to ischemic stroke models that 
transiently block cerebral arteries for different periods of time to induce different patterns 
of cerebral ischemia and reperfusion (Dobbin et al. 1989, Ek et al. 2015, Sage et al. 
1984). Occluding the carotid artery for 15 minutes induces transient BBB breakdown as 
soon as 3 hours that lasts for up to 24 hours (Dobbin et al. 1989, Ek et al. 2015), 
paralleling the transient BSCB breakdown that occurs within 1 day of painful root 
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compression (Figure 3.2). A compressed root undergoes more structural deformation and 
load-relaxation after 15 minutes of compression than after just 3 minutes (Rothman et al. 
2010); it is possible that the shorter duration of compression may not deform the root 
tissue to an extent that induces physical compression of the vasculature within, thereby 
not blocking blood flow to the spinal cord and not inducing ischemia. An inflammatory 
insult to the root similarly does not mechanically disrupt the nerve root and, therefore, 
does not block blood flow to the spinal cord. Since an inflammatory injury also does not 
induce BSCB breakdown (Figure 3.3), BSCB breakdown may be at least partially 
controlled by ischemia due to physical impingement of the root vasculature.  
Systemic inflammation may be one mechanism by which compression-induced 
BSCB breakdown facilitates pain. Serum concentrations of IL-7, IL-12, IL-1α and TNF-α 
correlate to the severity of pain at day 1 (Table 3.1), which is when BSCB breakdown is 
most robust (Figure 3.2). Of these cytokines, spinal IL-1α and TNF-α have been shown to 
mediate pain after the nerve root compression injury examined in this chapter (Rothman 
et al. 2009, Rothman and Winkelstein 2010). Painful nerve root compression increases 
IL-1α and TNF-α transcription in the ipsilateral spinal cord as early as 1 hour after 
compression; both are likely produced by glial cells since IL-1α expression is exclusively 
localized to astrocytes in the spinal cord at 1 hour of compression (Rothman and 
Winkelstein 2010). By day 1 after compression, IL-1α and TNF-α transcription levels in 
the spinal cord return to normal (Rothman et al. 2009), but at that time spinal TNF-α 
protein expression is elevated (Figure 3.2D). Since cells within the spinal parenchyma are 
not transcribing TNF-α by day 1 after nerve root compression (Rothman et al. 2009) and 
TNF-α expression co-localizes with IgG in the spinal cord (Figure 3.2D) (Smith et al. 
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2015), peripheral TNF-α is likely transported from the blood into the spinal parenchyma 
rather than being produced by cells within spinal cord at this time.  
The early breakdown of the BSCB after painful compression may also promote 
the extravasation of peripheral immune cells into the spinal parenchyma. Spinal 
microglial expression is elevated by day 7 exclusively after a painful compression, and 
not a non-painful compression (Rothman et al. 2010). Increases in spinal microglia can 
be attributed to the migration of microglia from other locations within the CNS, division 
of local microglia, or through the transmigration of peripheral immune cells into the CNS 
(Inoue 2006, McMahon et al. 2005, Milligan and Watkins 2009, Stollg and Jander 1999, 
Sweitzer et al. 2002, Vallejo et al. 2010, Watkins et al. 2001). The early BSCB 
breakdown induced after a 15-minute compression may facilitate the extravasation of 
peripheral cells into the spinal parenchyma and contribute to the increase in spinal 
microglia that is evident by day 7. In agreement, a chromic gut-induced inflammatory 
nerve root insult, which does not induce BSCB breakdown (Figure 3.3), also does not 
increase the spinal microglia population at day 7 after insult (Rothman and Winkelstein 
2007). Although that chromic gut nerve root insult is inflammatory in nature, systemic 
concentrations of inflammatory cytokines are not elevated at day 1 when pain is present 
(Table 3.2; Figure 3.3). Since pro-inflammatory serum cytokines can induce BSCB 
breakdown de novo (Echeverry et al. 2011, Huber et al. 2001, Pan and Kastin 2007), the 
lack of systemic inflammation produced after an inflammatory root insult may be 
responsible for the lack of BSCB breakdown after that painful inflammatory insult 
(Figure 3.3).  
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Although the roles of TNF-α and IL-1β in the development of radicular pain are 
well established, the contributions of IL-7 and IL-12 to pain are controversial (Chen et al. 
2013, Heitzer et al. 2012, Matute Wilander et al. 2014, Zhang et al. 2015). Clinically, IL-
7 transcription and expression were shown to be elevated in intervertebral disc cells from 
patients experiencing low back pain (Zhang et al. 2015). However, serum concentrations 
of IL-7 in patients with cancer-related pain increase within 3 hours of an analgesic opioid 
treatment (Heitzer et al. 2012). Additionally, serum levels of IL-12 are elevated in 
females with work-related musculoskeletal pain (Matute Wilander et al. 2014); in 
contrast, administration of IL-12 subcutaneously reduces mechanical allodynia and 
hyperalgesia for up to 4 hours when administered 9 days after a painful chronic 
constriction of the sciatic nerve (Chen et al. 2013). In the current study, serum 
concentrations of both IL-7 and IL-12 positively correlate to the severity of pain at day 1 
following root compression (Table 3.1). Together with previous literature, it is clear that 
the roles of serum IL-7 and IL-12 in pain severity likely depend on the cause of pain. 
Studies blocking IL-7 and IL-12 systemically following painful root injury would provide 
more information on whether elevated serum concentrations of those cytokines contribute 
to the development of behavioral sensitivity. 
The studies presented in this chapter emphasize the significance of BSCB 
breakdown in pain and support targeting this early injury-induced phenomenon as a novel 
and promising therapeutic route. The vascular-stabilizing agent, APC, was administered 
at 1 hour after a compressive-injury that induces BSCB breakdown (Figure 3.4). This 
time point was chosen as a conservative estimate based on a previous study reporting that 
BSCB permeability is not induced until at least 6 hours after peripheral nerve crush 
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(Beggs et al. 2010). In a complementary pilot study (n=3 rats), BSCB breakdown was 
measured at 6 hours after a painful nerve root compression in order to investigate whether 
BSCB breakdown occurs prior to day 1. Spinal cord tissue was harvested from rats at 6 
hours a painful nerve root compression, immunolabeled for IgG and compared to tissue 
harvested at day 1 after a painful compression or a sham surgery. IgG labeling was not 
apparent in the ipsilateral spinal cord at 6 hours after a painful compression and does 
resemble expression in sham tissue at day 1 (Figure 3.5). The marked increase in IgG 
labeling by day 1 after a painful compression (Figures 3.1 & 3.5) suggests that the BSCB 
is disrupted between 6 and 24 hours after a 15-minute root compression. Since blood 
flow to the surrounding neural tissue is still not completely re-established by 3 hours after 
a 2-second root compression (Igarashi et al. 2005), it is possible that the 15-minute 
compression reduces blood flow to the spinal parenchyma on the order of hours after 
injury. Blood reperfusion after cerebral ischemia induces a breakdown of the BSCB for 
up to 1 day (Dobbin et al. 1989, Ek et al. 2015, Sage et al. 1984). It is possible that 
reperfusion of the ipsilateral spinal cord does not become completely restored until after 
6 hours following a painful root compression and that such reperfusion contributes to 
BSCB breakdown, similar to the ischemia, and subsequent reperfusion, that is observed 
in parallel with the BBB breakdown after ischemic stroke.  
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Although treating a painful compression with intravenous APC completely 
inhibits pain development (Figure 3.4), this enzyme is a potent anticoagulant (Bernard et 
al. 2001, Finfer et al. 2008, Marti-Carvajal et al. 2012) and, therefore, is clinically unsafe 
for use after traumatic injuries such as a nerve root compression. Determining a treatment 
modality that activates the APC pathway to rescue vascular permeability, while at the 
same time promotes coagulation would be an ideal candidate to block BBB disruption 
and prevent development of pain after traumatic neural injury. This hypothesis is further 
explored in Chapter 5 through investigations of salmon thrombin’s effects on painful 
nerve root compression-induced BSCB through its preferential activation of protein C. 
 
3.7. Integration & Conclusions 
The studies presented in this chapter are the first to demonstrate that nerve root 
compression injury induces an early, but delayed, transient opening of the BSCB at the 
same spinal level and same side as the injury (Figure 3.2). The timing of BSCB 
breakdown parallels the timing of pain development (Figure 3.2A). Previous studies have 
Figure 3.5. IgG expression in the ipsilateral spinal dorsal horn is not elevated by 6 hours after a 
painful 15-minute nerve root compression. IgG is minimally expressed in the ipsilateral spinal dorsal 
horn at 6 hours after nerve root compression, at levels similar to sham expression at 24 hours after 
surgery. By 24 hours after compression IgG labeling is robust. 
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reported that other painful mechanical-based nerve injuries induce BSCB disruption 
(Beggs et al. 2010, Echeverry et al. 2011, Gordh et al. 2006). Nerve root compression, 
with or without inflammatory components, imposed chronically disrupts spinal 
vasculature as evidenced by increased spinal expression of endothelial cellular adhesion 
markers by 1 week after injury (Rutkowski et al. 2002). Increased Evans Blue 
extravasation into the ipsilateral spinal dorsal horn is still evident at 3 weeks after the 
initiation of nerve root compression (Kobayashi et al. 2008). Although these chronic 
mechanical nerve root injuries increase spinal vascular permeability, the studies in this 
chapter are the first to show that a transient compression of the nerve root induces BSCB 
disruption (Figure 3.2) and contributes to the onset of pain (Figure 3.4). In contrast, the 
inflammatory nerve root insult used in these studies does not disrupt the BSCB, despite 
producing pain (Figure 3.3).  
Because an inflammatory insult does not mechanically disrupt the structures, 
whether neuronal or vascular, within the nerve root and also does not induce BSCB 
breakdown, the mechanical root deformation applied during compression may facilitate 
the BSCB breakdown, which is remote from the injury. The greater extent of spinal 
vascular permeability that is induced by a compressive, rather than an inflammatory, 
insult may also contribute to the downstream spinal glial activation that is induced to a 
greater extent by compression than a chromic gut insult (Rothman and Winkelstein 
2007). The concentration of four pro-inflammatory cytokines (IL-7, IL-12, IL-1α, TNF-
α) correlates to the behavioral sensitivity at day 1 after different durations of root 
compression (Table 3.1; Figure 3.2D). At this same time, TNF-α expression is elevated in 
the ipsilateral spinal dorsal horn in anatomical regions that also express the serum-
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derived protein, IgG (Figure 3.2D). The co-localization of TNF-α and IgG suggests that 
TNF-α, and likely other cytokines that are upregulated during BSCB disruption, 
extravasate into the spinal parenchyma from the blood, providing one explanation for 
how increased permeability of the BSCB to blood components may exacerbate spinal 
neuroinflammation and possibly pain. Of particular interest, thrombin crosses a 
compromised BBB after stroke and exacerbates the associated edema (Bushi et al. 2013, 
Kawai et al. 2001, Lee et al. 1997). Further, exogenous thrombin administered into the 
CNS has been shown to induce pain for up to 8 days (Narita et al. 2005), providing 
evidence for thrombin possibly contributing to pain development if present in the spinal 
parenchyma after nerve root compression. The involvement of spinal thrombin in pain is 
further investigated in Chapter 4 of this thesis. 
The findings from this chapter provide multiple layers of clinical relevance for the 
early identification and intervention of radicular pain. Since only compression-induced 
pain correlates to pro-inflammatory cytokine expression in the serum and only that 
painful compression induces BSCB breakdown, it is possible that elevations in serum IL-
7, IL-12, IL-1α and TNF-α may enhance BSCB breakdown after neural injury. Further, 
serum levels of these cytokines may have potential as serum biomarkers for painful 
neural compression that induces BSCB breakdown. Further studies evaluating if these 
cytokines are only upregulated when the BSCB is compromised, or whether their 
elevation follows a different temporal profile than does BSCB breakdown, would be 
advantageous to inform clinicians on whether the BSCB is compromised. By day 1 after 
a painful compression, pro-inflammatory cytokine concentrations are elevated in the 
serum, the BSCB is disrupted, and pain is developed. As such, measuring all three of 
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these responses, i.e. serum cytokine concentration, BSCB permeability, and behavioral 
sensitivity, at time points earlier than 1 day after compression would provide a more 
complete picture of the contribution of systemic cytokines and BSCB breakdown to the 
development of pain.  
Therapies that combine the administration of neuroprotective agents, which are 
typically prevented from reaching the CNS due to an intact BBB (Wong et al. 2013), at 
times of BSCB breakdown followed by agents that restore BSCB integrity might be ideal 
for preventing the development of neuropathic pain. A shortcoming of the current studies 
is that IgG immunolabeling only reveals the accumulation of that serum protein in the 
CNS. Therefore, robust spinal IgG immunolabeling at day 1 indicates that the BSCB was 
disrupted at, or before, day 1. In order to understand the dynamic responses of BSCB 
permeability, administration of visually absorptive or fluorescent tracers that do not 
normally cross the BBB, such as Evans Blue or NaFlu (Beggs et al. 2010, Echeverry et 
al. 2011), at early time points between 6 hours and 1 day after painful root compression 
would provide a more detailed temporal profile for BSCB breakdown and, so, a better 
understanding of the most effective timing for therapeutic intervention after injury. The 
current studies were focused on measured the accumulation of serum components, rather 
than the real-time permeability of the BSCB after compression, in order to establish 
whether proteins from the serum do in fact interact with cells in the spinal parenchyma 
and possibly contribute to the early pathologies and development of pain at day 1.    
Since TNF-α expression increases in both the blood and the spinal cord (Figure 
3.2D), serum factors likely cross a compression-induced compromised BSCB. Studies in 
Chapter 4 investigate whether thrombin, a bioactive enzyme expressed in the 
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bloodstream, can also cross the BSCB after a painful root compression allowing it to 
interact with cells within the CNS and to contribute to nociceptive processes. Those 
studies test the hypothesis that endogenous thrombin extravasates into the spinal 
parenchyma in areas that undergo BSCB breakdown after painful nerve root compression 
(Chapter 4). Thrombin activity is measured by immunolabeling for the expression of 
fibrin(ogen), the enzymatic polymeric product of thrombin (Boon 1993, Di Cera 2008), 
in the spinal cord after painful and non-painful compressions. The half-life of a fibrin clot 
ranges from hours to days at physiological temperature depending on the conditions 
(Shainoff and DiBello 2003). Although the early BSCB breakdown after compression 
returns to normal levels by day 7 (Figure 3.2), fibrin(ogen) might still be present in the 
CNS at times later than when IgG is cleared (Cooper et al. 2013). As such, spinal 
fibrin(ogen) is measured at both days 1 and 7 after painful and non-painful nerve root 
compression.  
Previous studies have shown that thrombin-activated central PAR1 can induce 
astrocyte activation (Choi et al. 2008, Nicole et al. 2005, Niego et al. 2011) and 
behavioral sensitivity (Narita et al. 2005). In order to determine whether compression-
induced spinal thrombin activity may lead to spinal astrocyte activation and pain 
development, thrombin activity is blocked with the specific inhibitor hirudin (Narita et al. 
2005) prior to a 15-minute compression. The effect of thrombin activity in the spinal cord 
on the development of pain without any compression-induced biomechanical inputs was 
investigated by administering rat thrombin intrathecally to naïve rats. Studies in Chapter 
4 also begin to investigate the role of the thrombin-activated spinal PAR1 in the 
development of pain and spinal glial activation by administering the PAR1 antagonist, 
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SCH79797 (El Eter and Aldrees 2012, Manaenko et al. 2013), with either an injection of 
rat thrombin or a painful 15-minute compression. Together the studies in Chapter 4 
investigate one mechanism by which BSCB breakdown may facilitate the development of 
compression-induced pain and begin to define a novel role for spinal thrombin, and its 
activation of PAR1 centrally, in the development of neuropathic pain and spinal glial 
activation.    
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Chapter 4 
Defining the Contribution of Spinal Thrombin to 
Compression-Induced Spinal Astrocyte Activation 
& Pain through PAR1 
 
Parts of this chapter are adapted from: 
 
Smith JR, Winkelstein BA. Spinal thrombin activity is elevated following nerve root 
injury in the rat and initiates pain through the protease-activated receptor-1. Pain, 
submitted. 
 
 
4.1. Overview 
 Breakdown of the blood-brain barrier (BBB) or blood-spinal cord barrier (BSCB) 
is a pathological response in the central nervous system (CNS) that is induced by many 
types of traumatic injuries and neuropathic disorders, including spinal cord injury, 
traumatic brain injury, ischemic stroke, multiple sclerosis, Parkinson’s disease and 
Alzheimer’s disease (Hawkins and Davis 2005, Hirsch and Hunot 2009, Maikos and 
Shreiber 2007, Popovich et al. 1996, Ryu and McLarnon 2009, Sandoval and Witt 2008, 
Zlokovic 2008). Recently, studies have identified that BSCB breakdown can also occur 
after peripheral nerve injuries that are remote from the spinal cord itself, such as a sciatic 
nerve ligation or transection (Beggs et al. 2010, Cahill et al. 2014, Echeverry et al. 2011). 
The studies in Chapter 3 demonstrate that BSCB breakdown occurs transiently within 1 
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day of a painful nerve root compression and contributes to the development of pain after 
that injury (Smith et al. 2015). Increased permeability of the BSCB often complicates 
spinal pathologies by facilitating the extravasation of pro-inflammatory cytokines and 
chemokines into the spinal parenchyma (Banks et al. 1995, Echeverry et al. 2011, Pan et 
al. 1997, Pan and Kastin 2007, Sharief and Thompson 1992). Of note, tumor necrosis 
factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), both of which have been reported to 
cross a compromised BSCB barrier (Banks et al. 1995, Echeverry et al. 2011, Pan and 
Kastin 2007), also contribute to pain once they are active in the spinal cord after nerve 
root injury (de Souza Grava et al. 2012, Rothman et al. 2009, Rothman and Winkelstein 
2010). Findings from the studies in Chapter 3 suggest that an increase in spinal TNF-α 
expression at day 1 after painful root compression is at least partially attributed to its 
extravasation across the BSCB since TNF-α co-localizes with the serum protein 
immunoglobulin G (IgG) (Figure 3.2) (Smith et al. 2015). However, it is not known 
whether other blood-borne proteins or enzymes also extravasate into the spinal 
parenchyma and contribute to spinal pathologies and pain following injury.  
 Of particular interest, thrombin is a serum enzyme that is not found in the CNS 
under normal healthy conditions but has been implicated in CNS pathology. For example, 
endogenous thrombin contributes to BBB breakdown after ischemic stroke and 
potentiates the inflammation and edema in the brain that are associated with injury and 
unfavorable patient outcomes (Junge et al. 2004, Kawai et al. 2001, Lee et al. 1997, Liu 
et al. 2010). When thrombin is exogenously administered into the CNS it can induce 
astrocyte activation (Liu et al. 2010, Nishino et al. 1993); separately thrombin has been 
shown to produce pain (Narita et al. 2005). Together, these pro-inflammatory effects of 
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thrombin in the CNS highlight a potential pathological role for this enzyme in painful 
neuropathic disorders. Thrombin is a versatile enzyme and can activate a large number 
substrates, many of which are cell bound receptors that when activated initiate cell 
signaling cascades (Di Cera 2008, Lane et al. 2005). Thrombin-induced activation of 
astrocytes has largely been attributed to its cleavage of the protease-activated receptor-1 
(PAR1) (Choi et al. 2008, Fan et al. 2005, Nicole et al. 2005). As such, endogenous 
thrombin is hypothesized to extravasate into the spinal parenchyma during the BSCB 
breakdown that occurs after painful nerve root injury and contributes to astrocyte 
activation and pain through its activation of spinal PAR1. 
The studies presented in this chapter focus on addressing Aim 2 and are broken 
into two major sections. Studies in Section 4.3 measure whether thrombin is present in 
the spinal cord after separate painful and non-painful nerve root compressions and also 
determine the contribution of spinal thrombin to nerve root-mediated pain through its 
activation of PAR1. Studies outlined in Section 4.4 investigate whether spinal thrombin 
activity contributes to spinal astrocytic activation, which has been previously documented 
at day 7 after a painful nerve root compression injury (Hubbard and Winkelstein 2005, 
Rothman et al. 2010, Rothman and Winkelstein 2007). Because thrombin alone has been 
shown also to induce vascular leakiness (Komarova et al. 2007, Liu et al. 2010), the role 
of spinal thrombin in BSCB breakdown after painful root compression is investigated in 
parallel studies (Section 4.4).  
Studies in Sections 4.3 and 4.4 utilize the same nerve root compression injury 
model in the rat as presented in Chapter 3. By administering various pharmacologic 
agents to manipulate the thrombin/PAR1 signaling pathway centrally, the studies 
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investigate whether spinal thrombin contributes to BSCB breakdown, spinal glial 
activation, and pain following painful nerve root compression. The selective thrombin 
inhibitor, hirudin, was administered intrathecally prior to a painful root compression in 
order to block spinal thrombin; the effects of hirudin on spinal thrombin activity, via 
immunolabeling for fibrin(ogen), and the development of mechanical hyperalgesia was 
measured over 7 days (Section 4.3). The effects of hirudin on compression-induced 
BSCB breakdown and spinal astrocyte activation were also measured by immunolabeling 
for IgG at day 1 and for glial fibrillary acidic protein (GFAP) at day 7 after injury 
(Section 4.4). These time points were selected because BSCB breakdown is evident for 1 
day after compression and spinal GFAP expression is robust by day 7, respectively. 
Exogenous rat thrombin was administered in naïve rats in order to measure its capability 
of inducing mechanical hyperalgesia (Section 4.3). BSCB breakdown and spinal 
astrocyte activation were measured by immunolabeling for IgG and GFAP at the time 
(day 1) when behavioral sensitivity is most robust after injection (Section 4.4). Lastly, in 
order to determine whether thrombin acts through PAR1 in the spinal cord to induce pain, 
BSCB breakdown and astrocyte activation, a PAR1 antagonist, SCH79797, was 
administered prior to an injection of rat thrombin and prior to a painful compression, 
separately (Sections 4.3 and 4.4). Together, these studies begin to define if there is a 
pathophysiologic role of spinal thrombin activation of PAR1 in the BSCB breakdown and 
glial activation that are associated with nerve root-mediated pain. 
 
 
  87 
4.2. Relevant Background 
Chronic pain affects over 100 million adults in the United States each year, which 
is greater than the numbers of people affected by cancer, heart disease and diabetes 
combined (Institute of Medicine (US) Committee on Advancing Pain Research 2011, 
Tsang et al. 2008). Despite the relatively high prevalence of painful disorders, current 
available treatments are not effective at treating all of the presenting symptoms (Arner 
and Meyerson 1988, Baron et al. 2010, Dworkin et al. 2003, Finnerup et al. 2010), partly 
owing to the fact that the biochemical mechanisms maintaining pain after neuropathic 
injuries within the peripheral or CNS (Baron et al. 2010, Scholz and Woolf 2007, Woolf 
2004, Woolf and Mannion 1999) are not fully understood. Such insults have been shown 
to induce a host of cellular and biochemical cascades within the CNS that contribute to 
both the initiation and maintenance of pain (Milligan and Watkins 2009, Scholz and 
Woolf 2007, Watkins et al. 2001). Previous studies have shown that mechanical injury to 
either a peripheral nerve or nerve root increases the permeability of the BSCB (Beggs et 
al. 2010, Echeverry et al. 2011, Gordh et al. 2006, Kobayashi et al. 2008), which 
facilitates the transmission of serum molecules into the CNS where they interact with, 
and activate, resident neuronal and glial cells (Ballabh et al. 2004, Radu et al. 2013, 
Webb and Muir 2000). We recently showed that BSCB breakdown occurs exclusively 
after nerve root compression that also induces pain and that blocking early BSCB 
breakdown prevents pain from developing (Smith et al. 2015). Yet, it is not known if 
certain serum proteins that extravasate into the CNS during increased BSCB permeability 
contribute to the development of nerve root induced pain.   
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 Thrombin is a bioactive blood-borne enzyme that does not interact with neural 
cells under normal healthy conditions, but when it is introduced into the CNS, it induces 
cellular cascades that promote pain (Garcia et al. 2010, Niego et al. 2011, Nishino et al. 
1993). Human thrombin that is continuously infused at high concentrations over 7 days 
into the rat midbrain induces elevated vimentin-positive astrocytes (Nishino et al. 1993). 
Although that study did not measure behavioral sensitivity, spinal astrocyte activation has 
been shown to occur in parallel with pain induced by a variety of neuropathic pain 
conditions in animal models (Hubbard and Winkelstein 2005, Rothman et al. 2010, 
Rothman and Winkelstein 2007). Spinal thrombin also has been related to the 
development of pain; intrathecal administration of thrombin induces tactile allodynia in 
naïve mice that lasts for up to 10 days and blocking spinal thrombin activity prior to a 
sciatic nerve ligation produces less pain than an untreated injury for up to 7 days (Narita 
et al. 2005). Together, these studies suggest that spinal thrombin may induce mechanical 
allodynia and may contribute to that pain that develops after neural injury. Yet, it is not 
known how thrombin is produced in the CNS or whether and how it may enter the CNS 
after injury; further, it remains unknown if such a response is specific to painful injury.   
Although thrombin is a key enzyme in clot formation by cleaving fibrinogen into 
fibrin, it also initiates a variety of subcellular signaling cascades by activating cell surface 
receptors or cell bound substrates (Coughlin 2000, Di Cera 2008). Of the known 
thrombin activated receptors, mammalian thrombin preferentially activates protease-
activated receptor-1 (PAR1), which is expressed in multiple cell types within the CNS, 
including neurons, astrocytes and microglia (Shavit et al. 2011, Suo et al. 2002, Vellani et 
al. 2010). PAR1 activation in the CNS has been implicated in glial activation and related 
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inflammatory responses (Bunnett 2006, Fan et al. 2005, Nicole et al. 2005, Suo et al. 
2002). Administration of the synthetic peptide, TFLLR, which selectively activates 
PAR1, into the striatum of mice induces local astrocyte activation and proliferation 
(Nicole et al. 2005). Not only does selective activation of PAR1 induce 
neuroinflammatory cascades, but blocking PAR1 activation or suppressing PAR1 
expression also attenuates thrombin-induced inflammation (Choi et al. 2008, Scarisbrick 
et al. 2012). For example, blocking PAR1 activation with the small molecule inhibitor, 
SCH79797, in glial cultures inhibits protease-induced astrocytic activation as well as 
astrocytic production of the pro-inflammatory proteins, IL-6 and matrix 
metalloproteinase-9 (MMP-9), (Choi et al. 2008, Scarisbrick et al. 2012). Further, when 
microglia from mice lacking PAR1 are stimulated by thrombin they produce significantly 
less TNF-α compared to wild type microglia (Suo et al. 2002), suggesting that thrombin 
acts through PAR1 to initiate this pro-inflammatory cascade. Because PAR1-/- mice 
exhibit less astrocyte activation in the regions of a wound after a cortical incision (Nicole 
et al. 2005), it is possible that injury-induced astrocytic activation may depend on PAR1 
expression. Despite PAR1’s implication in glial-controlled inflammatory processes and 
the well-established role of gliosis in pain (McMahon et al. 2005, Milligan and Watkins 
2009, Vallejo et al. 2010, Watkins et al. 2001), no study has defined the contribution of 
thrombin’s activation of spinal PAR1 pain.  
 The first set of studies in this Chapter test the hypothesis that thrombin 
extravasates into the spinal parenchyma in areas that undergo BSCB breakdown after 
painful nerve root injury, inducing behavioral sensitivity through its enzymatic activation 
of PAR1 (Section 4.3). Complementary studies utilized a controlled nerve root 
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compression injury in the rat and a variety of pharmacological interventions. First, the 
ability of thrombin to act enzymatically in the spinal cord after a nerve root compression 
that induces mechanical hyperalgesia was examined. Spinal immunolabeling for 
fibrin(ogen), which labels fibrin and fibrinogen, was evaluated as a proxy of spinal 
thrombin activity and was co-immunolabeled with the serum-derived IgG to reveal 
regions where thrombin is localized to areas of increased BSCB permeability. Spinal 
thrombin activity was then inhibited using hirudin prior to a painful nerve root 
compression and mechanical hyperalgesia was monitored in the forepaw ipsilateral to 
injury over time to determine whether spinal thrombin contributes to the development of 
compression-induced pain. The last part of these studies tested whether spinal thrombin 
acts through PAR1 to produce pain using the PAR1 inhibitor, SCH79797, administered 
intrathecally. Rat thrombin was delivered to naïve rats, with or without pre-treatment 
with SCH79797, and bilateral mechanical hyperalgesia was measured for up to 7 days. 
SCH79797 was also given prior to a painful nerve root compression; mechanical 
hyperalgesia was measured in the ipsilateral forepaw for 7 days and spinal fibrin(ogen) 
and IgG were labeled at days 1 and 7 after that injury to investigate whether spinal PAR1 
is requisite for development of radicular pain, even under conditions of elevated spinal 
thrombin activity. 
The second set of studies in this chapter expands the first set of studies and tests 
the hypothesis that increases in spinal thrombin after painful root compression contribute 
to spinal astrocyte activation through its activation of spinal PAR1 (Section 4.4). Because 
thrombin is a known inducer of vascular permeability (Komarova et al. 2007, Liu et al. 
2010) and BSCB breakdown is robust at day 1 after a painful compression (Figure 3.2) 
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(Smith et al. 2013), the contribution of spinal thrombin to that early compression-induced 
BSCB was also investigated. The expression of PAR1 in spinal astrocytes after painful 
and non-painful compressions was measured over time in order to determine whether 
modulations in astrocytic PAR1 expression occur exclusively in response to a painful 
root injury. The contribution of compression-induced spinal thrombin on BSCB 
breakdown and spinal astrocyte activation was investigated by using a hirudin pre-
treatment before injury and immunolabeling for IgG at day 1 and GFAP at day 7 after 
injury. The direct action of thrombin, absent any other stimuli, on both of these spinal 
pathologies was then measured in order to investigate the sole effects of spinal thrombin 
without any other injurious inputs. Rat thrombin was given intrathecally to naïve rats and 
spinal IgG and GFAP were measured at day 1 when mechanical hyperalgesia is most 
robust (Smith and Winkelstein 2015). Lastly, in order to investigate the involvement of 
spinal PAR1 in BSCB breakdown and astrocyte activation in the spinal cord, SCH79797 
was administered prior to a painful rat thrombin administration or painful nerve root 
compression and spinal IgG and GFAP expression were measured. The collective 
findings from both of the complementary studies investigating the role of spinal thrombin 
and its activation of PAR1 on the induction of pain, spinal astrocyte activation, and 
BSCB breakdown are discussed and integrated in Sections 4.5 and 4.6. 
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4.3. Defining the Contribution of Spinal Thrombin & PAR1 Activation 
to Pain 
4.3.1. Study Design 
4.3.1.1. Assessing Compression-Induced Spinal Thrombin Effects on Pain  
In order to determine whether endogenous thrombin is enzymatically active in the 
spinal cord after neural injury, immunohistochemical techniques were used to label spinal 
fibrin(ogen) expression after different durations of nerve root compression that either do 
or do not induce pain (Rothman et al. 2010). A 15-minute (15min, n=10), 3-minute 
(3min, n=10) or 0-minute (sham, n=11) compression was separately applied to the nerve 
root using previously described surgical procedures on day 0 (Rothman et al. 2010). 
Mechanical hyperalgesia was measured in the ipsilateral forepaw in rats on day 0 before 
surgery (baseline) and on days 1, 3, 5 and 7 after surgery. Time-dependent differences in 
paw withdrawal threshold between 15min (n=5), 3min (n=5) and sham (n=6) were 
determined using a two-way repeated measures ANOVA (group x day) with Tukey’s 
Honestly Significant Difference test.  
Spinal cord tissue at C7 was harvested on day 1 (15min, n=5; 3min, n=5; sham, 
n=5) or day 7 (15min, n=5; 3min, n=5; sham, n=6) in separate groups, in order to 
evaluate the temporal spinal fibrin(ogen) immunolabeling extent and pattern. Spinal 
fibrin(ogen) expression in the ipsilateral dorsal horn was quantified using densitometry 
(Nicholson et al. 2012, Rothman et al. 2010), and compared to fibrin(ogen) expression in 
matching spinal tissue from normal naïve rats. Significant differences were evaluated 
using a two-way ANOVA (group x day) with Tukey’s test. The spinal tissue taken from 
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the rats undergoing a 15-minute compression was also immunolabeled for fibrin(ogen) 
with the serum component, IgG, in order to determine whether spinal thrombin activity is 
localized to spinal regions that undergo BSCB breakdown.  
 In a complementary study, spinal thrombin activity was blocked prior to imposing 
the painful 15-minute compression in order to assess whether nerve root-induced spinal 
thrombin contributes to the development of pain after that injury. Rats received an 
intrathecal injection of hirudin, a selective thrombin inhibitor, 1 day prior to nerve root 
compression (hir+15min, n=6). Mechanical hyperalgesia was measured in the ipsilateral 
forepaw before hirudin (day -1), after hirudin but before surgery (day 0), and on 
alternating days (1, 3, 5, and 7) after injury. The ipsilateral paw withdrawal threshold was 
compared between hir+15min and 15min (n=5) and statistical differences in withdrawal 
threshold between hir+15min and 15min were determined using a two-way repeated 
measures ANOVA (group x day) with Tukey’s test.  
At day 7, spinal cord tissue was harvested from rats that were given hirudin 
intrathecally with a 15-minute compression and immunolabeled for fibrin(ogen) and IgG. 
An additional group of rats received an intrathecal injection of hirudin before undergoing 
a 15-minute root compression; spinal cord tissue was harvested from those rats at day 1 
after injury (n=5) and immunolabeled for fibrin(ogen). Quantification of fibrin(ogen) 
expression for hir+15min was compared to fibrin(ogen) expression in comparable tissue 
from rats undergoing a 15-minute compression (day 1, n=5; day 7, n=6) but not receiving 
hirudin treatment; spinal fibrin(ogen) expression was normalized to expression in naïve 
tissue and differences were compared using a two-way ANOVA (group x day) with 
Tukey’s test.  
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4.3.1.2. Investigating the Effects of Thrombin-Activated Spinal PAR1 on 
Pain 
In order to determine the effects of spinal thrombin on non-injury induced pain, 
rat thrombin was administered via a single intrathecal injection to naïve rats (RTh, n=6). 
Mechanical hyperalgesia was measured in the bilateral forepaws on day 0 before, and on 
days 1, 3, 5 and 7 after, thrombin injection; the left and right paw withdrawal thresholds 
were averaged for each rat since this treatment is ubiquitous and not expected to have 
preferential effects on hyperalgesia in the bilateral forepaws. The average paw 
withdrawal threshold at days 1, 3, 5, and 7 were compared to baseline (day 0) thresholds 
using separate two-tailed paired t-tests in order to determine if the threshold on each of 
those days is changed from baseline.  
A separate complementary study was performed to assess whether spinal 
thrombin acts through PAR1 to induce pain. Rats received a single injection of rat 
thrombin (RTh, n=6) at day 0 and mechanical hyperalgesia was measured in the bilateral 
forepaws at day 0 before, and at day 1 after, the thrombin injection. In a separate group of 
rats, the small molecule PAR1 inhibitor, SCH79797, was injected intrathecally 1 day 
before the rat thrombin administration (SCH+RTh n=6). Mechanical hyperalgesia was 
measured bilaterally prior to SCH injection (day -1), after SCH treatment but before rat 
thrombin injection (day 0), and on day 1 after rat thrombin administration. Differences in 
the average bilateral paw withdrawal threshold between the SCH+RTh and RTh groups 
were detected using a two-way repeated measure ANOVA (group x day) with Tukey’s 
test.  
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4.3.1.3. Determining the Effects of Spinal PAR1 Activation on Compression-
Induced Pain 
In order to examine whether PAR1 activation contributes to the development of 
pain after a compressive nerve root injury, SCH79797 was administered a day before a 
15-minute nerve root compression (SCH+15min, n=7) in a separate group of rats. Since 
the vehicle for SCH79797 contains dimethyl sulfoxide (DMSO), which is not 
biologically inert (Galvao et al. 2014, Qi et al. 2008), control groups were included in 
which DMSO was administered intrathecally at 1 day before either a 15-minute root 
compression (DMSO+15min, n=5) or a sham surgical procedure (DMSO+sham, n=5). 
Ipsilateral forepaw mechanical hyperalgesia was measured on the day before (day -1) 
SCH79797 or vehicle injection, on day 0 after injection but before surgery, and on days 
1, 3, 5 and 7 after surgery. Differences in withdrawal threshold between SCH+15min, 
DMSO+15min and DMSO+sham were compared with a two-way repeated measures 
ANOVA (group x day) with Tukey’s test.  
In order to determine whether thrombin remains active in the spinal cord over 
time despite the SCH79797 treatment, spinal tissue was harvested on day 1 from separate 
groups of rats receiving a 15-minute compression with either a SCH79797 or a DMSO 
vehicle pre-treatment. Fibrin(ogen) labeling was measured in spinal cord tissue at day 1 
(SCH+15min, n=6; DMSO+15min, n=4) and day 7 (SCH+15min, n=7; DMSO+15min, 
n=5; DMSO+sham, n=5) and compared using a two-way ANOVA (group x day) with 
Tukey’s test.    
 
 
  96 
4.3.2. Specific Detailed Methods 
 4.3.2.1. Animals 
All studies were performed using adult male Holtzman rats (Harlan Sprague-
Dawley; Indianapolis, IN). Rats were housed under conditions approved by the United 
State Department of Agriculture (USDA) and the Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC) in a temperature- and light-
controlled room with free access to water and food. All operational and experimental 
procedures were approved by the University of Pennsylvania Institutional Animal Care 
and Use Committee (IACUC) and carried out under the guidelines of the Committee for 
Research and Ethical Issues of the International Association for the Study of Pain (IASP) 
(Zimmermann 1983).  
 
 4.3.2.2. Surgical Procedures for Nerve Root Compression 
Surgical procedures were performed under inhalation isoflurane anesthesia (4% 
for induction, 3% for maintenance). Previously reported protocols were followed for 
administering nerve root compression injury (Chang and Winkelstein 2011, Nicholson et 
al. 2012, Rothman et al. 2010). Briefly, rats were placed in a prone position, a midline 
incision was made along the back of the neck and the paraspinal muscles were removed 
to expose the C6 and C7 vertebrae. A C6-C7 hemilaminectomy and partial facetectomy 
was performed on the right side to expose the right C7 dorsal nerve root. A small incision 
was made in the dura over the C7 root and a calibrated 10gf microvascular clip (World 
Precision Instruments; Sarasota, FL) was applied to the exposed root. The root was 
compressed for either 3 or 15 minutes after which the clip was removed and the wound 
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was closed by 3-0 polyester suture and surgical staples. Rats were allowed to recover in 
room air with continual free access to food and water. Sham operated rats underwent 
identical surgical procedures except did not undergo nerve root compression. 
 
 4.3.2.3. Optimization of Dosing of the Pharmacologic Agents 
Three separate drugs were administered in the studies in this chapter: hirudin, rat 
thrombin, and SCH79797. Initial doses for each agent were chosen based on previous 
studies in the literature and review of the doses that had behavioral effects. Hirudin was 
administered prior to a 15-minute nerve root compression and its ability to inhibit the 
development of pain over 7 days was evaluated. Only one previous study was identified 
that administered hirudin intrathecally (Narita et al. 2005). In that study, hirudin was 
administered intrathecally at a dose of 30pmol/day for a 25g mouse for 8 days after a 
sciatic nerve ligation; that dose prevented mechanical allodynia from developing during 
the dosing period and for 8 days after the cessation of treatment (Narita et al. 2005). It is 
important to note that 1 NIH unit (U) of thrombin is equivalent to 8.85±2.01pmol of 
thrombin (Hemker 2012), and 1U of hirudin neutralizes 1U of thrombin at 37°C. 
Adjusting for the weight of a rat being approximately 15 times as large as a mouse, 
hirudin was chosen to be initially administered only once at a dose of 4.2U/rat (n=6), 
injected intrathecally at 1 day prior to a painful nerve root compression. Since that initial 
dose was sufficient to prevent the development of pain for at least 7 days in the rat, 
hirudin was given at 4.2U/rat for all studies in this chapter. 
Rat thrombin was administered intrathecally to naïve rats and its ability to 
produce mechanical hyperalgesia was tested in the bilateral forepaws over 7 days. A 
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previous study reported that a single intrathecal injection of thrombin (1pmol/mouse) in 
naïve mice produced mechanical allodynia for at least 8 days (Narita et al. 2005). Further, 
rat thrombin infused into the midbrain of rats at a rate of 0.5U/hour induces a significant 
increase in local astrocyte activation after 7 days of constant infusion (Nishino et al. 
1993). Based on those reports, three doses of rat thrombin were chosen for pilot studies in 
order to measure their effect on mechanical hyperalgesia: 0.04U/rat (RTh 0.04, n=4), 
0.4U/rat (RTh 0.4, n=5) and 4U/rat (RTh 4, n=6). Mechanical hyperalgesia was measured 
on day 0 before injection (baseline) and on days 1, 3, 5, and 7 after injection. Significant 
differences in hyperalgesia were evaluated using individual paired t-tests comparing the 
withdrawal threshold at each day to corresponding baseline thresholds, for each dose 
separately. Of the pilot doses, only the highest (4U/rat) produced a significant drop in the 
paw withdrawal threshold, which was apparent at days 1 and 3 after injection (Figure 
4.1). The two lower doses (0.04 and 0.4U/rat) did not alter the threshold at day 1, 
although the 0.4U/rat dose did induce a delayed significant drop in forepaw withdrawal 
threshold that was evident at day 3 (Figure 4.1). As such, a dose of rat thrombin for 
4U/rat was chosen for the rest of the studies in this chapter. 
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 Spinal PAR1 was blocked with the small molecule inhibitor, SCH79797, 
administered intrathecally 1 day before a painful compression. A previous study found 
that an intrathecal injection of 25µg/kg of SCH79797 was effective at reducing edema in 
the brain within 1 day after a surgically-induced brain injury, whereas a dose of 1µg/kg 
did not (Manaenko et al. 2013). In another study, SCH79797 was administered 
intraperitoneally at doses over a range of 10-250µg/kg, with 25-100µg/kg of SCH79797 
reducing brain water content at day 1 after subarachnoid hemorrhage (Yan et al. 2013). 
The effects of two different intrathecal doses of SCH79797 (25µg/kg, n=4; 50µg/kg, n=7) 
on mechanical hyperalgesia when given intrathecally prior to a painful compression were 
measured over 7 days. A vehicle control containing dimethyl sulfoxide (DMSO; 0µg/kg, 
n=5) in phosphate buffered saline (PBS) was also included for comparison purposes. 
Mechanical hyperalgesia was measured on day 0 before injection (baseline) and on days 
Figure 4.1. Mechanical hyperalgesia in the bilateral forepaws in response to a single intrathecal 
injection of rat thrombin given at 0.04, 0.4, and 4U/rat. The highest dose of rat thrombin (4U/rat, 
RTh 4) administered intrathecally induced a significant drop in withdrawal threshold at day 1 
(*p=0.035) and day 3 (*p=0.019) after injection compared to baseline. Rat thrombin administered at 
0.4U/rat (RTh 0.4) induced a significant drop in threshold at day 3 (#p=0.044) compared to baseline, 
whereas when administered at 0.04U/rat (RTh 0.04) rat thrombin did not alter the withdrawal 
thresholds compared to baseline at any day tested. Data are mean±SD. 
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1, 3, 5, and 7 after root compression. Differences in hyperalgesia were determined using a 
two-way ANOVA (group x day) with Tukey’s test comparing between both doses of 
SCH79797 and the vehicle.  
 
 
 
As expected, the vehicle treatment did not prevent the development of mechanical 
hyperalgesia and induced a significant drop in withdrawal threshold for the ipsilateral 
forepaw at day 1 compared to baseline (day 0) (Figure 4.2).  Of the treatment doses 
tested, only 50µg/kg of SCH79797 was sufficient to inhibit the production of mechanical 
hyperalgesia at day 1 after compression (Figure 4.2); therefore, that dose (50µg/kg) of 
SCH79797 was used for the studies in this chapter.  
 
Figure 4.2. Mechanical hyperalgesia in the ipsilateral forepaw after a 15-minute compression 
treated with SCH79797 at 50µg/kg, 25µg/kg, and 0µg/kg. Pre-treating a painful compression with a 
DMSO-containing vehicle (SCH(0)+15min) induced a significant decrease (#p=0.010) in the 
withdrawal threshold of the ipsilateral forepaw, at day 1 after compression compared to baseline. 
SCH79797 given at 50µg/kg (SCH(50)+15min) abolished the compression-induced decrease in 
threshold at day 7. The 25µg/kg dose of SCH79797 (SCH(25)+15min) did not eliminate that drop 
(*p=0.037) in withdrawal threshold at day 1 after compression from baseline. Data are mean±SD. 
  101 
4.3.2.4. Preparation & Intrathecal Administration of Agents 
Thrombin from rat plasma (Sigma Aldrich; St. Louis, MO) was dissolved in 
sterile phosphate-buffered saline (PBS; Mediatech, Inc.; Manassas, VA) and stored at 
-80°C until further use, avoiding repeated freeze-thaw cycles. Rat thrombin was 
administered to rats via intrathecal injection at a final dose of 4U/rat (Narita et al. 2005). 
Hirudin (Sigma Aldrich; St. Louis, MO) was dissolved in sterile PBS, stored at -20°C and 
administered intrathecally (4.2U/rat) 1 day prior to any surgical procedures (day -1) 
(Narita et al. 2005).  
SCH79797 dihydrochloride (N3-Cyclopropyl-7-[[4-(1-ethylethyl)phenyl]methyl]-
7H-pyrrolo[3,2-f]quinazoline-1,3-diamine dihydrochloride; Tocris; Bristol, United 
Kingdom) was fully dissolved in DMSO (Sigma Aldrich; St. Louis, MO) at a stock 
concentration of 10mg/ml and was stored at -20°C. When ready for use, the DMSO 
SCH79797 solution was diluted with sterile PBS and administered intrathecally 
(50µg/kg) 1 day before surgery or rat thrombin administration (El Eter and Aldrees 2012, 
Manaenko et al. 2013). A DMSO vehicle control was also included for comparison 
purposes; DMSO alone was diluted in sterile PBS (1:15) and intrathecally delivered to 
rats 1 day prior to surgery.  
All drug solutions were administered in the intrathecal space between the L4 and 
L5 vertebrae via a lumbar puncture via a 25G needle and syringe (Rothman and 
Winkelstein 2010). Lumbar puncture volume was the same (30µl) injection for each 
treatment. The paw withdrawal thresholds for rats in the dosing studies for rat thrombin 
and SCH79797 are detailed in Appendix A. 
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4.3.2.5. Behavioral Assessment of Mechanical Hyperalgesia 
Behavioral sensitivity was defined as the response threshold of the rat forepaw to 
an applied mechanical stimulus. Mechanical thresholds were measured using previously 
defined methods applying a series of von Frey filaments of increasing strength to the 
forepaw (Chang and Winkelstein 2011, Chaplan et al. 1994, Lee and Winkelstein 2009). 
On each testing day, rats were acclimated for 15 minutes to the testing apparatus, which 
consisted of an elevated mesh-floored cage. A series of calibrated von Frey filaments 
(1.4, 2, 4, 6, 8, 10, 15, and 26 g) (Stoelting; Wood Dale, IL) was applied in ascending 
order to the plantar surface of the forepaw until stimulation by a filament induced a 
positive response, which consisted of the rat withdrawing its forepaw and often was 
accompanied with shaking or licking of the paw (Chang and Winkelstein 2011, Chaplan 
et al. 1994, Lee and Winkelstein 2009). On each testing day rats underwent three 
consecutive rounds of testing. In each round, the filaments were applied for five 
stimulations until a positive response was elicited. If a rat responded to two consecutive 
filaments, the lower strength filament was recorded as the paw withdrawal threshold. If 
no filament elicited a response, then the highest magnitude filament (26g) was recorded 
as the threshold. On each testing day, the mechanical threshold was measured three times 
for each forepaw tested and averaged for each rat across the rounds. 
For groups that received intrathecal injection(s) but did not undergo surgical 
procedures (i.e. RTh and SCH+RTh), the forepaw withdrawal threshold was measured in 
both the left and the right forepaws on each testing day. The withdrawal thresholds were 
then averaged between the bilateral forepaws for each rat on each testing day so that only 
one threshold value was included for each rat for analysis. For groups that underwent 
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surgery to expose the right C7 nerve root (for either a compression injury or a sham 
procedure, with or without treatments), the withdrawal threshold was measured only in 
the forepaw on the side ipsilateral to surgery and were averaged across the three testing 
rounds on each day.  
 
4.3.2.6. Tissue Harvest, Immunofluorescent Labeling & Quantification of 
Fibrin(ogen) 
Rats were deeply anaesthetized with an overdose of sodium pentobarbital (Oak 
Pharmaceuticals Inc.; Lake Forest, IL) administered intraperitoneally at a dose of 
65mg/kg in order to prepare for tissue harvest. Rats were transcardially perfused with 1% 
PBS until blood ran clear and then with 300ml of 4% paraformaldehyde (Sigma; St. 
Louis, MO). The C7 spinal cord was exposed via a C6-C7 full laminectomy and 
facetectomy and harvested en bloc. Cervical spinal tissue was post-fixed overnight in 4% 
paraformaldehyde, transferred to 30% sucrose for one week at 4°C and then embedded in 
OCT medium (Sakura Finetek USA, Inc.; Torrance, CA) for cryosectioning. Fixed spinal 
cord tissue was sectioned axially at a 14µm thickness along the long-axis and mounted 
directly onto slides for immunolabeling. C7 spinal cord tissue was also harvested from 
naïve rats (n=2) and included in tissue processing for normal comparison. 
Spinal cord sections at the C7 level were fluorescently co-immunolabeled for 
fibrin(ogen), as a proxy for thrombin activity (Cortes-Canteli et al. 2012), and 
immunoglobulin G (IgG), as an indicator of BSCB breakdown (Echeverry et al. 2011, 
Poduslo et al. 1994). Briefly, slide-mounted tissue sections were blocked in 5% normal 
goat serum (Vector Laboratories; Burlingame, CA) with 0.3% Triton X-100 (Bio-Rad 
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Laboratories; Hercules, CA) for 1 hour at room temperature. Slides were incubated over 
night at 4°C with FITC-labeled rat fibrin(ogen) (1:100; Dako; Carpinteria, CA) followed 
by a 2-hour incubation at room temperature with goat anti-rat IgG Alexa Fluor 568 
(1:200; Life Technologies; Carlsbad, CA). Slides were then washed with PBS and water 
and cover slipped with fluoro-gel with TRIS buffer (Electron Microscopy Sciences; 
Hatfield, PA).  
The ipsilateral dorsal horn was digitally imaged at 10x for 2-6 spinal sections for 
each rat. Fibrin(ogen) labeling was quantified in images that were uniformly cropped to 
include the dorsal horn using a custom densitometry MATLAB script (Rothman et al. 
2010). A pixel intensity threshold was set in order to include positive fibrin(ogen) 
labeling in C7 spinal cord tissue from normal naïve rats; this threshold was kept constant 
for all analyses. The percent of the total pixels in the tissue area that was above that 
threshold of positive labeling for fibrin(ogen) in normal tissue was taken as the percent 
positive pixels in each tissue section (Nicholson et al. 2012, Rothman and Winkelstein 
2007). Percent positive fibrin(ogen) was then normalized to labeling in tissue from naïve 
rats and data were represented as expression relative to normal tissue. Differences in 
fibrin(ogen) labeling in the spinal cord was determined between groups (as outlined in 
Section 4.3.1) using separate two-way ANOVAs (group x day) with a Tukey’s test. 
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4.3.3. Results 
4.3.3.1. Painful Nerve Root Compression Promotes Extravasation of Spinal 
Thrombin that Contributes to Pain 
A 15-minute nerve root compression significantly reduces the paw withdrawal 
threshold of the ipsilateral forepaw compared to baseline levels, reflecting an increase in 
pain, that is induced by day 1 (p<0.001) (Figure 4.3A). That reduction in threshold from 
baseline is maintained until day 7 (p<0.001) (Figure 4.3A). At day 1, the rats undergoing 
a 15-minute compression also exhibit a significantly lower (p<0.001) withdrawal 
threshold than those undergoing a corresponding sham procedure and this difference is 
also detected until day 7 (Figure 4.3A). In contrast, a 3-minute compression does not 
induce any change in paw withdrawal threshold from baseline at any time point probed 
(Figure 4.3A). However, when comparing the overall group responses, rats undergoing a 
3-minute compression do exhibit significantly lower (p=0.028) withdrawal thresholds 
compared to those exposed to a sham surgery, and overall, the withdrawal threshold is 
not different compared to rats undergoing a 15-minute compression (Figure 4.3A).  
 In parallel with the production of pain at day 1, a 15-minute compression also 
induces a marked increase in fibrin(ogen) immunolabeling in the ipsilateral spinal dorsal 
horn (Figure 4.3B). The 3-minute compression exhibits less spinal fibrin(ogen) labeling 
compared to a 15-minute compression and only a slight increase when compared to sham 
levels, which are virtually absent (Figure 4.3B). When quantified, a 15-minute 
compression induces a significant increase (p<0.001) in spinal fibrin(ogen) compared to 
sham at day 1 (Figure 4.3C). At day 7, spinal fibrin(ogen) decreases to sham levels for 
both of the compression durations (Figure 4.3B). Spinal fibrin(ogen) expression is 
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significantly reduced (p=0.003) at day 7 after a 15-minute compression as compared to 
the levels of fibrin(ogen) at day 1 (Figure 4.3C). When assessing overall differences 
between groups, spinal fibrin(ogen) expression induced by a 15-minute compression is 
significantly higher than levels induced by either a 3-minute compression (p=0.0015) or a 
sham procedure (p=0.0001) (Figure 4.3C). 
 
 
  
Figure 4.3. Spinal fibrin(ogen) expression increases early after painful nerve root compression in 
areas of BSCB breakdown. (A) A 15-minute compression (15min) significantly reduces the 
withdrawal threshold at days 1 and 7 relative to corresponding responses at day 0 (^p<0.001) and to 
sham responses (*p<0.001) at both days 1 and 7. (B) Fibrin(ogen) is robustly expressed at day 1 in the 
spinal dorsal horn (dotted white outline) for 15min, but is minimally expressed for sham and 3min. (C) 
The trends are similar for both days, with 15min significantly increasing (*p<0.001) the percent 
fibrin(ogen) compared to levels after sham at day 1. By day 7 after 15min, percent fibrin(ogen) is 
significantly reduced (#p=0.003) compared to its expression at day 1. (D) Spinal fibrin(ogen) and IgG 
are highly co-localized (indicated by yellow) on day 1 after 15min. All data are mean±SD. 
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The robust expression of fibrin(ogen) labeling in the ipsilateral spinal cord 
induced at day 1 after the painful 15-minute compression strongly co-localizes with IgG 
labeling (Figure 4.3D). The co-localization of fibrin(ogen) with the serum-derived IgG 
suggests that thrombin likely extravasates into the spinal parenchyma with other serum 
proteins at times when BSCB breakdown occurs, which happens only after neural injury 
that also induces pain (Figure 3.2).  
 
4.3.3.2. Inhibiting Spinal Thrombin Prevents Nerve Root Pain  
Spinal fibrin(ogen) is elevated by day 1 after a painful 15-minute compression; 
this increase in fibrin(ogen) significantly decreases (p<0.001) by day 7 after that injury 
(Figures 4.3B & 4.4). A single intrathecal administration of hirudin substantially reduces 
the compression-induced increases in fibrin(ogen) and IgG labeling that are evident at 
day 1 in the ipsilateral spinal cord (Figure 4.4A). When quantified, hirudin treatment 
significantly reduces (p=0.006) spinal fibrin(ogen) expression at day 1 compared to an 
untreated 15-minute compression (Figure 4.4B). By day 7, the spinal fibrin(ogen) 
expression pattern is not different between an untreated 15-minute compression and a 
compression that was pre-treated with hirudin (Figure 4.4A). Indeed, the quantified spinal 
fibrin(ogen) expression is not different between those two groups at day 7 (Figure 4.4B). 
These results confirm that hirudin pre-treatment of nerve root compression prevents the 
enzymatic activity of thrombin in the spinal cord early after injury.  
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The withdrawal threshold in the ipsilateral forepaw is significantly reduced 
(p<0.001) from the corresponding baseline levels by day 1 and for all subsequent days 
tested after a 15-minute nerve root compression (Figure 4.5). Pre-treating with hirudin 1 
day before that painful compression prevents the compression-induced reduction in the 
forepaw withdrawal threshold (Figure 4.5). Rats undergoing compression alone exhibit a 
significantly lower (p<0.011) threshold than rats receiving hirudin intrathecally at day 1 
prior to a compression for all days tested (Figure 4.5).  
 
Figure 4.4. Intrathecal hirudin pre-treatment prior to a painful nerve root compression reduces 
spinal fibrin(ogen). (A) Spinal fibrin(ogen) and IgG immunolabeling increase at day 1 after a 15-
minute compression (15min), but decrease by day 7. Intrathecal pre-treatment with hirudin 1 day before 
that 15-minute compression (hir+15min) reduces spinal fibrin(ogen) and IgG expression at day 1 
compared to levels for an untreated compression. (B) Quantification of spinal fibrin(ogen) expression 
relative to expression in tissue from normal naïve rats shows significantly lower (*p=0.006) levels for 
hir+15min compared to 15min at day 1; fibrin(ogen) expression for 15min is also significantly lower 
(#p<0.001) at day 7 than day 1. Data are mean±SD. 
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4.3.3.3. Spinal Thrombin Initiates Pain through PAR1 Activation 
Rats receiving a single intrathecal injection of rat thrombin (4U/rat) exhibit a 
significant decrease (p=0.032) in the withdrawal threshold at day 1 (Figure 4.6A). The 
paw withdrawal threshold remains significantly lower (p=0.018) than baseline levels at 
day 3 after an injection of rat thrombin, but returns to baseline levels by day 5 (Figure 
4.6A). A single intrathecal injection of rat thrombin induces a significant reduction 
(p<0.001) in the bilateral withdrawal threshold on day 1 compared to the threshold at day 
0 (Figure 4.6B). However, blocking spinal PAR1 with intrathecal SCH79797 prior to the 
rat thrombin administration prevents the development of the mechanical hyperalgesia at 
day 1 that is produced by rat thrombin alone. The withdrawal thresholds at day 1 in rats 
treated with SCH79797 prior to rat thrombin are not different from the thresholds before 
the thrombin administration (at day 0) (Figure 4.6B).  
Figure 4.5. Intrathecal hirudin prior to a painful nerve root compression prevents the 
development of mechanical hyperalgesia. Mechanical hyperalgesia, measured by the withdrawal 
threshold of the ipsilateral forepaw, is significantly reduced from baseline by a 15-minute nerve root 
compression (15min) at day 1 lasting for up to 7 days after injury (^p<0.001). Pre-treating with hirudin 
(hir+15min) at 1 day before injury (day -1) prevents the compression-induced reduction in withdrawal 
threshold; the paw withdrawal threshold for hir+15min is significantly greater (*p<0.011) than 15min 
on all 7 days. Data are mean±SD. 
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4.3.3.4. Blocking PAR1 Inhibits Nerve Root-Induced Pain 
Intrathecally blocking PAR1 with SCH79797 prior to a 15-minute compression 
prevents compression-induced mechanical hyperalgesia. By day 3, SCH79797 treatment 
prevents (p<0.0065) the drop in withdrawal threshold that is evident with a 15-minute 
compression receiving vehicle pre-treatment, which is sustained for up to 7 days after 
injury (Figure 4.7). Overall, SCH79797 reduces hyperalgesia to sham levels; the same is 
evident each testing day except for day 7, when a compression treated with SCH79797 
exhibits a significantly lower (p=0.020) threshold compared to a sham procedure treated 
Figure 4.6. Intrathecal rat thrombin induces mechanical hyperalgesia, which is inhibited by 
intrathecal SCH79797. (A) The bilateral forepaw withdrawal threshold is significantly reduced 
(^p<0.032) at days 1 and 3 after intrathecal rat thrombin (RTh, 4 U/rat). (B) In separate rats, at day 1 
(d1) after RTh, the bilateral withdrawal threshold is significantly reduced (^p<0.001) from baseline 
(d0), whereas pre-treating with the PAR1 inhibitor, SCH79797, 1 day before (d-1) giving rat thrombin 
(SCH+RTh) prevents any changes in forepaw withdrawal threshold. Data are mean±SD. 
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with vehicle (p=0.020) (Figure 4.7). Of note, at day 1, the withdrawal thresholds are not 
different for rats undergoing root compression with vehicle treatment and those receiving 
a sham operation with vehicle treatment (Figure 4.7). In contrast, the respective untreated 
compression and sham groups at this same time point exhibit a significant difference in 
mechanical hyperalgesia (Figure 4.3A). However, by day 3 after a compression with a 
vehicle treatment, the typical development of a significantly lower (p<0.001) withdrawal 
threshold than sham responses are evident (Figure 4.7). The increased sensitivity relative 
to sham responses is maintained until day 7 (Figure 4.7). 
 
 
 
Spinal fibrin(ogen) expression is robustly increased over normal levels at day 1 
after a 15-minute compression with a vehicle injection (Figure 4.8A). This response 
parallels the increase in fibrin(ogen) expression that is evident in the ipsilateral spinal 
Figure 4.7. Blocking spinal PAR1 activation with SCH79797 attenuates compression-induced 
mechanical hyperalgesia. A 15-minute nerve root compression pre-treated with DMSO exhibits a 
significant decrease (*p<0.001) in ipsilateral paw withdrawal threshold by day 3 that lasts for up to 7 
days compared to vehicle-treated sham (DMSO+sham). SCH79797 (SCH+15min) prevents that 
hyperalgesia; the withdrawal threshold for SCH+15min is significantly higher (**p<0.0065) than 
DMSO+15min by day 3, and that response lasts until day 7. On day 7, the withdrawal threshold for 
SCH+15min is significantly lower (*p=0.020) than DMSO+sham. Data are mean±SD. 
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cord at day 1 after an untreated compression (Figure 4.3). However, unlike SCH79797 
treatment which returns mechanical hyperalgesia to sham levels (Figure 4.7), blocking 
spinal PAR1 with SCH79797 does not attenuate the compression-induced elevation in 
fibrin(ogen); spinal fibrin(ogen) expression is similar at day 1 for a compression treated 
with either SCH79797 or the vehicle (Figure 4.8). By day 7, spinal fibrin(ogen) 
expression is reduced to normal expression levels following a compression with either 
SCH79797 or vehicle treatment (Figure 4.8A). Elevated spinal fibrin(ogen) expression at 
day 1 after the compression with treatment or vehicle are significantly reduced (p<0.001) 
by day 7 (Figure 4.8B). Fibrin(ogen) expression in the ipsilateral dorsal horn is not 
different for any groups probed at day 7 (Figure 4.8B). The paw withdrawal thresholds 
for each rat included in Section 4.3.3 are summarized in Appendix A. Appendix B 
summarizes quantification of spinal fibrin(ogen) expression for each rat in these studies. 
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4.4. Evaluating the Effects of Spinal Thrombin & PAR1 Activation on 
BSCB Breakdown & Astrocyte Activation 
4.4.1. Study Design & Surgical Groups 
 4.4.1.1. Quantifying Spinal Astrocytic PAR1 Expression 
Since compression-induced spinal thrombin activity is hypothesized to activate 
astrocytes in the spinal cord through PAR1, the spinal astrocytic expression of PAR1 was 
measured over time after root compression injuries. Briefly, a 15-minute (15min, n=9), 3-
minute (3min, n=8) or 0-minute (sham, n=10) compression was separately applied to the 
right C7 nerve root using previously described surgical procedures on day 0 (Section 
Figure 4.8. Intrathecal inhibition of PAR1 activation with SCH79797 does not reduce spinal 
fibrin(ogen) expression. (A) Increased spinal immunolabeling of fibrin(ogen) and IgG is evident at 
day 1 after 15-minute compression either with SCH79797 (SCH+15min) or vehicle (DMSO+15min) 
treatment compared to expression in normal tissue. At day 7, spinal fibrin(ogen) decreases for both 
SCH+15min and DMSO+15min relative to corresponding levels at day 1 and is similar to DMSO-
treated sham (DMSO+sham). (B) Quantification of fibrin(ogen) labeling relative to expression in 
normal rats shows significant decreases (#p<0.001) at day 7 relative to day 1 after SCH+15min and 
DMSO+15min. Data are mean±SD. 
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4.3.2.2) (Rothman et al. 2010). Spinal cord tissue at C7 was harvested on day 1 (15min, 
n=5; 3min, n=4; sham, n=4) or day 7 (15min, n=4; 3min, n=4; sham, n=6) in separate 
groups, in order to evaluate the temporal expression of the co-localization of GFAP and 
PAR1 in the ipsilateral spinal dorsal horn. Spinal GFAP was co-immunolabeled with 
PAR1 and the co-localization was quantified; co-localized GFAP and PAR1 labeling was 
normalized to labeling in naïve tissue and differences between groups over time were 
determined using a two-way ANOVA (group x day) with Tukey’s test. 
 
4.4.1.2. Measuring the Effects of Compression-Induced Spinal Thrombin 
Activity on BSCB Breakdown & Astrocyte Activation 
In order to assess the effect of compression-induced spinal thrombin activity on 
BSCB breakdown and glial activation, thrombin was blocked intrathecally with hirudin 
prior to imposing a painful 15-minute nerve root compression. The methods for the 
intrathecal injection of hirudin and for the surgical methods of the root compression 
injury are detailed in Section 4.3.2.4. Briefly, rats received an intrathecal injection of 
hirudin (4.2U/rat) 1 day prior to a 15-minute C7 nerve root compression (hir+15min, 
n=6). In order to measure BSCB breakdown, fixed C7 spinal cord tissue was harvested at 
day 1 since BSCB breakdown is evident at day 1 after a 15-minute compression (Figure 
3.2) (Smith et al. 2015). IgG immunolabeling was quantified in the ipsilateral spinal cord 
and was compared between compression with hirudin treatment and matching tissue from 
that same time point after an untreated 15-minute compression (15min, n=5). Spinal IgG 
labeling was normalized to expression in naïve tissue and differences between the 
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hir+15min and 15min groups were determined using a one-way ANOVA with Tukey’s 
test. 
A separate group of rats receiving hirudin treatment and a painful root 
compression were perfused at day 7 (hir+15min, n=5) to measure astrocyte activation, 
since spinal GFAP is robustly elevated at day 7 after painful nerve root compression 
(Rothman et al. 2010, Rothman and Winkelstein 2007). GFAP expression in the 
ipsilateral spinal cord was immunolabeled and quantified. Details about the specific 
methods for the GFAP immunolabeling are the same as described in Section 4.4.2.3. 
Spinal GFAP expression was normalized to expression in naïve tissue and compared to 
normalized GFAP expression in tissue from matching rats at day 7 after undergoing a 15-
minute compression (15min, n=6) without hirudin treatment. Differences in spinal GFAP 
labeling between groups were determined using a one-way ANOVA with Tukey’s test.  
 
4.4.1.3. Measuring the Effects of Spinal PAR1 on BSCB Breakdown & 
Astrocyte Activation 
In order to determine the effects of spinal thrombin and its activation of PAR1 on 
non-injury induced, but painful, BSCB breakdown and astrocyte activation, rat thrombin 
was intrathecally administered (4U/rat; RTh, n=5) to naïve rats or to rats receiving an 
intrathecal injection of the PAR1 inhibitor, SCH79797 (50µg/kg) at 1 day earlier 
(SCH+RTh, n=6). Additionally, rats receiving an intrathecal injection of a PBS vehicle 
were included for immunohistochemical comparisons (PBS, n=2). Because rat thrombin 
induces the most substantial increase in mechanical hyperalgesia at day 1 (Figures 4.1 & 
4.6), BSCB breakdown and spinal astrocyte activation were both measured at day 1. 
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Bilateral C7 spinal cord tissue was harvested and immunolabeled for IgG and GFAP. IgG 
and GFAP expression were separately quantified and compared between the RTh, 
SCH+RTh, and PBS groups using separate one-way ANOVAs with Tukey’s test for each 
label of neuroinflammation.  
 
4.4.1.4. Defining the Role of PAR1 in Compression-Induced Spinal Astrocyte 
Activation  
In order to determine if spinal PAR1 activation contributes to BSCB breakdown 
at day 1 or astrocyte activation at day 7 after a painful nerve root compression, 
SCH79797 (50µg/kg) was administered 1 day before a 15-minute nerve root compression 
(SCH+15min, n=13). Vehicle controls were included in which DMSO in PBS (1:15) was 
administered intrathecally at 1 day before either a 15-minute root compression 
(DMSO+15min, n=8) or a sham surgery (DMSO+sham, n=4). Methods for the surgeries 
and the intrathecal injections are detailed in Section 4.3.2.4. Fixed C7 spinal cord tissue 
was harvested at day 1 (SCH+15min, n=6; DMSO+15min, n=4) or day 7 (SCH+15min, 
n=7; DMSO+15min, n=4; DMSO+sham, n=4) and immunolabeled for IgG and GFAP, 
respectively. Details about the methods for the quantification of spinal IgG and GFAP 
expression can be found in Sections 4.4.2.2 and 4.4.2.3, respectively. IgG expression in 
the ipsilateral spinal cord at day 1 after injury was compared for a compression with 
SCH79797 or vehicle treatment using a one-way ANOVA with Tukey’s test. Spinal 
GFAP labeling was measured at day 7 after injury and compared between a compression 
treated with SCH79797 or vehicle, and a sham operation with vehicle treatment, using a 
one-way ANOVA with Tukey’s test. 
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4.4.2. Detailed Immunohistochemical Techniques  
4.4.2.1. Immunohistochemistry for Co-localization of GFAP & PAR1 
Fixed spinal cord sections at the C7 level were fluorescently co-immunolabeled 
for PAR1 and GFAP. Slide-mounted tissue was blocked in 5% normal goat serum 
(Vector Laboratories; Burlingame, CA) with 0.3% Triton X-100 (Bio-Rad Laboratories; 
Hercules, CA) for 1 hour at room temperature. Slides were incubated over night at 4°C 
with rabbit anti-PAR1 (1:100; Abcam; Cambridge, UK) and mouse anti-GFAP (1:750; 
Dako; Carpinteria, CA) followed by a 2-hour incubation at room temperature with goat 
anti-rabbit Alexa Fluor 488 (1:250; Life Technologies; Carlsbad, CA) and goat anti-
mouse Alex Fluor 568 (1:1000; Life Technologies; Carlsbad, CA). Slides were then 
washed with PBS and water, and cover slipped with fluoro-gel with TRIS buffer 
(Electron Microscopy Sciences; Hatfield, PA). The ipsilateral dorsal horn of 2-6 sections 
from each rat was digitally imaged at 10x. Spinal astrocytic PAR1 was quantified using a 
custom co-localization MATLAB script (Dong et al. 2013). The percent of co-localized 
pixels labeling PAR1 and GFAP in spinal sections was further normalized to the percent 
co-localization in spinal cord tissue from naïve rats (n=2). 
 
4.4.2.2. Immunofluorescent Labeling & Quantification of IgG 
Slide-mounted spinal cord tissue was fluorescently immunolabeled for rat IgG by 
blocking with 0.3% Triton-X100 (Bio-Rad Laboratories; Hercules, CA) for 1 hour at 
room temperature and then incubating with goat anti-rat IgG Alexa Fluor 568 (1:200; 
Life Technologies; Carlsbad, CA) for 2 hours at room temperature. Slides were washed 
with PBS and cover slipped with fluoro-gel with TRIS buffer (Electron Microscopy 
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Sciences; Hatfield, PA). The ipsilateral spinal dorsal horn was digitally imaged at 10x in 
2-6 spinal sections for each rat. Total spinal IgG was quantified using a custom 
MATLAB script (Nicholson et al. 2012, Rothman et al. 2010). The percent of pixels 
labeling IgG in tissue sections was further normalized to the percent positive IgG labeling 
in spinal cord tissue from normal naïve rats (n=2). 
 
4.4.2.3. Immunofluorescent Labeling & Quantification of GFAP 
For GFAP immunolabeling, the same procedures were followed as described in 
Section 4.4.2.1, except without the PAR1 primary antibody and matching secondary. The 
ipsilateral dorsal horn was imaged at 20x in 2-6 spinal sections per rat. Total spinal 
GFAP expression was quantified using a custom MATLAB script (Nicholson et al. 2012, 
Rothman et al. 2010). The percent of pixels labeling GFAP in spinal cord sections was 
normalized to the percent positive labeling in spinal cord tissue from naïve rats (n=2). 
 
4.4.3. Results 
 4.4.3.1. Spinal Astrocytic PAR1 Increases after Painful Compression 
 Spinal PAR1 co-localizes with GFAP in all groups at all times probed (Figure 
4.9A), bolstering the fact that spinal astrocytes express PAR1. A nerve root compression, 
applied for either 3- or 15-minutes, induces a qualitative increase in the co-localization of 
PAR1 with GFAP in the spinal cord on the side ipsilateral to injury (Figure 4.9A). That 
increase in astrocytic PAR1 is significant for both the non-painful 3-minute (p=0.018) 
and the painful 15-minute (p=0.001) compressions compared to sham. Yet, only a painful 
15-minute nerve root compression induces a significant increase in spinal astrocytic 
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PAR1 expression at day 7; that increase is over both sham expression at day 7 (p<0.001) 
and the expression at day 1 that is evident after a 15-minute compression (p=0.024) 
(Figure 4.9B). The quantification of the spinal co-localization of PAR1 and GFAP in the 
ipsilateral spinal cord for each rat in this study is provided in Appendix B. 
 
 
 
 
 
Figure 4.9. Spinal astrocytic PAR1 increases by day 7 after a 15-minute nerve root compression. 
(A) Spinal PAR1 (green) and GFAP (red) co-localize (yellow) in the ipsilateral spinal cord to a greater 
degree at day 7 after either a 3-minute (3min) or a 15-minute (15min) compression. (B) Only a 15-
minute compression induces a significant increase in percent spinal PAR1 co-localization with GFAP at 
day 7 after compression; this is significant compared to sham levels at that same day (*p<0.001) and 
expression levels at day 1 for 15min (#p=0.024). Data are presented as mean±SD. 
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4.4.3.2. Hirudin Prevents Compression-Induced BSCB Breakdown & Spinal 
Astrocyte Activation 
 Blocking spinal thrombin activity with a single intrathecal injection of hirudin at 
day 1 before a painful root compression significantly reduces (p=0.002) the spinal 
expression of IgG that is robustly increased at day 1 after a painful compression (Figure 
4.10A & 4.10B). By day 7, hirudin also significantly decreases (p=0.021) spinal GFAP 
expression in comparison to expression of GFAP at that time point after a compression 
without any treatment (Figure 4.10). Quantification of the spinal IgG expression at day 1 
and GFAP expression at day 7 for each rat in this study is detailed in Appendix B. 
 
 
Figure 4.10. Intrathecal hirudin prevents spinal IgG accumulation at day 1 and spinal astrocyte 
activation at day 7 after painful root compression. (A) IgG expression in the ipsilateral spinal cord at 
day 1 and GFAP expression at day 7 are markedly reduced following treatment with hirudin after 
compression (hir+15min) compared to compression alone (15min). (B) Quantified IgG expression 
relative to expression in normal rats is significantly reduced (*p=0.002) for hir+15min compared to 
15min at day 1. (C) Hirudin significantly decreases (*p=0.021) spinal GFAP expression at day 7 
compared to expression after a compression alone. Data are presented as mean±SD. 
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4.4.3.3. Spinal Thrombin Induces BSCB Breakdown through PAR1 
A single intrathecal injection of rat thrombin increases the spinal expression of 
GFAP and IgG at day 1 after injection compared to an injection of PBS (Figure 4.11A). 
Blocking PAR1 activation in the spinal cord with SCH79797 given prior to the 
administration of the rat thrombin reduces both spinal GFAP and IgG labeling compared 
to rat thrombin alone (Figure 4.11A). Intrathecal thrombin significantly increases spinal 
IgG at day 1 compared to a PBS injection; blocking PAR1 prior to injecting the rat 
thrombin prevents that increase in IgG (Figure 4.11B). In contrast, an injection of rat 
thrombin does not significantly increase spinal GFAP expression at day 1 (Figure 4.11C). 
There is no difference in GFAP expression between any group despite intrathecal rat 
thrombin inducing a slight, but not significant (p=0.054), elevation in spinal GFAP 
expression compared to the PBS injection (Figure 4.11C). Quantification of the IgG and 
GFAP expression at day 1 in the bilateral spinal cord for each rat in this portion of the 
study is detailed in Appendix B. 
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4.4.3.4. Blocking Spinal PAR1 does not Reduce Spinal IgG or GFAP 
Expression after Compression 
A painful compression with vehicle treatment (given 1 day before compression) 
increases IgG expression in the ipsilateral spinal cord at day 1 over normal levels (Figure 
4.12A). Blocking spinal PAR1 with SCH79797 prior to the root compression induces an 
even more marked increase in spinal IgG expression (Figure 4.12A). In fact, spinal IgG 
expression at day 1 is significantly greater (p<0.001) for a compression treated with 
SCH79797 compared to IgG labeling observed in tissue after a compression without 
Figure 4.11. Intrathecal rat thrombin induces spinal IgG extravasation 1 day later, which is 
attenuated by intrathecal SCH79797. (A) Spinal GFAP and IgG expression are qualitatively 
increased at day 1 after a single intrathecal injection of rat thrombin (RTh) compared to an injection of 
PBS. Pre-treating with SCH79797 intrathecally (SCH+RTh) 1 day before RTh reduces the appearance 
of spinal GFAP and IgG at day 1. (B) Spinal IgG expression relative to levels in normal rats is 
significantly increased (*p<0.001) at day 1 after intrathecal RTh. That thrombin-induced elevation in 
spinal IgG expression is significantly attenuated (**p<0.001) by pre-treating with SCH79797. (C) 
There is no difference between any groups in the percent GFAP normalized to expression in naïve rats 
at day 1. Data are presented as mean±SD. 
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treatment (Figure 4.12A). Spinal GFAP expression appears similar between all groups at 
day 7 and is not different when quantified (Figure 4.12C). Detailed quantification of the 
IgG expression at day 1 and GFAP expression at day 7 in the ipsilateral spinal cord for 
each rat in this study is detailed in Appendix B. 
 
 
 
4.5. Discussion 
This is the first study to demonstrate that a compressive nerve root injury 
increases spinal thrombin activity, which contributes to spinal astrocyte activation and the 
mechanical hyperalgesia that both develop. Additionally, spinal thrombin at least 
partially contributes to early compression-induced BSCB breakdown and the 
Figure 4.12. Intrathecal SCH79797 does not prevent compression-induced elevations in spinal 
IgG at day 1 or spinal GFAP at day 7. (A) IgG expression in the ipsilateral spinal cord is robust at 
day 1 after a 15-minute compression pre-treated with a DMSO vehicle (DMSO+15min) compared to 
expression in normal tissue. Spinal IgG labeling after pre-treating with SCH79797 (SCH+15min) is 
even more robust. Normalized spinal IgG expression is significantly increased (*p<0.001) at day 1 after 
SCH+15min compared to DMSO+15min. (B) Spinal GFAP expression is minimal for all groups 
(DMSO+sham, DMSO+15min, SCH+15min) at day 7. Data are mean±SD. 
  124 
development of pain through its activation of PAR1 (Figures 4.5 & 4.11). Thrombin 
activity, as evaluated by positive labeling for fibrin(ogen), is increased in the ipsilateral 
spinal cord at day 1 only after a transient nerve root compression that also induces pain 
(Figure 4.3). That expression of fibrin(ogen) is present in spinal regions where BSCB 
breakdown also occurs (Figure 4.3D). A single intrathecal dose of hirudin prevents the 
painful compression-induced increases in spinal fibrin(ogen) and IgG at day 1 (Figures 
4.4 & 4.10) and the increase in spinal GFAP at day 7 (Figure 4.10). Blocking spinal 
thrombin with hirudin is also sufficient to prevent the development of pain after a 15-
minute compression (Figure 4.5). These findings suggest that thrombin activity in the 
spinal cord is requisite for the onset of pain after nerve root injury and may contribute to 
sustained astrocyte activation in the spinal cord.  
The role of spinal thrombin in pain development is further supported by the 
findings that a single intrathecal injection of rat thrombin is potent enough to produce 
behavioral sensitivity for up to 3 days in naïve rats (Figure 4.6A). That single 
administration of exogenous thrombin also induces BSCB breakdown at day 1 when 
hyperalgesia is maximal (Figure 4.11). Blocking PAR1 activation with the antagonist, 
SCH79797, prior to injection of rat thrombin prevents the development of thrombin-
induced mechanical hyperalgesia (Figure 4.6B), indicating that thrombin may act 
centrally through PAR1 to modulate nociceptive mechanisms. SCH79797 is also 
sufficient to block rat thrombin-induced BSCB at day 1 (Figure 4.6). Further supporting 
the PAR1 pathway in thrombin-mediated pain, blocking spinal PAR1 activation prior to a 
painful compression also prevents the development of pain after injury (Figure 4.7). 
However, blocking PAR1 with SCH79797 does not mitigate the spinal fibrin(ogen) and 
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IgG deposition that is evident at day 1 after painful compression (Figures 4.8 & 4.12). 
Thrombin still extravasates into the spinal parenchyma even when blocking PAR1 with 
SCH79797, suggesting that thrombin is capable of activating substrates in the spinal cord 
in addition to PAR1. Therefore, thrombin’s activation of other substrates within the 
spinal cord does not contribute to radicular pain. Since SCH79797 and its vehicle 
(DMSO) each separately attenuate spinal astrocyte activation at day 7 after painful 
compression (Figure 4.12), it is possible that spinal thrombin does not activate astrocytes 
through PAR1 activation. For example, astrocytes also expression PAR3 and PAR4 
(Wang et al. 2002), which are activated by thrombin. Activation of PAR4 in astrocytes in 
vitro even exerts toxic effects (Wang et al. 2002), suggesting that thrombin may 
contribute to spinal astrocyte activation following painful compression through PAR4. 
Despite SCH79797 and DMSO both attenuating spinal astrocyte activation, intrathecal 
SCH79797 also attenuates pain, whereas the DMSO vehicle does not (Figure 4.7). 
Therefore, spinal PAR1 activation does contribute to nociception following root 
compression and might do so through non-glial mechanisms. Since neurons also express 
PAR1 and activation of neuronal PAR1 has been shown to sensitize nociceptive neurons 
(Vellani et al. 2010), SCH79797 might reduce the neuronal hyperexcitability that is 
evident by day 7 after compression. 
 Circulating thrombin has been previously hypothesized to cross a compromised 
BSCB and thereby contribute to neuroinflammatory processes in the CNS (Suo et al. 
2004). Yet, this is the first in vivo study demonstrating that thrombin enters the CNS in 
areas of BSCB breakdown that appear after nerve root compression injury and that 
thrombin is required for pain (Figure 4.3). Spinal thrombin activity is elevated exclusively 
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after a painful nerve root compression and is abundant at day 1 when pain is first evident 
(Figure 4.3) (Hubbard and Winkelstein 2005, Rothman et al. 2010). Spinal fibrin(ogen) 
expression increases along the same time course as the breakdown of the BSCB after this 
painful root injury (Smith et al. 2015); spinal fibrin(ogen) and IgG (Smith et al. 2015) 
expression both increase by day 1 and return to normal levels by day 7 (Figure 4.3). In 
fact, fibrin(ogen) is co-expressed with the serum protein IgG, suggesting that thrombin 
enters the spinal parenchyma from the periphery. Additionally, the spinal expression of 
fibrin(ogen), the polymeric enzymatic product of thrombin, suggests that thrombin is 
capable of exerting enzymatic activity once in the spinal parenchyma. Yet, fibrin(ogen) is 
used in the current study as a proxy for thrombin activity, elevation in fibrin(ogen) in 
regions of BSCB breakdown could also be due to fibrin or fibrinogen crossing the BSCB 
and accumulating in the spinal cord. However, exogenous fibrin in the brain does not 
adversely affect neuronal health, nor does it induce local inflammation (Hultman et al. 
2014). Therefore, it is not likely that the increases in spinal fibrin(ogen) that are evident 
after a compression injury are responsible for those pathologic mechanisms that are 
involved in the development of pain. Blocking fibrin’s enzymatic precursor, thrombin, 
centrally prior to compression prevents pain (Figure 4.5) and further supports thrombin’s 
presence in the spinal parenchyma as contributing to pain after injury. Although previous 
studies have demonstrated that pain-related pro-inflammatory cytokines can cross the 
BSCB when its integrity is compromised (Echeverry et al. 2011, Pan et al. 1997), this is 
the first report that serum-derived enzymes can also enter the spinal parenchyma and 
appear to initiate nociceptive cascades.  
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The transient early elevation in spinal thrombin activity after a painful 
compression (Figure 4.3) contributes to the spinal astrocytic activation that is evident by 
day 7 after that injury since blocking spinal thrombin with hirudin prevents astrocyte 
activation at day 7 (Figure 4.10) (Rothman and Winkelstein 2007). Further, although only 
a trend, intrathecal rat thrombin also increases spinal GFAP expression at day 1 
compared to a PBS vehicle (Figure 4.11); however, the PBS vehicle group only 
represents spinal cord tissue from 2 rats and the statistical test did not have enough 
power. In order to reach a power of 0.8 the PBS vehicle group would need to be 
expanded out to at least 3 rats. This is a limitation of that study and one rat should have 
been added to the PSB vehicle group in order to accurately test whether spinal GFAP 
expression was different between the vehicle group and the group that received an 
injection of rat thrombin. Rat astrocytes express multiple thrombin-activated receptors 
(Figure 4.9) (Shavit et al. 2011, Wang et al. 2002), and activation of astrocytic PAR1, in 
particular, induces glial activation and proliferation (Fan et al. 2005, Nicole et al. 2005, 
Wang et al. 2002). Following this same painful root compression, spinal GFAP has been 
reported to be marginally elevated by day 1 and more robustly increased by day 7 
(Rothman and Winkelstein 2007). Thrombin activity is elevated in the spinal parenchyma 
by day 1 and is no longer present in the spinal cord by day 7 (Figures 4.3) when both pain 
and astrocytic activation persist (Rothman et al. 2010, Rothman and Winkelstein 2007). 
Therefore, the early spinal thrombin activity induced by a painful compression may be an 
initiator of sustained spinal astrocyte activation.  
Although these studies confirm a role for thrombin activity in both nerve root-
mediated glial activation and pain, evaluating the expression of fibrin(ogen) only captures 
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the accumulation of thrombin’s enzymatic products and does not provide information on 
the dynamic expression profile of thrombin activity. A recent study reported a method by 
which thrombin activity can be quantitatively measured in vitro within brain slices 
excised after an ischemic insult via the middle cerebral artery (Bushi et al. 2013). By 
applying a fluorescent thrombin substrate on fresh brain slices after ischemia, thrombin 
activity was found to increase by 24 hours after ischemia, but only on the side ipsilateral 
to the insult (Bushi et al. 2013). By taking fresh slices of C7 spinal cord tissue at 1 day 
after a painful nerve root compression, this fluorogenic method for detecting thrombin 
activity could be used to determine whether thrombin is actually active in the spinal 
parenchyma at day 1 when fibrin(ogen) accumulation is evident (Figure 4.3).  
To investigate whether spinal thrombin contributes to nerve root compression-
induced pain, we selectively blocked thrombin activity prior to a painful injury. When 
hirudin is given before the compression it prevents the deposition of fibrin(ogen) in the 
spinal parenchyma (Figure 4.4), confirming that hirudin is sufficient to block thrombin 
from enzymatically producing fibrin(ogen) in the spinal cord. That single treatment of 
hirudin is potent enough to completely inhibit the development of pain for up to 1 week 
after compression (Figure 4.5), which is in agreement with a previous study showing that 
intrathecal hirudin prevents mechanical and thermal sensitivity after a sciatic nerve 
ligation in the mouse during and after the treatment period (Narita et al. 2005). However, 
in contrast to that study in which repetitive hirudin dosing marginally suppresses pain 
(Narita et al. 2005), a single dose of hirudin completely prevents pain after a root 
compression (Figure 4.5). A sciatic nerve ligation also induces breakdown of the BSCB 
lasting for up to 30 days (Beggs et al. 2010, Echeverry et al. 2011), in contrast to a 15-
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minute nerve root compression which only induces BSCB breakdown for a single day 
(Smith et al. 2015). It is possible that a sciatic nerve injury permits thrombin 
extravasation into the spinal parenchyma for a much longer duration (up to 30 days) than 
does the transient root compression, and hence allows thrombin to exert sustained activity 
within the spinal cord. Since hirudin is relatively stable in vivo and retains 60-80% of its 
activity after 24 hours (Kaiser et al. 2012), it is still active in the spinal cord at the time 
when the root undergoes compression, and likely remains active after the breakdown of 
the BSCB. Spinal thrombin is likely only active is the spinal parenchyma for 
approximately the same duration as the BSCB permeability (1 day) after compression 
since its half-life is on the order of hours (Vogel et al. 1979). A single dose of hirudin 
likely remains active for the entire duration of increased thrombin activity and, therefore, 
likely fully blocks spinal thrombin’s contribution to pain.   
In contrast to hirudin’s completely preventing nerve root-induced pain, pain is 
only partially attenuated by inhibiting the action of TNF-α or IL-1 in the spinal cord prior 
to injury (Rothman and Winkelstein 2007, Rothman and Winkelstein 2010). Once in the 
CNS, thrombin induces glial production of pro-inflammatory cytokines (Choi et al. 2008, 
Fan et al. 2005, Simmons et al. 2013). Thrombin is an upstream inducer of pro-
inflammatory cytokine production (Simmons et al. 2013, Suo et al. 2004). Therefore, 
blocking the action of just one pro-inflammatory cytokine in the CNS might not attenuate 
pain to the same degree as does blocking thrombin since thrombin contributes to spinal 
inflammation. Blocking thrombin in the spinal cord may also attenuate the local 
inflammatory responses that contribute to the development of pain, further enhancing its 
anti-nociceptive effects. Future studies should examine whether blocking spinal thrombin 
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activity explicitly reduces spinal pro-inflammatory cytokine expression exhibited after 
painful root compression.  
Spinal thrombin’s contribution to nerve root-induced pain is supported by the 
findings that a single intrathecal injection of rat thrombin induces pain for up to 3 days in 
the absence of any other injury-induced inputs (Figure 4.6A). Yet, more robust 
behavioral sensitivity has been reported in mice receiving a single injection of thrombin, 
with mechanical allodynia persisting for up to 10 days (Narita et al. 2005). Since the 
current study administered a comparable amount of thrombin in rats, the disparity in the 
duration of pain following the central administration of thrombin might depend on the 
species being treated in comparison to the species in which the exogenous thrombin is 
derived. Narita et al. (2005) did not specify which species of thrombin was used; it is 
possible that thrombin derived from a non-murine species was administered. 
Administering “non-self” proteins, including thrombin, induces a complex immune 
response (Ballard et al. 2010, Laidmae et al. 2006, Lawson 2006), and if administered to 
the CNS might exacerbate neuroinflammation and contribute to the extended period of 
mechanical allodynia that was observed in the murine study.  
Blocking spinal thrombin significantly blunts BSCB breakdown at day 1 after a 
painful compression (Figures 4.4A & 4.10). Although BSCB breakdown is requisite for 
thrombin extravasation into the spinal parenchyma, it is possible that hirudin also 
prevents spinal thrombin’s prolonged activation of neurovascular endothelial cells 
thereby reducing the extent of compression-induced BSCB breakdown. Exogenous rat 
thrombin administered intrathecally significantly increases spinal IgG within 1 day 
(Figure 4.11), further implicating that spinal thrombin activity in the induction of BSCB 
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breakdown, even without any other injury inputs. The ability of thrombin to induce 
vascular permeability in the spinal cord at least partially depends on its activation of 
PAR1; blocking activation of spinal PAR1 with SCH79797 significantly inhibits BSCB 
breakdown induced after a spinal injection of rat thrombin (Figure 4.11). However, 
blocking PAR1 prior to a painful compression does not attenuate injury-induced BSCB 
breakdown (Figure 4.12), suggesting that thrombin is not the only contributor to the 
breakdown of BSCB after painful nerve root compression. For example, microendothelial 
permeability is controlled by intracellular actomyosin contractility that can be induced by 
activated neutrophils, TNF-α, and histamine, in addition to thrombin (Nooteboom et al. 
2002, Rigor et al. 2013). Of those inducible factors, TNF-α expression is increased in the 
spinal cord on the side ipsilateral to the root injury by 1 hour after compression (Rothman 
et al. 2009, Rothman and Winkelstein 2010), and also likely contributes to the BSCB 
breakdown that is also evident in that spinal region. 
 Blocking spinal PAR1 activation prior to a nerve root injury produces similar 
behavioral results as does pre-treating with hirudin (Figures 4.5 & 4.7); both treatments 
prevent nerve root-induced pain for at least 7 days. Yet, in contrast to hirudin, SCH79797 
does not alter pain outcomes immediately (by day 1) (Figure 4.7). Unlike hirudin, which 
was administered in an inert saline vehicle, the vehicle (DMSO) used to deliver 
SCH79797 is not biologically inert and has been shown to be neurotoxic in some cases in 
a dose-dependent manner (Galvao et al. 2014, Qi et al. 2008). In fact, pre-treatment with 
the DMSO vehicle in the sham group in this study appears to induce a slight increase in 
mechanical hyperalgesia at day 1 (Figure 4.7), which is not typical for sham operated rats 
(Figure 4.3A) (Hubbard and Winkelstein 2005, Rothman and Winkelstein 2007, Smith 
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and Winkelstein 2015). A recent study demonstrated that treating CA1 neurons in 
hippocampal brain slices with DMSO for up to 5 hours reduces the threshold for action 
potential firing in response to an electrical stimulus (Tamagnini et al. 2014). In the 
current study, DMSO also might decrease the threshold for neuronal firing in the spinal 
cord, thereby contributing to central sensitization. That pro-nociceptive effect of DMSO 
on neurons might outweigh the anti-inflammatory effects that it produces via modulating 
spinal glia (Figure 4.12) (Lapuente Chala et al. 2013), and contribute a painful root 
compression treated with the DMSO vehicle inducing behavioral sensitivity but at the 
same time reducing spinal astrocyte activation. Although hirudin and SCH79797 both 
inhibit pain (Figures 4.5 & 4.7), SCH79797 is not sufficient to prevent early nerve-root 
induced spinal fibrin(ogen) deposition or BSCB breakdown (Figure 4.8). Since 
SCH79797 reduces pain without also reducing spinal fibrin(ogen) expression, 
fibrin(ogen) is not likely an initiator of pain. In fact, the use of fibrin gels to treat spinal 
cord injury has been widely investigated since fibrin matrices promote neuronal regrowth 
(Itosaka et al. 2009, Uibo et al. 2009, Winer et al. 2009). Since this polymeric enzymatic 
product of thrombin does not actively contribute to nociception, spinal thrombin’s 
activation of PAR1 and inflammation likely promotes its role in pain development after 
nerve root compression.  
This study establishes a novel contribution for spinal thrombin activity in the pain 
that develops after neural injuries that are associated with BSCB breakdown. Previous 
reports emphasize the extravasation of pro-inflammatory cytokines and the 
transmigration of immune cells into the CNS as contributing to neuroinflammation and 
pain (Ballabh et al. 2004, Echeverry et al. 2011, Webb and Muir 2000). The findings of 
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the current study extend existing models implicating the contribution of BSCB 
breakdown to pain by demonstrating that bioactive thrombin also enters the spinal 
parenchyma after nerve root injury and is requisite for pain onset. Blocking the enzymatic 
activity of thrombin in the spinal cord before a nerve root compression completely 
prevents the development of pain and substantially reduces the longer-term spinal 
astrocytic activation (Figures 4.5 & 4.10). Findings from this study support the notion 
that spinal thrombin induces pain through its activation of PAR1 centrally (Figures 4.6 & 
4.7); yet, defining which CNS cell type(s) express PAR1 and are most likely to contribute 
to pathological mechanisms that do contribute to nociception are needed. Nonetheless, 
these findings have implications not only for the treatment of painful neuropathic 
injuries, but also for the host of other neuropathic disorders that induce, and are 
exacerbated by, BSCB breakdown like ischemic stroke, Alzheimer’s disease, Parkinson’s 
diseases and multiple sclerosis, among others (Hirsch and Hunot 2009, Sharief and 
Thompson 1992, Zlokovic 2008, Zlokovic 2011).  
 
4.6. Integration & Conclusions 
BSCB breakdown after a nerve root compression is only evident when behavioral 
sensitivity is also present (Figure 3.2), and that breakdown contributes to pain (Figure 
3.4). Root compression-induced BSCB breakdown facilitates the spinal extravasation of 
TNF-α (Figure 3.2), which when expressed in the spinal cord has been shown to 
contribute to the development of mechanical allodynia after root trauma (Rothman and 
Winkelstein 2010). The studies in this chapter demonstrate that endogenous thrombin 
  134 
also extravasates into the spinal parenchyma where there is BSCB breakdown from a 
painful compression (Figure 4.3). Once in the spinal cord, thrombin contributes to the 
development of pain, both after a 15-minute nerve root compression and after exogenous 
rat thrombin administration into the spinal cord (Figures 4.5 & 4.6). Although intrathecal 
rat thrombin only induces marginal spinal astrocytic activation at day 1 when pain was 
present (Figure 4.11), blocking thrombin activity with hirudin does reduce spinal 
astrocyte activation at a later time (i.e. day 7) after painful compression (Figure 4.10). 
Spinal thrombin activity is likely greater following a root compression than an injection 
of rat thrombin since BSCB permeability increases after painful compression for at least 
1 day (Figure 3.2); therefore, thrombin may enter the spinal parenchyma over that entire 
day. The different degrees of spinal astrocyte activation after those insults likely depends 
on the amount of thrombin activity. Since blocking spinal PAR1 with SCH79797 
prevents pain from developing after either insult (Figures 4.6 & 4.7), spinal thrombin is 
taken to mediate pain through PAR1 regardless of how it is induced. Although PAR1 is 
important for thrombin’s induction of nociception in the CNS, these studies do not 
determine whether thrombin activates astrocytes through PAR1. Antagonizing PAR1 
prior to a painful compression reduces the spinal astrocyte activation that is typically 
evident at day 7, but the vehicle treatment also reduces spinal GFAP (Figure 4.12). Since 
SCH79797 blocks compression-induced pain but DMSO does not (Figure 4.7), this 
spinal astrocytic activation is not likely the sole regulator of nociception following 
painful root compression. Regardless, endogenous thrombin activity in the spinal cord 
appears to play an important role in nerve root-mediated pain by contributing to spinal 
astrocytic activation and exacerbating BSCB breakdown. 
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Although these studies focus on the role of rat thrombin in pain, thrombin derived 
from non-mammalian species has been shown to influence pain outcomes differently. For 
example, treating a painful root compression with salmon thrombin at the injury site 
prevents the development of behavioral sensitivity (Weisshaar et al. 2011). Thrombin 
controls cellular processes through its enzymatic activation of many cell receptors, 
including PAR1, PAR3, PAR4, and endothelial-bound protein C (Coughlin 2000, Di 
Cera 2008, Lane et al. 2005). In many cellular cascades, including coagulation, 
inflammation, and endothelial permeability, thrombin’s activation of PAR1 exerts the 
exact opposite cellular effects than its activation of endothelial-bound protein C 
(Bouwens et al. 2013, Di Cera 2008, Griffin 1995, Komarova et al. 2007, Vergnolle et al. 
1999). For example, here we demonstrate that spinal rat thrombin activates PAR1 and 
induces vascular leakiness (Figure 4.11); but, mammalian thrombin can also stabilize 
endothelial barriers when it is bound to thrombomodulin by activating endothelial-bound 
protein C (Esmon 1993, Xu et al. 2005, Yang et al. 2006). Thrombin’s enzymatic activity 
is guided towards particular substrates through a variety of molecular events, such as 
binding to a cofactor or altered sodium concentration, which modulate the chemistry and 
three-dimensional structure of thrombin (Gandhi et al. 2011, Jacques et al. 2000, Lane et 
al. 2005). Since various species of thrombin have naturally-evolved structures that are 
slightly different (Dang et al. 1997, Doolittle 2011, Tort et al. 2003), this diversity might 
influence the innate affinity of each species of thrombin for its substrates. Salmon 
thrombin is hypothesized to initiate pain-related pathways that are opposite from those of 
mammalian thrombin because it might exhibit different activation rates of thrombin-
cleavable cell receptors. The studies in Chapter 5 investigate the differential effects 
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between salmon and human thrombin on BSCB breakdown and pain induced after a 
painful nerve root compression, as well as on endothelial barrier permeability and 
astrocyte activation in vitro.  
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Chapter 5 
Differential Effects of Salmon & Human 
Thrombin on Vascular Permeability, Astrocyte-
Induced Inflammation, & Pain 
 
Parts of this chapter are included in both a published paper and a submitted manuscript: 
 
Smith JR, Syré PP, Oake SA, Nicholson KJ, Weisshaar CL, Cruz K, Bucki R, Baumann 
BC, Janmey PA, Winkelstein BA. Salmon and human thrombin differentially regulate 
radicular pain, glial-induced inflammation and spinal neuronal excitability through 
protease-activated receptor-1. PLoS One (2013) 8(11):e0080006. 
 
Smith JR, Galie PA, Slochower DR, Weisshaar CL, Janmey PA, Winkelstein BA. 
Salmon-derived thrombin inhibits development of chronic pain through an endothelial 
barrier protective mechanism dependent on APC. Biomaterials, accepted. 
 
5.1. Overview 
 Less than 50% of patients in neuropathic pain trials achieve satisfactory pain 
relief with currently available treatments (O'Connor and Dworkin 2009). According to 
the neuropathic pain special interest group (NeuPSIG) of the International Association 
for the Study of Pain (IASP) the standard set of FDA approved treatments that are first 
recommended for neuropathic pain patients include tricyclic antidepressants (e.g. 
norepinephrine and serotonin reuptake inhibitors), anticonvulsants (such as gabapentin 
and pregabalin) and the 5% lidocaine patch (Dworkin et al. 2003, Finnerup et al. 2010, 
O'Connor and Dworkin 2009). All of these treatments selectively target the neuronal 
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aspects of nociception; they either modulate synaptic concentration of monoamine 
neurotransmitters (e.g. norepinepherin and serotonin) (Sindrup et al. 2005), increase the 
neurotransmitters in synapses that inhibit excitatory neuronal signaling by binding to 
voltage gated calcium channels (i.e. gamma-Aminobutyric acid, GABA) (Gilron 2007, 
O'Connor and Dworkin 2009), or block sodium channel function (Argoff 2000, Meier et 
al. 2003). Although the classic view of nociception involves aberrant neuronal signaling, 
it has become widely accepted that glia, including astrocytes and microglia, are also 
powerful modulators of the propagation and maintenance of pain (Inoue 2006, McMahon 
et al. 2005, Vallejo et al. 2010, Watkins et al. 2001). Glial cells contribute to nociception 
by releasing pro-inflammatory cytokines, which further stimulate neurons, and by 
modifying their expression of various neurotransmitter receptors, thereby dysfunctionally 
modulating the synaptic concentration of neurotransmitters (DeLeo and Yezierski 2001, 
Inoue 2006, Latremoliere and Woolf 2009, Milligan and Watkins 2009, Rothman et al. 
2009, Rothman and Winkelstein 2010, Scholz and Woolf 2007, Vallejo et al. 2010, 
Volterra and Meldolesi 2005, Vranken 2009). Therapeutic strategies for treating chronic 
neuropathic pain that dually target both the neuroinflammatory cascades involved in pain 
and the neuronal dysfunction are promising replacements for current first-line treatments.  
The studies presented in Chapters 3 and 4 together demonstrate that blood-spinal 
cord-barrier (BSCB) breakdown induced by painful nerve root compression is 
responsible for the infiltration of endogenous thrombin into the spinal parenchyma, and 
that blocking an initiator (BSCB breakdown) or outcome (thrombin activity in the spinal 
cord) of this cascade prevents the development of radicular pain. Although studies in 
Chapter 3 establish that activated protein C (APC), a known protector of vascular 
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breakdown, is effective at blocking the BSCB breakdown that is induced by day 1 after a 
painful nerve root compression injury (Figure 3.4) (Smith et al. 2015), this enzyme is not 
an ideal clinical treatment because its inherent anticoagulant properties prevent the 
clotting that is necessary to stop bleeding (Bernard et al. 2001, Finfer et al. 2008, Marti-
Carvajal et al. 2012). For traumatic nerve root compression, which mechanically disrupts 
axonal and vascular integrity within the root (Garfin et al. 1995, Olmarker et al. 1989, 
Yoshizawa et al. 1989), APC is even less ideal since internal bleeding is also evident at 
the site of trauma to the root. Activating the APC pathway without hampering the 
coagulation that promotes local healing, or administering APC in conjunction with a 
procoagulant agent would be ideal alternate strategies for inhibiting BSCB breakdown. 
Recent approaches in protein therapy have focused on modifying the inherent structure of 
mammalian thrombin in order to direct its affinity towards protein C instead of the 
protease-activated receptors (PARs), in order to stabilize endothelial barriers while 
maintaining the ability to form clots (Dang et al. 1997, Marino et al. 2010). Interestingly, 
native thrombin produced in non-mammalian species exhibits slightly modified protein 
structures from thrombin derived from mammals (Dang et al. 1997, Laidmae et al. 2006, 
Manseth et al. 2004) and potentially induces different cell signaling cascades because of 
the modified substrate affinities (Michaud et al. 2002, Sharp et al. 2012, Weisshaar et al. 
2011). As such, the studies outlined in this chapter investigate the whole body, cellular, 
and enzymatic effects of salmon thrombin compared to human thrombin in relation to 
pain, BSCB breakdown and spinal inflammation.  
The work presented in this chapter focuses on the experiments that are outlined in 
Aim 3 and test the specific hypotheses that salmon thrombin exhibits unique effects on 
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vascular permeability and glial inflammation, both of which contribute to its analgesic 
capabilities after painful neural trauma. It is further hypothesized that salmon thrombin’s 
effects on endothelial cells and astrocytes depend on its rates of substrate activation that 
are distinct from human thrombin. An in vivo model of painful nerve root compression in 
the rat was used to investigate different effects of salmon and human thrombin on the 
compression-induced development of behavioral hypersensitivity and early BSCB 
breakdown (Section 5.3). For those in vivo studies, salmon thrombin was applied directly 
to the nerve root since we have previously shown that salmon thrombin is analgesic when 
administered this way (Weisshaar et al. 2011). To determine whether salmon thrombin 
acts directly on endothelial cells to promote vascular integrity, studies in Section 5.3 also 
include in vitro microchannel experiments designed to measure human endothelial cell 
barrier permeability in the presence of an inflammatory inducer of vascular leakiness, 
tumor necrosis factor-alpha (TNF-α) (Galie et al. 2014, Nooteboom et al. 2002, Sharief 
and Thompson 1992). Section 5.4 details studies measuring the comparative effects of 
salmon and human thrombin on the maintenance of nerve root compression-induced pain. 
They further utilize mixed glial-neuronal cortical cultures to investigate the ability of 
salmon thrombin to induce astrocytic production of inflammatory cytokines that are 
involved in pain; effects are compared to those of human thrombin. Lastly, a variety of 
fluorogenic peptide assays were designed and utilized to quantify the comparative 
cleavage rates of PAR1, PAR3 and PAR4 (Section 5.3), as well as the rate of APC 
generation (Section 5.4), in order to provide comparative measures of the substrate 
selectivity profiles for salmon and human thrombin. A combined background is provided 
(Section 5.2) for the effects of both species of thrombin on vascular protection and glial-
  141 
induced inflammation. Yet, the methods and results investigating how salmon thrombin 
influences vascular integrity (Section 5.3) and glial inflammation (Section 5.4) are 
presented as separate sections because they are induced by different thrombin-mediated 
cellular signaling cascades. This chapter concludes with a presentation of discussion and 
conclusions that integrate findings from each of the separate studies. 
 
5.2. Relevant Background 
Neck pain is estimated to affect up to 70% of the general adult population, with 
substantial annual physical burdens, health care costs, and associated disabilities (Cote et 
al. 2004, Haldeman et al. 2009, Strine and Hootman 2007). Neuropathic pain is classified as 
pain resulting from a direct insult, whether mechanical or inflammatory, to neural tissue, 
which can become chronic and persist long after the initial injury due to a variety of 
biochemical changes in the central nervous system (CNS) (Scholz and Woolf 2007, 
Woolf and Mannion 1999). The cervical dorsal nerve roots, which are comprised of 
sensory axons, are especially susceptible to injurious mechanical loading. The nerve roots 
bridge the peripheral and the central nervous systems and are physically surrounded by 
cerebrospinal fluid and enclosed within the dura (Maikos et al. 2008, Ommaya 1968). 
Although the dura and cerebrospinal fluid (CSF) protect the nerve root from the normal 
physiological motions of the surrounding bony structures that make up the intervertebral 
foramen, under pathological conditions normal neck motions can become injurious (Reid 
1960). Further, when the spine undergoes rapid, non-physiological movements the roots 
can be compressed, even transiently, and can produce pain or numbness that radiates 
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down the extremities (Abbed and Coumans 2007, Caridi et al. 2011, Hubbard and 
Winkelstein 2005, Nicholson et al. 2012, Nicholson et al. 2011, Panjabi et al. 2006, Wall 
and Melzack 1994). Compressive nerve root injuries can occur from anatomical changes 
in the dimensions of the intervertebral foramen due to disc herniation, spondylosis and/or 
spinal trauma (Abbed and Coumans 2007, Krivickas and Wilbourn 2000, Panjabi et al. 
2006). Despite the prevalence and debilitating nature of neck pain (Cote et al. 2004, 
Haldeman et al. 2009, Strine and Hootman 2007), the current understanding of the 
cellular mechanisms that initiate and maintain pain and potential therapeutic targets for 
providing effective treatment are lacking.   
Using a model of cervical nerve root compression, our lab has defined many 
neuronal and glial mechanisms that contribute to nerve root-mediated pain. A transient 
(15-minute) compression applied to the nerve root induces immediate and long-term 
cellular modifications at the site of injury, as well as in the spinal dorsal horn where the 
injured afferents synapse (Chang and Winkelstein 2011, Hubbard et al. 2008a, Hubbard 
and Winkelstein 2005, Rothman et al. 2009, Winkelstein and DeLeo 2002). Within 1 
hour after a painful root compression, pro-inflammatory cytokines, including TNF-α, 
interleukin-1 beta (IL-1β) and IL-6, are transcribed and secreted by cells within the spinal 
cord on the side ipsilateral to the injured root (Rothman et al. 2009, Rothman and 
Winkelstein 2010). Independently blocking the actions of IL-1 or TNF-α prior to that 
nerve root compression attenuates pain for up to 1 week after injury (Rothman et al. 
2009, Rothman and Winkelstein 2010). Although the early (within hours) inflammatory 
response that is produced by cells within the CNS subsides within 1 day, spinal microglia 
and astrocytes are already activated at day 1 (Rothman et al. 2009, Rothman and 
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Winkelstein 2007, Winkelstein and DeLeo 2002). Glial activation in the spinal cord 
remains elevated at 1 week after injury (Hubbard and Winkelstein 2005, Rothman et al. 
2010); at that same time, the axons within the injured nerve root exhibit degeneration and 
their transport of neuropeptides, such as substance P and calcitonin gene-related protein 
(CGRP), to the dorsal horn is disrupted (Hubbard et al. 2008a, Hubbard and Winkelstein 
2008, Kangrga and Randic 1990, Smullin et al. 1990). Axonal degeneration after painful 
nerve root compression is accompanied by infiltration of macrophages around the injured 
area, both of which persist for at least 2 weeks, paralleling the presence of pain (Chang 
and Winkelstein 2011). Based on the complicated timing of inflammation and neuronal 
dysfunction after painful nerve root injury, mitigating both the early inflammatory 
response(s) and promoting nerve root health after neural injury has the potential to 
attenuate the associated persistent pain that also develops.  
Blood-brain barrier (BBB) disruption is characteristic of many neurological 
disorders, including stroke, Parkinson’s disease and multiple sclerosis, and contributes to 
the associated neuroinflammation and neurodegeneration in those diseases (Sandoval and 
Witt 2008, Winkler et al. 2014, Zlokovic 2008, Zlokovic 2011). Recent studies have 
demonstrated that BSCB breakdown also is induced early after a mechanical injury to a 
peripheral nerve or nerve root (as reported in Chapter 3) (Beggs et al. 2010, Echeverry et 
al. 2011, Smith et al. 2015). Disruption of the BBB permits the extravasation of 
neurotoxic factors into the CNS that can impair the normal neuronal function and 
exacerbate inflammation (Webb and Muir 2000, Zlokovic 2008). Blocking the BSCB 
breakdown that occurs early and transiently after a 15-minute nerve root compression via 
APC administration early after injury completely prevents pain development (Chapter 3) 
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(Smith et al. 2015), highlighting BSCB breakdown as a promising target for preventing 
not only the inflammation localized to the spinal cord, but also the pain that develops as a 
result of compression-induced BSCB breakdown.  
The protease thrombin, most recognized for its role in the coagulation cascade, 
also regulates a variety of endothelial processes via its enzymatic activation of cell-bound 
receptors or proteins (Di Cera 2008). Thrombin can initiate distinct signaling cascades 
depending on the cofactor it binds and the substrate it cleaves (Bouwens et al. 2013, Di 
Cera 2008, Griffin 1995, Komarova et al. 2007). Thrombin can activate PAR1, PAR3 and 
PAR4, but has the highest affinity for PAR1 due to a hirudin-like sequence of amino 
acids positioned near the extracellular cleavage site that interacts with exosite I of 
thrombin (Jacques et al. 2000, Luo et al. 2007). In its unbound state, mammalian 
thrombin increases vascular permeability by directly activating PAR1 on the endothelial 
surface (Coughlin 2000, Di Cera 2008). In contrast, when bound to thrombomodulin, 
thrombin cleaves endothelial-bound protein C into APC, which stabilizes vascular 
stability (Esmon 1993, Griffin 1995, Ye et al. 1992). Intravenously administered APC 
after a painful nerve root compression completely prevents BSCB breakdown (Smith et 
al. 2015), emphasizing the potency of the APC pathway in protecting vascular integrity 
and its effectiveness in treating BSCB disruptive disorders. Although clinical trials have 
tested APC for its enhancement of endothelial barriers in sepsis, stroke and traumatic 
brain injury (Bernard et al. 2001, Petraglia et al. 2010, Zlokovic and Griffin 2011), its 
strong anticoagulant effects hamper its clinical safety (Bernard et al. 2001). For this 
reason, mutagenesis and protein engineering studies manipulate specific peptide domains 
within thrombin’s structure to increase its innate affinity for protein C instead of PAR1, 
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while maintaining its ability to cleave fibrinogen (Dang et al. 1997, Gibbs et al. 1995, 
Marino et al. 2010, Zlokovic and Griffin 2011).  
In addition to endothelial responses, thrombin can also mediate glial responses 
that contribute to inflammation and even contribute to nociception within the CNS 
(Garcia et al. 2010, Narita et al. 2005, Niego et al. 2011, Nishino et al. 1993). Cleavage of 
astrocytic PAR1 contributes to astrocyte activation and production of inflammatory 
cytokines (Boven et al. 2003, Fan et al. 2005, Nicole et al. 2005, Niego et al. 2011, 
Nishino et al. 1993, Simmons et al. 2013). Similarly, human thrombin induces the 
transcription and secretion of IL-1β, TNF-α and IL-6 by astrocytes in culture as early as 6 
hours and lasting for up to 24 hours (Boven et al. 2003, Fan et al. 2005, Simmons et al. 
2013). In addition to PAR1 activation inducing inflammation, PAR1-/- mice exhibit 
significantly less glial fibrillary acidic protein (GFAP) expression after a cortical stab 
wound compared to wild type mice (Nicole et al. 2005), suggesting that astrocyte 
expression of PAR1 in the CNS might be requisite for astrocytic activation.  
Thrombin’s role in pain is controversial since this enzyme is capable of both 
initiating and attenuating pain depending on its concentration and the site of its 
administration (Asfaha et al. 2002, Fang et al. 2003, Narita et al. 2005, Weisshaar et al. 
2011). At low concentrations (1.5x10-17–1.5x10-14mol/mouse), intrathecally-administered 
human thrombin attenuates the behavioral sensitivity that is typically induced by a 
painful N-Methyl-D-aspartic acid (NMDA) intrathecal stimulus (Fang et al. 2003); but, it 
also induces sustained mechanical allodynia when administered intrathecally alone at a 
higher concentration (1x10-12 mol/mouse) (Narita et al. 2005). Peripherally, a single 
injection of human thrombin in the rat forepaw transiently decreases the mechanical 
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algesia (i.e. sensitivity to mechanically-induced pain) that is evoked by a noxious 
stimulus (Asfaha et al. 2002). Together, these studies imply that thrombin may contribute 
to the pro-inflammatory responses within the CNS that potentiate pain states. Yet, it is 
not known if a thrombin-like enzyme that activates different substrates compared to 
human thrombin, would also induce those same inflammatory and algesic responses.   
Interestingly, fish differ significantly from mammals in their inflammatory 
responses and produce naturally-evolved enzymes with slightly distinct capabilities from 
their mammalian counterparts (Doolittle 2011). Specifically, thrombin derived from 
salmon exhibits nearly indistinguishable clotting capabilities, but initiates different cell 
signaling cascades compared to human thrombin (Doolittle 2011, Michaud et al. 2002, 
Smith et al. 2013, Weisshaar et al. 2011). The salmon coagulation factor, fibrin, which is 
formulated by fibrinogen and thrombin, both derived from salmon, has been shown to 
attenuate pain when administered at the nerve root immediately after its painful 
compression (Weisshaar et al. 2011). This same treatment by salmon fibrin also prevents 
the infiltration of phagocytotic macrophages that are normally evident at the root after its 
compression (Weisshaar et al. 2011), supporting the anti-inflammatory capabilities of 
salmon coagulation factors. In comparison to its human counterpart, salmon fibrin 
promotes more locomotor and bladder function recovery after traumatic spinal cord 
injury without intensifying pain, suggesting that it is also neuroprotective (Sharp et al. 
2012). Although salmon fibrin has already been shown to have analgesic properties, it is 
not known if salmon thrombin alone can attenuate pain. Further, it is unknown if salmon 
thrombin exhibits a different affinity for protein C and the PARs compared to 
mammalian thrombin, which might promote its abilities to protect spinal vascular 
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integrity and to reduce the inflammation that occurs after root compression, both of 
which are known to contribute to the development of pain (DeLeo and Yezierski 2001, 
Smith et al. 2015, Watkins et al. 2001). 
The first set of studies in this chapter investigates the potential of salmon 
thrombin as a vascular protecting agent using both in vivo and in vitro approaches in 
comparison to the effects of human thrombin on vascular protection (Section 5.3). A 
painful nerve root compression model in the rat was used to define the differential effects 
of salmon and human thrombin on mediating the nerve root compression-induced BSCB 
breakdown at day 1. Supplementary in vitro studies were performed to define salmon 
thrombin’s effect on inflammation-induced endothelial permeability, with and without 
serum components, in comparison to human thrombin. In order to establish whether 
salmon thrombin activates protein C with a higher affinity than does human thrombin, 
APC generation rates produced by salmon and human thrombin were measured and 
compared using a fluorogenic peptide assay (Section 5.3). These complementary studies 
integrate in vivo and in vitro assays and are augmented by an in silico study using protein 
modeling of fish and human thrombin to identify mechanistic differences that may 
explain the experimental observations (Section 5.5). 
The second portion of studies in the chapter was designed to test the hypothesis 
that salmon thrombin exhibits unique analgesic properties compared to its human analog 
that are dependent on its activation profile of PARs and its induction of glial-controlled 
inflammation. In order to evaluate salmon thrombin’s effects on glial-induced 
inflammation and pain (Section 5.4) rats undergoing a 15-minute nerve root compression 
were immediately treated with either salmon or human thrombin applied directly to the 
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nerve root. Following injury and treatment, mechanical allodynia (i.e. pain produced in 
response to a normally non-noxious mechanical stimulus) was measured over 7 days. 
Mixed cultures of astrocytes and neurons derived from embryonic rat brain cortices were 
used to define if the two species of thrombin differentially control IL-1β and TNF-α 
transcription early after thrombin treatment (Section 5.4). Proteolytic differences between 
salmon and human thrombin were measured using fluorogenic synthetic peptides 
corresponding to the cleavage sequences of PAR1, PAR3 and PAR4 (Section 5.4). 
Together, the results from Sections 5.3 and 5.4 demonstrate that salmon thrombin 
exhibits the distinct capability of activating protein C which leads to its inhibition of 
vascular disruption while only weakly activating PAR1, thereby preventing it from 
inducing inflammation; these findings are discussed and integrated in Sections 5.5 and 
5.6.  
  
5.3. Evaluating Salmon Thrombin as a Vascular Protecting Agent 
5.3.1. Methods 
5.3.1.1. Study Objectives & Design 
The purpose of this study was to evaluate the effectiveness of salmon thrombin at 
preventing the BSCB breakdown and pain that are evident after a 15-minute nerve root 
compression (as shown in Figure 3.2) and to determine whether it acts through protein C 
to protect endothelial barriers, integrating in vivo and in vitro methods. For the in vivo 
portion of this study (Section 5.3.1.2), rats undergoing painful nerve root compression 
were treated with salmon thrombin, human thrombin, or neurobasal media as a vehicle 
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control. Since findings from studies in Section 3.3 identified day 1 as the time when 
BSCB breakdown is maximal (Figure 3.2), spinal IgG was labeled and quantified on day 
1 after the injury and with the different treatments. To test whether salmon thrombin 
directly protects endothelial barriers, an in vitro microchannel setup was used to measure 
the relative effects of salmon and human thrombin on inflammation-induced vascular 
permeability (Section 5.3.1.3). Those experiments were performed in the presence of 
serum to expose the endothelial surface to protein C, as well as under serum-free 
conditions in order to determine if thrombin acts through surface receptors or serum 
components to modulate permeability. The production rate of APC also was compared 
between salmon and human thrombin using a fluorogenic peptide assay to determine if 
the two species exhibit different protein C activation rates (Section 5.3.1.4). Section 
5.3.1.5 of this methods section describes modeling methods used to perform comparative 
protein modeling of fish and human thrombin. 
 
5.3.1.2. Compression-Induced BSCB Breakdown & Mechanical Allodynia 
Salmon thrombin (0.04U/rat; Sea Run Holdings; Freeport, ME) or human 
thrombin (0.04U/rat; Sigma Aldrich; St. Louis, MO) was dissolved in 20µl of neurobasal 
media and separately administered to treat a 15-minute nerve root compression. Salmon 
thrombin (15min+STh, n=5) or human thrombin (15min+HTh, n=4) solutions were 
delivered directly on top of the C7 nerve root immediately after removal of the 10-gram 
force clip that had applied compression (Chapter 3.3.1.1) (Rothman and Winkelstein 
2010, Smith et al. 2013, Weisshaar et al. 2011). A control group received 20µl of the 
neurobasal media alone to account for the effects of the compression and the vehicle 
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treatment (15min+veh, n=5). A separate group of rats also underwent a sham operation 
(n=3), as described in Chapter 3, to serve as surgical controls.  
Rats underwent behavioral testing prior to surgery (day 0) and on day 1 after the 
procedures. Mechanical allodynia was used to quantify behavioral sensitivity in the 
forepaw ipsilateral to the injury and was measured by counting the number of forepaw 
withdrawals in response to 30 stimulations by a 4g von Frey filament (Stoelting Co., 
Wood Dale, IL) (Rothman et al. 2010, Smith et al. 2013). The number of paw 
withdrawals was averaged for each group on each day; differences were compared using 
a two-way repeated measures ANOVA (group x day) with Tukey’s HSD test. At day 1, 
spinal cord tissue at C7 on the side ipsilateral to the injury was harvested and fixed for 
immunolabeling of spinal IgG, as described in Section 3.3.1.3. Differences in ipsilateral 
spinal IgG between groups were determined using a two-way ANOVA (group x side) 
with Tukey’s HSD test.  
 
5.3.1.3. Human Umbilical Vein Endothelial Cell Culture & Microchannel 
Experiments 
Human Umbilical Vein Endothelial Cell (HUVEC)-lined microchannels were 
created as previously described (Galie et al. 2014). HUVECs were graciously provided as 
a gift from the Janmey lab. A stainless steel acupuncture needle was used to create a 
400µm diameter channel within a central chamber of the microfluidic device filled with 
collagen (BD Biosciences; Franklin Lakes, NJ) at a concentration of 2mg/ml (Figure 5.1). 
HUVECs were injected into the channel (10,000 cells/cm2) and tight junctions were 
allowed to form by applying flow (5µl/min) for 24 hours. After sealing the vessels, FITC-
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labeled dextran (70kDa; Sigma Aldrich; St. Louis, MO) and TNF-α (100ng/ml; Sigma 
Aldrich; St. Louis, MO) were perfused through the HUVEC-lined channels. Separate 
cell-lined channels were treated with dextran and TNF-α and separately stimulated with 
either salmon thrombin (1U/ml) or human thrombin (1U/ml). A separate set of tests were 
performed with the HUVECs exposed to serum free flow for 4 hours before stimulation 
by TNF-α, with or without either species of thrombin. Fluorescent dextran permeation 
into the collagen was tracked over 10 minutes by taking a fluorescent image every minute 
at 4x magnification. The diameter of the flow-front was measured at three points along 
the channel length in each image using ImageJ software, averaged and normalized to the 
channel diameter (Galie et al. 2014). The slope of the normalized front diameter over 
time was divided by the slope of the change in diameter over time that was induced by 
TNF-α alone in order to directly compare the effects of the two species of thrombin on 
the flux. Experiments were run in triplicate and differences in normalized dextran flux 
were compared between groups using a one-way ANOVA.  
 
 
 
Figure 5.1. Schematic of microfluidic in vitro setup. The microfluidic device is comprised of UV-
cured polydimethylsiloxane with an inner chamber of collagen. A cylindrical channel (400µm) is 
created within the collagen construct and HUVECs are seeded on the inner lumen of the chamber. Flow 
was applied (5µl/ml) to form vessels with the HUVECs (Galie et al. 2014). 
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5.3.1.4. Activated Protein C Substrate Assay  
Salmon and human thrombin (1U/ml) were separately added to solutions 
containing protein C (19µg/ml; Haematologic Technologies Inc.; Essex Junction, VT) 
and a fluorogenic peptide mapping the cleavage site of the substrate for APC (Leu-Ser-
Thr-Arg; 50µg/ml; Sigma Aldrich; St. Louis, MO) (Ohno et al. 1981). The fluorescent 
intensity of the solutions was read at 380nm/460nm (ex/em) every 10 seconds for 300 
seconds. Controls included salmon and human thrombin separately in solution with the 
APC substrate in order to account for any substrate activation by either species of 
thrombin alone. Experiments were run in triplicate and differences in the rate of APC 
production induced by salmon and human thrombin were measured using a t-test.  
 
5.3.1.5. Comparative Protein Modeling of Fish & Human Thrombin  
In a complementary study, the protein structures of fish and human thrombin were 
compared to determine if the specific regions within the thrombin structure that control 
substrate affinity differ between the two species of thrombin. The human thrombin 
autolysis loop (residue 146 to 149e) was absent from the crystal structure of thrombin. 
Therefore, the autolysis loop (UniProt: P00734) was modeled into a previously validated 
crystal structure for human thrombin bound to a short peptide of protein C (PDB: 4DT7 
chain B). The thrombin model containing the autolysis loop was created by generating 
100 potential human thrombin models, and the final structure was the average of the ten 
models with the lowest overall Discrete Optimized Protein Energy score (Eswar et al. 
2006, Fiser et al. 2000, Marti-Renom et al. 2000, Sali 1995). The sequence for trout 
thrombin (UniProt: Q5NKF9) (Figure 5.2), which is the most similar fully sequenced 
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protein to salmon thrombin (Griffin 1995), was then threaded into the human thrombin 
crystal structure.   
 
 
 
A model for protein C was created by submitting the full peptide sequence for 
protein C (UniProt: P04070) to the Protein Homology/analogY Recognition Engine V2.0 
(Phyre 2) webserver (Kelley and Sternberg 2009). Using PDB code 4O03 as a template, 
89% of the residues were modeled at >90% confidence. The full protein C model was 
refined using a steepest descent minimization in the Gromacs simulation (Pronk et al. 
Figure 5.2. Comparison of the amino acid sequences for thrombin derived from human (Homo 
sapien) and rainbow trout (Salmo gairdneri). The primary structure of human thrombin (HTh, top 
line) exhibits strong agreement with the structure of fish thrombin (FTh, bottom line), except for in the 
autolysis loop (boxed in blue), which partially controls thrombin’s interaction with protein C.  
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2013) software in the presence of water and ions. A short (100ps) NVT simulation was 
used to further equilibrate the protein structure. The full protein C was then aligned with 
the short protein C peptide (QEDQVDPR) in the human thrombin structure (PDB: 4DT7) 
with an RMSD of 3.0Angstroms over 65 atoms. 
 
5.3.2. Results  
Salmon thrombin that is applied directly to the nerve root immediately after a 15-
minute compression significantly reduces (p=0.0148) mechanical allodynia, quantified as 
the number of paw withdrawals, elicited by a 4g stimulus on day 1 compared to responses 
for compression treated with human thrombin (Figure 5.3A). Treatment of a 15-minute 
compression with human thrombin induces a significantly greater (p=0.016) number of 
paw withdrawals compared to sham operated rats and is not different from the responses 
after the neurobasal media vehicle treatment (Figure 5.3A). The individual paw 
withdrawal data for each rat in each group are provided in Appendix A.  
Paralleling the pain responses, salmon thrombin induces significantly less 
(p<0.0009) IgG labeling in the ipsilateral spinal cord on day 1 after compression 
compared to treatment with either human thrombin or vehicle (Figure 5.3B). Both the 
human thrombin and vehicle treated compression injuries induce a significant increase 
(p<0.0065) in IgG in the ipsilateral spinal cord compared to the levels in the contralateral 
spinal cord (Figure 5.3B). A detailed summary of the quantification of IgG expression in 
the ipsilateral spinal cord for each rat in this study is provided in Appendix B. 
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TNF-α induces endothelial barrier permeability in HUVEC-lined microchannels, 
which is evident by the flux of fluorescent dextran out of the channel in the presence or 
absence of serum (Figure 5.3C). The addition of salmon thrombin with TNF-α in the 
HUVEC vessels blunts the propagation of the fluorescent front into the collagen, but only 
in the presence of serum (Figure 5.3C). In contrast, human thrombin with TNF-α only 
exacerbates the rate of dextran flux out of the channel (Figure 5.3C); this elevation in 
dextran flow rate over TNF-α alone induced by human thrombin occurs both in the 
Figure 5.3. Analgesic salmon thrombin prevents vascular disruption in the spinal cord and in 
vitro dependent on protein C. (A) Mechanical allodynia (quantified by the number of paw 
withdrawals) is significantly reduced (**p=0.0148) on day 1 after a nerve root compression treated with 
salmon thrombin (15min+STh) compared to treatment with human thrombin (15min+HTh). The 
number of paw withdrawals for 15min+HTh is significantly greater (*p=0.016) than sham and not 
different from vehicle-treatment with compression (15min+veh). (B) There is minimal IgG labeling 
after 15min+STh in the ipsilateral dorsal horn on day 1, which is significantly less than 15min+HTh 
(*p<0.0001) and 15min+veh (#p=0.0009). Both 15min+HTh and 15min+veh exhibit robust ipsilateral 
spinal IgG labeling that is significantly greater (**p<0.0065) than the labeling on the respective 
contralateral sides. (C) HUVEC-lined microchannels exhibit increased FITC-dextran flux into the 
surrounding collagen when treated with TNF-α with or without serum. Salmon thrombin (TNF-α+STh) 
significantly reduces (*p=0.0073) the TNF-α-induced flux compared to human thrombin (TNF-
α+HTh), but only in the presence of serum. TNF-α+STh and TNF-α+HTh are not different in serum-
free conditions. (D) STh produces APC significantly faster (*p=0.008) than HTh. Data are mean±SD. 
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presence and the absence of serum. Salmon thrombin significantly reduces (p=0.0073) 
the TNF-α-induced dextran flux through the HUVEC channels compared to human 
thrombin, but only in HUVEC cultures exposed to serum. The normalized rates of 
dextran diffusion for each treatment group in both serum containing and serum free 
conditions are detailed in Appendix D. 
Salmon thrombin produces APC at a rate approximately 45-times faster than does 
human thrombin (Figure 5.3D); indeed, that increase in rate is significant (p=0.008). The 
reactions within this experiment are coupled; thrombin activates protein C within the test 
solution and the generated APC activates the fluorogenic substrate. The rate of substrate 
cleavage in a solution containing human thrombin with protein C is not different than the 
rate produced by a control solution of human thrombin alone with the substrate, 
suggesting that human thrombin is incapable of generating APC. Appendix E summarizes 
the detailed rates of production of APC by both species of thrombin. 
The predicted model of fish thrombin is highly aligned with the crystal structure 
for human thrombin with an RMSD=0.51Å over the 265 residues (Figure 5.4). The 
peptide sequence that makes up the autolysis loop within the thrombin structures varies 
between the two species (Figures 5.2 & 5.4). That difference in sequence of amino acids 
is translated into a predicted geometric difference in crystal structures between the two 
species of thrombin (Figure 5.4). Introducing the protein C crystal into the crystalized 
structures of human and fish thrombin shows that the autolysis loop for both species of 
thrombin interacts closely with protein C, but that human thrombin may sterically inhibit 
protein C interaction more than salmon thrombin (Figure 5.4).  
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Fig. 5.4. Protein structure for thrombin derived from fish and from human differs in the autolysis 
loop, which partially controls thrombin’s specificity for protein C. Aligned amino acid sequences 
for the B chains of human thrombin (HTh) and fish thrombin (Salmo gairdneri, FTh) exhibit a key 
divergence in the autolysis loop (blue). A crystal structure for HTh (magenta) bound to a small peptide 
of protein C (PDB:4DT7) and the created homology model for FTh (orange) have strong alignment 
(RMSD=0.51Å over 265 residues) shown in ribbon representation. The autolysis loop (in blue) does not 
retain the same structure between species. The residues within both autolysis loops are represented 
below as sticks to visualize predicted close interactions with protein C (green cage structure). 
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5.4. Evaluating Salmon Thrombin’s Effects on Glial-Induced 
Inflammation & Pain 
5.4.1. Methods 
5.4.1.1. Formulation of Human & Salmon Thrombin 
 Thrombin from human plasma (Sigma Aldrich; St. Louis, MO) lyophilized from a 
sodium citrate buffer was reconstituted in sterile water to a concentration of 100U/ml, 
according to manufacturer protocols. Salmon thrombin (Sea Run Holdings; Freeport, 
ME) was prepared from precipitates derived from anticoagulated salmon blood, as 
previously described (Michaud et al. 2002, Smith et al. 2015, Weisshaar et al. 2011, 
Winer et al. 2009, Zhang et al. 2013). Salmon thrombin was reconstituted in a buffer 
consisting of 1M NaCl, 1mM EGTA, 20mM Tris, pH 7.0 and 0.6mg/ml sucrose, at a 
concentration of >1000U/ml (Weisshaar et al. 2011). Stock solutions of human and 
salmon thrombin were aliquoted and stored at -80°C until used for testing. The activity of 
human and salmon thrombin was determined prior to each experiment using either the 
fluorogenic thrombin substrate III (Calbiochem; San Diego, CA) diluted in PBS or the 
chromogenic substrate Chromozym TH (Roche; Nutley, NJ); this procedure ensured that 
equivalent activity between thrombin species were used in each study. 
 
5.4.1.2. Surgical Protocol & Behavioral Assessment 
In vivo experiments were performed on male Holtzman rats (Harlan Sprague-
Dawley; Indianapolis, IN), weighing 358 ± 26g at the start of the study. Rats were housed 
under conditions compliant with the U.S. Department of Agriculture and Association for 
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Assessment and Accreditation of Laboratory Animal Care including a 12−12 hour 
light−dark cycle and free access to food and water.  
A transient compression of the right C7 dorsal nerve root was applied for 15 
minutes (Hubbard and Winkelstein 2005, Rothman et al. 2009, Weisshaar et al. 2011). 
Briefly, surgical procedures were performed under inhalation anesthesia with the rat in 
the prone position (4% isoflurane for induction, 2% for maintenance). An incision was 
made from the base of the skull to the T2 spinous process. Along the dorsal region of the 
spine, the posterior bones and the facet joint on the right side of the C6/C7 spinal levels 
were removed in order to expose the right C7 dorsal nerve root. A hole was made in the 
dura and the cervical nerve root was compressed for 15 minutes with a calibrated 10gf 
microvascular clip (World Precision Instruments; Sarasota, FL). Following clip removal, 
any blood was cleared from the compressed nerve root and 20µl of either salmon 
(15min+STh, n=13) or human (15min+HTh, n=11) thrombin (2U/ml in neurobasal 
media) was added to the nerve root. A separate control group received a vehicle treatment 
(15min+veh, n=12) of only 20µl of neurobasal media. Sham operated rats (sham, n=5) 
were included to serve as a surgical control, underwent all surgical procedures except for 
compression of the nerve root, and did not receive vehicle or treatment. 
Behavioral sensitivity was assessed in the forepaw by measuring mechanical 
allodynia on days 1, 3, 5 and 7 after injury (Hubbard and Winkelstein 2005, Weisshaar et 
al. 2011). Allodynia was also measured for each rat before any surgical procedures in 
order to establish baseline responses (day 0). Prior to each testing session rats were 
placed in elevated cages with mesh bottoms and allowed to acclimate for 15 minutes. 
Mechanical allodynia was measured by stimulating the plantar surface of the forepaw on 
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the side ipsilateral to the injury, using 1.4, 4 and 10g von Frey filaments (Stoelting Co.; 
Wood Dale, IL). Testing sessions consisted of three rounds of 10 stimulations with each 
filament, separated by 10 minutes of rest. A positive response was defined as a paw 
withdrawal and was often accompanied by licking or shaking of the paw. The number of 
paw withdrawals elicited by each filament in a session was counted, averaged and 
reported as the measurement of mechanical allodynia for that day. Two-way repeated 
measures ANOVAs (group x day) with Tukey’s test determined statistical differences in 
mechanical allodynia between a nerve root compression treated with vehicle, human 
thrombin, or salmon thrombin, and sham for each testing filament.  
 
5.4.1.3. Culture of Dissociated Brain Cortices 
Primary cortical cultures were isolated from embryonic day 18 rat pup brains 
(Miller et al. 2009). The meninges were removed and the remaining cortices were 
dissected and dissociated at 37°C in neurobasal media (Invitrogen Corp.; Carlsbad, CA) 
with trypsin (0.3mg/ml; Sigma-Aldrich; St. Louis, MO) plus DNase I (0.2mg/ml; 
Amersham Biosciences; Piscataway, NJ). After 20 minutes, soybean trypsin inhibitor 
(0.5mg/ml; Gibco; Grand Island, NY) was added and the tissue was broken apart by 
manual pipetting. Cell solutions were centrifuged at 1000rpm for 5 minutes and the 
remaining pellet was re-suspended in DMEM with Glutamax (Gibco; Grand Island, NY) 
supplemented with fetal bovine serum (FBS; Gibco; Grand Island, NY). Cells were 
filtered through 60µm and 28µm Nitex meshes sequentially and plated at a density of 
4x106 cells/ml on T75 tissue culture flasks treated with poly-D-lysine (PDL; Sigma 
Aldrich; St. Louis, MO). Cultures were maintained at 37°C and 5% CO2 and the media 
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was replaced every 3 or 4 days. Mixed cultures were re-plated at a concentration of 2x106 
cells/ml onto 60mm PDL-coated culture dishes at 14 days in vitro (DIV).  
 
5.4.1.4. Real Time RT-PCR for Cytokine mRNA 
 Early upregulation of spinal pro-inflammatory cytokine (IL-1β, TNF-α, and IL-6) 
production has been directly implicated in nerve root-mediated pain, with blocking either 
IL-1β or TNF-α after a painful compression significantly reducing behavioral sensitivity 
(Rothman et al. 2009, Rothman and Winkelstein 2010). For this reason, levels of 
transcription of these two pro-inflammatory cytokines induced in primary cortical 
cultures by salmon and human thrombin were measured using real time reverse 
transcriptase polymerase chain reaction (RT-PCR). In order to distinguish the direct 
effect of both species of thrombin on inflammatory cytokine production, separate mixed 
cultures were treated with salmon (STh, n=5) or human (HTh, n=5) thrombin (1U/ml) at 
20 DIV (day 0). At 4 hours after treatment, cells were washed with PBS and RNA was 
harvested using Qiagen’s RNeasy mini kit (Qiagen; Valencia, CA). The concentration 
and quality of the RNA samples were measured using a NanoDrop spectrometer 
(NanoDrop Technologies; Wilmington, DE). RNA samples (0.5µg total RNA) were 
treated with DNTP (Invitrogen; Carlsbad, CA) and random primers (Invitrogen; 
Carlsbad, CA) for 5 minutes at 65°C before they were reverse transcribed according to 
manufacturer protocols using Superscript III reverse transcriptase (Invitrogen; Carlsbad, 
CA) and the RNase inhibitor, RNaseOUT (Invitrogen; Carlsbad, CA), at 50°C for 45 
minutes.  
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Synthesized cDNA was used for real-time PCR with specific primer sequences 
for the pro-inflammatory cytokines, IL-1β (Fwd: 5’-CAC CTC TCA AGC AGA GCA 
CAG-3’, Rev: 5’-GGG TTC CAT GGT GAA GTC AAC-3’) and TNF-α (Fwd: 5’-ATC 
ATC TTC TCA AAA CTC GAG TGA CAA-3’, Rev: 5’-CTG CTC CTC TGC TTG GT-
3’) (Rothman et al. 2009). Each reaction contained equal amounts of synthesized cDNA, 
appropriate primers, and SYBR green master mix (Applied Biosystems; Foster City, CA). 
Real time PCR was performed using an ABI-7300 system (Applied Biosystems; Foster 
City, CA) under the following conditions: 50°C for 2 minutes, 95°C for 10 minutes, 
followed by 40 cycles of 95°C for 15 minutes and 60°C for 1 minute. All samples were 
run in duplicate and a no-cDNA standard was included for each run.  
Expression of the target genes were normalized to levels of the housekeeping 
gene, cyclophilin-A (Fwd: 5’-TAT CTG CAC TGC CAA GAC TGA GTG-3’, Rev: 5’-
CTT CTT GCT GGT CTT GCC ATT CC-3’). The expression of the target gene in the 
groups treated with thrombin were normalized to levels in untreated controls (UT, n=8) 
from each cortical dissociation using the ∆∆Ct method (Rothman et al. 2009). Gene 
expression levels were reported as the fold-difference compared to untreated control 
levels. Values were averaged within groups and differences between HTh treated, STh 
treated and untreated cultures were tested using a one-way ANOVA, with post-hoc 
Tukey HSD test.  
 
5.4.1.5. PAR-Based Synthetic Peptide Cleavage 
Since PAR1, PAR3 and PAR4 are the main receptors through which thrombin 
modulates cellular responses (Bunnett 2006, Coughlin 2000, Jacques et al. 2000, Luo et 
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al. 2007), the relative cleavage rates of PAR-based peptides by salmon and human 
thrombin were measured in order to determine if salmon thrombin preferentially activates 
one receptor over another. Fluorogenic synthetic peptide substrates were designed 
corresponding to the amino acid sequence at the human PAR1, 3 and 4 cleavage sites at 
greater than 85% purity (Abgen; San Diego, CA). The peptides were comprised of a 
hydroxyl group, the three amino acids terminal to the native receptor’s extracellular 
cleavage site and an amido-4-methylcoumarin (AMC) functional group that fluoresces 
when hydrolyzed from the peptide (Table 5.1).  
 
Table 5.1. Peptide sequences of PARs expressed in Homo sapiens with the cleavage site underlined, 
hirudin sequence bolded and the corresponding fluorogenic modifications listed. 
receptor peptide fluorogenicity 
PAR1  Asp-Pro-Arg (DPR-AMC) AMC 
PAR3 Pro-Ile-Lys (PIK-AMC) AMC 
PAR4 Ala-Pro-Arg (APR-AMC) AMC 
PAR1-hir (DNP)-WFPEYKDNPNRLLFSRPDL-Abz FRET 
 
The peptide substrates (40µM) were separately added to PBS at 37°C and 
vortexed. Human (HTh, n=2) or salmon (STh, n=2) thrombin at 1U/ml was added to each 
solution, vortexed and immediately placed in the fluorimeter. The substrate solutions 
were excited at 346nm and the fluorescent intensity was measured at 446nm and recorded 
over a period of 5 minutes. Substrate hydrolysis was reported as the slope of 4 minutes of 
the intensity versus time data. Differences in cleavage rates for each PAR-based substrate 
were determined between salmon and human thrombin using a Student’s t-test.  
A peptide sequence on an exodomain of PAR1, also known as the hirudin-like 
sequence, interacts with exosite I of thrombin (see Figure 5.4) and facilitates mammalian 
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thrombin’s cleavage of PAR1 in vivo (Jacques et al. 2000, Seeley et al. 2003). A 
modified PAR1-based fluorescence resonance energy transfer (FRET) peptide (PAR1-
hir) was designed to include the hirudin-like amino acid sequence in order to more 
accurately model the native PAR1 receptor
 
(Table 5.1)
. 
The PAR1-hir FRET substrate 
(40µM) was diluted in PBS at 37°C and 1U/ml of each species of thrombin (n=4/group) 
was added, separately, to the solutions. Immediately following the addition of thrombin, 
the mixture was excited at 298nm and the fluorescence at 355nm was recorded for 60 
seconds. All substrate cleavage data are reported as the slope of the intensity-time plot 
fitted to 20 seconds of linear data. The difference between STh and HTh was determined 
using a Student’s t-test.  
 
5.4.2. Results 
A 15-minute nerve root compression treated with neurobasal media vehicle 
induces a significant increase (p<0.012) in the number of ipsilateral paw withdrawals 
compared to sham responses overall, for each filament strength tested (1.4, 4 and 10g) 
(Table 5.2; Figure 5.5). Salmon thrombin treatment of a nerve root compression 
significantly reduces the number of paw withdrawals elicited by all of the filament 
strengths overall relative to vehicle treatment (p<0.028) (Table 5.2; Figure 5.5). In fact, 
when considering the overall response, treating a painful compression with salmon 
thrombin reduces the number of paw withdrawals to sham levels in response to all 
filaments (Table 5.2; Figure 5.5).  When human thrombin is applied to the compressed 
nerve root, allodynia responses are not different from those induced by compression with 
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the vehicle and are significantly higher (p<0.047) than the responses for salmon thrombin 
treatment (Table 5.2; Figure 5.5).  
 
 
 
Figure 5.5. Salmon thrombin attenuates mechanical allodynia in the ipsilateral forepaw after a 
painful nerve root compression. The number of withdrawals by the ipsilateral forepaw is significantly 
elevated (p<0.012) after a 15-minute compression treated with the vehicle (15min+veh), compared to 
sham overall, for all filament strengths (1.4, 4, 10g). Treating a compression with salmon thrombin 
(15min+STh) reduces (p<0.028) the number of paw withdrawals compared to 15min+veh and is not 
different from sham overall, for all filaments. Treating a compression with human thrombin 
(15min+HTh) does not alter mechanical allodynia from vehicle treatment and the overall allodynia 
response is significantly elevated over the sham (p<0.009) and the 15min+STh (p<0.047) groups, for 
each filament. The 15min+veh group exhibits significantly more paw withdrawals than the sham group 
on day 1 for all filament strengths (#p<0.010) and this elevation is maintained until day 3 (#p=0.036) 
for testing with the 10g filament. Salmon thrombin significantly reduces the number of paw 
withdrawals compared to vehicle treatment on day 3 for the 10g filament (&p=0.006). Compared to 
responses after 15min+HTh, the 15min+STh group exhibits significantly fewer paw withdrawals on 
day 1 for the 1.4g filament (**p=0.003) and on each individual testing day for the 10g filament 
(**p<0.027). The number of paw withdrawals is significantly higher for 15min+HTh than sham on day 
1 for the 1.4g filament (*p<0.001), for days 1 and 3 for testing with the 4g filament (*p<0.041), and for 
all days for testing with the 10g filament (*p<0.027). Data are represented as mean±SD.  
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The differences in mechanical allodynia between a compression with vehicle 
treatment and a sham operation are most robust at day 1 (Figure 5.5), with the number of 
paw withdrawals elicited by each filament being significantly higher (p<0.010) for the 
compression with vehicle treatment than a sham response at day 1 (Table 5.2; Figure 
5.5). Yet, overall a painful compression treated with human thrombin does not prevent 
the increase (p<0.009) in the number of withdrawals for testing with all three filament 
strengths (Table 5.2; Figure 5.5). The number of paw withdrawals elicited by a 10g 
filament for compression with human thrombin treatment is significantly higher 
(p<0.027) than sham on each day of testing (Table 5.2; Figure 5.5). Further, salmon 
thrombin significantly attenuates (p<0.027) compression-induced allodynia on every 
testing day compared to human thrombin in response to stimulation by the 10g filament 
(Table 5.2; Figure 5.5). All of the mechanical allodynia data for each rat on each test day 
in response to the 1.4, 4 and 10g von Frey filaments are summarized in Appendix A. 
 
Table 5.2. Statistical differences in the number of paw withdrawals between a 15-minute compression 
treated with salmon thrombin (STh), human thrombin (HTh), or vehicle, and sham procedures summarized 
by the von Frey filament strength and day, as well as overall.  
 
1.4g 4g 10g 
day 1 
p=0.003 STh < HTh   
p<0.001 HTh > sham   
p=0.010 vehicle > sham 
p=0.006 HTh > sham   
p=0.002 vehicle > sham 
p<0.001 STh < HTh   
p<0.001 HTh > sham   
p=0.004 vehicle > sham 
day 3 none p=0.041 HTh > sham 
p=0.004 STh < HTh   
p=0.006 STh < vehicle   
p=0.027 HTh > sham   
p=0.036 vehicle > sham 
day 5 none none p<0.001 STh < HTh   p=0.006 HTh > sham 
day 7 none none p=0.027 STh < HTh   p=0.013 HTh > sham 
overall 
p=0.024 STh < HTh   
p=0.028 STh < vehicle   
p=0.009 HTh > sham   
p=0.012 vehicle > sham 
p=0.047 STh < HTh   
p=0.022 STh < veh   
p=0.007 HTh > sham   
p=0.004 vehicle > sham 
p=0.004 STh < HTh   
p=0.014 STh < veh   
p<0.001 HTh > sham   
p=0.003 veh > sham 
 
  167 
The IL-1β and TNF-α mRNA levels produced by mixed cortical cultures are 
significantly upregulated at 4 hours after treatment with human thrombin compared to 
untreated controls (p<0.001) (Figure 5.6). In contrast to the pro-inflammatory responses 
induced by human thrombin, mixed cultures treated with salmon thrombin express IL-1β 
and TNF-α mRNA at the same levels as untreated cultures and at levels significantly 
lower than in the cultures treated with human thrombin (p<0.002) (Figure 5.6). The 
specific expression levels of IL-1β and TNF-α mRNA induced by human and salmon 
thrombin in astrocytic cultures is detailed in Appendix F. 
 
 
 
Salmon thrombin hydrolyzes the fluorogenic PAR1 peptide mapping the cleavage 
site of PAR1 (Table 5.1) significantly slower (p=0.004) than does human thrombin 
(Figure 5.7A). Salmon thrombin also cleaves the PAR1 peptide including the cleavage 
site and the hirudin sequence (Table 5.1) at a significantly slower rate than does human 
Figure 5.6. Salmon thrombin does not increase pro-inflammatory cytokines in cortical cultures at 
4 hours after treatment. IL-1β and TNF-α mRNA are significantly upregulated at 4 hours after 
treatment with human thrombin (HTh) at 1U/ml compared to untreated cultures (UT) (*p<0.001). 
Salmon thrombin (STh), at the same concentration, induces levels of IL-1β and TNF-α transcription 
that are significantly less than human thrombin treatment (HTh) (**p<0.002) and not different from 
levels in UT. Data are mean±SD. 
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thrombin (p<0.001) (Figure 5.7A). The peptides corresponding to the PAR3 and PAR4 
cleavage sites are cleaved at rates that are indistinguishable between salmon and human 
thrombin (Figure 5.7B) and that are substantially slower than that for either PAR1 
peptide (Figure 5.7). Appendix E contains the summary of specific studies quantifying 
the activation rate of these PAR-based peptides by both species of thrombin. 
 
 
 
5.5. Discussion 
Collectively, these results are the first to show that salmon thrombin attenuates 
behavioral sensitivity generated by a painful nerve root compression and suggest that 
unique cellular and sub-cellular mechanisms promote its analgesic properties. Even a 
single dose of salmon thrombin placed directly in contact with the injured nerve root 
inhibits the development of pain (Figure 5.3A), an effect that is sustained for up to 7 days 
Figure 5.7. Salmon thrombin cleaves peptides mapping the PAR1 cleavage site slower than 
human thrombin. (A) Hydrolysis of the fluorogenic PAR1 peptides with only the PAR1 cleavage site 
(PAR1) is significantly (*p=0.004) faster for human thrombin (HTh) than for salmon thrombin (STh). 
HTh also cleaves the PAR1 peptide sequence that includes a hirudin-like binding site (PAR1-hir) 
significantly faster (*p<0.001) than does STh. (B) Hydrolysis of the fluorogenic peptides mapping the 
PAR3 and PAR4 cleavage sites are not different between STh and HTh. Data are mean±SD. 
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after the initial injury and is not evident with human thrombin (Figure 5.5). Salmon 
thrombin also blocks the nerve root-induced BSCB disruption that is typically observed 
at day 1 when pain is also observed (Figure 5.3). Of note, salmon thrombin actively 
blocks inflammation-induced endothelial barrier disruption, but only in the presence of 
serum (Figure 5.3C), and does not induce astrocytic transcription of TNF-α or IL-1β 
(Figure 5.6). The biological differences between these two species of thrombin can be 
explained by their differences in substrate activation rates; specifically, salmon thrombin 
activates PAR1 slower, and generates APC faster, than does human thrombin (Figures 
5.3D & 5.7). Since salmon thrombin actively prevents vascular disruption without 
stimulating glial-induced inflammation, this therapeutic is also promising for other 
neurodegenerative disorders that are exacerbated by BBB breakdown (Hawkins and 
Davis 2005, Hirsch and Hunot 2009, Sandoval and Witt 2008, Sharief and Thompson 
1992, Winkler et al. 2014, Zlokovic 2008, Zlokovic 2011). 
Salmon thrombin given immediately after a painful nerve root compression 
attenuates pain by day 1 and is effective for at least 7 days after injury, whereas human 
thrombin does not reduce behavioral sensitivity at this dose and administration route 
(Figures 5.3A & 5.5). Salmon and other teleosteans, or bony fish, evolved in parallel to 
humans and, in turn, exhibit less complicated clotting and inflammation cascades than 
mammals (Doolittle 2011, Tort et al. 2003). Because inflammation and pain are highly 
integrated biological cascades (DeLeo and Yezierski 2001, Scholz and Woolf 2007), it is 
possible that salmon produce coagulation proteins that do not elicit the pro-inflammatory 
and pro-nociceptive responses that are induced by their human counterparts. Salmon 
fibrin, which is the product of thrombin and fibrinogen, also attenuates pain after this 
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same root compression (Weisshaar et al. 2011), confirming the analgesic properties of 
multiple coagulation factors derived from salmon.  
Unlike fish thrombin, mammalian (rodent) thrombin has been shown to 
transiently induce pain and its inhibition in the CNS by intrathecal hirudin prior to neural 
injury reduces sensitivity for up to 8 days after a peripheral nerve (Narita et al. 2005) or a 
nerve root injury (Figure 4.5). Interestingly, human thrombin has been reported to both 
induce and attenuate pain depending on the concentration and the anatomical location of 
its administration (Asfaha et al. 2002, Chang et al. 2010, Fang et al. 2003, Narita et al. 
2005). In the current study, both salmon and human thrombin were administered at 
2U/ml, a concentration at which their enzymatic activity toward fibrinogen is not 
different (Smith et al. 2013). Further, both species of thrombin were administered in the 
same location directly on top of the compressed nerve root, which removes the potential 
variability due to the site of administration. Thrombin’s enzymatic activity is directed by 
its chemical and structural interaction with its substrates (Dang et al. 1997, Gandhi et al. 
2011, Seeley et al. 2003), and in turn controls which substrate it activates (Fuentes-Prior 
et al. 2000, Jacques et al. 2000, Xu et al. 2005). Salmon thrombin exhibits high affinity 
for protein C and low affinity for PAR1 (Figures 5.3D & 5.7), which is likely controlled 
by the differences in protein structure between the two species that is revealed in the 
comparative protein model (Figure 5.4). Therefore, the observed differences in analgesia 
produced by these two species of thrombin are independent of both concentration and 
location and likely depend on their different inherent substrate affinity profiles and the 
induced downstream cellular signaling cascades.  
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This work is the first to show that salmon thrombin innately blocks endothelial 
vessel permeability – both in the spinal cord after painful nerve root compression (Figure 
5.3B) and in HUVEC microvessels induced by TNF-α stimulation (Figure 5.3C). 
Interestingly, the effects of salmon thrombin on endothelial cells are potent enough to 
combat those effects that are induced by the relatively high dose of TNF-α used to disrupt 
HUVEC barriers (Figure 5.3C). Stimulation of HUVEC monolayers with TNF-α at even 
0.5ng/ml induces significant monolayer permeability (Nooteboom et al. 2002), whereas 
the dose of TNF-α (100ng/ml) used in this study was 200-times greater. The fact that 
salmon thrombin only prevents TNF-α-induced vascular disruption in the presence of 
serum (Figure 5.3C) suggests that its favorable effects on endothelial cells occur 
indirectly through serum proteins, likely serum-derived protein C (Riewald et al. 2002), 
and not via endothelial cell-expressed receptors, such as the PARs. In biological systems, 
mammalian thrombin is also capable of stabilizing endothelial barriers, but only when 
bound to thrombomodulin (Bouwens et al. 2013, Riewald et al. 2002). However, 
mammalian thrombin preferentially binds to, and activates, PAR1 over thrombomodulin 
which causes it to primarily disrupt vasculature (Coughlin 2000, Esmon 1993, Ye et al. 
1992). This endothelial-disrupting effect of human thrombin is demonstrated by the in 
vivo and in vitro studies in this chapter as well (Figure 5.3C). Since salmon thrombin is 
capable of producing APC in the absence of thrombomodulin (Figure 5.3D), it may be 
implied that the innate chemistry and structure of salmon thrombin does not inhibit its 
interaction with protein C, which is typically observed for mammalian-derived thrombin. 
Therefore, naturally-derived salmon thrombin might be a promising alternative to 
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synthetically modified versions of mammalian thrombin that exhibit a higher affinity for 
protein C.  
In addition to exerting distinct effects on endothelial cells, salmon thrombin does 
not appear to contribute to pro-inflammatory cytokine production in mixed neuronal-glial 
cultures, which is in contrast to the effects of human thrombin (Figure 5.6). Human 
thrombin induces the transcription of IL-1β and TNF-α at 4 hours after treatment (Figure 
5.6), which is consistent with other reports that glial cultures produce IL-1β, TNF-α, IL-6 
and a variety of other cytokines by 8 hours after stimulation by human thrombin (Boven 
et al. 2003, Choi et al. 2008, Fan et al. 2005, Simmons et al. 2013). In the same painful 
radiculopathy model used in the current work (Figures 5.3 & 5.5), rat thrombin has been 
shown to extravasate into the spinal parenchyma by day 1 (Figure 4.3) (Smith and 
Winkelstein 2015), where it can interact with both neurons and astrocytes. That painful 
root compression also induces an early increase in the spinal transcription and expression 
of TNF-α and IL-1β, both of which contribute to pain development (Rothman et al. 2009, 
Rothman et al. 2011). Since human thrombin increases the transcription of TNF-α and 
IL-1β in neural populations in vitro (Figure 5.6), it is possible that rat thrombin stimulates 
spinal cells to produce these cytokines when it is present in the spinal cord after root 
injury, thereby contributing to the production of pain. Since salmon thrombin does not 
initiate inflammation in cultures derived from the CNS at the concentration tested in this 
study (Figure 5.6), using salmon thrombin as a treatment for neural injury is not expected 
to exacerbate inflammatory states that contribute to pain. 
 Salmon thrombin may also prevent pain development after root compression by 
promoting neuronal health. By day 14 after a 15-minute nerve root compression, the 
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injured root exhibits disruption in the normal striated patterning of myelin basic protein 
(MBP) and axonal degeneration (Chang and Winkelstein 2011, Hubbard and Winkelstein 
2005, Hubbard and Winkelstein 2008). Those hallmarks of axonal demyelination are also 
accompanied by increases in the phagocytotic macrophage population and sustained pain 
(Chang and Winkelstein 2011). However, salmon thrombin prevents that axonal 
demyelination and significantly reduces the macrophage infiltration at the root (Figure 
5.8) (Smith et al. 2013). In agreement, a previous study showing that thrombin and fibrin, 
both derived from salmon, also reduce nerve root compression-induced macrophage 
infiltration at the injured root at an earlier time point (day 7) (Weisshaar et al. 2011). Yet, 
human thrombin may actually exacerbate both myelin disruption and macrophage 
infiltration (Figure 5.8) (Smith et al. 2013), which may be a mechanism by which it 
further contributes to neurodegeneration after trauma. Indeed, mammalian thrombin has 
been shown to induce neurite retraction and apoptosis in neuronal cultures when given at 
concentrations above 10U/ml for 24 hours (Garcia et al. 2015, Striggow et al. 2000). 
Although human thrombin was administered at a lower dose (2U/ml) after nerve root 
compression (Smith et al. 2015, Smith et al. 2013), it is possible that in combination with 
the rat thrombin that is likely present at the site of injury due to the bleeding from the 
tissue trauma, the combined increase in mammalian thrombin is sufficient to exacerbate 
the axonal degeneration in the rat (Figure 5.8). Distinct from the effects of human 
thrombin, salmon thrombin has also been shown to reduce spinal neuronal 
hyperexcitability at day 7 after painful nerve root compression (Smith et al. 2013). 
Salmon thrombin’s protection of axonal structure in the compressed root and suppression 
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of hyperexcitability centrally (Smith et al. 2013), further support salmon thrombin as a 
neuroprotective treatment for pain.  
 
 
 
The unique cellular effects exerted by salmon thrombin are likely due to its 
distinct substrate activation profile from that of human thrombin: its higher activation rate 
of protein C and its slower activation rate of PAR1 (Figure 5.3D & 5.7A). The cleavage 
rates of the PAR3 and PAR4 peptides by either species of thrombin are much slower than 
for PAR1 (Figure 5.7B), suggesting that activation of PAR3 and PAR4 is not responsible 
for the different cellular outcomes induced by the two species of thrombin. In biological 
Figure 5.8. Salmon thrombin preserves nerve root health and prevents inflammation after painful 
compression. (A) Uncompressed nerve roots from un-operated (normal) rats exhibit myelin basic 
protein (MBP; green) labeling in a uniform striated pattern and no immunoreactivity for macrophages 
(Iba1; red). On day 7 after a painful root compression treated with neurobasal media (15min+veh), 
MBP is disrupted and Iba1 is evident. MBP and Iba1 labeling is similar after human thrombin treatment 
(15min+HTh) to vehicle treatment. Salmon thrombin (15min+STh) produces the same striated MBP 
labeling with minimal Iba1 as seen in normal roots, and both of which are less than treatment with 
vehicle or human thrombin. (B) Quantified positive Iba1 labeling normalized to expression in naïve 
nerve root tissue (represented by the dotted line at 1) is significantly increased (#p<0.001) for 
compression treated with human thrombin compared to normal. Percent Iba1 labeling in roots treated 
with salmon thrombin is not different from a vehicle treatment or normal, but is significantly less 
(*p=0.035) than Iba1 labeling for human thrombin treatment. Figure modified from Smith et al. 2013.  
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systems, mammalian thrombin exhibits the highest affinity for PAR1 because exosite I of 
thrombin is highly attracted to a sequence of amino acids on an extracellular loop of 
PAR1 that resembles hirudin (Gandhi et al. 2011, Jacques et al. 2000, Seeley et al. 2003). 
Hirudin is a natural peptide that is secreted from leeches and is a potent and specific 
inhibitor of the enzymatic activity of mammalian thrombin (Rydel et al. 1990). The 
studies in this chapter identify that salmon thrombin is substantially less effective than 
human thrombin at activating PAR1, even when that hirudin-like sequence is included in 
the fluorogenic peptide (Figure 5.7A). This reduced rate of PAR1 activation suggests that 
salmon thrombin might exhibit a lower affinity than human thrombin for hirudin and 
peptides with similar sequences. In fact, salmon thrombin, at the same concentration used 
in this study, is inhibited less effectively by hirudin than human thrombin (Smith et al. 
2013), further supporting that exosite I of salmon thrombin might not induce the same 
high affinity for hirudin that human thrombin does. The amino acid sequence of exosite I 
for salmon thrombin is slightly modified compared to that of human thrombin (Figure 
5.2); those amino acid substitutions might prevent salmon thrombin from interacting with 
the hirudin-like sequence in PAR1 and contribute to the reduction in PAR1 activation 
rate compared to human thrombin that is observed here (Figure 5.7A). Mammalian 
thrombin induces astrocyte activation and pro-inflammatory cytokine release through its 
cleavage of PAR1 expressed in astrocytes (Nicole et al. 2005, Niego et al. 2011, Nishino 
et al. 1993). Since salmon thrombin activates PAR1 less effectively (Figure 5.7A) and 
induced less astrocytic production of TNF-α and IL-1β (Figure 5.6) compared to human 
thrombin, it can be inferred that salmon thrombin may not induce inflammation because 
of its inability to activate PAR1.   
  176 
Salmon thrombin also produces APC more effectively than human thrombin, even 
in the absence of thrombomodulin (Figure 5.3D). Thrombomodulin is requisite for 
mammalian thrombin’s activation of protein C; it binds to exosite I preventing thrombin 
from activating PAR1 and other substrates recognized by exosite I (Fuentes-Prior et al. 
2000, Pineda et al. 2004). There is evidence that thrombomodulin might also alter the 
shape of the thrombin epitope that interfaces with protein C, thereby changing the 
confirmation of residues that sterically inhibit the interaction in the unbound confirmation 
(Xu et al. 2005, Ye et al. 1992). Salmon thrombin exhibits amino acid substitutions in 
exosite I compared to human thrombin that change the charges of those regions (Figure 
5.2). Specifically the Threonine and Tyrosine contained in exosite I of human thrombin 
are amino acids that contain neutral and hydrophobic side chains, respectively (Figure 
5.2). Those residues are substituted with a hydrophobic Alanine and a very hydrophobic 
Phenylalanine in salmon thrombin (as shown in Figure 5.2), which are non-conservative 
amino acid substitutions and might modify the native structure of salmon, compared to 
human, thrombin. Since thrombomodulin sterically changes the structure of human 
thrombin in order to bind to protein C (Xu et al. 2005, Ye et al. 1992), salmon thrombin’s 
already modified structure might enable it to bypass that requisite thrombomodulin 
binding exhibited by mammalian thrombin and directly interact with protein C (Fuentes-
Prior et al. 2000, Rezaie and Yang 2003, Xu et al. 2005, Yang et al. 2006).  
The comparative thrombin structural models show that salmon thrombin exhibits 
the most radical changes from human thrombin in the autolysis loop region (Figure 5.4). 
Part of that loop in human thrombin is comprised of Threonine, Alanine, Asparagine and 
Valine, which are amino acids that contain side chains that are neutral, hydrophobic, 
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hydrophilic and very hydrophobic, respectively (Figures 5.2 & 5.4). In contrast, that 
region of the autolysis loop of salmon thrombin is one amino acid shorter and made up of 
a trimer of Serine, which is neutrally charged (Figures 5.2 & 5.4). Removing the nine 
amino acids that make up the autolysis loop can effectively inhibit thrombin’s activation 
of PAR1, allowing it to activate protein C more efficiently (Dang et al. 1997). Although 
the autolysis loop in salmon thrombin is only one amino acid shorter than its human 
counterpart, its composition of all neutral residues may facilitate salmon thrombin’s 
interaction with protein C. The comparative protein structural model even suggests that 
the autolysis loop of human thrombin may sterically inhibit proper binding with protein C 
more so than that loop salmon thrombin (Figure 5.4). Synthetically modifying the amino 
acid sequence of the autolysis loop in human thrombin to match that of salmon thrombin 
and measuring its rate of protein C would confirm if the autolysis loop directs protein C 
binding and would identify how to manipulate that regions of thrombin in order to 
facilitate protein C binding while maintaining clotting capabilities.   
The studies in this chapter assume that salmon thrombin’s vascular protective 
effects depend on protein C because salmon thrombin only blocks vascular permeability 
when endothelial cells are exposed to protein C-containing serum and because it activates 
protein C at a high rate (Figure 5.3). Administering an antibody to block protein C 
activation in conjunction with salmon thrombin, either at the root in vivo or in HUVEC 
microvessels exposed to TNF-α and serum, would confirm whether salmon thrombin 
prevents vessel permeability through protein C. Pre-treating serum-starved HUVEC 
channels with protein C prior to TNF-α and salmon thrombin would also verify that 
salmon thrombin activates protein C to prevent barrier disruption. Relatedly, these in 
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vitro studies are only able to suggest that human thrombin-induced astrocytic 
inflammation depends on its activation of PAR1, because human thrombin both activates 
PAR1 more effectively and induces more pro-inflammatory cytokine production than 
does salmon thrombin. To investigate whether human thrombin indeed acts through 
PAR1 to initiate the transcription of IL-1β and TNF-α, future studies should administer 
the PAR1 blocker SCH79797 in conjunction with human and salmon thrombin to 
astrocyte cultures. However, administering salmon thrombin directly to the nerve root 
would not be pragmatic clinically. Since intravenous APC is effective at blocking 
compression-induced BSCB breakdown (Figure 3.4), investigating whether a similar 
route of intravenous salmon thrombin can also prevent BSCB breakdown and pain 
development would determine if salmon thrombin is still analgesic when administered in 
this more clinically-favorable route. Further, since BSCB breakdown does not occur for 
at least 6 hours after a painful root compression injury (Figure 3.5) (Beggs et al. 2010), 
dosing studies that systematically manipulate the administration time of salmon thrombin 
would provide more information about the window of time in which that treatment is 
effective at inhibiting pain development.  
In summary, the results of this study highlight the analgesic, vascular protecting, 
and anti-inflammatory properties of salmon thrombin that do not exist with human 
thrombin. Salmon thrombin ameliorates BSCB breakdown (Figure 5.3B), in parallel with 
its ability to combat inflammation-induced vascular disruption in vitro (Figure 5.3C), 
likely through its activation of the APC pathway (Figure 5.3D). That in vivo treatment of 
salmon thrombin also completely inhibits the pain that develops after a nerve root 
compression injury. Taken together, all of these vascular-related findings support salmon 
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thrombin as an ideal early treatment for neuropathic injuries that induce BBB breakdown 
and lead to pain. Further, salmon thrombin itself does not potently activate PAR1 or 
induce inflammation (Figures 5.6 & 5.7), in contrast to its human counterpart. Yet, 
salmon thrombin does exhibit the same enzymatic ability to cleave fibrinogen (Smith et 
al. 2013) and to form fibrin clots (Michaud et al. 2002) as human thrombin. Salmon 
thrombin’s clotting capabilities is a key distinguishing feature between it and APC as 
potential therapeutics for BBB disruptive disorders since APC prevents clot formation in 
vivo (Bernard et al. 2001, Finfer et al. 2008, Marti-Carvajal et al. 2012). Additionally, 
salmon thrombin has been reported to have an increased stability compared to 
mammalian thrombin during gamma irradiation for sterility (Laidmae et al. 2006), 
supporting potential safety for this protein therapy in treating various disorders in 
humans. Salmon thrombin contains a naturally evolved structure that enables it to 
innately activate vascular protective pathways, while not inducing the same inflammatory 
cascades as mammalian thrombin. Salmon thrombin is not only a promising therapy for 
painful neural injury, but its naturally modified structure from human thrombin will 
inform future mutagenesis studies aiming to direct thrombin’s affinity towards protein C 
without severely preventing its ability to form clots. 
 
5.6. Integration & Conclusions 
Studies in Chapter 4 provide evidence that rat thrombin, either endogenously or 
exogenously introduced into the rat spinal cord, initiates behavioral sensitivity and is, at 
least partially, responsible for nerve root compression-induced pain and spinal astrocyte 
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activation. Unlike rat thrombin that induces pain when administered in the CNS (Figure 
4.6) (Narita et al. 2005), salmon thrombin inhibits nerve root compression-induced pain 
(Figures 5.3A & 5.5) (Weisshaar et al. 2011). Also, distinct from human thrombin, 
salmon thrombin prevents compression-induced BSCB breakdown (Figure 5.3B) and 
attenuates TNF-α-induced vascular disruption (Figure 5.3C), likely through its unique 
activation of protein C (Figure 5.3D). Salmon thrombin also does not initiate astrocyte 
transcription of pro-inflammatory cytokines (Figure 5.6) and actively protects against the 
axonal degeneration and infiltration of immune cells that are typically observed within 
the compressed nerve root in pain states (Figure 5.8). This anti-inflammatory response is 
in contrast to human thrombin’s induction of the astrocytic transcription of pro-
inflammatory cytokines in vitro and promoting macrophage infiltration at the nerve root 
(Figures 5.6 & 5.8). Thrombin induces inflammatory cascades in astrocytes and immune 
cells through its activation of PAR1 (Choi et al. 2008, Fan et al. 2005). Since salmon 
thrombin activates PAR1 less effectively than does human thrombin (Figure 5.7), this 
likely contributes to the lack of pro-inflammatory cytokine transcription induced in 
astrocytes by salmon thrombin (Figure 5.6). The studies in this chapter demonstrate that 
salmon and human thrombin exert distinct effects on pain, vascular permeability and 
astrocyte activation (Figures 5.3, 5.5, 5.6 & 5.8), and that those differences are likely 
controlled by the substrate specificity of each species of thrombin (Figures 5.3D and 5.7)  
Salmon thrombin, administered to the injury site immediately after a 15-minute 
compression, prevents the BSCB breakdown (Figure 5.3B) that is typically evident by 
day 1 (Figure 3.2). Similar vascular protecting effects are also evident when APC is 
administered intravenously at 1 hour after a root compression (Figure 3.4), suggesting 
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that those two treatments (salmon thrombin and APC) might activate the same cell 
signaling pathway(s). Further supporting this hypothesis, salmon thrombin produces APC 
markedly faster than human thrombin (Figure 5.3D), and likely prevents endothelial 
barrier disruption indirectly through its activation of protein C within the serum (Figure 
5.3C). Thrombin, derived from salmon and other species, degrades on the order of hours 
under physiological conditions (Laidmae et al. 2006, Michaud et al. 2002). Yet, salmon 
thrombin given only once and immediately after root compression is not only sufficient 
to prevent BSCB breakdown early after injury, but also promotes neuronal structural 
health within the root (Figure 5.8), reduces spinal neuronal hyperexcitability (Smith et al. 
2013), and attenuates pain (Figure 5.5) for up to 1 week. Identifying if those longer-term 
physiologically protecting effects depend on the unique effects of salmon thrombin or 
purely the reduction in the early breakdown of the BSCB, would further define the 
pathophysiological mechanisms induced after compression-induced BSCB breakdown.  
 Despite being a natural protein, salmon thrombin has been shown to be safe in 
vivo (Laidmae et al. 2006), supporting its potential as a therapeutic agent. Two main 
concerns of protein therapy include: (1) contamination with infectious agents that could 
potentially infect the patient and (2) immunogenicity reactions within the patient 
(Barbosa and Celis 2007, De Groot and Scott 2007). Naturally-derived proteins are often 
exposed to heat-treatments or gamma-irradiation in order to rid them of infections agents 
prior to human use, but sometimes these procedures are not effective at removing all 
viruses, such as the human parvovirus (Hino et al. 2000, Kawamura et al. 2002). The 
human body temperature is 37°C and as low as -2°C in cold water fish, depending on the 
temperature of the water (Tort et al. 2003). Viruses in salmon are non-hazardous to 
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humans because of the difference in basal body temperature between these species, 
thereby removing the threat of infectious agent transmissibility into humans from purified 
salmon thrombin (Wang et al. 2000). Further, treating salmon thrombin with gamma 
irradiation does not reduce its enzymatic activation of fibrinogen into fibrin (Laidmae et 
al. 2006), further supporting the use of thrombin, or other proteins, derived from salmon 
for various human treatments.  
In addition to contamination, patient immune response to foreign proteins has the 
potential to be very problematic. Antibodies towards the epitope of the foreign protein are 
produced when introduced into a foreign body, which can cause tolerance to and reduced 
efficacy for, future treatments with that protein (Barbosa and Celis 2007, De Groot and 
Scott 2007). For example, a single intraperitoneal administration of salmon thrombin or 
fibrin in mice or rabbits elevates the serum concentration of antibodies for both foreign 
proteins, a response that is even more robust after a second administration 30 days later 
(Laidmae et al. 2006). Therefore, tolerance to salmon thrombin might develop, thereby 
reducing its suitability for multiple treatments over time. However, just one 
administration of salmon thrombin is sufficient to prevent pain development, block 
BSCB breakdown, and attenuate neural injury and inflammation (Figures 5.3, 5.5 & 5.8), 
which eliminates the need for repeated dosing and reduces the tolerance-based issues in 
relation to salmon thrombin’s as a therapeutic (Barbosa and Celis 2007, De Groot and 
Scott 2007). Even more severe immune reactions occur when antibodies towards foreign 
proteins cross-react with an analogous endogenous protein (Barbosa and Celis 2007, De 
Groot and Scott 2007). Antibody recognition of endogenous thrombin would be 
especially harmful because of its major role in coagulation (Boon 1993, Di Cera 2008); 
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antibodies produced in response to bovine thrombin used in surgery can result in a 
prolonged clotting time clinically (Ortel et al. 2001). However, immune studies with 
salmon thrombin and fibrin show that antibodies towards those proteins do not cross-
react with the proteins from the host species in either case (Laidmae et al. 2006), 
suggesting that salmon thrombin would induce long-term clotting complications when 
used as an analgesic treatment.  
In addition to the thrombin-induced endothelial and astrocytic effects examined in 
the studies in this chapter, mammalian thrombin is a known regulator of cellular 
mechanics (Cuerrier et al. 2009, Suidan et al. 1997). Thrombin administered to 
endothelial cells at 10nM in vitro increases their expression of actin stress fibers, 
corresponding to an almost doubling in cellular stiffness after only 40 minutes of 
stimulation (Cuerrier et al. 2009). Astrocytes also exhibit changes in their mechanical 
responses after thrombin exposure: 20 minutes of thrombin stimulation (0.2nM) induces 
astrocyte spreading and formation of focal adhesions in vitro (Suidan et al. 1997). Studies 
in Chapter 4 demonstrate that rat thrombin extravasates into the spinal parenchyma across 
a compromised BSCB after painful root compression (Smith and Winkelstein 2015), 
which allows for it to interact with cells within the CNS. Thrombin within the spinal cord 
may also modify the mechanics of the resident contractile cells, including astrocytes, 
which make up a majority of mechanical substrate for neurons (Shreiber et al. 2009, 
Vallejo et al. 2010), as well as endothelial cells. In fact, spinal astrocytes become 
activated at days 1 and 7 after this same painful nerve root trauma (Rothman et al. 2010); 
since neurons respond to the stiffness of their mechanical substrate (Betz et al. 2011, 
Flanagan et al. 2002, Koch et al. 2012, Lamoureux et al. 1998), it is hypothesized that in 
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astrocyte mechanics are altered in response to neural injury. Accordingly, the studies 
outlined in Chapter 6 investigate whether a painful nerve root compression induces 
changes in astrocytic and endothelial expression of the intermediate filament vimentin, 
which is a known mediator of cell shape and cytoplasmic stiffness (Buehler 2013, Guo et 
al. 2013, Janmey and McCulloch 2007, Lu et al. 2011, Wang and Stamenovic 2002).  
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Chapter 6 
 
Effects of Root Compression on Spinal Astrocytic 
Activation & Endothelial Vimentin Expression  
 
 
6.1. Overview 
The tissue in the central nervous system (CNS) is structurally unique from other 
tissues in that it lacks an extensive extracellular matrix (ECM) (Gaudet and Popovich 
2014, Hynes and Naba 2012, Zimmermann and Dours-Zimmermann 2008). Instead, the 
CNS is comprised of a loose meshwork of hyaluronan, sulfated proteoglycans, and 
tenascin-R surrounding a hierarchical structure of neurons and support cells, including 
glia and endothelial cells (Barros et al. 2011, Gaudet and Popovich 2014, Wong et al. 
2013). Because of its structure, the bulk mechanical properties of CNS tissue are heavily 
influenced by those mechanical properties of cells within it (Shreiber et al. 2009). At the 
cellular level, astrocytes create a mechanical barrier between the neurons and the vascular 
endothelial cells and provide the main mechanical substrate for those neurons (Volterra 
and Meldolesi 2005). These three cell types (neurons, astrocytes, and endothelial cells) 
interact closely and together form the “neurovascular unit”, which regulates the normal 
function and pathological dysfunction within the CNS (Abbott et al. 2006, Halassa et al. 
2007, Hawkins and Davis 2005, Zlokovic 2010). While much is known about the 
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physiological relationship between these cells, it is not known if they alter their 
mechanics in response to insults outside of the CNS.  
The mechanical response of a cell can be described by measuring its stiffness 
and/or viscoelastic response, and many other parameters (Janmey and McCulloch 2007). 
Cellular mechanics are controlled intracellularly by the cytoskeleton (Fletcher and 
Mullins 2010), which is an integrated structure comprised of filamentous actin, 
intermediate filaments and microtubules that act as scaffolding to support the cell 
membrane. Since the cytoskeletal filaments are dynamic structures, changes in the 
intracellular mechanics also contribute to cell. The roles of actin and microtubules in 
cellular mechanics have been well established; because these polymeric filaments are 
highly dynamic they contribute to changes in cell shape, cell motility or migration, and 
transport of organelles within a cell (Buehler 2013, Fletcher and Mullins 2010, Janmey 
and McCulloch 2007, McBeath et al. 2004). Only recently has the roles of the 
intermediate filaments in cellular mechanics begun to be elucidated. 
Since the intermediate filaments are the most stable of the cytoskeletal 
components, they directly influence cellular integrity (Buehler 2013, Herrmann et al. 
2007). One intermediate filament in particular, vimentin, has been shown to control 
cytoplasmic stiffness (Guo et al. 2013, Janmey et al. 1991, Wang and Stamenovic 2002). 
An ischemia-induced increase in astrocytic vimentin expression corresponds to an 
increase in cytoplasmic stiffness in vitro (Lu et al. 2011). Because vimentin filaments can 
withstand significantly more mechanical deformation than microtubules, actin, and other 
intermediate filaments (Guo et al. 2013, Janmey et al. 1991), vimentin has been suggested 
to have an important role in regulating cellular stiffness. Many neuronal functions have 
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been shown to depend on mechanical cues, such as applied tension, applied compression, 
and substrate stiffness (Ahmed et al. 2012, Flanagan et al. 2002, Georges et al. 2006, 
Koch et al. 2012). Because astrocytes are the main mechanical substrate for neurons in 
the spinal cord (Volterra and Meldolesi 2005), changes in their stiffness might directly 
modulate neuronal function. Due to the role of sustained activation of spinal astrocytes in 
the maintenance of traumatic radicular pain (Rothman et al. 2010, Rothman and 
Winkelstein 2007), it is hypothesized that spinal astrocytes modulate their expression of 
vimentin after a painful nerve root compression.  
The studies in this chapter address Aim 4 of this thesis and measure changes in 
spinal astrocytic vimentin expression following painful and non-painful nerve root 
compressions. The experiments test the general hypothesis that painful nerve root 
compression modifies the astrocytic expression of an intermediate filament that has a role 
in cellular mechanical integrity (Section 6.3). Astrocytic vimentin was measured by co-
immunolabeling the ipsilateral spinal cord for vimentin with the astrocytic marker, glial 
fibrillary acidic protein (GFAP), at days 1 and 7 following painful and non-painful nerve 
root compressions, separately. In order to investigate whether spinal thrombin mediates 
compression-induced changes in astrocytic vimentin expression, spinal thrombin was 
blocked with hirudin prior to a painful compression and the co-localization of vimentin 
and GFAP was quantified at day 7. The effects of hirudin and salmon thrombin, which 
separately inhibit the development pain after compression (Chapters 4 and 5) (Smith et al. 
2015, Smith and Winkelstein 2015), on spinal astrocytic vimentin expression was also 
investigated at day 7 after a painful compression in order to determine if changes in 
astrocytic vimentin are specific to pain-related behaviors. 
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Vimentin is also expressed in endothelial cells and partially regulates the integrity 
of endothelial monolayers. Vimentin helps to maintains cellular integrity when expressed 
as long stable filaments dispersed throughout the cytoplasm (Buehler 2013, Guo et al. 
2013). Phosphorylation of vimentin filaments disassembles their intracellular 
organization and causes those filaments to aggregate around the nucleus (Grin et al. 
2012). Decreases in the stability of endothelial vimentin, via phosphorylation, has been 
shown to correspond to increased endothelial barrier permeability (Liu et al. 2014, Liu et 
al. 2010). The permeability of the blood-spinal cord barrier (BSCB) transiently increases 
early after a painful nerve root compression and stabilizes by day 7 (Chapter 3) (Smith et 
al. 2015), suggesting microvascular endothelial function to be compromised in response 
to neural compression. In the studies measuring astrocytic vimentin expression (Section 
6.3), a majority of the vimentin labeling was found to localize to spinal vasculature, so 
additional studies were performed also to measure endothelial vimentin expression in 
response to root compression (Section 6.4). Vimentin was co-immunolabeled with von 
Willebrand factor (VWF), as a proxy for endothelial cells, at days 1 and 7 after separate 
painful and non-painful nerve root compressions. The effects of treating a painful 
compression with hirudin or salmon thrombin on spinal endothelial vimentin expression 
were also quantified at day 7 in order to determine if these analgesic treatments rectify 
compression-induced changes in endothelial vimentin. The responses of both astrocytic 
and endothelial vimentin expression to nerve root compression insults are discussed and 
integrated with the other studies in this thesis in Sections 6.5 and 6.6. 
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6.2. Relevant Background 
 Intermediate filaments perform many roles within cells; they maintain cell shape, 
resist tensile loads, transmit mechanotransductive signals, act as a substrate for 
phosphorylation reactions in the cytoplasm and stabilize connectivity between cells 
within a tissue (Guo et al. 2013, Herrmann et al. 2007, Janmey et al. 1991). The structure 
of intermediate filaments is rich in α-helices allowing the filament to undergo a range of 
molecular unfolding with applied stretch (Buehler 2013). This structural feature enables 
intermediate filaments to resist much higher tensile loads than other cytoskeletal 
filaments (Buehler 2013, Guo et al. 2013, Janmey et al. 1991). One intermediate filament 
in particular, vimentin, greatly influences the mechanical integrity of the cell cytoplasm; 
fibroblasts derived from vimentin deficient (vim-/-) mice exhibit half the cytoplasmic 
stiffness compared to wild type fibroblasts (Guo et al. 2013). Vimentin is expressed in a 
variety of cell types within the CNS including astrocytes and endothelial cells, and its 
expression within those cells is modulated after pathological insults (Liu et al. 2010, Lu 
et al. 2011, Pekny and Pekna 2004). Since neuronal function and dysfunction at least 
partially depends on the stiffness of the local environment (Ahmed et al. 2012, Flanagan 
et al. 2002, Koch et al. 2012), it is hypothesized that changes in the stiffness of 
astrocytes, which comprise much of the mechanical substrate for neurons in the CNS, 
may facilitate aberrant signaling by neurons and other cells in the spinal cord.  
Although the expression of vimentin, along with GFAP, has been shown recently 
to correlate positively with astrocyte stiffness in vitro (Lu et al. 2011), increases in 
astrocytic vimentin expression is more often investigated as an indicator of glial 
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activation (Calvo et al. 1991, Pekny and Pekna 2004). Both vimentin and GFAP are 
upregulated in the spinal cord by day 7 after chronic constriction of the sciatic nerve and 
those increases last for up to 28 days in parallel with pain persistence (Cao et al. 2015). 
However, astrocytic expression of GFAP and vimentin does not always follow the same 
temporal profile. Ischemic injury induced in the middle cerebral artery increases numbers 
of cells positive for GFAP and numbers of cell positive for vimentin in nearby cortical 
regions within 48 hours (Barreto et al. 2012). However, only the number of GFAP-
positive cells remains elevated for 30 days, whereas the number of cells positive for 
vimentin returns to normal by that time (Barreto et al. 2012). Although both intermediate 
filaments are established markers of astrocyte activation, it is not known if, or how, 
vimentin and GFAP expression in astrocytes is differentially regulated in response to 
different parameters of neural injury, such as the duration of a transient neural 
compression injury. Further, it is not known if vimentin expression within astrocytes is 
associated with pain from that injury.  
Endothelial vimentin controls a variety of endothelial processes (Gonzales et al. 
2001, Liu et al. 2014, Tsuruta and Jones 2003). Disruption of endothelial vimentin with 
withaferin A increases endothelial monolayer permeability in vitro (Liu et al. 2014), 
suggesting that vimentin expression and stability maintains integrity of the endothelial 
barriers. This is further supported by a pervious study showing that vascular integrity is 
disrupted in vim-/- mice as evidenced by a substantial increase in the paracellular 
transmigration of blood mononuclear cells into the lymph nodes and spleen (Nieminen et 
al. 2006). When endothelial cells express a form of vimentin that resists phosphorylation, 
and therefore disruption, it prevents the breakdown of endothelial monolayers that is 
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induced by lipopolysaccharide (LPS) (Liu et al. 2014). This stabilization of endothelial 
vimentin preventing endothelial layer permeability supports a role for vimentin in 
augmenting vascular integrity. Vascular breakdown occurs in the spinal cord within a day 
of a painful root compression and is restored by 1 week (Chapter 3) (Smith et al. 2015). 
Yet, the structural changes that endothelial cells undergo in order to facilitate that 
breakdown and subsequent recovery are not fully understood. Modifications in 
endothelial vimentin expression over time might contribute to the changes in BSCB 
integrity that are induced by a painful nerve root compression injury (Chapter 3) (Smith 
et al. 2015).  
The different durations of nerve root compression that have been investigated in 
the studies in this thesis induce varying levels of BSCB permeability, spinal astrocyte 
activation and pain along different time courses (Nicholson et al. 2011, Rothman et al. 
2010, Smith et al. 2015). A 15-minute compression induces a substantial breakdown in 
the ipsilateral BSCB which occurs at the same time as the development of mechanical 
hyperalgesia by day 1 (Chapter 3). BSCB breakdown is induced after the shorter, 3-
minute compression and pain responses are less robust than those induced by a 15-minute 
compression (Chapters 3 & 4) (Nicholson et al. 2012, Rothman et al. 2010, Smith et al. 
2015). By day 7, spinal GFAP expression is robustly elevated after a 15-minute 
compression when pain is still present (Rothman et al. 2010). Although mechanical 
allodynia is still not evident at day 7 after a 3-minute compression, there is a moderate 
increase in GFAP expression in the spinal cord, albeit to a lesser degree than that induced 
by the 15-minute compression (Rothman et al. 2010). Together, these findings suggest 
that early compression-induced BSCB breakdown occurs exclusively with the 
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development of pain after injury, but that sustained spinal glial activation may be induced 
by any mechanical compression, regardless of whether it produces pain. Due to the 
apparent roles of vimentin in both astrocytic activation and vascular permeability 
(Barreto et al. 2012, Gonzales et al. 2001, Haseloff et al. 2006, Liu et al. 2014, Liu et al. 
2009, Lu et al. 2011), the studies in this chapter were designed to measure the response of 
vimentin expression in spinal astrocytes (Section 6.3) and endothelial cells (Section 6.4) 
after painful and non-painful injuries to the nerve root, in order to investigate whether 
modifications in spinal vimentin expression are specific to compression that induces pain.  
The first set of studies in this chapter was designed to test the hypothesis that 
painful nerve root compression activates spinal astrocytes and modifies their expression 
of intermediate filaments that have a role in cellular mechanical integrity. Because of the 
apparent role of vimentin in controlling cellular stiffness and since increases in astrocytic 
vimentin correlate to increased cell stiffness (Lu et al. 2011), vimentin expression was 
quantified in spinal astrocytes in response to a root compression. Astrocytic vimentin was 
measured by co-immunolabeling for vimentin and GFAP in the ipsilateral spinal cord 
separately at days 1 and 7 after a 15-minute and a 3-minute compression. Studies in 
Chapter 4 demonstrate that blocking spinal thrombin activity with hirudin prevents 
painful compression-induced BSCB breakdown at day 1 and spinal astrocyte activation at 
day 7 (Smith et al. 2015, Smith and Winkelstein 2015). As such, the effects of blocking 
spinal thrombin with hirudin on spinal astrocytic vimentin expression are also measured 
in order to determine whether thrombin might contribute to the changes in astrocyte 
mechanics (Section 6.3). In contrast to hirudin, salmon thrombin also induces analgesia 
but does not mitigate the compression-induced spinal astrocytic activation at day 7 
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(Weisshaar et al. 2011). Therefore, the effects of salmon thrombin on spinal astrocytic 
vimentin expression are also measured at day 7 (Section 6.3).  
Since immunolabeling for spinal vimentin revealed that expression of this 
intermediate filament is evident in vascular structures, studies were extended to quantify 
spinal endothelial vimentin expression at days 1 and 7 following the same nerve root 
compressive insults (Section 6.4). Vimentin was co-immunolabeled with the marker for 
endothelial cells (VWF) at days 1 and 7 after a painful 15-minute and a non-painful 3-
minute compression. Since hirudin and salmon thrombin each prevent spinal vascular 
disruption at day 1 after the painful compression (Chapter 4) (Smith and Winkelstein 
2015), spinal endothelial vimentin was measured also at day 7 after compression with 
those treatments (Section 6.4).  
 
6.3. Measuring Total Spinal Vimentin & Astrocytic Vimentin 
Expression after Root Compression 
6.3.1. Methods 
 6.3.1.1. Root Compression & Tissue Harvest Procedures 
 Surgical procedures for these studies were performed as described in Section 
3.3.1.1 of this thesis (Nicholson et al. 2011, Rothman et al. 2010). Briefly, adult male 
Holtzman rats were anesthetized using inhalation isoflurane anesthesia and the right C6 
and C7 vertebrae were cleared of the paraspinal muscle. The right C7 dorsal nerve root 
was then exposed via C6/C7 hemilaminectomy and partial facetectomy. That nerve root 
was compressed for either 15 minutes (15min, n=12) or 3 minutes (3min, n=9) with a 
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10gf microvascular clip (Nicholson et al. 2011, Rothman et al. 2010). Separate rats 
underwent the same surgical procedures, but did not receive a compression (sham, n=9) 
to serve as a surgical control. Spinal cord tissue from the C7 spinal level was harvested 
from rats on day 1 (15min, n=7; 3min, n=5; sham n=4) or day 7 (15min, n=5; 3min, n=4; sham 
n=5) after surgery and was fixed with 4% paraformaldehyde and cryosectioned for 
subsequent immunohistochemical processing and analysis (as described in Section 
3.3.1.1). 
  
 6.3.1.2. Spinal Cord Immunohistochemistry for Vimentin & GFAP 
 In order to investigate the expression of spinal vimentin and astrocytic vimentin 
over time, vimentin was co-immunolabeled with GFAP. Fixed spinal cord tissue was 
cryosectioned axially at 14µm and mounted on slides. Spinal cord sections were 
incubated in a blocking solution consisting of 5% normal goat serum (Vector 
Laboratories; Burlingame, CA) with 0.3% Triton-X100 (Bio-Rad Laboratories; Hercules, 
CA) in phosphate buffered saline (PBS) for 1 hour at room temperature. Slides were then 
incubated with goat-anti-vimentin raised in rabbit (1µg/ml; Abcam; Cambridge, MA) and 
goat-anti-GFAP raised in mouse (1:750; Millipore; Billerica, MA) overnight at 4°C. 
After rinses with PBS, tissue sections were incubated in goat-anti-rabbit Alexa Flour 488 
and goat-anti-mouse Alexa Fluor 568 (1:1000; Life Technologies; Carlsbad, CA) for 2 
hours at room temperature. Slides were washed with PBS and cover slipped with TRIS 
buffer (Electron Microscopy Sciences; Hatfield, PA) for imaging.  
The ipsilateral dorsal horn was imaged at 20x for 2-6 spinal sections for each rat. 
Total spinal vimentin was quantified using a custom MATLAB densitometry script 
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(Nicholson et al. 2012, Rothman et al. 2010) to measure the percent of the total pixels 
that were positively labeled for vimentin. The percent of pixels labeling vimentin in 
tissue sections was further normalized to the percent positive vimentin labeling in spinal 
cord tissue from normal naïve rats (n=2). Differences in the normalized percent vimentin 
expression were determined between a 15-minute compression, a 3-minute compression 
and sham at day 1 and day 7 using two-way ANOVAs (group x day) with Tukey’s 
honestly significant difference test. 
Spinal astrocytic vimentin was also measured in the same tissue sections using a 
MATLAB script that quantified the percent of co-localized pixels that were labeled for 
both vimentin and GFAP (Dong et al. 2013). The percent of co-localized vimentin and 
GFAP pixels was then compared to the percent of co-localized pixels in spinal tissue 
from normal rats (n=2). Differences in the normalized percent vimentin co-localized with 
GFAP were determined between groups at days 1 and 7 using two-way ANOVAs (group 
x day) with Tukey’s test. 
 
 6.3.1.3. Hirudin Pre-treatment Prior to Painful Root Compression 
 In order to investigate whether compression-induced spinal thrombin activity 
contributes to changes in astrocytic vimentin expression, spinal thrombin was inhibited 
by administering hirudin intrathecally 1 day prior to a 15-minute nerve root compression 
using methods described previously (Section 4.3.2.4) (Smith and Winkelstein 2015). 
Briefly, hirudin (4.2U/rat; Sigma Aldrich; St. Louis, MO) was injected via lumbar 
puncture with a 25G needle (Smith and Winkelstein 2015). At 24 hours after hirudin 
administration, rats underwent a 15-minute C7 nerve root compression (hir+15min, n=6). 
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Spinal cord tissue was harvested from rats at day 7 after the compression and prepared 
for immunohistochemistry as described in Section 3.3.1.1. Spinal cord tissue from 
matching rats that received a 15-minute compression without any treatment (15min, n=5) 
were included for immunohistochemical comparison. Using methods described in Section 
3.3.1.1, ipsilateral C7 spinal cord tissue from rats receiving a 15-minute compression 
with or without hirudin was co-labeled for vimentin and GFAP. The percent of pixels 
labeled positively for vimentin and the percent of pixels labeled positively for vimentin 
co-localized with GFAP, were each separately normalized to respective levels in tissue 
from normal naïve rats. Differences in normalized vimentin and normalized co-
localization of vimentin and GFAP between hir+15min and 15min were determined using 
one-way ANOVA with Tukey’s test.  
 
 6.3.1.4. Salmon Thrombin Treatment 
 In order to investigate whether an analgesic treatment of salmon thrombin 
prevents compression-induced modifications in astrocytic vimentin expression, salmon 
thrombin was administered after a 15-minute nerve root compression as described 
previously (Section 5.3.1.2) (Smith et al. 2013, Smith et al. 2015, Weisshaar et al. 2011). 
Briefly, salmon thrombin (0.04U/rat; Sea Run Holdings; Freeport, ME) was dissolved in 
20µl of neurobasal media and administered directly on top of the right C7 nerve root 
immediately after its compression for 15 minutes (15min+STh, n=7). A separate group of 
rats received a treatment of human thrombin (0.04U/rat; Sigma Aldrich; St. Louis, MO) 
dissolved in neurobasal media applied to the nerve root immediately after a 15-minute 
compression (15min+HTh, n=4). 
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Spinal cord tissue was harvested from rats at day 7 after compression with 
treatment and prepared for immunohistochemistry as described in Section 3.3.1.1. Spinal 
cord tissue from matching rats receiving a sham operation (sham, n=6) was included for 
immunohistochemical comparison as well. Fixed C7 tissue was co-immunolabeled for 
vimentin and GFAP, as described in Section 6.3.1.2. The ipsilateral dorsal horn was 
imaged and the percent of pixels positively labeled for vimentin, as well as the percent of 
pixels that was co-labeled for vimentin and GFAP each were quantified using MATLAB 
scripts and reported relative to expression in normal tissue. Differences in the normalized 
percent vimentin and the normalized percent co-localization of vimentin and GFAP at 
day 7 between the 15min, 15min+STh and 15min+HTh groups were compared using a 
one-way ANOVA with Tukey’s test. 
 
6.3.2. Results  
Vimentin is expressed in the ipsilateral spinal cord in all groups probed at day 1 
and day 7 and is localized to the vasculature (Figure 6.1A). Each of a painful 15-minute 
and a non-painful 3-minute nerve root compression induces a robust increase in vimentin 
expression in the ipsilateral spinal cord at day 7 after compression (Figure 6.1A). Spinal 
vimentin labeling is significantly elevated after a 15-minute compression (p<0.001) and a 
3-minute compression (p<0.001) compared to labeling after a sham procedure, both 
overall and at day 7 (Figure 6.1B). The increase in spinal vimentin that is observed at day 
7 after a 3-minute compression is significant compared to its own expression at day 1 
(p<0.001), but spinal vimentin at day 7 after a 15-minute compression is not significantly 
increased compared to its expression at day 1 (Figure 6.1). At day 1, all groups, including 
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sham, exhibit approximately a 2-fold increase in spinal vimentin over normal levels 
(Figure 6.1).  
 
 
 
Quantification of the percent of pixels that are positively labeled for both 
vimentin and GFAP, as a proxy for astrocytic vimentin, reveals that both a 15-minute 
Figure 6.1. Spinal vimentin increases at day 7 following nerve root compressions of different 
durations, but spinal astrocytic vimentin only increases after a painful compression. (A) Vimentin 
(green) is more robustly expressed in the ipsilateral spinal dorsal horn at day 7 after a 3-minute (3min) 
or 15-minute (15min) compression compared to sham levels. GFAP (red) and vimentin co-localization 
(yellow) is slightly elevated after a 3min compression, but is more evident after a 15min compression. 
(B) Spinal vimentin expression normalized to expression in normal tissue is significantly higher 
(*p<0.001) than sham at day 7 after each of a 3min and 15min compression. Total vimentin expression 
at day 7 after a 3min compression is also significantly increased (#p<0.001) compared to its expression 
levels at day 1. (C) Co-localization of vimentin and GFAP normalized to levels in naïve tissue, is 
significantly increased (*p=0.024) over sham only after a 15min compression at day 7. Data are 
mean±SD. 
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compression (p<0.001) and a 3-minute compression (p=0.024) induce significant 
increases in astrocytic vimentin compared to sham overall (Figure 6.1C). A 3-minute 
compression induces a 5.3-fold increase over normal in spinal astrocytic vimentin 
expression at day 7, but that is not different from expression at that day after a sham 
operation or a 15-minute compression (Figure 6.1C). Only a 15-minute compression, 
which elevates astrocytic vimentin 5.8-fold over normal, induces a significant increase 
(p=0.023) in astrocytic vimentin over sham at day 7, although with a large degree of 
variability (Figure 6.1C). Astrocytic vimentin expression is close to normal levels on both 
day 1 and day 7 after a sham operation (Figure. 6.1). 
Blocking spinal thrombin with hirudin 1 day before a painful nerve root 
compression prevents the development of pain for up to 7 days following injury (Figure 
4.5) (Smith and Winkelstein 2015). A 15-minute compression induces a robust increase 
in total and astrocytic vimentin in the ipsilateral spinal dorsal horn at day 7 over normal 
levels (Figure 6.2A). Spinal astrocytic vimentin expression at day 7 is significantly 
reduced (p=0.048) when treating a painful compression with hirudin compared to an 
untreated compression (Figure 6.2). In fact, intrathecal hirudin reduces astrocytic 
vimentin to normal levels at day 7 (Figure 6.2C). Interestingly, total vimentin 
expression in the ipsilateral spinal cord after a 15-minute compression treated with 
hirudin is even more robust than after an untreated compression (Figure 6.2A). Indeed, 
total spinal vimentin labeling is significantly increased (p<0.001) in rats receiving a 15-
minute compression with hirudin than in rats receiving only a compression (Figure 
6.2B).  
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Salmon thrombin, administered to the nerve root immediately after a painful 
compression, prevents the development of mechanical allodynia for up to 7 days; that 
anti-nociceptive effect is not evident when treating the compression with human 
thrombin (Figures 5.3 & 5.5) (Smith et al. 2013, Smith et al. 2015). Vimentin 
expression in the ipsilateral spinal cord is higher than normal and sham levels at day 7 
when the 15-minute compression is treated with salmon thrombin (Figure 6.3A). This 
apparent elevation in spinal vimentin at day 7 after a compression treated with salmon 
Figure 6.2. Intrathecal hirudin attenuates the compression-induced increase in spinal astrocytic 
vimentin at day 7. (A) At day 7 after a 15-minute (15min) compression, total spinal vimentin (green) 
and its co-localization (yellow) with GFAP (red) are substantially increased in the ipsilateral spinal cord 
compared to levels in normal tissue. Vimentin expression is greater at day 7 after hirudin administered 
1 day before compression (hir+15min) compared to an untreated compression. There is more co-
localized vimentin and GFAP at day 7 in the hir+15min group compared to 15min. (B) Quantification 
of total spinal vimentin expression normalized to levels in naïve tissue is significantly (*p<0.001) 
increased at day 7 for the hir+15min group over the 15min group. (C) The percent of co-localized 
pixels labeling GFAP and vimentin is significantly decreased (*p=0.048) in the hir+15min group 
compared to the 15min group. Data are mean±SD.  
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thrombin is significant over both a sham procedure (p<0.001) and a compression 
treated with human thrombin (p=0.004) (Figure 6.3B). Spinal astrocytic vimentin is 
elevated 4-fold over normal levels for a salmon thrombin treated compression. Despite 
this fold-increase over normal, astrocytic vimentin expression is not significantly 
different for a 15-minute compression treated with salmon thrombin than sham at day 7 
(Figure 6.3C). Only the human thrombin treated compression exhibits significantly 
more (p=0.018) spinal astrocytic vimentin than sham at day 7 (Figure 6.3C).  
 
 
Figure 6.3. Salmon thrombin does not reduce the compression-induced increase in spinal 
astrocytic vimentin at day 7. (A) Spinal vimentin (green) expression is more robust in the ipsilateral 
spinal cord at day 7 after a 15-minute compression treated with human thrombin (15min+HTh) than 
after a sham procedure or in normal tissue. Vimentin labeling is greater for treatment with salmon 
thrombin (15min+STh) than with human thrombin. The co-localization (yellow) of vimentin and GFAP 
(red) labeling is slightly more robust in the 15min+HTh group than in the other groups. (B) Normalized 
quantification of spinal vimentin expression is significantly greater for a 15min+STh than each of the 
sham (**p<0.001) and 15min+HTh (&p=0.002) groups at day 7. The 15min+HTh group also exhibits 
significantly more spinal vimentin labeling than sham at day 7 (*p=0.004). (C) Co-localization of 
vimentin and GFAP expression is significantly elevated (*p=0.018) after 15min+HTh compared to 
sham levels. Astrocytic vimentin expression for 15min+STh is not different from sham or 15min+HTh.  
Data are presented as mean±SD. 
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A detailed summary of the quantification of spinal vimentin expression and 
astrocytic vimentin expression in the ipsilateral spinal cord for each rat in the studies in 
Section 6.3 is provided in Appendix B. 
 
6.4. Measuring Spinal Endothelial Vimentin after Root Compression 
6.4.1. Methods 
 6.4.1.1. Root Compression & Treatment Procedures 
 Surgical procedures for the nerve root compression with and without treatment, 
are detailed in Section 6.3.1. Three separate groups of rats received surgery. In order to 
determine the effect of painful and non-painful compression on changes in spinal 
endothelial vimentin expression, rats received a compression to the C7 nerve root via a 
10gf microvascular clip for either 15 or 3 minutes (as described in Section 3.3.1.1) 
(Nicholson et al. 2011, Rothman et al. 2010). Separate rats underwent sham procedures to 
serve as a surgical control. 
 A separate group of rats was used in order to investigate the effects of blocking 
spinal thrombin on compression-induced changes in endothelial vimentin expression in 
the ipsilateral spinal cord at day 7. Briefly, rats received an intrathecal injection of 
hirudin (4.2U/rat in 30µl PBS) 1 day before receiving the painful C7 nerve root 
compression for 15-minutes (Sections 3.3.1.3 and 6.3.1.1). Separate rats underwent a 
compression without pre-treatment for comparison purposes. 
 The comparative effects of salmon and human thrombin on spinal endothelial 
vimentin expression after painful compression also were investigated using another set of 
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rats. Briefly, the C7 nerve root was compressed for 15 minutes and was immediately 
treated with either salmon thrombin (0.04U/rat) or human thrombin (0.04U/rat) in 20µl 
neurobasal media (see Sections 5.4.1.2 & 6.3.1.4) (Smith et al. 2013, Smith et al. 2015). 
Sham operated rats were also included to serve as a surgical control and did not receive 
any treatment. Methods for the compression surgery and thrombin treatments are 
described in more detail in Section 6.3.1.4. 
 
 6.4.1.2. Spinal Cord Immunohistochemistry for Vimentin & VWF 
Spinal cord tissue was harvested after perfusion with paraformaldehyde (as in 
Section 3.3.1.1). Tissue was cryosectioned at 14µm and mounted on glass slides (see 
Section 3.3.1.1) (Smith et al. 2013, Smith and Winkelstein 2015). Slides were blocked in 
a solution consisting of 5% normal goat serum (Vector Laboratories; Burlingame, CA) 
with 0.3% Triton-X100 (Bio-Rad Laboratories; Hercules, CA) in PBS for 1 hour at room 
temperature and then incubated with goat-anti-vimentin raised in rabbit (1µg/ml; Abcam; 
Cambridge, MA) and goat-anti-VWF raised in mouse (1:75; Abcam; Cambridge, MA) 
overnight at 4°C. Tissue sections were then rinsed and incubated in goat-anti-rabbit 
Alexa Flour 488 (1:1000; Life Technologies; Carlsbad, CA) and goat-anti-mouse Alexa 
Fluor 568 (1:500; Life Technologies; Carlsbad, CA) for 2 hours at room temperature. The 
ipsilateral dorsal horn was imaged at 20x in 2-6 spinal sections from each rat. Spinal 
endothelial vimentin expression was quantified using a custom co-localization MATLAB 
script, as described in Section 6.3.1.2 (Dong et al. 2013). The percent of co-localized 
vimentin and VWF pixels was normalized to the percent of co-localized pixels in spinal 
tissue from naïve rats (n=2).  
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Statistical differences in the normalized percent of co-localized vimentin and 
VWF pixels was determined in the separate combinations of groups outlined in Section 
6.4.1.1. Differences in the percent of co-localized pixels at days 1 and 7 after a 15-minute 
compression (15min; day 1, n=8; day 7, n=4), a 3-minute compression (3min; day 1, n=5; 
day 7, n=4) and a sham surgery (day 1, n=4; day 7, n=6) were determined using a two-
way ANOVA (group x day) with Tukey’s honestly significant difference test. Differences 
in the percent co-localization at day 7 after a 15-minute compression alone (15min, n=4) 
and a compression pre-treated intrathecally with hirudin (hir+15min, n=6) was 
determined using a one-way ANOVA with Tukey’s test. Lastly, differences in 
endothelial vimentin expression were compared at day 7 after a painful 15-minute 
compression treated with salmon thrombin (15min+STh, n=8), or with human thrombin 
(15min+HTh, n=4), and a sham procedure (n=6) using a one-way ANOVA with Tukey’s 
test.  
 
6.4.2. Results 
 The co-localization of vimentin with VWF, to indicate endothelial vimentin, is 
elevated at day 7 for both compression durations (i.e. 15-minute or 3-minute) in 
comparison to sham at that time and respective levels at day 1 (Figure 6.4A). Yet, only a 
3-minute compression induces a significant increase (p<0.001) in spinal endothelial 
vimentin compared to sham, at day 7 and overall (Figure 6.4B). That elevation in spinal 
endothelial vimentin induced by a 3-minute compression at day 7 is also significant 
(p<0.001) compared to the corresponding expression at day 1 (Figure 6.4). Despite not 
exhibiting significant differences on the individual days probed, a 15-minute compression 
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induces a 2.2-fold increase (p<0.001) in endothelial vimentin in the ipsilateral spinal 
cord, which is significant compared to sham overall (Figure 6.4B). Expression of 
endothelial vimentin at days 1 and 7 after sham procedures is at normal levels (Figure 
6.4). Values for vimentin co-localization with VWF for each rat is included in Appendix 
B. 
 
 
Figure 6.4. Nerve root compression induces an increase in spinal endothelial vimentin at day 7. 
(A) Spinal co-localization (yellow) of vimentin (green) and VWF (red) is qualitatively increased at day 
7 after a 3-minute (3min) or a 15-minute (15min) compression compared to sham expression at day 7 or 
expression by any group at day 1. (B) The percent co-localization of vimentin and VWF normalized to 
expression in naïve tissue is significantly elevated only at day 7 after a 3min compression and only over 
sham at day 7 (*p<0.001) and its corresponding expression at day 1 (#p<0.001). Data are mean±SD. 
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 Intrathecally treating with hirudin before a 15-minute nerve root compression 
increases the co-localization of vimentin and VWF labeling at day 7 relative to levels 
observed for an untreated 15-minute compression and normal tissue (Figure 6.5). Spinal 
endothelial vimentin is elevated 4.5-fold over normal after hirudin treatment and that 
increase is significant (p<0.001) at day 7 compared to expression levels after 
compression alone (Figure 6.5). Appendix B includes a detailed summary of the 
quantification of the co-localization of vimentin with VWF expression in the ipsilateral 
spinal cord for each rat in this study. 
 
 
 
Figure 6.5. Intrathecal hirudin elevates compression-induced spinal endothelial vimentin at day 7. 
The co-localization (yellow) of vimentin (green) and VWF (red) labeling is more robust in the 
ipsilateral spinal cord at day 7 after a compression that is pre-treated with hirudin (hir+15min) 
compared to compression alone (15min). That increase in endothelial vimentin is significant 
(*p<0.001). Values are mean±SD. 
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 Endothelial vimentin expression increases in the ipsilateral spinal cord at day 7 
after a 15-minute compression treated with either salmon or human thrombin, separately, 
over both normal and sham levels (Figure 6.6). However, spinal endothelial vimentin 
expression increases nearly 3-fold over normal levels; this increase is significantly 
greater (p<0.001) than expression at day 7 after sham (Figure 6.6). A detailed summary 
of the quantification of the co-localization of vimentin and VWF in the ipsilateral spinal 
cord for each rat is provided in Appendix B. 
 
 
 
 
 
Figure 6.6. Salmon thrombin increases endothelial vimentin expression in the ipsilateral spinal 
cord at day 7 after a 15-minute compression. There is more co-localized (yellow) vimentin (green) 
and VWF (red) at day 7 after a 15-minute compression with human thrombin (15min+HTh) compared 
to sham; yet, this increase is not significant. Spinal endothelial vimentin is significantly elevated 
(*p<0.001) over sham levels after treating a 15-minute compression with salmon thrombin 
(15min+STh). Data are mean±SD. 
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6.5. Discussion 
Spinal astrocytic vimentin is increased after mechanical trauma to the nerve root 
(Figure 6.1), paralleling the extent of mechanical hyperalgesia that is produced after 
compressive injury (Figure 4.3) (Smith and Winkelstein 2015). A 15-minute compression 
induces mechanical hyperalgesia and allodynia by day 1, both of which are maintained 
for at least 7 days (Figures 3.2 & 4.3) (Chang and Winkelstein 2011, Rothman et al. 
2010, Smith et al. 2015, Smith and Winkelstein 2015). That painful compression also 
increases spinal expression of astrocytic vimentin over sham expression (Figure 6.1). The 
behavioral studies in Chapter 4 demonstrate that a 3-minute compression also induces a 
decrease in paw withdrawal threshold compared to sham overall (Figure 4.3), 
corresponding to an increase in hyperalgesia. But, withdrawal thresholds induced by a 3-
minute compression are not statistically different from thresholds for sham or a 15-
miunte compression either at day 1 or day 7 (Figure 4.3) (Smith and Winkelstein 2015), 
suggesting that the pain response is graded depending on the duration of compression. 
Overall, spinal astrocytic vimentin expression is increased over sham, but that elevation 
is not different from sham or a 15-minute compression at either day 1 or day 7 (Figure 
6.1). This lack of difference parallels the mechanical hyperalgesia profile that is seen 
after a 3-minute compression (Figure 4.3). Further supporting the association between 
spinal astrocytic vimentin and behavioral responses, treating a painful compression with 
hirudin reduces astrocytic vimentin expression to normal levels (Figure 6.2) and prevents 
the development of mechanical hyperalgesia (Figure 4.5).  
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The 3-minute compression, which induces a marginal increase in mechanical 
hyperalgesia, does not induce a significant increase in mechanical allodynia (Nicholson et 
al. 2012, Rothman et al. 2010). A previous study measured mechanical allodynia for up 
to 7 days using a 4g filament, which is typically a non-noxious stimulus, and found that 
allodynia did not develop at any day after a 3-minute root compression (Rothman et al. 
2010). Although that 3-minute compression induces a drop in paw withdrawal threshold 
by up to 26% from baseline levels, the thresholds at days 1 and 7 are 10.4±5.3g and 
14.2±9.2g, respectively (Figure 4.3) (Smith and Winkelstein 2015). Those mechanical 
thresholds are both at least one standard deviation above the 4g stimulus used to measure 
mechanical allodynia (Nicholson et al. 2012, Rothman et al. 2010). As such, it can be 
inferred that behavioral sensitivity would not be evident by testing with a 4g stimulus. 
Spinal astrocytic vimentin expression is graded following a root compression depending 
on the duration of compression (Figure 6.1), similar to hyperalgesia induced after those 
compressive insults (Figure 4.3) (Smith and Winkelstein 2015). Because the shorter, 3-
minute, compression does not induce mechanical allodynia (Rothman et al. 2010), 
astrocytic vimentin expression seems to parallel mechanical hyperalgesia, and not 
allodynia, suggesting that the amount of spinal astrocytic activation may contribute to the 
severity of sustained pain following root compression.  
Interestingly, salmon thrombin prevents the development of mechanical allodynia 
after a 15-minute compression (Chapter 5) (Smith et al. 2013, Smith et al. 2015, 
Weisshaar et al. 2011). The current studies demonstrate that astrocytic vimentin 
expression is elevated 4-fold over normal when treating a painful compression with 
salmon thrombin, albeit those responses are not different from sham levels at day 7 
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(Figure 6.3), thus suggesting that salmon thrombin does not entirely prevent the spinal 
astrocytic activation produced by painful compression, albeit preventing allodynia. Of 
note, mechanical hyperalgesia has not been measured following salmon thrombin 
treatment. Since salmon thrombin does not completely prevent the compression-induced 
elevation in spinal astrocytic vimentin, it is possible that salmon thrombin also does not 
entirely prevent compression-induced mechanical hyperalgesia. It is possible that the 
withdrawal threshold after a painful compression treated with salmon thrombin is 
reduced relative to sham, but not below 4g, and as such the rat would not respond when 
the paw is stimulated by a mechanical force that is 4g or lower, thereby not inducing 
measurable mechanical allodynia.  
 In contrast to spinal astrocytic vimentin, endothelial vimentin expression is 
elevated after either duration of nerve root compression at day 7, regardless of whether 
that compression also induces mechanical hyperalgesia (Figure 6.4). In fact, the 3-minute 
compression, which produces slight behavioral sensitivity (Figures 3.2 & 4.3) (Smith et 
al. 2015, Smith and Winkelstein 2015), induces an even more robust increase in 
endothelial vimentin compared to the painful 15-miunte compression, although this 
difference is not significant (Figure 6.4). Both analgesic treatments used in this chapter 
(hirudin and salmon thrombin) also induce marked increases in spinal endothelial 
vimentin expression at day 7, both of which are over three times greater than normal 
(Figures 6.5 & 6.6). Hirudin and salmon thrombin prevent pain-related behaviors from 
developing but induce substantial elevations in spinal endothelial vimentin expression, 
suggesting that increased endothelial vimentin might be protective and/or promoting of 
anti-nociception. Since expression of vimentin in vascular endothelial cells contributes to 
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vascular integrity (Liu et al. 2014, Stasek et al. 1992), the increase in spinal endothelial 
vimentin may help to protect the BSCB from being disrupted. 
The increases in spinal astrocytic and endothelial vimentin evident after a painful 
nerve root compression (Figures 6.1 and 6.4) suggest that a variety of spinal cell types 
respond to a neural injury, despite being remote from the tissue injury itself. Compression 
of nerve root tissue compromises the integrity of the axons and vasculature within the 
injured tissue; in the case of nerve root compression both the injured axons and 
vasculature directly connect to the spinal parenchyma. The nerve root recovers to only 
75% of its original width after 15 minutes of compression (Rothman et al. 2010). That 
macroscopic structural response is associated with the longer-term breakdown of the 
structural integrity of axons in the root by day 7 (Hubbard et al. 2008b, Hubbard and 
Winkelstein 2008, Nicholson et al. 2011). Disruption of neurofilament expression and 
demyelination of axons, both of which are evident at day 7 after a painful compression, 
are further associated with altered transport of neuropeptides to the spinal dorsal horn 
(Hubbard et al. 2008a, Hubbard et al. 2008b). Spinal astrocytes that are localized to 
injured afferent synapses respond to synaptic fluctuations of neuropeptides such as 
substance P, glial cell line-derived neurotrophic factor (GDNF), and ATP, and become 
activated (Milligan and Watkins 2009, Nakagawa and Kaneko 2010, Watkins et al. 
2001). In contrast to a 15-minute compression, the nerve root width is almost completely 
restored to its unloaded geometry after 3 minutes of compression (Rothman et al. 2010), 
and there is no compromise of structural integrity at day 7 (Nicholson et al. 2011). Thus, 
the less injurious 3-minute compression likely does not disrupt spinal neuropeptide 
concentrations or transport to the same extent as a 15-minute compression, thereby not 
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inducing astrocyte activation to as great of a degree. Astrocytic vimentin is also more 
robustly elevated after a 15-minute, than a 3-minute, compression (Figure 6.1). In 
contrast, endothelial vimentin is upregulated robustly after both durations of compression 
(Figure 6.4), suggesting that astrocytic regulation of vimentin is more sensitive to root 
trauma than endothelial vimentin. The lack of apparent association between endothelial 
responses and synaptic concentrations of neuropeptides is supported by the configuration 
and functionality of the neurovascular unit. Astrocytes act as a physical and trophic 
buffer between neuronal synapses and the microvascular endothelial cells (Radu et al. 
2013, Zlokovic 2010). As such, fluctuations in synaptic peptides, which are evident 
exclusively after a painful compression by day 7 (Hubbard et al. 2008a), might not 
directly affect endothelial cells due to the physical encasement of synapses by astrocytes.  
  In addition to neuronal input, cells within the spinal cord also respond to vascular 
changes such as ischemia, which is a reduction in blood flow thereby producing an 
inadequate oxygen supply. Transient compression of the nerve root has been shown to 
induce an immediate drop in blood flow to the spinal cord (Kobayashi et al. 2008, 
Olmarker et al. 1989, Yoshizawa et al. 1989), creating an ischemic environment 
transiently in the spinal cord. Although the duration of ischemia after compression 
depends on the magnitude of compression (Rydevik et al. 1981, Rydevik et al. 1984), a 
previous study demonstrated that blood flow within the nerve root remains compromised 
for up to 3 hours after just 2 seconds of 45gf compression (Igarashi et al. 2005). Although 
the magnitude of compression was lower in this study (10gf), that load was the same for 
both of the compression durations suggesting that both a 15-minute compression and a 3-
minute compression may induce the same level of spinal ischemia, at least during 
  213 
compression. In vitro, although endothelial cells decrease their expression of vimentin 
transiently when exposed to hypoxia for 30 minutes, endothelial vimentin expression is 
restored to levels even higher than pre-hypoxic ones within 1 hour (Liu et al. 2010). 
Since the spinal endothelium is likely exposed to ischemia during, and maybe after, a 
nerve root compression, and either duration of compression in this study leads to an 
increase in spinal endothelial vimentin at day 7 (Figure 6.4), spinal endothelial vimentin 
likely responds to ischemic inputs that result from nerve root compression.   
The compression-induced increase in endothelial vimentin might contribute to 
restoring BSCB stability, which is evident at day 7 after either compression duration 
(Figure 3.2). BSCB breakdown is evident at day 1 exclusively after a 15-minute nerve 
root compression, but not a 3-minute compression (Figure 3.2). At that same time, spinal 
endothelial vimentin is not different for either compression duration from normal levels 
(Figure 6.4). An increase in endothelial vimentin expression has been previously 
associated with strengthened endothelial barrier integrity in vitro (Liu et al. 2010, Liu et 
al. 2014). Since endothelial vimentin is not altered after a 15-minute compression (Figure 
6.4), vimentin likely does not control vascular permeability at day 1 after compression. 
Instead a reduction in endothelial tight junctions might contribute to the decreased 
integrity of the spinal vasculature at day 1 after a 15-minute compression (Ballabh et al. 
2004, Echeverry et al. 2011, Hawkins and Davis 2005). At day 7, however, spinal 
endothelial vimentin is increased 2- to 2.5-fold over normal levels after either 
compression duration (Figure 6.4). Yet, at that time the BSCB integrity is restored and 
the BSCB integrity remains intact after the 3-minute compression (Figures 3.2 & 4.3) 
(Smith et al. 2015, Smith and Winkelstein 2015).  Taken together, the delayed increase in 
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endothelial vimentin might result from a downstream effect of compression-induced 
ischemia and might help to stabilize endothelial barriers after neural compression. 
The association between increased spinal endothelial vimentin expression and 
BSCB integrity at day 7 after painful compression is supported by the effects of both of 
the pharmacologic treatments used in the current study. Intrathecally pre-treating a 15-
minute compression with hirudin prevents the breakdown of the BSCB, which is evident 
at day 1 after compression (Figure 4.4) (Smith and Winkelstein 2015). Hirudin is 
hypothesized to prevent BSCB breakdown by inhibiting the activity of spinal thrombin 
after compression, since thrombin is an inducer of vascular leakiness (Coughlin 2000, 
Komarova et al. 2007). Thrombin applied at 1U/ml to endothelial cultures induces the 
phosphorylation of vimentin within 15-30 seconds (Bormann et al. 1986). Since 
phosphorylation of vimentin decreases the stability of the filament and induces 
endothelial layer permeability (Grin et al. 2012, Liu et al. 2010), blocking the early 
elevation in spinal thrombin after compression with hirudin might partially prevent 
BSCB breakdown by stabilizing the integrity of vimentin filaments in the endothelium. 
Similarly, salmon thrombin also prevents BSCB breakdown at day 1 (Figure 5.3), and, as 
such, likely reduces spinal thrombin extravasation after compression. The early vascular 
protection induced by both hirudin and salmon thrombin also leads to a longer lasting 
increase in endothelial vimentin at day 7 (Figures 6.5 & 6.6). The association between the 
early stability of spinal vasculature and the later increase in endothelial vimentin suggests 
that protecting BSCB breakdown early after neural compression might facilitate sustained 
vascular integrity.   
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 The fact that expression of vimentin increases in both spinal astrocytes and 
endothelial cells after painful nerve root compression suggests that spinal cells may 
respond by changing their mechanical properties after a neural injury, even when that 
trauma is remote from the spinal cord itself. Increases in astrocytic and endothelial 
vimentin have been shown to independently correlate with increases in cytoplasmic 
stiffness (Guo et al. 2013, Lu et al. 2011). Of those two cells, astrocytes comprise a 
majority of the cellular makeup of the spinal cord and significantly contribute to the 
tensile stiffness of the spinal cord (Shreiber et al. 2009, Vallejo et al. 2010). The 
elevation in astrocytic vimentin observed at day 7 (Figure 6.1) may contribute to an 
increase in the stiffness of the spinal cord after a painful nerve root compression. In 
contrast, compressive stiffness of the spinal cord decreases for up to 8 weeks after a 
hemisection injury (Saxena et al. 2012). A hemisection injury compromises the local 
cellular and extracellular integrity of the spinal cord itself and the lesion is repopulated by 
activated astrocytes, oligodendrocytes, immune cells, and connective tissue elements that 
collectively form a glial scar (Fitch and Silver 2008, Hausmann 2003). Yet, the 
macroscale changes in mechanical integrity of the spinal parenchyma after spinal cord 
injury are robust and likely dominate any contributions from changes in the mechanical 
properties of the resident cells. Since a nerve root compression is remote from the spinal 
cord and does not produce bulk structural changes to the spinal cord, any mechanical 
changes in the spinal parenchyma must be due to changes of the mechanical responses of 
the cells, or of the ECM proteins, in the spinal cord. Since spinal astrocytes are activated, 
i.e. express more GFAP and vimentin, at day 7 after a painful root compression (Figure 
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6.1) (Hubbard and Winkelstein 2005, Rothman et al. 2010), they may also influence the 
bulk mechanics of the spinal parenchyma at that time.  
Spinal astrocytes are the main mechanical substrate for nearby neurons (Volterra 
and Meldolesi 2005), External mechanical inputs control a variety of neuronal functions, 
such as growth cone formation and propagation, neurite extension and synaptic vesicle 
transport within axons (Ahmed et al. 2012, Flanagan et al. 2002, Koch et al. 2012, 
Siechen et al. 2009). A change in neuronal substrate stiffness, i.e. astrocyte stiffness, 
would modulate neuronal intracellular tension and, therefore, might disrupt or enhance 
neurotransmitter vesicle trafficking within those neurons (Ahmed et al. 2012, Siechen et 
al. 2009). Modifying neuronal vesicle movement also would affect synaptic concentration 
of neurotransmitters, which would modulate the hyperexcitability of spinal neurons 
(Latremoliere and Woolf 2009, Scholz and Woolf 2007). Neuronal hyperexcitability 
increases in the spinal cord by day 7 after this painful nerve root compression (Zhang et 
al. 2013). Although no study to date has measured the electrophysiological responses of 
neurons to substrate stiffness, it is possible that the increase in astrocytic vimentin, and 
possibly astrocytic stiffness, may, at least in part, contribute to the hyperexcitability that 
is evident in the spinal cord at day 7 after compressive injury by modulating neuronal 
intracellular transport.  
There are several limitations associated with the current study. Measuring 
vimentin expression alone does not provide information about the functionality of this 
intermediate filament. For example, the subcellular organization of vimentin, as well as 
the state of its phosphorylation, both contribute to this intermediate filaments control over 
cytoplasmic stiffness (Buehler 2013, Li et al. 2006, Liu et al. 2014). Phosphorylation of 
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vimentin can be induced with the steroidal lactone, Withaferin A, which disrupts the 
stability of vimentin filaments (Grin et al. 2012, Liu et al. 2014). Administering 
Withaferin A intrathecally at day 7 after painful compression, when astrocytic and 
endothelial vimentin are upregulated (Figures 6.1 & 6.2), would determine whether the 
upregulation in vimentin influences pain and the associated cellular responses in the 
spinal cord at that time. Also, the mechanical properties of the spinal parenchyma were 
not measured directly. Microscopic techniques to measure compressive stiffness, such as 
microindentation or atomic force microscopy (AFM), allow measurement of regional 
mechanical properties of biological tissues (Levental et al. 2010, Lin and Horkay 2008). 
Measuring the micromechanics of the spinal cord in regions that exhibit increased 
astrocytic vimentin expression at day 7 after painful nerve root compression, would 
determine whether the spinal parenchyma undergoes stiffness changes that correspond to 
changes in cell mechanics. Pilot studies did utilize a custom microindentation device to 
measure the stiffness of the spinal parenchyma in anatomical regions and at times in 
which astrocyte activation is evident after painful compression. However, the variability 
in measurements produced by that approach was greater than any trending differences 
between groups. As such, a more sensitive indentation device or AFM might be more 
suitable for detecting any differences in spinal cord stiffness after painful nerve root 
compression. 
Nevertheless, this is the first study to investigate the response of the intermediate 
filament, vimentin, within spinal astrocytes and endothelial cells after a peripheral neural 
injury. Astrocytic vimentin undergoes a delayed elevation at day 7 after nerve root 
compression (Figure 6.1), along the same profile as spinal GFAP (Rothman et al. 2010, 
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Rothman and Winkelstein 2007), and is associated with the mechanical hyperalgesia that 
is produced (Figure 4.3). Spinal hirudin prevents both compression-induced elevations in 
astrocytic vimentin and mechanical hyperalgesia for up to 7 days (Figures 4.5 & 6.2), 
further supporting the association between increased spinal astrocytic vimentin and pain. 
In contrast to astrocytic vimentin responses, endothelial vimentin is increased in the 
spinal cord at day 7 after a nerve root compression, regardless of whether pain develops 
or not (Figure 6.4). Endothelial vimentin is further upregulated at day 7 after compression 
with either of the analgesic treatments investigated in this study (i.e. hirudin and salmon 
thrombin) (Figures 6.5 & 6.6), suggesting that an increase in endothelial vimentin might 
even be protective.  
 
6.6. Integration & Conclusions 
 This study did not test the original hypothesis that the stiffness of regions in the 
spinal parenchyma that exhibit elevated astrocyte activation following painful nerve root 
compression is modified. This hypothesis was explored in pilot studies by utilizing a 
custom microindentation device with a 255µm diameter probe (Levental et al. 2010). The 
relatively small size of the indentation probe allowed for regional measurements since it 
could spatially resolve the ipsilateral and contralateral sides of the spinal cord. However, 
the sensitivity of the device, and therefore variation within and between samples, did not 
produce reliable data. As such, the original hypothesis was adapted to quantify an aspect 
of the microscale mechanical response of astrocytes and with the aim of investigating 
whether spinal astrocytes respond mechanically when activated after a painful nerve root 
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compression. Measuring the astrocytic expression of the intermediate filament, vimentin, 
was chosen because of vimentin’s already-established association with astrocyte 
activation and its independent role in contributing to cytoplasmic stiffness (Guo et al. 
2013, Lu et al. 2011, Pekny and Pekna 2004). By measuring astrocytic vimentin after 
each of a 15-minute and a 3-minute compression, that induce different levels of 
mechanical hyperalgesia (Figure 4.3) (Smith and Winkelstein 2015), this study suggests 
that spinal astrocytes may alter their mechanical response to a peripheral neural injury 
(Figure 6.1), in association with pain production.  
Immunolabeling spinal vimentin as the means to quantify its expression allowed 
for the observation that vimentin is highly localized to vasculature within the spinal cord. 
Endothelial vimentin expression fortifies endothelial barriers (Gonzales et al. 2001, Liu et 
al. 2014, Lu et al. 2011). Because studies in Chapters 3 and 4 show that the spinal 
vasculature increases its permeability to both IgG and thrombin transiently at day 1 after 
a painful nerve root compression (Figures 3.2 & 4.3) (Smith et al. 2015, Smith and 
Winkelstein 2015), the current study also quantified changes in endothelial vimentin 
expression over time after compressive injury. Endothelial vimentin increases by day 7 in 
the spinal cord after both a 15-minute and a 3-minute compression (Figure 6.4), a time 
when the BSCB integrity is either re-established or maintained, respectively (Figure 3.2) 
(Smith et al. 2015). Since a nerve root compression, regardless of the duration, may 
directly induce ischemia in the spinal cord by disruption of the root vasculature, the 
delayed increase in endothelial vimentin is likely due to vascular ischemia. However, this 
was not explicitly investigated. Additionally, both hirudin and salmon thrombin, which 
prevent the development of behavioral sensitivity for up to 7 days after painful 
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compression (Figures 4.5 & 5.5) (Smith et al. 2013, Smith and Winkelstein 2015), and 
also induce substantial elevations in endothelial vimentin at this time (Figures 6.5 & 6.6). 
Thus, increased spinal endothelial vimentin likely plays a protective, rather than a 
pathological, role in the spinal cord after painful nerve root compression.   
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Chapter 7 
Synthesis & Future Work 
 
 
7.1. Introduction 
Approximately 116 million adults in the United States are affected by chronic 
pain each year with an associated annual national economic cost of more than $600 
billion (Institute of Medicine (US) Committee on Advancing Pain Research 2011). 
Despite the astounding number of lives impacted by chronic pain in our country and 
across the world (Bouhassira et al. 2008, Breivik et al. 2006, Hasselstrom et al. 2002), the 
available treatments options still are often ineffective at mitigating symptoms (Dworkin 
et al. 2003, Finnerup et al. 2010, O'Connor and Dworkin 2009). The pharmacologic 
agents that are FDA-approved and recommended to treat chronic pain, such as tricyclic 
antidepressants, anticonvulsants and the lidocaine patch, each target only a single 
neuronal mechanism that contributes to nociception  (Argoff 2000, Dworkin et al. 2003, 
Finnerup et al. 2010, Gilron 2007, Meier et al. 2003, O'Connor and Dworkin 2009, 
Sindrup et al. 2005). Although aberrant neuronal signaling does ultimately control 
nociception (Latremoliere and Woolf 2009, Woolf and Mannion 1999), the 
pathophysiological contributions of spinal glial and endothelial cells influence neuronal 
signaling and contribute to central sensitization, which maintains pain. Spinal astrocytes 
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become activated after neuropathic injury that leads to pain; they stimulate neurons by 
releasing pro-inflammatory molecules and increase synaptic excitatory neurotransmitter 
concentration by downregulating neurotransmitter receptors expression at spinal synapses 
(Abbott et al. 2006, Haydon and Carmignoto 2006, Radu et al. 2013, Volterra and 
Meldolesi 2005). Although astrocytes have been established as contributing to 
nociception in a variety of ways, the pathological roles of endothelial cells, which 
comprise the blood-spinal cord barrier (BSCB), and their contribution to pain after 
peripheral neural injury were not well defined prior to the studies in this thesis. As 
increased research defines the non-neuronal mechanisms that contribute to and maintain 
pain (Halassa et al. 2007, Inoue 2006, McMahon et al. 2005, Milligan and Watkins 2009, 
Radu et al. 2013, Scholz and Woolf 2007, Vallejo et al. 2010), new pharmacologic 
treatments that target both neuronal and non-neuronal cascades may likely provide better 
control against nociception and lead to effective pain relief. 
 Sustained nerve and nerve root injuries that produce chronic pain-related 
behaviors in rodent models have been shown to induce a breakdown of the BSCB early 
after neural injury, despite those injuries being remote from the spinal cord itself (Beggs 
et al. 2010, Cahill et al. 2014, Echeverry et al. 2011, Gordh et al. 2006, Kobayashi et al. 
2008). However, if and how BSCB breakdown contributes to the development of pain 
after those injuries had not been defined before. The studies in this thesis demonstrate 
that BSCB breakdown occurs by 1 day after a transient nerve root compression, only if 
that compression also induces pain (Figure 3.2) (Smith et al. 2015). Compression-induced 
BSCB breakdown, albeit even if only transient, is necessary for the development of pain 
after a compressive neural injury (Figure 3.4) (Smith et al. 2015). BSCB breakdown after 
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nerve root compression facilitates the extravasation of serum components including 
immunoglobulin G (IgG), tumor necrosis factor alpha (TNF-α), and thrombin into the 
spinal parenchyma (Figures 3.2 & 4.3) (Smith et al. 2015, Smith and Winkelstein 2015). 
Of those, spinal thrombin has been shown to induce mechanical allodynia and astrocyte 
activation when exogenously administered directly into the central nervous system (CNS) 
(Narita et al. 2005, Nishino et al. 1993). Yet, prior to the studies presented in this thesis it 
was not known if thrombin crosses a compromised BSCB and if it contributes to the 
development of pain after a nerve root injury.  
The studies in Chapter 4 demonstrate that thrombin is elevated in the spinal cord 
following a painful root compression and is both sufficient and necessary for the 
development of pain and spinal astrocyte activation after that injury (Smith and 
Winkelstein 2015). Elevated thrombin activity in the spinal cord also exacerbates BSCB 
breakdown at day 1 and facilitates the longer-term glial activation that is evident at day 7 
after a painful nerve root injury (Figures 4.10 & 4.11). Further, spinal thrombin 
contributes to the development of BSCB breakdown and pain following neural injury at 
least partially through its activation of the protease-activated receptor-1 (PAR1) in the 
spinal cord (Figures 4.7 & 4.11). In contrast to rat thrombin, thrombin derived from 
salmon has been shown to initiate distinct and favorable outcomes on pain, vascular 
permeability, and astrocyte-induced inflammation due to its reduced ability to activate 
PAR1 and its heightened affinity for protein C (Chapter 5). The contribution of neural 
compression to modifications in the spinal expression of the intermediate filament, 
vimentin, was also established. Astrocytic vimentin exhibits a delayed upregulation after 
a painful nerve root compression and is associated with the resulting sustained 
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mechanical hyperalgesia (Figure 6.1). In contrast, spinal endothelial vimentin is elevated 
at day 7 after any root compression, regardless of the behavioral hypersensitivity pattern 
that develops – pain or otherwise.  
The key findings of this thesis are that BSCB breakdown and spinal thrombin 
activity, which is facilitated by BSCB breakdown, both contribute to the development of 
pain following mechanical neuropathic injury (Figures 3.2, 3.4, 4.3 and 4.5). Those 
findings are discussed in the context of the broader literature related to nerve root 
compression, the mechanisms of root compression that lead to neurovascular unit 
dysfunction in the spinal cord, and nociception (Section 7.2). This chapter concludes in 
Section 7.3 with a discussion of the limitations of this work and areas for future work that 
would supplement the findings from this thesis. The broad hypothesis of this thesis was 
that compressive nerve root injury disrupts the integrity of the blood-spinal cord barrier 
allowing for serum molecules, including thrombin, to extravasate into the spinal 
parenchyma and induce a host of cascades, including spinal PAR1 activation, mechanical 
modifications in activated spinal glia, and pain. Blocking BSCB breakdown with 
molecules, such as activated protein C, that stabilize the vascular integrity prevents nerve 
root-induced pain; this action is mimicked by salmon thrombin through its unique 
substrate specificity profile which is distinct from mammalian thrombin. The studies in 
this thesis support the general hypotheses and are further described in Section 7.2.  
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7.2. Summary & Synthesis of Major Findings 
 Macroscopic deformation of the nerve root tissue mechanically compromises the 
axons and vasculature within the neural tissue (Figure 7.1). Afferent conduction, blood 
flow and nutrient flow are all reduced within the nerve root during the compression and 
the extent of their reduction increases with increasing time of compression (Garfin et al. 
1995, Igarashi et al. 2005, Olmarker 1991, Pedowitz et al. 1992, Yoshizawa et al. 1989). 
The afferent axons within the root synapse in the spinal dorsal horn and the blood vessels 
in the dorsal nerve root directly supply oxygen and nutrients to the spinal parenchyma 
(Almeida et al. 2004, Antonacci et al. 1998, Martini et al. 2003). Because of the 
anatomical apposition of the nerve root and the spinal cord, mechanically compromising 
the axonal and vascular structures in the nerve root also manifests immediately in the 
spinal cord. For example, only 6.6 minutes into a 10gf compression of the nerve root, 
spinal electrophysiological activity is substantially reduced (Nicholson et al. 2011), and 
just 2 seconds of 45gf root compression reduces blood flow to the spinal cord for up to 3 
hours (Igarashi et al. 2005). Within the spinal cord, afferent synapses and microvascular 
endothelial cells are physically separated, yet trophically coupled, by spinal astrocytes. 
Spinal astrocytes respond to fluctuations in synaptic neurotransmitter concentrations and 
local ischemia rapidly (del Zoppo 2009, Scholz and Woolf 2007, Takano et al. 2009), 
suggesting that the alterations in spinal neuronal activity and spinal ischemia induced 
during and after a painful nerve root compression likely both contribute to spinal 
astrocytic responses.  
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The permeability of the spinal vasculature increases between 6 hours and 1 day 
after a transient nerve root compression along the same temporal profile as the 
development of pain (Figures 3.2 & 3.5) (Smith et al. 2015). BSCB permeability 
develops at the same spinal level as the root injury and is only evident on the side 
Figure 7.1. The BSCB is transiently disrupted early after painful root compression facilitating the 
extravasation of thrombin into the spinal cord. Mechanically loading the nerve root imposes bulk 
deformation to the axons and vasculature within the neural tissue. During compression, spinal action 
potential firing and spinal blood flow are both reduced. Altered neuronal signaling and neuropeptide 
release immediately stimulates the local astrocytes encasing the synapse. Breakdown of the BSCB 
occurs between 6 and 24 hours after painful compression, which facilitates the extravasation of serum-
derived thrombin, TNF-α, IgG, and likely a host of other molecules, into the spinal parenchyma. By 1 
day, and for up to 7 days, after a painful compression spinal astrocytes become activated, paralleling the 
profile for mechanical hyperalgesia. The integrity of the BSCB is re-established by day 7 after painful 
compression, a time when spinal astrocytes are robustly activated and spinal neurons are 
hyperexcitable. Also by day 7, the axons within the nerve root undergo degeneration and their transport 
of neuropeptides to the spinal cord is disrupted.  
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ipsilateral to injury (Figures 3.2 & 7.2), supporting the spatial association between a 
mechanical injury to the nerve root and the resulting vascular dysfunction. Spinal 
ischemia is induced for at least the duration of that painful nerve root compression (15 
minutes), and might be sustained for up to 1-3 hours following the release of the 
compression (Igarashi et al. 2005, Yoshizawa et al. 1989). Ischemia in the brain produced 
by transiently occluding the middle cerebral artery produces blood-brain barrier (BBB) 
breakdown immediately upon reperfusion of the cerebral tissue (Dobbin et al. 1989, Sage 
et al. 1984). It is possible that reperfusion of the spinal vasculature that originates in the 
nerve root, is delayed for up to 3 hours after the root compression (Igarashi et al. 2005). 
Assuming that the BSCB and the BBB respond similarly to ischemia and subsequent 
reperfusion, the BSCB would be compromised at a maximum of 3 hours after the root 
compression. However, BSCB breakdown is not yet evident even by 6 hours after a 
painful compression (Figure 3.5). Therefore, spinal ischemia induced by a transient nerve 
root compression does not entirely control the BSCB breakdown that is evident at day 1 
following a painful nerve root compression (Smith et al. 2015).  
Immediate altered afferent activity in the spinal cord from compression of the 
nerve root may contribute to BSCB breakdown indirectly through spinal astrocytic 
responses. Increases in synaptic concentrations of glutamate, gamma-Aminobutyric acid 
(GABA) and ATP released from synaptic terminals after axonal injury initiate 
intracellular calcium oscillations in nearby astrocytes (del Zoppo 2009, Takano et al. 
2009). Astrocytic calcium fluctuations lead to a host of intracellular cascades within 
astrocytes including an increase in their transcription of the pro-inflammatory cytokines 
TNF-α, interleukin-1 beta (IL-1β), and IL-6 (Hansson and Ronnback 2003, Norris et al. 
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1994). Following a painful root compression spinal astrocytes upregulate their production 
of each of TNF-α, IL-1β, and IL-6 within 1 hour (Figure 7.1) (Rothman et al. 2009, 
Rothman and Winkelstein 2010). This almost instantaneous activation of spinal 
astrocytes following a root compression that is remote from the spinal cord might be a 
direct result from the altered afferent activity. Both TNF-α and IL-1β separately induce 
permeability of the spinal vasculature (Echeverry et al. 2011, Hoffmann et al. 2004, 
Nooteboom et al. 2002, Pan and Kastin 2007, Sharief and Thompson 1992). TNF-α 
increases myosin light chain phosphorylation within endothelial cells which causes actin 
stress fiber formation, cell contraction and ultimately vascular disruption (Petrache et al. 
2001). TNF-α-induced vascular permeability is not induced until 4 hours after endothelial 
stimulation and persists for 48 hours (Petrache et al. 2001). Since astrocytic production of 
TNF-α begins within 1 hour in the spinal cord after a painful root compression, that 
increase in spinal TNF-α may contribute to the local BSCB breakdown that is initiated 
between 6 and 24 hours after compression. The proposed causality between spinally-
produced TNF-α and BSCB breakdown is further supported by the chromic gut 
inflammatory root insult not inducing BSCB breakdown (Figures 3.4 & 7.2), and also not 
increasing the spinal transcription of TNF-α (Rothman et al. 2009).  
Since TNF-α potently induces vascular permeability (Nooteboom et al. 2002, Pan 
and Kastin 2007, Sharief and Thompson 1992), the systemic upregulation of TNF-α at 
day 1 after a painful compression also likely contributes to the robust breakdown in the 
BSCB that is observed by day 1 after painful compression (Figures 3.2 & 7.2). Increased 
BSCB permeability that develops after a painful compression is only evident at the same 
spinal level as the root injury and is only evident on the side ipsilateral to injury (Figures 
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3.2 & 7.2) (Smith et al. 2015). The increase in TNF-α in the serum at day 1 is a systemic 
increase and, therefore, would likely reach vasculature of the entire body including the 
spinal cord on both the ipsilateral and contralateral sides of the compression. Although 
TNF-α is a known inducer of vascular permeability (Nooteboom et al. 2002, Pan and 
Kastin 2007, Sharief and Thompson 1992) and is increased systemically early after 
compression, BSCB breakdown occurs exclusively in the spinal cord on the side 
ipsilateral to injury, suggesting that serum elevation of TNF-α is not the sole cause of 
BSCB breakdown after painful compression.  
 
 
 
Collectively, the studies in this thesis demonstrate that systemic and spinal 
inflammation, which are typically separated by an intact BSCB, are integrated with each 
Figure 7.2. The transient increase in BSCB permeability that occurs after a painful nerve root 
compression promotes the extravasation of serum proteins into the spinal parenchyma in 
association with compressive pain. Spinal expression of IgG, fibrin(ogen) (as a proxy for thrombin) 
and TNF-α are upregulated at day 1 only after a compressive nerve root injury that also produces pain; 
expression of those proteins is not evident after a painful inflammatory insult or a non-painful 
compression. Also at day 1, serum pro-inflammatory cytokine levels are also increased exclusively after 
a painful root compression and levels of TNF-α, IL-1α, Il-7, and IL-12 correlate with pain severity. By 
day 7, spinal IgG and thrombin levels return to normal in all groups, despite the pain still being present. 
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other during periods when the permeability of the BSCB is elevated after a painful 
compression. The integration of peripheral and central inflammatory cascades is evident 
by the increase in serum-exclusive proteins (i.e. IgG and thrombin) in the spinal 
parenchyma, as well as the upregulation of TNF-α systemically and spinally (Chapters 3) 
(Figure 7.1) (Smith et al. 2015, Smith and Winkelstein 2015). Although TNF-α 
transcription returns to pre-injury levels by day 1 after a painful root compression 
(Rothman et al. 2009, Rothman and Winkelstein 2010), the studies in this thesis is the 
first to implicate systemic TNF-α as extravasating into the spinal parenchyma after a 
painful compressive root injury (Chapter 3) (Smith et al. 2015). The early activity of 
spinal TNF-α, along with IL-1β, IL-6, and monocyte chemoattractant protein-1 (MCP-1), 
have been previously established as contributing to the development of pain from nerve 
or nerve root injury (Choi et al. 2015, Jeon et al. 2009, Kawasaki et al. 2008, Olmarker et 
al. 2003, Rothman and Winkelstein 2010). Although the systemic expression of MCP-1 
does not strongly correlate with mechanical hyperalgesia at day 1 when BSCB 
breakdown occurs after painful root compression (Table 3.1), MCP-1 can independently 
induce vascular leakiness when it is elevated in the circulatory system (Echeverry et al. 
2011, Sharief and Thompson 1992). Because MCP-1 is produced downstream of TNF-α 
and IL-1β by astrocytes in culture (Lu et al. 2014), the early upregulation of those 
cytokines in the spinal parenchyma might lead to increased MCP-1 at times later than day 
1. If spinal MCP-1 peaks later than day 1, it is possible that the spinal vasculature 
remains permeable for longer than just 24 hours.  
In fact, in pilot studies related to Aim 1 of this thesis, Evan’s Blue dye, which 
binds to albumin and is excluded from the CNS when administered intravenously, was 
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evident in the brain at day 3 after a painful nerve root compression (pilot data based on 
n=1 rat/group) (Figure 7.3). That increase in BBB permeability at times later than day 1 
that is implied by Evan’s blue staining in the midbrain at day 3 has multiple implications. 
Although BSCB breakdown was not measured at times between days 1 and 7, those pilot 
studies suggest that CNS vasculature may remain permeable for longer than 1 day after a 
painful root compression. IgG is cleared from the CNS through its efflux across the BBB 
via the FcRn receptor (Cooper 2013, Zhang and Padridge 2001). That IgG clearance from 
the CNS has a half-life of 10-12 hours in the rat (Zhang and Padridge 2001), suggesting 
that a majority of IgG would be cleared from the spinal parenchyma within 1 day after 
the BSCB is reestablished. Because spinal IgG labeling is at sham levels by day 7 after a 
painful compression (Figure 3.2), it is possible that the BSCB is still compromised at day 
3, and possibly for up to 6 days, after a painful compression. Additionally, the presence 
of Evans blue dye in the midbrain (Figure 7.3), suggests that a peripheral neural injury 
may induce a widespread breakdown of the BSCB and the BBB.    
 
 
 
Figure 7.3. Evan’s Blue extravasation in the midbrain at day 3 after a 15-minute compression or 
sham surgery. Evan’s blue, which binds to albumin in the circulation, extravasates into the midbrain of 
rats at day 3 after undergoing a 15-minute nerve root compression (15min). Evan’s blue is less 
pronounced after a sham operation. 
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In addition to pro-inflammatory cytokines in the CNS having well-established 
roles in inducing vascular permeability and promoting pain, the studies in this thesis 
demonstrate that endogenous thrombin in the spinal cord contributes to 
neuroinflammation, BSCB breakdown and the development of pain following a transient 
root compression (Figure 7.4) (Chapter 4) (Smith and Winkelstein 2015). In the 
circulatory system, thrombin is activated from its zymogen prothrombin at locations of 
vascular trauma (Boon 1993). Circulating thrombin likely stays close to the location of 
injury due to its high affinity for substrates involved in coagulation and receptors 
localized to the endothelial surface of blood vessels (Boon 1993, Coughlin 2000, Di Cera 
2008, Esmon 1993, Jacques et al. 2000). Because the nerve root is anatomically adjacent 
to the spinal cord, it is probable that thrombin is transported from the root vasculature to 
the microvasculature of the spinal dorsal horn early after injury. Similar to TNF-α, 
thrombin induces vascular monolayer breakdown by stimulating the phosphorylation of 
the myosin light chain which leads to cellular contraction via the actomyosin complex 
(Cuerrier et al. 2009, Nobe et al. 2005, Rigor et al. 2013, Satpathy et al. 2004). Therefore, 
the elevation of thrombin in the blood stream of the spinal vasculature might contribute to 
BSCB breakdown. The ratio of hirudin to thrombin for effectively blocking thrombin 
activity is 1:1 (Hemker 2012). As such, since blocking spinal thrombin activity with 4.2U 
of hirudin attenuates compression-induced BSCB breakdown (Figures 4.10 & 7.4), 
suggests that approximately 4U of thrombin is expressed in the spinal cord following 
painful compression. In fact, rat thrombin administered at 4U directly to the spinal cord, 
which would allow for its interaction with the spinal microvasculature, induces BSCB 
permeability within 1 day after administration (Figures 4.11 & 7.4). Together, these 
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studies indicate that a concentration of thrombin on the order of 1-10U is sufficient to 
induce BSCB breakdown and contributes to the increased BSCB permeability that is 
evident following painful nerve root compression. 
Thrombin extravasates into the spinal parenchyma early during periods of BSCB 
breakdown exclusively after a compressive insult that also induces behavioral sensitivity 
(Figures 4.3 & 7.4). Arguably even more importantly, blocking spinal thrombin activity 
with a single pre-treatment of hirudin prior to painful compression is potent enough to 
completely prevent the development of nerve root compression-induced pain (Figure 
4.5). Based on this, thrombin appears to play a role in nociceptive mechanisms 
contributing to neuropathic pain. Spinal astrocytes express PAR1 (Figure 4.9) and prior 
studies have localized PAR1 expression to astrocytic end-feet (Junge et al. 2004, Shavit 
et al. 2011), which tightly appose spinal the vasculature. As such, thrombin, which 
extravasates through the microvascular fenestrations during BSCB breakdown, would 
immediately interact with astrocytes through PAR1. Thrombin, at concentrations on the 
same order as 4U, induces astrocytic production of nitrous oxide (NO), inducible NO 
synthase (iNOS), and pro-inflammatory cytokines through its activation of PAR1 (Boven 
et al. 2003, Fan et al. 2005, Malik and Fenton 1992, Meli et al. 2001, Suo et al. 2002). 
Those compounds are known to directly stimulate neurons and may lead to thrombin’s 
enhancement of nociceptive processing (Scholz and Woolf 2007, Watkins and Milligan 
2001). In vitro, thrombin (1-10U) also enhances the release of NO induced by either 
TNF-α or interferon-gamma (IFN-γ) (Meli et al. 2001, Suo et al. 2004), suggesting that 
spinal thrombin potentiates neuroinflammation following a painful root compression. 
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In addition to interacting with endothelial cells and astrocytes in the 
neurovascular unit, spinal thrombin would also directly interact with spinal neurons. 
Thrombin has been shown to produce a biphasic response in neurons through its 
activation of PAR1, but in a concentration-dependent manner (Fang et al. 2003, Gingrich 
et al. 2000, Suo et al. 2004). At very low concentrations (3pM, or approximately 0.3U) 
thrombin attenuates NMDA-induced biting and scratching, which is indicative of 
thrombin producing anti-nociceptive behaviors, when administered intrathecally in mice 
(Fang et al. 2003). Yet, at a 10-fold higher concentration (3U/ml), thrombin potentiates 
Figure 7.4. Summary of spinal thrombin’s contribution to the development of root compression-
induced pain and associated spinal neuroinflammation. A painful root compression induces the 
extravasation of thrombin into the spinal parenchyma by day 1. Spinal thrombin contributes to the 
development of mechanical hyperalgesia, early BSCB breakdown, and longer-term astrocyte activation; 
as indicated by blocking compression-induced thrombin with hirudin and by administering rat thrombin 
(RTh) intrathecally to naïve rats. Thrombin contributes to pain and neuroinflammation through its 
activation of PAR1 since blocking spinal PAR1 with SCH79797 prevented the development of 
mechanical hyperalgesia and BSCB breakdown following a painful stimulus. 
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NMDA-induced electrical currents in hippocampal brain slices (Gingrich et al. 2000), 
indicating that it enhances glutamate signaling at higher concentrations in the CNS. The 
concentration of thrombin in the spinal cord after painful root compression is likely 
between 1 and 10U, since 4.2U of hirudin blocked spinal thrombin-induced astrocyte 
activation and pain (Chapter 4). The concentration of thrombin being between 1 and 10U 
in the spinal cord implies that thrombin is likely more pro-nociceptive than anti-
nociceptive after a painful compression. Thrombin controls neuronal signaling through its 
activation of neuronal PAR1 (Fang et al. 2003, Gingrich et al. 2000, Shavit et al. 2011, 
Vellani et al. 2010). Within the dorsal root ganglion (DRG) in the mouse, PAR1 localizes 
to approximately 15% of the neuronal cell bodies, and is mainly expressed in small 
diameter nociceptive neurons of the peptidergic subtype (Vellani et al. 2010). Since the 
afferents of the DRG synapse in the spinal dorsal horn, it is likely that the nociceptive 
afferent synaptic terminals in the spinal cord also express PAR1, thereby being 
susceptible to thrombin-induced stimulation. Thrombin expressed in the spinal cord early 
after a painful compression may directly stimulate PAR1-expressing neurons, sensitizing 
them to increased synaptic glutamate. 
Salmon thrombin only weakly activates PAR1 and is much less efficient at 
activating PAR1 than human thrombin at the same concentration (1U/ml) (Figures 5.7 & 
7.5). Because mammalian thrombin is both pro-inflammatory and vascular disrupting 
through its activation of PAR1 (Di Cera 2008, Lee et al. 1997, Nicole et al. 2005, Nishino 
et al. 1993, Simmons et al. 2013), salmon thrombin would not initiate those same 
neuroinflammatory responses within the CNS. In fact, salmon thrombin does not induce 
TNF-α and Il-1β transcription in mixed neural cultures at 1U/ml, when human thrombin 
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does (Figures 5.6 & 7.5) (Smith et al. 2013). When salmon thrombin is applied directly 
on top of a compressed nerve root and the exposed spinal parenchyma, it likely interacts 
with many cells within those anatomical regimes. In vitro, salmon thrombin actively 
blocks the vascular disruption that is induced by TNF-α (Figures 5.3 & 7.5) (Smith et al. 
2015). Although the use of HUVECs in the in vitro study did not closely mimic the 
complex interactions of spinal microvascular endothelial cells and other support cells of 
the BSCB, the implications of salmon thrombin blocking vascular disruption can be 
assumed to be maintained in spinal vasculature. Salmon thrombin is administered via a 
bath application to the nerve root and spinal cord; as such, salmon thrombin is expected 
to directly contact the endothelial cells of the spinal microvasculature. Because TNF-α is 
transcribed by spinal astrocytes almost immediately after a painful compression 
(Rothman et al. 2009, Rothman and Winkelstein 2010), local increases in spinal TNF-α 
are hypothesized to stimulate microvascular endothelial cell contraction and contribute to 
the breakdown of the BSCB within 24 hours (Figure 7.1). Salmon thrombin applied to the 
spinal tissue likely inhibits the TNF-α-induced disruption of the BSCB following painful 
compression. Indeed, a single treatment of salmon thrombin substantially inhibits the 
breakdown of the BSCB following painful compression (Figure 3.2 & 7.5) (Smith et al. 
2015). Salmon thrombin protects endothelial barriers by potently activating protein C in 
the absence of thrombomodulin (Figure 5.3) (Smith et al. 2015). Because salmon 
thrombin activates protein C to protect vasculature and also does not initiate 
neuroinflammation through PAR1, salmon thrombin is a very promising therapeutic for 
vascular disrupting disorders within the CNS, including ischemic stroke, Parkinson’s 
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disease, and multiple sclerosis (Hawkins and Davis 2005, Winkler et al. 2014, Zlokovic 
2010, Zlokovic 2011). 
 
 
 
The studies in this thesis demonstrate that spinal endothelial cells and astrocytes 
respond mechanically to a painful compressive nerve root injury, both early and later 
after that injury (Figure 7.6). Between 6 hours and 1 day after a painful mechanical nerve 
root injury, BSCB permeability increases (Figure 7.1) (Smith et al. 2015). A breakdown 
of the spinal vasculature is likely due to the microvascular endothelial cells contracting 
Figure 7.5. Salmon thrombin prevents pain and neuroinflammation induced early after painful 
root compression leading to sustained neuroprotection. Salmon thrombin prevents vascular 
disruption and does not induce astrocytic-transcription of TNF-α and IL-1β in vitro. When applied to 
neural tissue after nerve root compression, salmon thrombin blocks BSCB breakdown at day 1, in 
parallel with also preventing pain from developing. By day 7 after compression, salmon thrombin 
preserves nerve root health and reduces glial activation and neuronal hyperexcitability within the spinal 
cord, in conjunction with its prevention of pain at this time point. 
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and compromising the integrity of the transendothelial junctions (Riewald et al. 2002, 
Rigor et al. 2013, Satpathy et al. 2004). By day 7 after a painful compression, BSCB 
permeability is reduced along with upregulation of endothelial and astrocytic vimentin. 
Vimentin intermediate filaments act to sustain cytoplasmic integrity and, in turn, when 
expressed within endothelial cells, fortify endothelial barriers (Bormann et al. 1986, 
Buehler 2013, Liu et al. 2014). By day 7 after a painful root compression spinal 
endothelial vimentin expression is upregulated and the BSCB integrity is re-established 
(Figures 6.4, 7.1 & 7.6). As such, elevated endothelial vimentin may contribute to the 
increased mechanical integrity of the spinal vasculature at that time. A 3-minute 
compression, which does not induce BSCB breakdown (Figures 3.2, 7.2 & 7.6) (Smith et 
al. 2015), induces a delayed increase in spinal endothelial vimentin, similar to that which 
is evident after the painful compression (Figure 6.4 & 7.6). Since the two durations of 
compression induce different levels of BSCB breakdown but the same robust elevation in 
spinal endothelial vimentin, microvascular endothelial vimentin is taken as not being 
modulated as a downstream effect of the early alterations in endothelial function 
controlling vascular permeability. In contrast to endothelial vimentin, spinal astrocytic 
vimentin is exclusively elevated following a painful nerve root compression (Figures 6.1 
& 7.6). Increased astrocytic vimentin correlates to increased cellular stiffness (Lu et al. 
2011), which may suggest that spinal astrocytes increase their stiffness following a 
painful neural trauma. Preventing the early increase in spinal thrombin activity with 
hirudin prior to a painful compression reduces astrocytic vimentin expression at day 7 to 
levels of the less painful 3-minute compression (Figure 7.6). In combination with the 
anti-nociceptive and BSCB-protective effects of hirudin, these studies collectively 
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suggest that early exposure of the spinal parenchyma to thrombin after compression 
injury disrupts spinal endothelial barriers, induces longer term changes in astrocyte 
activation and mechanics, and contributes to the development of pain. 
 
 
 
7.2. Limitation & Future Work 
 The studies presented in this thesis demonstrate that pain symptoms that are 
initiated and sustained by mechanical loading of the nerve root are complex responses 
controlled by neuronal, astrocytic and endothelial dysfunction within the neurovascular 
unit of the spinal cord. Although the findings from the studies in this thesis represent a 
Figure 7.6. Schematic representation of spinal responses of astrocytic and endothelial vimentin 
expression after root compression in relation to pain. A painful (15-minute; 15min) nerve root 
compression induces a delayed increase in spinal astrocytic vimentin expression at day 7. In contrast, 
spinal endothelial vimentin is elevated at day 7 after either nerve root compression duration, regardless 
of the pain produced at this time. Spinal hirudin administration prior to a painful compression prevents 
compression-induced increases in astrocytic vimentin expression and prevents the development of pain. 
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substantial step towards understanding the role of vascular endothelial cell dysfunction 
and the downstream effects of that in the development of neuropathic pain, there are 
several assumptions and limitations that must be considered for integrating these 
findings. As such, this section addresses several critical limitations and also outlines areas 
for future investigation that would enhance the understanding of how thrombin influences 
neuronal and non-neuronal cells leading to the aberrant nociceptive mechanisms that 
contribute to chronic pain.  
 A wide range of spinal responses occur within hours following a painful nerve 
root compression, and many of those have been shown to independently contribute to the 
development of pain (Nicholson et al. 2011, Rothman et al. 2009, Rydevik et al. 1984). 
Measuring BSCB breakdown at day 1 and day 7 provides only brief snapshots of a very 
complex spinal response. The BBB is known to undergo a biphasic breakdown in 
response to transient ischemia; studies report a slight breakdown of the BBB within 
minutes that is re-established and then more robustly compromised at 12-48 hours 
following an ischemic insult (Dobbin et al. 1989, Sage et al. 1984). Although a painful 
compression was shown to induce BSCB breakdown by day 1, it is also possible that the 
BSCB undergoes increased permeability at times even earlier than 1 day. If BSCB 
breakdown, even if only marginal, occurs within minutes of the ischemia that may be 
induced following a painful nerve root compression, it is possible that the extravasation 
of serum factors would contribute to the early activation of spinal neurons and glia. 
Additionally, pain is maintained for up to 4 weeks following a mechanical nerve root 
injury (Rothman et al. 2007), so investigating BSCB breakdown at later times would also 
provide a more complete picture of how spinal vascular dysfunction contributes to pain. 
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A recent study utilized dynamic contrast-enhanced magnetic resonance imaging (DCE-
MRI) to define the spatiotemporal profile of BSCB breakdown after spared nerve injury 
(Cahill et al. 2014). That non-invasive technique allows for the dynamic measurement of 
BSCB permeability over time instead of selecting multiple termination points requiring 
the use of multiple rats. That study showed that BSCB breakdown spanned from the 
lumbar spinal cord into the thoracic segments of the spinal cord in a transient manner, 
peaking between 24 and 36 hours (Cahill et al. 2014). Employing DCE-MRI in 
conjunction with a painful nerve root compression, which transiently induces pain, would 
provide more information about the time course of BSCB breakdown in relation to the 
development of pain. Additionally, BSCB breakdown was not confirmed to induce pain 
in absence of a compressive nerve root insult. Radiation (2-50Gy) administered to the 
cervical spinal cord has been shown to induce BSCB breakdown within 24 hours, which 
gradually returns to pre-radiation permeability over the course of 2 weeks (Li et al. 2004). 
Inducing BSCB permeability in the cervical spinal cord via the application of radiation 
would help to determine whether BSCB breakdown itself can induce pain without the 
other injurious inputs that are associated with painful nerve root compression.  
 Although spinal thrombin activity was suggested to increase, via elevated spinal 
fibrin(ogen) labeling, following painful nerve root compression (Smith and Winkelstein 
2015), thrombin activity was not explicitly measured. The activity of thrombin in the 
spinal cord could be measured by utilizing a fluorogenic thrombin activity assay (Bushi 
et al. 2013). Slices of spinal cord tissue taken at times between 6 and 24 hours after a 
painful root compression could be bathed with the fluorogenic thrombin substrate and 
imaged to determine the spatiotemporal patterning of spinal thrombin enzymatic activity. 
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Additionally, the studies in this thesis only infer that spinal thrombin is derived from the 
periphery. Circulating thrombin becomes inactive by circulating thrombin inhibitors 
within hours after it is originally activated from the prothrombin zymogen (Boon 1993, 
Vogel et al. 1979). Because the enzymatic product of thrombin – fibrin – is present in the 
spinal parenchyma 24 hours after painful root compression (Figure 4.3) (Smith and 
Winkelstein 2015), it is possible that thrombin is continually produced in the circulatory 
system for up to 1 day after an injury. Measuring thrombin activity in the serum and 
spinal parenchyma after painful compression would determine if there is an association 
between thrombin concentrations in the periphery and the CNS. In order to confirm that 
spinal thrombin originates systemically after painful compression, fluorescently-labeled 
thrombin could be administered intravenously and fluorescence could be measured in the 
spinal cord at times after a painful compression.  
 The studies of this thesis did not consider the interaction of thrombin with other 
cells resident within the CNS. Activation of microglial PAR1 by thrombin or a PAR1 
activating peptide induces microglial proliferation (Suo et al. 2002). However, thrombin 
stimulation of microglial cells does not induce microglial production of TNF-α (Suo et al. 
2002), suggesting that thrombin stimulation of microglial cells may not directly 
contribute to their production of pro-inflammatory cytokines. Although spinal microglia 
potentiate neuropathic pain through their production of pro-inflammatory molecules, 
spinal thrombin may not directly contribute to their activation. Measuring microglial 
activation and production of pro-inflammatory cytokines following intrathecal thrombin 
injection or after painful nerve root injury pre-treated with hirudin would determine 
whether spinal thrombin contributes to spinal inflammation through its activation of 
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spinal microglia. Additionally, thrombin is a known activator of platelets within the 
circulatory system, inducing platelet aggregation with other platelets as well as with other 
inflammatory cells in the blood stream (Langer and Chavakis 2013). During increased 
BSCB permeability, endothelial cells upregulate their expression of platelet-endothelial 
cell adhesion molecule-1 (PECAM-1) (Rutkowski et al. 2002), which enables the 
adhesion of platelets to the endothelial cell surface. Endothelial-bound platelets interact 
with circulating monocytes and facilitate the transmigration of monocytes into the spinal 
parenchyma (Cicmil et al. 2000, Langer and Chavakis 2013), which further potentiates 
inflammation. Because BSCB breakdown likely occurs in parallel with the extravasation 
of thrombin into the spinal parenchyma (Chapters 3 and 4), thrombin-activated platelets 
bound to vasculature walls might facilitate monocyte infiltration into the spinal 
parenchyma and contribute to the development of pain. Studies investigating the effect of 
spinal thrombin on platelet and microglial activation are needed in order to fully 
characterize the influence of thrombin on spinal cell populations that are involved with 
nociception. 
The interaction between neurons, astrocytes, and endothelial cells of the 
neurovascular unit plays an important role in the development and maintenance of 
nociceptive states induced by painful nerve root compression. However, the specific 
mechanisms by which thrombin disrupts or enhances such crosstalk to promote 
sensitization were not established by the studies here. It is hypothesized that 
mechanically injuring the afferent axons within the nerve root immediately increases the 
synaptic concentration of glutamate and ATP to stimulate the local astrocytes. Measuring 
synaptic concentrations of these two excitatory neuropeptides within the first hour after a 
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painful root compression and in parallel with measuring ERK phosphorylation or calcium 
signaling within astrocytes, as measures of their activation, would confirm a causal 
relationship between the two responses. Additionally, the astrocytic production of TNF-α 
was hypothesized to produce endothelial barrier disruption, facilitating thrombin’s 
diffusion into the spinal parenchyma. Measuring spinal thrombin activity and levels of 
TNF-α and IgG would provide a more complete picture of the sequence in which those 
responses occur. 
A major limitation of the studies in this thesis is that mechanical properties of the 
spinal parenchyma were not directly measured in areas that undergo spinal astrocyte 
activation following painful root compression. It is nearly impossible to measure the 
stiffness of individual cells as they natively reside within a tissue. Since astrocytes 
contribute to the macroscopic mechanical stiffness of the spinal cord (Shreiber et al. 
2009), measuring the compressive stiffness of the spinal cord in regions that undergo 
astrocytic activation following painful compression would help to define the response of 
spinal micromechanics to root injury. The original hypothesis was explored in pilot 
studies by using a custom microindentation device with a 255µm diameter probe 
(Levental et al. 2010). The relatively small size of the indentation probe allowed for 
regional measurements since it could spatially resolve the ipsilateral and contralateral 
sides of the spinal cord. However, the sensitivity of the device, and therefore variation 
within and between samples, prevented that technique from producing reliable data. 
Atomic force microscopy using cantilevers that have been adapted to measure stiffness 
on the micrometer scale (Mackay and Kumar 2013), might better capture slight 
modulations in mechanical changes of the spinal parenchyma at that scale. That 
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technique was not utilized because an atomic force microscope that exhibited a wide 
enough range in the z-axis to account for spinal cord slice thickness and indentation depth 
(together at least 1mm) was not available. As such, measuring astrocytic vimentin 
expression as a proxy for changes in cell mechanics was explored. Because astrocytes 
robustly upregulate their expression of vimentin by day 7 after painful compression, 
probing the stiffness of the spinal parenchyma at this later time point would be ideal 
because the changes in astrocytic mechanics at that time are more likely to modulate 
spinal parenchymal stiffness. 
Modifications in spinal cord stiffness could also occur because of extracellular 
matrix (ECM) protein deposition or degradation. It has been previously shown that the 
dorsal root entry zone of the spinal parenchyma undergoes deposition of chondroitin 6-
sulfate proteoglycans and tenascin at 2 weeks after a nerve root lesion (Pindzola et al. 
1993). Those ECM molecules are hypothesized to create a biomechanical barrier to 
axonal re-growth by modulating the stiffness of the spinal parenchyma. Because cell 
mechanics are modulated in response to changes in substrate stiffness (Ahmed et al. 
2012, Discher et al. 2005, Flanagan et al. 2002), changes in cell mechanics may possibly 
parallel changes in ECM stiffness. Measuring the expression of proteoglycans and 
tenascin within the spinal cord in parallel with measuring changes in cellular mechanics 
would provide a more complete picture of the whether the mechanical microenvironment 
of the spinal ECM and the cells within might contribute to spinal nociceptive signaling. 
This thesis did not investigate how changes in the mechanical properties of 
astrocytes might contribute to nociceptive signaling. Manipulating the mechanics of cells 
within the spinal cord after painful compression would begin to elucidate whether 
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changes in astrocytic cellular mechanics do, in fact, contribute to pain. Pharmacologically 
disrupting vimentin filament stability with Withaferin A (Grin et al. 2012) after a painful 
root compression at times when astrocytic vimentin is upregulated, would determine if 
increases in astrocytic vimentin expression functionally contribute to nerve root-mediated 
pain. Yet, changes in the expression of the intermediate filament vimentin does not fully 
capture the wide range of mechanical changes that cells of the spinal cord might undergo 
after painful nerve root compression. Of note, dynamic cellular contraction, which also 
contributes to cell stiffness, is controlled by the actomyosin complex (Fletcher and 
Mullins 2010, Maekawa et al. 1999, McBeath et al. 2004). Phosphorylation of RhoA and 
Rho associated kinase (ROCK) occur upstream of actomyosin-controlled cell contraction 
(Maekawa et al. 1999). Blocking ROCK with an intrathecal injection of H-1152 at day 7 
after painful L5 spinal nerve transection attenuates mechanical hyperalgesia for at least 
45 minutes (Tatsumi et al. 2005), suggesting that actively blocking cell contraction may 
be anti-nociceptive at least transiently. Administering H-1152 at times before pain onset 
would provide useful information on whether changes spinal cellular mechanics 
contribute to the development of nerve root-induced pain.  
Salmon thrombin was shown to prevent the development of mechanical allodynia 
following a compressive nerve root injury (Chapter 5). In contrast to the other treatments 
used throughout this thesis, i.e. activated protein C (APC), hirudin and SCH79797, the 
effectiveness of salmon thrombin preventing compression-induced mechanical 
hyperalgesia was not investigated. Changes in the withdrawal threshold of the forepaw to 
a mechanical stimulus is a more sensitive metric for measuring evoked mechanical 
sensitivity and as such should have been measured following a painful compression 
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treated with salmon thrombin. Additionally, salmon thrombin’s effects on thermal 
hyperalgesia was not measured. Activating PAR1 on peptidergic neurons expressing 
transient receptor potential vanilloid subfamily 1 (TRPV1), which transmits nociceptive 
signals in response to noxious heat stimuli, sensitizes their response to electrical 
stimulation (Vellani et al. 2010). Salmon thrombin prevents BSCB breakdown and, thus, 
the extravasation of thrombin into the spinal parenchyma. The absence of spinal thrombin 
after painful compression would, in turn, prevent the activation of neuronal PAR1; 
therefore, it is possible that salmon thrombin would also prevent thermal sensitivity after 
a painful root compression.  
Although salmon thrombin was shown to be a suitable treatment for neuropathic 
pain by targeting and preventing BSCB breakdown following painful root compression 
(Chapter 5), a few barriers remain in the way of its clinical success. Administering 
salmon thrombin immediately after injury and directly on top of the nerve root and spinal 
cord was the only dosing method investigated in these studies and is not clinically 
feasible. Administering salmon thrombin via intrathecal injection would be a viable 
delivery route and would remove the need for surgery. However, lumbar punctures are 
not routinely performed except for in rare cases, including delivery of nerve blocks 
during childbirth and diagnosing diseases of the CNS (Boon et al. 2004). Therefore 
intrathecal delivery of salmon thrombin is also not a preferred delivery route. Injecting 
salmon thrombin intravenously would also facilitate its delivery to spinal vasculature, but 
this delivery mode is potentially dangerous since excess thrombin could lead to blood 
clots (Boon 1993, Griffin 1995). Since salmon thrombin was shown to be effective at 
blocking BSCB breakdown and pain when administered at the site of injury immediately 
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after root compression, its clinical application might be better suited as a treatment that is 
administered at the site of surgery within the central nervous system as a prevention of 
post-surgical pain.  
Salmon thrombin is hypothesized to be analgesic if administered at any time 
before the breakdown of the BSCB after injury since it prevents BSCB breakdown to 
attenuate pain (Chapters 3 & 5). APC was administered intravenously at 1 hour after 
painful compression and was sufficient to prevent BSCB breakdown and pain at day 1 
after injury (Figure 3.4), suggesting that salmon thrombin could also be administered at 
least at 1 hour after a transient compression and still possibly prevent pain development. 
Yet, pilot studies performed in our lab determined that administering salmon thrombin at 
1 day after a painful 15-minute compression demonstrated that salmon thrombin does not 
prevent behavioral sensitivity when administered at that time. Therefore, salmon 
thrombin might in fact need to be delivered very early after an injury in order to be 
effective. The requisite immediate administration of salmon thrombin is a major 
limitation to using this treatment after injury because patients may not seek treatment 
until after pain has developed and persisted for some time. However, a patient may be 
admitted to the hospital in cases of traumatic injury to the neck or spine, which would be 
an appropriate application for salmon thrombin might as a pain treatment. Additionally, 
the nerve root compression injury examined in this thesis was only transient and induced 
transient BSCB breakdown. A disc herniation or spinal stenosis may impinge a nerve root 
chronically, which might induce BSCB breakdown that lasts for a longer time period; as 
such, the therapeutic window could be longer than 1 day for those pathologies and would 
allow targeting BSCB breakdown with salmon thrombin a more viable option.  
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Another clinical barrier to salmon thrombin is that it is a natural protein and, thus 
presents a risk for immunogenicity issues including tolerance. This could hinder salmon 
thrombin as a potential therapeutic because it may only be effective when administered 
the first time. In vivo studies have defined that antibodies to salmon thrombin develop by 
day 20 after a single injection in mice (Laidmae et al. 2006), suggesting that a second 
dose administered after antibodies towards salmon thrombin have already developed may 
not be as effective. The effectiveness of salmon thrombin at preventing BSCB breakdown 
and pain after multiple doses should be explored using pre-clinical animal studies prior to 
its use in clinical studies. If salmon thrombin only retains effectiveness with one dose, 
this would greatly hamper its clinical potential at treating BBB disruptive disorders. 
Those studies only suggest that salmon thrombin protects vasculature through its 
preferential activation of protein C (Figure 5.3) (Smith et al. 2015); this hypothesis was 
not explicitly tested. Using HUVEC microchannels, salmon thrombin was shown to 
prevent TNF-α disruption when the cells were exposed to serum, which contains protein 
C, prior to running the experiment (Figure 5.3). Blocking the activation of protein C with 
antibodies in conjunction with administering salmon thrombin to HUVEC channels 
would establish whether salmon thrombin does indeed protect vascular integrity through 
protein C. At the molecular level, APC prevents vascular disruption by enzymatically 
cleaving PAR1 at Argenine-46, which is at a different location on the extracellular 
domain of PAR1 than mammalian thrombin activates (Arg-42) (Mosnier et al. 2012). By 
non-canonically activating PAR1 (i.e. at Arg-46 and not Arg-42), APC initiates a distinct 
and opposite signaling pathway than mammalian thrombin’s activation of PAR1, which 
is also referred to as biased agonism (Zhao et al. 2014). It is also possible that salmon 
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thrombin activates the APC pathway in part by directly activating PAR at PAR1 at Arg-
46. Creating a fluorogenic peptide corresponding to the Arg-46 cleavage site of PAR1 
would be an initial step towards fully understanding the unique enzymatic actions of 
salmon thrombin towards protein C. Because protein C must be bound to the endothelial 
protein C receptor (EPCR) in order to induce vascular protection (Bouwens et al. 2013, 
Esmon 1993, Xu et al. 2005), using knock out mice that do not express EPCR would 
provide valuable insight into whether salmon thrombin protects vascular integrity in vivo 
through its activation of endothelial-bound protein C. 
An important question that was not addressed in the studies of this thesis was 
whether salmon thrombin out-competes the effects of mammalian thrombin at the site of 
root injury to provide analgesic effects. Because of the inherent bleeding that occurs at 
the surgical site during the administration of a compressive nerve root insult, rat thrombin 
would contact the nerve root and spinal cord during and after the injury. Salmon 
thrombin is administered at the site of injury, after the compression, thereby acting in the 
same location as the rat thrombin. Yet, this is the case also for sham conditions; which 
were not investigated in these studies. In order to test whether the anti-inflammatory and 
vascular protective effects of salmon thrombin counteract those pro-inflammatory and 
vascular disruptive effects induced by mammalian thrombin, separate in vitro studies 
with astrocytic cultures and HUVEC microchannels could be performed with equivalent 
doses of salmon and rat thrombin administered simultaneously. Both TNF-α and 
mammalian thrombin stimulate vascular permeability through the phosphorylation of the 
myosin light chain (Cuerrier et al. 2009, Nobe et al. 2005, Nooteboom et al. 2002, 
Komarova et al. 2007, Satpathy et al. 2004). Because salmon thrombin actively prevents 
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TNF-α-induced vascular disruption, it is hypothesized that salmon thrombin may also 
attenuate the vascular disruptive effects of mammalian thrombin.  
The structural comparison between fish and human thrombin defined the autolysis 
loop as having the most radical residue substitutions (Figure 5.4), which translated into 
differences in the three-dimensional structure of that region of the molecule (Smith et al. 
2015). In order to confirm that this region of salmon thrombin contributes to its 
preferential activation of protein C over PAR1, mutagenesis studies could substitute the 
fish thrombin sequence for the autolysis loop into the human thrombin structure and 
measure the activation rate produced by that mutated thrombin towards protein C and 
PAR1. It is also possible that salmon thrombin preferentially activates protein C through 
the collective amino acid substitutions throughout its entire structure. Mutagenesis 
studies have defined other regions within human thrombin’s structure that contribute to 
its preferential activation of PAR1 versus protein C. For example, a double point 
mutation of W215 and E217, each replaced by alanine, increases the anti-inflammatory 
properties of human thrombin through its increased affinity for protein C (Verbout et al. 
2015). However, W215 and E217 are conserved between the structures of human and 
trout thrombin, suggesting that those residues do not enhance salmon thrombin’s affinity 
for protein C. Within human thrombin, R35 has been identified to sterically inhibit 
human thrombin’s interaction with protein C when unbound from thrombomodulin (Yang 
et al. 2006). Although trout thrombin expresses lysine and not arginine at the 35th residue 
location (Figure 5.2), both amino acids are hydrophilic indicating that this substitution is 
conservative and also likely does not control the difference in substrate affinity between 
salmon and human thrombin. In any case, the salmon thrombin molecule should be fully 
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sequenced and more thoroughly compared to the structure of human thrombin in order to 
define the substituted residues that play the largest role in controlling the substrate 
affinity for salmon thrombin. 
In summary, the studies presented in this thesis define the contribution of BSCB 
breakdown, and its subsequent facilitation of thrombin extravasation into the spinal 
parenchyma, to mechanically-induced nerve root-mediated pain. Behavioral sensitivity 
induced by painful root compression can be initiated through sensitization of compressed 
afferents and is, at least partially, maintained by contributions from endothelial cells and 
astrocytes. Excessive release of excitatory neurotransmitters at spinal afferent synapses 
may initiate astrocyte activation almost immediately and is evident by their transcription 
of pro-inflammatory and pro-nociceptive cytokines. Of those cytokines, TNF-α, not only 
enhances nociceptive activity in neurons, but it might also directly contribute to a 
disruption in the spinal vasculature within hours following a compressive root injury. 
That breakdown of the BSCB permits the transmission of thrombin from the periphery 
into the spinal parenchyma allowing thrombin to directly activate spinal endothelial cells, 
glia and neurons. Certainly, additional studies are needed to define the exact cellular 
targets of spinal thrombin and how thrombin contributes to dysfunctional nociceptive 
signaling of the neurovascular unit. Yet, the studies in this thesis help establish an 
integral role of spinal endothelial dysfunction in the development of pain and support the 
consideration of endothelial cells as having a role in contributing to the 
neuroinflammatory responses in the spinal cord that initiate and maintain pain after 
neural trauma. 
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Appendix A 
Mechanical Behavioral Sensitivity 
 
 
This appendix contains the mechanical sensitivity responses for all rats included 
in the behavioral studies that are presented in Chapters 3-5. Measurements of mechanical 
hyperalgesia and mechanical allodynia were used to quantify behavioral sensitivity in 
response to a stimulus throughout the studies in this thesis. Each table in this appendix 
summarizes the behavioral data arranged by each study, with the tables arranged by the 
order that the studies are presented in the chapters.  
The baseline responses (day 0) and corresponding post-surgery responses (up to 
day 7) were measured. An increase in mechanical hyperalgesia is defined as a drop in the 
mechanical threshold (in grams) for a rat to withdrawal its paw. The withdrawal 
thresholds were determined by applying a discrete series of von Frey filaments to the 
specified paw in an ascending order of force (1.4g-26g). The filament that evoked the 
paw to be withdrawn, was recorded as the threshold if the next consecutive filament also 
elicited a response (see Section 3.3.1.2 for further details). An elevation in mechanical 
allodynia corresponds to an increase in the number of paw withdrawals elicited in 
response to a typically non-noxious stimulation; to measure allodynia, the 1.4g, 4g and 
10g strength von Frey filaments were used in these studies. A total of 10 stimulations by 
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each filament was applied to the paw for each rat three separate times and averaged on 
each testing day (see Section 5.4.1.2 for details).   
Tables A.1.1-A.1.4 summarize the paw withdrawal threshold data that are 
included in the studies characterizing blood-spinal cord barrier (BSCB) breakdown after 
painful and non-painful nerve root insults in Chapter 3. Additionally, the withdrawal 
thresholds on days 1, 3, 5 and 7 are normalized to corresponding baseline thresholds (at 
day 0), which is how those data are presented in that chapter. Table A.1.1 details the 
withdrawal thresholds for the ipsilateral forepaw for each rat on days 1, 3, 5 and 7 after a 
sham operation, a 3-minute compression (3min), and a 15-minute compression (15min). 
The nerve root compression was applied unilaterally to the C7 dorsal nerve root with a 
calibrated 10gf microvascular clip (see Section 3.3.1.1 for details). Sham operated rats 
underwent the same surgical procedures with no applied compression. The corresponding 
withdrawal thresholds for the forepaw contralateral to injury side for each rat after sham, 
3min and 15min are itemized in Table A.1.2. Since hyperalgesia developed only in the 
forepaw ipsilateral to a 15-minute nerve root compression (Figure 3.2), the subsequent 
studies measured the withdrawal threshold only in the forepaw ipsilateral to injury, unless 
otherwise specified. Mechanical hyperalgesia on days 1 and 7 after an inflammatory 
insult produced by application of chromic gut suture to the nerve root (chromic) is 
detailed in Table A.1.3. That table also includes the corresponding thresholds from rats at 
day 1 and day 7 after a 15-minute compression (15min) and a sham surgery. For details 
about the surgical procedures for the chromic gut insult are provided in Section 3.4.1.1. 
Lastly, Table A.1.4 summarizes the withdrawal thresholds for rats receiving an 
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intravenous injection of activated protein C (APC) (0.2mg/kg rat) at 1 hour after a 15-
minute compression (15min+APC) (described further in Section 3.5.1.1), as well as the 
corresponding thresholds from rats at day 1 after an untreated compression. 
 Studies in Chapter 4 utilized pharmacological agents to manipulate various 
aspects of the thrombin/protease-activated receptor-1 (PAR1) pathway in the spinal cord 
and measured the effects on mechanical hyperalgesia. Tables A.2.1-A.2.7 summarize 
those withdrawal threshold data and appear in the order in which those data are presented 
in Chapter 4. Rat thrombin was administered intrathecally in order to measure the effects 
of spinal thrombin on pain. Withdrawal thresholds were measured in the bilateral 
forepaws and averaged between paws for each rat since this insult is not expected to 
favor either side. In pilot studies optimizing a dose that was sufficient to induce 
behavioral sensitivity, withdrawal thresholds were measured at day 0, before and at days 
1, 3, 5, and 7 after, an intrathecal injection of rat thrombin at doses of 0.04U/rat, 0.4U/rat, 
and 4U/rat (Table A.2.1). The PAR1 antagonist, SCH79797, was administered as a single 
intrathecal injection to block spinal PAR1 activation prior to a 15-minute nerve root 
compression. Two doses of SCH79797 were piloted in dosing studies, 25ug/kg and 
50ug/kg, as well as a vehicle which contained no SCH79797 (0µg/kg). Withdrawal 
thresholds in the ipsilateral forepaw were measured at day -1 prior to SCH79797 
injection, at day 0 after the injection, and at days 1, 3, 5 and 7 after a 15-minute 
compression (provided in Table A.2.2). See Section 4.3.2.3 for more details on the dosing 
of intrathecal rat thrombin and SCH79797.  
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Studies in Chapter 4 measured spinal fibrin(ogen) as a proxy for thrombin activity 
at days 1 and 7 following a sham operation, a 3-minute compression or a 15-minute 
compression. Mechanical hyperalgesia was measured prior to surgery (day 0), and at each 
of day 1 and day 7 after sham surgery or compression; those behavioral data are 
presented in Table A.2.3. Hirudin, a selective inhibitor of thrombin activity, was 
intrathecally administered (4.2U/rat) 1 day before a 15-minute compression in order to 
block spinal thrombin (hir+15min). To assess the effects of blocking spinal thrombin on 
compression-induced pain, mechanical hyperalgesia was measured prior to hirudin (day -
1), prior to compression (day 0) and over 7 days after the compression (Table A.2.4). 
Exogenous rat thrombin was separately administered intrathecally (4U/rat) to naïve rats 
and mechanical hyperalgesia was measured in the bilateral forepaws and averaged 
between paws because that intrathecal injection provides a bilateral insult. Average paw 
withdrawal thresholds for days 0 through 7 following intrathecal rat thrombin are 
summarized in Table A.2.5.  
In order to investigate the role of spinal PAR1 activation in thrombin-induced and 
nerve root-induced pain, SCH79797 was separately administered at 1 day prior to 
intrathecal injection of rat thrombin or painful root compression. Since intrathecal rat 
thrombin produced the most robust behavioral responses at day 1 after injection, 
mechanical hyperalgesia was only measured prior to SCH79797 injection (day -1), before 
compression (day 0) and at day 1 after compression, for both rat thrombin alone and rat 
thrombin together with SCH79797 administration (Table A.2.6). Lastly, SCH79797 was 
given intrathecally at 1 day before a 15-minute compression (SCH+15min). Because the 
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vehicle (DMSO) is not inert, those studies also included separate groups that received a 
vehicle treatment before sham (DMSO+sham) or a compression (DMSO+15min). 
Behavioral responses were measured prior to the pre-treatment (day -1), at day 1 after 
treatment but before compression (day 0), and for up to 7 days after the compression 
(Table A.2.7). Please see Section 4.3.2.4 for more details on the intrathecal dosing and 
administration of all of the pharmacologic agents administered in the studies presented in 
Chapter 4. 
The studies in Chapter 5 define the role of salmon thrombin in painful 
compression-induced mechanical allodynia by administering salmon thrombin directly to 
the nerve root after its compression (Section 5.4.1.2). Mechanical allodynia was chosen 
as the metric to quantify behavioral sensitivity for those studies based on a previous study 
showing that salmon thrombin prevents allodynia for up to 7 days after a nerve root 
compression (Weisshaar et al. 2011). The ability of salmon thrombin to prevent early 
BSCB breakdown and development of behavioral sensitivity after a painful compression 
was investigated at day 1 (Table A.3.1). As such, mechanical allodynia was measured 
prior to the surgery (day 0) and on day 1 after a sham operation with no treatment (sham), 
and a 15-minute compression treated with either a vehicle (15min+veh), salmon thrombin 
(15min+STh), or human thrombin (15min+HTh); testing was performed only using a 4g 
von Frey filament (Table A.3.1). The longer term effects of salmon thrombin on nerve 
root health was also measured at day 7 after injury. As such mechanical allodynia 
produced after those same treatment groups was measured for up to 7 days using the 1.4g 
(Table A.3.2), 4g (Table A.3.3) and 10g (Table A.3.4) strength filaments.   
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Table A.1.1. Withdrawal thresholds (g) and thresholds normalized to baseline in the 
ipsilateral forepaw following sham, 3-minute compression (3min), and 15-minute 
compression (corresponding to studies in Section 3.3). 
 
withdrawal threshold (g) withdrawal threshold (fold over baseline) 
 
group rat day 0 day 1 day 3 day 5 day 7 day 0 day 1 day 3 day 5 day 7 
ip
si
la
te
ra
l 
sham 
84 9.67 10.33 17.00 18.67 16.33 0.50 1.07 1.76 1.93 1.69 
115 26.00 22.33 26.00 11.67 15.00 1.36 0.86 1.00 0.45 0.58 
124 18.67 26.00 18.67 22.33 26.00 0.97 1.39 1.00 1.20 1.39 
159 22.33 17.00 15.00 15.00 20.50 1.17 0.76 0.67 0.67 0.92 
3min 
83 8.83 6.00 10.33 15.00 7.33 0.62 1.79 1.16 1.47 0.91 
85 8.17 8.00 9.33 9.67 9.33 0.53 0.98 1.14 1.27 1.22 
113 6.33 6.00 10.33 4.67 6.00 0.44 1.40 1.35 0.70 0.90 
118 26.00 15.00 26.00 26.00 22.33 1.70 0.86 0.86 1.00 0.72 
120 26.00 22.33 26.00 22.33 26.00 1.70 0.86 1.00 1.00 1.00 
15min 
86 7.50 4.00 2.67 4.00 3.33 0.45 0.53 0.36 0.53 0.44 
109 22.33 2.47 6.00 4.67 3.33 1.35 0.11 0.27 0.21 0.15 
110 19.67 1.40 1.60 1.40 3.33 1.19 0.07 0.08 0.07 0.17 
112 16.00 2.47 4.67 4.00 2.27 0.97 0.15 0.29 0.25 0.14 
158 17.00 5.33 8.00 7.33 6.67 1.03 0.31 0.47 0.43 0.39 
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Table A.1.2. Withdrawal thresholds (g) and thresholds normalized to baseline in the 
contralateral forepaw following sham, 3-minute compression (3min), and 15-minute 
compression (corresponding to studies in Section 3.3). 
  
withdrawal threshold (g) withdrawal threshold (fold over baseline) 
 
group rat day 0 day 1 day 3 day 5 day 7 day 0 day 1 day 3 day 5 day 7 
co
n
tra
la
te
ra
l 
sham 
84 10.67 26.00 17.00 26.00 20.67 0.67 2.44 1.59 2.44 1.94 
115 24.17 26.00 26.00 11.00 15.00 1.51 1.08 1.08 0.46 0.62 
124 14.00 22.33 13.33 13.33 26.00 0.88 1.60 0.95 0.95 1.86 
159 15.00 18.67 15.00 15.00 17.00 0.94 1.24 1.00 1.00 1.13 
3min 
83 9.50 17.00 11.00 14.00 8.67 0.62 1.79 1.16 1.47 0.91 
85 8.17 8.00 9.33 10.33 10.00 0.53 0.98 1.14 1.27 1.22 
113 6.67 9.33 9.00 4.67 6.00 0.44 1.40 1.35 0.70 0.90 
118 26.00 22.33 22.33 26.00 18.67 1.70 0.86 0.86 1.00 0.72 
120 26.00 22.33 26.00 26.00 26.00 1.70 0.86 1.00 1.00 1.00 
15min 
86 5.67 6.00 2.67 8.00 8.00 0.37 1.06 0.47 1.41 1.41 
109 20.50 22.33 26.00 22.33 13.33 1.32 1.09 1.27 1.09 0.65 
110 19.67 15.00 10.00 7.33 11.67 1.27 0.76 0.51 0.37 0.59 
112 16.67 7.33 11.00 6.67 8.00 1.08 0.44 0.66 0.40 0.48 
158 15.00 18.67 26.00 15.00 11.67 0.97 1.24 1.73 1.00 0.78 
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Table A.1.3. Withdrawal thresholds (g) and thresholds normalized to baseline in the 
ipsilateral forepaw on day 1 and day 7 after sham, chromic gut inflammatory insult 
(chromic), and 15-minute compression (15min) applied to the nerve root 
(corresponding to studies in Section 3.4). 
 
 
withdrawal threshold (g) withdrawal threshold  (fold over baseline) 
group rat day 0 day 1 day 7 day 0 day 1 day 7 
sham 
102 26.00 26.00 - 1.43 1.00 - 
106 8.67 10.33 - 0.48 1.19 - 
97 22.33 26.00 - 1.23 1.16 - 
152 17.83 11.00 - 0.98 0.62 - 
153 11.67 15.00 - 0.64 1.29 - 
155 22.33 13.33 - 1.23 0.60 - 
124 18.67 26.00 26.00 0.97 1.39 1.39 
84 9.67 10.33 16.33 0.50 1.07 1.69 
115 26.00 22.33 15.00 1.36 0.86 0.58 
159 22.33 17.00 20.50 1.17 0.76 0.92 
chromic 
164 24.17 10.00 - 1.34 0.41 - 
165 24.17 8.00 - 1.34 0.33 - 
166 17.83 10.33 - 0.99 0.58 - 
182 9.33 7.33 - 0.52 0.79 - 
183 20.67 8.00 - 1.14 0.39 - 
184 11.67 7.33 - 0.65 0.63 - 
185 18.67 11.00 - 1.03 0.59 - 
190 6.00 6.67 8.00 0.50 1.11 1.33 
191 20.50 8.00 8.00 1.71 0.39 0.39 
192 12.50 5.00 9.33 1.04 0.40 0.75 
193 9.00 4.00 4.67 0.75 0.44 0.52 
15min 
101 21.17 3.33 - 1.76 0.16 - 
104 9.00 2.47 - 0.75 0.27 - 
105 9.33 0.87 - 0.77 0.09 - 
94 14.00 4.00 - 1.16 0.29 - 
151 10.17 4.67 - 0.84 0.46 - 
100 8.67 1.60 - 0.72 0.18 - 
86 7.50 4.00 3.33 0.45 0.53 0.44 
109 22.33 2.47 3.33 1.35 0.11 0.15 
110 19.67 1.40 3.33 1.19 0.07 0.17 
112 16.00 2.47 2.27 0.97 0.15 0.14 
158 17.00 5.33 6.67 1.03 0.31 0.39 
Note: For this study, rats were followed for 1 or 7 days after injury in order to characterize the early and 
late BSCB permeability following these root insults. A dash (“-”) at day 7 indicates those rats for which the 
study was terminated at day 1. 
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Table A.1.4. Withdrawal thresholds (g) and thresholds normalized to baseline in the 
ipsilateral forepaw at day 1 after sham, 15-minute compression (15min), and 
compression treated with APC (15min+APC)  
(corresponding to studies in Section 3.5). 
 
 
withdrawal threshold (g) withdrawal threshold (fold over baseline) 
group rat day 0 day 1 day 0 day 1 
sham 
102 26.00 26.00 1.43 1.00 
106 8.67 10.33 0.48 1.19 
97 22.33 26.00 1.23 1.16 
152 17.83 11.00 0.98 0.62 
153 11.67 15.00 0.64 1.29 
155 22.33 13.33 1.23 0.60 
15min 
101 21.17 3.33 1.89 0.16 
104 9.00 2.47 0.80 0.27 
105 9.33 0.87 0.83 0.09 
94 14.00 4.00 1.25 0.29 
151 10.17 4.67 0.91 0.46 
100 8.67 1.60 0.77 0.18 
199 17.00 11.00 1.52 0.65 
15min+APC 
195 26.00 18.67 1.31 0.72 
197 13.33 11.67 0.67 0.88 
200 22.33 20.67 1.13 0.93 
203 22.33 11.67 1.13 0.52 
204 15.00 17.00 0.76 1.13 
201 22.33 18.67 1.10 0.84 
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Table A.2.1. Average withdrawal thresholds (g) in the bilateral forepaws in response 
to intrathecal rat thrombin (RTh) given at doses of 0.04U/rat, 0.4U/rat, and 4U/rat 
(corresponding to studies in Section 4.3.2.3). 
 
 
withdrawal threshold (g) 
group rat day 0 day 1 day 3 day 5 day 7 
RTh 0.04 
178 16.83 9.33 12.50 11.67 12.17 
179 20.50 8.33 10.00 12.50 11.83 
180 13.67 13.00 11.33 13.33 15.17 
181 16.00 6.67 9.83 14.17 16.83 
186 12.50 7.33 7.83 11.67 14.17 
RTh 0.4 
187 8.50 4.33 7.00 8.50 13.00 
188 15.17 8.00 7.00 9.67 9.50 
221 6.67 3.00 5.67 6.67 7.33 
222 8.50 9.83 8.50 7.00 7.00 
RTh 4 
205 26.00 5.67 17.83 22.33 18.67 
206 17.83 9.00 12.67 10.00 18.67 
219 9.50 4.00 5.00 6.00 5.33 
220 7.83 3.33 3.67 4.67 4.33 
207 10.17 9.00 10.67 14.17 12.50 
264 12.00 5.67 9.50 9.00 11.00 
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Table A.2.2. Withdrawal thresholds (g) in the ipsilateral forepaw after a 15-minute 
compression (15min) with SCH79797 at doses of 0µg/kg, 25µg/kg, and 50µg/kg 
(corresponding to studies in Section 4.3.2.3). 
 
 
withdrawal threshold (g) 
group rat day -1 day 0 day 1 day 3 day 5 day 7 
SCH(0)+15min 
217 8.00 8.00 1.40 4.00 3.33 3.33 
218 11.50 9.33 4.67 5.33 6.67 6.00 
230 13.33 13.33 3.33 5.33 6.67 5.33 
231 17.00 15.00 6.67 6.00 7.33 5.33 
232 9.67 8.67 3.33 4.00 4.00 4.67 
SCH(25)+15min 
211 22.33 18.67 9.67 10.00 16.33 17.00 
212 22.33 18.67 6.67 15.00 18.67 22.33 
215 15.00 11.67 7.33 11.00 9.33 9.33 
216 8.00 8.00 5.33 7.33 9.67 8.67 
SCH(50)+15min 
223 11.00 8.67 8.67 11.67 13.33 22.33 
224 9.33 7.33 5.33 5.33 6.67 6.00 
225 11.00 6.00 7.33 7.33 8.67 7.33 
226 15.00 22.33 11.67 13.33 18.67 15.00 
227 26.00 18.67 15.00 18.67 22.33 18.67 
228 11.67 10.00 10.00 7.00 9.33 8.00 
229 18.67 22.33 17.00 26.00 26.00 26.00 
 
 
  
 264 
 
Table A.2.3. Withdrawal thresholds (g) in the ipsilateral forepaw following sham, 3-
minute compression (3min), and 15-minute compression (15min)  
(corresponding to studies in Section 4.3.3.1). 
 
 
withdrawal threshold (g) 
group rat day 0 day 1 day 7 
sham 
84 9.67 10.33 16.33 
159 22.33 17.00 20.50 
115 26.00 22.33 15.00 
124 18.67 26.00 26.00 
119 11.33 14.00 16.33 
97 22.33 26.00 - 
152 17.83 11.00 - 
153 11.67 15.00 - 
155 22.33 13.33 - 
102 26.00 26.00 - 
3min 
118 26.00 15.00 22.33 
113 6.33 6.00 6.00 
85 8.17 8.00 9.33 
83 8.83 6.00 7.33 
120 26.00 22.33 26.00 
148 14.17 15.33 - 
149 17.50 8.67 - 
150 10.83 7.33 - 
154 11.67 8.00 - 
129 10.83 8.00 - 
15min 
109 22.33 2.47 3.33 
110 19.67 1.40 3.33 
112 16.00 2.47 2.27 
86 7.50 4.00 3.33 
116 17.00 4.67 6.67 
94 14.00 4.00 - 
100 8.67 1.60 - 
151 10.17 4.67 - 
156 22.33 4.00 - 
157 22.33 4.67 - 
Note: A dash (“-”) at day 7 indicates those rats for which the study was terminated at day 1. 
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Table A.2.4. Withdrawal thresholds (g) in the ipsilateral forepaw following a 15-
minute compression (15min) and a compression pre-treated with hirudin 
(hir+15min) (corresponding to studies in Section 4.3.3.2). 
 
 
withdrawal threshold (g) 
group rat day -1 day 0 day 1 day 3 day 5 day 7 
15min 
86 7.50 7.50 4.00 2.67 4.00 3.33 
109 22.33 22.33 2.47 6.00 4.67 3.33 
110 19.67 19.67 1.40 1.60 1.40 3.33 
112 16.00 16.00 2.47 4.67 4.00 2.27 
158 17.00 17.00 5.33 8.00 7.33 6.67 
hir+15min 
213 9.00 8.67 8.00 8.67 10.00 7.33 
214 15.00 13.33 8.00 11.00 11.00 8.00 
237 18.67 18.67 17.00 13.33 13.33 18.67 
238 22.33 18.67 13.33 13.33 15.00 15.00 
239 16.33 9.33 5.33 10.00 10.00 9.33 
240 26.00 22.33 22.33 18.67 22.33 22.33 
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Table A.2.5. Bilateral withdrawal thresholds (g) over 7 days following intrathecal 
rat thrombin (RTh) (corresponding to studies in Section 4.3.3.3). 
 
 
withdrawal threshold (g) 
group rat day 0 day 1 day 3 day 5 day 7 
RTh 
205 26.00 5.67 17.83 22.33 18.67 
206 17.83 9.00 12.67 10.00 18.67 
207 10.17 9.00 10.67 14.17 12.50 
219 10.42 4.00 5.00 6.00 5.33 
220 7.83 3.33 3.67 4.67 4.33 
264 12.00 5.67 9.50 9.00 11.00 
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Table A.2.6. Bilateral withdrawal thresholds (g) following intrathecal rat thrombin 
(RTh) and rat thrombin pre-treated with SCH79797 (SCH+RTh)  
(corresponding to studies in Section 4.3.3.3). 
 
 
withdrawal threshold (g) 
group rat day -1 day 0 day 1 
RTh 
247 12.17 12.17 7.00 
248 18.67 18.67 7.50 
249 17.00 17.00 5.50 
250 8.67 8.67 4.00 
251 22.33 22.33 9.50 
263 15.00 15.00 3.00 
SCH+RTh 
273 12.17 10.33 10.17 
274 8.33 10.83 9.50 
275 9.17 6.67 7.33 
276 16.00 8.33 8.33 
277 9.50 7.33 9.83 
278 8.67 7.33 11.33 
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Table A.2.7. Withdrawal thresholds (g) in the ipsilateral forepaw following sham 
with DMSO pre-treatment (DMSO+sham) and a 15-minute compression pre-
treated with either DMSO (DMSO+15min) or SCH79797 (SCH+15min) 
(corresponding to studies in Section 4.3.3.4). 
 
 
withdrawal threshold (g) 
group rat day -1 day 0 day 1 day 3 day 5 day 7 
DSMO+sham 
233 20.67 22.33 15.67 13.33 22.33 22.33 
234 13.33 9.33 4.67 11.00 13.33 22.33 
235 20.67 22.33 8.00 13.33 15.00 18.67 
236 22.33 26.00 11.67 18.67 26.00 22.33 
DMSO+15min 
217 8.00 8.00 1.40 4.00 3.33 3.33 
218 11.50 9.33 4.67 5.33 6.67 6.00 
230 13.33 13.33 3.33 5.33 6.67 5.33 
231 17.00 15.00 6.67 6.00 7.33 5.33 
232 9.67 8.67 3.33 4.00 4.00 4.67 
SCH+15min 
223 11.00 8.67 8.67 11.67 13.33 22.33 
224 9.33 7.33 5.33 5.33 6.67 6.00 
225 11.00 6.00 7.33 7.33 8.67 7.33 
226 15.00 22.33 11.67 13.33 18.67 15.00 
227 26.00 18.67 15.00 18.67 22.33 18.67 
228 11.67 10.00 10.00 7.00 9.33 8.00 
229 18.67 22.33 17.00 26.00 26.00 26.00 
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Table A.3.1. Number of withdrawals of the ipsilateral forepaw in response to a 4g 
filament at day 1 after a sham or 15-minute compression treated with vehicle 
(15min+veh), salmon thrombin (15min+STh), or human thrombin (15min+HTh) 
(corresponding to studies in Section 5.3.2). 
 
 
number of paw withdrawals 
group rat day 0 day 1 
sham 
152 0.5 0.0 
153 0.0 1.0 
155 0.0 0.0 
15min+veh 
T13 0.0 2.0 
T14 0.0 4.0 
T15 0.5 7.0 
T16 0.0 1.0 
163 0.0 3.0 
15min+STh 
T10 0.5 2.0 
T11 0.5 0.0 
T12 0.5 2.0 
161 0.0 0.0 
162 0.0 0.0 
15min+HTh 
243 1.0 5.0 
244 0.0 2.0 
245 0.0 8.0 
246 0.0 3.0 
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Table A.3.2. Number of withdrawals of the ipsilateral forepaw in response to a 1.4g 
filament for 7 days after a sham or 15-minute compression treated with vehicle 
(15min+veh), human thrombin (15min+HTh), or salmon thrombin (15min+STh) 
(corresponding to studies in Section 5.4.2). 
 
 
number of paw withdrawals 
group rat day 0 day 1 day 3 day 5 day 7 
sham 
7 1.0 0.0 0.0 0.0 0.0 
9 0.0 0.0 0.0 0.0 0.0 
11 0.0 0.0 0.0 3.0 0.0 
42 0.0 0.0 0.0 0.0 0.0 
43 0.0 0.0 0.0 0.0 0.0 
15min+veh 
29 0.0 3.0 2.0 2.0 0.0 
33 0.5 3.0 3.0 1.0 0.0 
14 0.5 5.0 3.0 2.0 4.0 
15 0.0 2.0 1.0 1.0 3.0 
40 0.0 2.0 2.0 2.0 1.0 
15min+HTh 
12 0.5 8.0 4.0 4.0 1.0 
13 0.0 5.0 1.0 0.0 2.0 
19 1.0 6.0 2.0 1.0 2.0 
36 0.0 4.0 0.0 1.0 0.0 
37 0.0 2.0 0.0 1.0 1.0 
38 0.0 2.0 1.0 2.0 4.0 
39 0.0 0.0 0.0 1.0 1.0 
15min+STh 
31 0.0 1.0 0.0 0.0 0.0 
32 0.5 0.0 1.0 0.0 0.0 
35 0.0 0.0 0.0 1.0 0.0 
16 0.0 0.0 0.0 0.0 0.0 
17 0.5 3.0 0.0 0.0 1.0 
18 0.0 2.0 0.0 1.0 1.0 
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Table A.3.3. Number of withdrawals of the ipsilateral forepaw in response to a 4g 
filament for 7 days after a sham or 15-minute compression treated with vehicle 
(15min+veh), human thrombin (15min+HTh), or salmon thrombin (15min+STh) 
(corresponding to studies in Section 5.4.2). 
 
 
number of paw withdrawals 
group rat day 0 day 1 day 3 day 5 day 7 
sham 
7 1.0 0.0 0.0 0.0 0.0 
9 0.5 1.0 0.0 1.0 3.0 
11 0.5 0.0 0.0 0.0 1.0 
42 0.0 0.0 0.0 0.0 1.0 
43 0.0 0.0 0.0 0.0 0.0 
15min+veh 
29 0.5 3.0 4.0 4.0 6.0 
33 1.0 3.0 3.0 2.0 7.0 
14 0.0 10.0 7.0 5.0 2.0 
15 0.5 4.0 2.0 2.0 4.0 
40 0.5 7.0 2.0 4.0 0.0 
15min+HTh 
12 0.0 6.0 6.0 4.0 3.0 
13 0.0 3.0 6.0 2.0 2.0 
19 1.0 11.0 8.0 6.0 5.0 
36 0.0 3.0 1.0 2.0 1.0 
37 0.0 4.0 3.0 2.0 1.0 
38 0.0 3.0 3.0 5.0 5.0 
39 0.0 3.0 0.0 1.0 2.0 
15min+STh 
31 1.0 1.0 0.0 2.0 0.0 
32 0.0 2.0 2.0 1.0 2.0 
35 0.0 0.0 0.0 1.0 0.0 
16 0.0 0.0 0.0 0.0 0.0 
17 1.0 4.0 4.0 1.0 2.0 
18 2.0 5.0 1.0 0.0 0.0 
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Table A.3.4. Number of withdrawals of the ipsilateral forepaw in response to a 10g 
filament for 7 days after a sham or 15-minute compression treated with vehicle 
(15min+veh), human thrombin (15min+HTh), or salmon thrombin (15min+STh) 
(corresponding to studies in Section 5.4.2). 
 
 
number of paw withdrawals 
group rat day 0 day 1 day 3 day 5 day 7 
sham 
7 0.0 0.0 3.0 0.0 3.0 
9 0.5 0.0 3.0 4.0 2.0 
11 0.0 0.0 1.0 2.0 1.0 
42 1.0 0.0 2.0 3.0 1.0 
43 1.5 2.0 2.0 1.0 1.0 
15min+veh 
29 0.5 4.0 5.0 6.0 7.0 
33 2.0 7.0 8.0 3.0 6.0 
14 1.0 9.0 8.0 5.0 5.0 
15 1.5 5.0 4.0 5.0 4.0 
40 0.0 8.0 12.0 10.0 10.0 
15min+HTh 
12 4.0 14.0 11.0 11.0 9.0 
13 0.5 11.0 5.0 3.0 4.0 
19 3.5 11.0 8.0 13.0 11.0 
36 1.0 10.0 7.0 6.0 7.0 
37 0.0 9.0 7.0 7.0 5.0 
38 0.5 8.0 8.0 8.0 7.0 
39 0.0 7.0 4.0 5.0 5.0 
15min+STh 
31 1.5 5.0 1.0 1.0 0.0 
32 7.5 0.0 3.0 1.0 3.0 
35 0.5 2.0 0.0 1.0 0.0 
16 0.5 0.0 1.0 1.0 1.0 
17 1.5 4.0 4.0 2.0 6.0 
18 4.5 7.0 1.0 2.0 3.0 
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Appendix B 
Quantified Immunohistochemistry of the Spinal 
Cord & Nerve Root 
 
 
This appendix summarizes the immunolabeling of target proteins in the dorsal 
horn of the spinal cord or nerve root that was quantified in the studies presented in 
Chapters 3-6 of this thesis. The tables provide values for each rat used in each study and 
are listed in the order that they appear in the thesis. Images are identified by the rat 
number (ID) followed by the image number (ID-number). For all studies, densitometry 
was performed using Matlab to quantify the positively-labeled pixels in each image 
(Densitometry.m). For some studies, quantification of the co-localization of pixels 
positively labeling two different target proteins was performed using a specialized co-
localization Matlab script (colocalizationKJN.m). See Appendix G for both Matlab 
scripts. All data are represented as percent expression of a target protein relative to the 
expression of that protein in tissue from normal naïve rats. For all studies, the expression 
of each target protein is quantified for the spinal dorsal horn on the side ipsilateral to 
injury or surgery. A selection of studies in Chapters 3 and 4 quantified protein labeling in 
the bilateral spinal cord; for those cases, the side of the spinal cord is indicated in the 
tables below. Spinal cord tissue was harvested at days 1 and/or 7 and 1-6 tissue section(s) 
per rat were included for each study, as indicated by each table. 
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Studies in Chapter 3 measured the spinal expression of immunoglobulin G (IgG), 
a serum protein not typically found in the CNS, as a proxy for blood-spinal cord barrier 
(BSCB) breakdown at days 1 and 7 after the different nerve root insults. Quantified 
spinal IgG for each rat in those studies is listed in Tables B.1.1-B.1.3. Table B.1.1 
summarizes the expression of IgG in the ipsilateral (ipsi) and contralateral (con) spinal 
dorsal horns at days 1 and 7 after a sham procedure, a 3-minute compression (3min), and 
a 15-minute compression (15min). The methods of the surgical and 
immunohistochemical procedures are provided in Section 3.3.1. Table B.1.2 provides the 
normalized IgG expression in the ipsilateral and contralateral spinal cord at days 1 and 7 
after a sham procedure, a painful inflammatory chromic gut insult (chromic), and a 
painful compression (15min) (see Section 3.4.1). BSCB breakdown was blocked with 
activated protein C (APC) given intravenously (0.2mg/kg) in order to determine if BSCB 
contributes to the development of pain. Table B.1.3 details the individual expression of 
IgG in the ipsilateral spinal cord after a painful 15-minute compression with or without 
APC given intravenously at 1 hour after injury (Section 3.5.1.1).  
The expression of fibrin(ogen), which is the enzymatic product of thrombin, was 
immunolabeled and quantified in the ipsilateral spinal cord after painful compression 
with various pharmacologic treatments; those data are summarized in Tables B.2.1-B.2.3 
and refer to studies in Chapter 4. Fibrin(ogen) expression was immunolabeled in the 
ipsilateral spinal cord at days 1 and 7 following a sham operation, a 3-minute 
compression (3min), and a 15-minute compression (15min) in the studies from Chapter 4 
(Table B.2.1); see Section 4.3.2.6 for details on the immunohistochemistry methods. In 
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order to determine if intrathecal hirudin given a day before compression (hir+15min) 
blocks spinal thrombin activity, spinal fibrin(ogen) was labeled in the ipsilateral spinal 
cord at 1 day after a painful compression with or without hirudin treatment (Table B.2.2). 
Spinal fibrin(ogen) was also measured at 1 day after compression pre-treated with the 
protease-activated receptor-1 (PAR1) inhibitor SCH79797 given 1 day before a 15-
minute compression (SCH+15min); corresponding tissue from rats receiving a DMSO 
vehicle prior to compression were also included for comparison (Figure B.2.3). 
In order to measure if spinal astrocytes modulate their expression of PAR1 
following various compressive insults to the nerve root, PAR1 and GFAP were co-
immunolabeled in the ipsilateral spinal cord after sham, a 3-minute compression (3min), 
and a 15-minute compression (15min) in studies from Chapter 4 (Table B.2.4). For the 
remaining studies in Chapter 4, BSCB breakdown and spinal astrocyte activation were 
quantified after treatments targeting the spinal thrombin/PAR1 signaling cascade in 
association with root compression. Spinal IgG was measured at day 1 after a painful 
compression pre-treated with the thrombin inhibitor hirudin (hir+15min) in order to 
determine if spinal thrombin contributes to BSCB breakdown early after compression 
(Table B.2.5). Relatedly, the effect of compression-induced spinal thrombin on spinal 
astrocyte activation was quantified by immunolabeling GFAP at day 7 after compression 
with and without intrathecal hirudin (Table B.2.6). Since mechanical hyperalgesia is 
maximum at day 1 after an intrathecal injection of rat thrombin in naïve rats (RTh), IgG 
and GFAP expression were co-immunolabeled in the bilateral spinal cord at day 1 after 
rat thrombin injection. Additionally, spinal PAR1 was blocked with SCH79797 prior to 
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rat thrombin (SCH+RTh) and IgG and GFAP expression were quantified at day 1 and 
compared with the rat thrombin injection alone (Table B.2.7). Since the thrombin 
injection did not favor one side, IgG and GFAP expression was measured in the left and 
right spinal cord and averaged between the two sides. Images are identified in applicable 
tables as the rat ID followed by the spinal cord section number followed by the side, 
either left (L) or right (R) (ID-number-side). SCH79797 was also administered at 1 day 
before a 15-minute compression (SCH+15min) to block spinal PAR1. IgG was measured 
in the ipsilateral spinal cord at day 1 (Table B.2.8) and spinal GFAP was measured using 
the densitometry Matlab code at day 7 (Table B.2.9) after compression with SCH79797 
(SCH+15min) or the DMSO vehicle (DMSO+15min). For expression of GFAP at day 7, 
a vehicle treated sham group was also included (DMSO+sham). 
Studies in Chapter 5 investigate the effect of salmon thrombin on nerve root-
induced pain, on BSCB breakdown and on macrophage infiltration at the nerve root. 
Salmon thrombin (15min+STh), human thrombin (15min+HTh), or the vehicle 
neurobasal media (15min+veh) was applied to the root immediately after a 15-minute 
compression (see Section 5.3.1.2 for more details). BSCB breakdown was measured in 
rats in those groups by immunolabeling the bilateral spinal cord for IgG at day 1 after 
compression (Table B.3.1). At day 7 after a 15-minute compression treated with vehicle, 
salmon thrombin or human thrombin, the extent of macrophage infiltration in the nerve 
root was measured by immunolabeling for Iba1 (Section 5.5). Iba1 expression was 
quantified in the ipsilateral nerve root using the Matlab densitometry script; those data 
are detailed in Table B.3.2. 
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Data from the studies in Chapter 6 measuring spinal vimentin, spinal astrocytic 
vimentin, and spinal endothelial vimentin after a compressive nerve root injury with 
various treatments are presented in Tables B.4.1-B.4.6. Vimentin expression and the co-
localized expression of vimentin and GFAP in the ipsilateral spinal cord were measured 
at day 1 and day 7 after sham, a 3-minute compression (3min), and a 15-minute 
compression (15min) (Table B.4.1). Spinal vimentin expression was quantified using the 
Matlab densitometry script and the astrocytic vimentin was quantified using the co-
localization code in Matlab. Table B.4.2 details the quantified expression of vimentin and 
astrocytic vimentin in the ipsilateral spinal cord at day 7 after compression pre-treated 
with hirudin at 1 day before compression (hir+15min) and compression alone (15min). 
Spinal vimentin and astrocytic vimentin expression at day 7 after sham or compression 
treated with human thrombin (15min+HTh) or salmon thrombin (15min+STh) are 
itemized in Table B.4.3. Spinal vimentin expression co-localized with von Willebrand 
factor (VWF), as a proxy for endothelial cells, at days 1 and 7 after sham, a 3-minute 
compression (3min), and a 15-minute compression (15min) is provided in Table B.4.4. 
The co-localization of positive pixels for vimentin and VWF was measured using the 
custom Matlab co-localization script (see Appendix G). The expression of endothelial 
vimentin in the ipsilateral spinal cord at day 7 was also quantified at day 7 following a 
15-minute compression with intrathecal hirudin given 1 day before compression 
(hir+15min) (Table B.4.5). Lastly, endothelial vimentin was labeled and quantified in the 
ipsilateral spinal cord at day 7 after sham or a compression treated with human thrombin 
(15min+HTh) or salmon thrombin (15min+STh).  
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Table B.1.1. Normalized IgG labeling in the ipsilateral (ipsi) and contralateral (con) 
spinal cord at days 1 and 7 after sham, 3-minute compression (3min), or 15-minute 
compression (15min) (corresponding to studies in Section 3.3.2). 
day group side rat image IgG (fold over normal) 
day 1 sham 
ipsi 
97 
97-01 201.005 
97-02 52.965 
152 
152-01 1.410 
152-02 2.350 
152-03 31.958 
152-04 28.041 
152-05 2.820 
152-06 19.269 
153 
153-01 2.037 
153-02 9.869 
153-03 17.702 
153-04 15.979 
153-05 0.470 
153-06 1.253 
155 
155-01 12.532 
155-02 59.999 
155-03 33.211 
155-04 64.855 
155-05 18.799 
155-06 37.441 
K258 
K258-01 0.432 
K258-02 36.319 
K258-03 4.756 
K258-04 42.372 
K258-05 10.809 
K258-06 34.590 
con 
97 
97-01 12.830 
97-02 21.055 
152 
152-01 5.170 
152-02 6.423 
152-03 24.282 
152-04 11.906 
152-05 9.399 
152-06 10.183 
153 
153-01 3.603 
153-02 6.423 
153-03 9.086 
153-04 7.206 
153-05 12.219 
153-06 10.026 
155 
155-01 9.086 
155-02 15.196 
155-03 5.483 
155-04 15.822 
155-05 1.723 
155-06 12.689 
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K258 
K258-01 12.539 
K258-02 0.432 
K258-03 11.674 
K258-04 5.188 
K258-05 7.350 
K258-06 15.133 
3min ipsi 
95 
95-01 58.887 
95-02 767.175 
95-03 178.635 
95-04 155.935 
95-05 93.430 
148 
148-01 5.013 
148-02 103.236 
148-03 4.230 
148-04 44.647 
148-05 15.509 
148-06 54.830 
150 
150-01 0.313 
150-02 1.097 
150-03 0.313 
150-04 1.410 
150-05 3.133 
150-06 2.350 
154 
154-01 146.473 
154-02 399.472 
154-03 370.804 
154-04 215.245 
154-05 237.803 
149 
149-01 182.974 
149-02 546.885 
149-03 393.833 
149-04 559.574 
149-05 467.774 
K251 
K251-01 31.131 
K251-02 47.128 
K251-03 77.827 
K251-04 45.831 
K251-05 47.993 
K251-06 11.242 
K253 
K253-02 0.865 
K253-03 1.297 
K253-04 1.297 
K253-05 1.729 
K253-06 2.162 
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con 
95 
95-01 3.948 
95-02 2.303 
95-03 5.922 
95-04 1.316 
148 
148-01 0.470 
148-02 11.749 
148-03 3.603 
148-04 8.146 
148-05 0.940 
148-06 8.459 
150 
150-01 0.000 
150-02 0.470 
150-03 0.157 
150-04 2.037 
150-05 1.880 
150-06 3.760 
154 
154-01 0.470 
154-02 0.157 
154-03 0.470 
154-04 10.653 
154-05 3.603 
149 
149-01 5.953 
149-02 12.376 
149-03 10.966 
149-04 28.825 
149-05 15.822 
K251 
K251-01 1.729 
K251-02 0.000 
K251-03 0.865 
K251-04 0.000 
K251-05 4.324 
K251-06 2.594 
K253 
K253-01 7.783 
K253-02 6.918 
K253-03 0.432 
K253-04 0.865 
K253-05 2.594 
K253-06 0.432 
15min ipsi 
94 
94-01 1601.132 
94-02 1584.354 
94-03 2628.198 
94-04 2594.972 
100 
100-01 559.731 
100-02 960.300 
100-03 1228.651 
100-05 1347.710 
100-06 1278.938 
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151 
151-01 12.532 
151-02 11.279 
151-03 122.035 
151-04 118.588 
156 
156-01 2080.997 
156-02 2221.949 
156-03 2437.702 
156-04 2036.895 
156-05 1443.683 
156-06 1603.228 
157 
157-01 378.333 
157-02 428.354 
157-05 347.275 
157-06 501.642 
con 
94 
94-01 5.922 
94-02 2.303 
94-03 27.634 
94-04 29.937 
100 
100-02 8.146 
100-03 4.230 
100-05 38.224 
100-06 30.548 
151 
151-01 4.856 
151-02 4.543 
151-03 5.640 
151-04 21.932 
156 
156-01 1.729 
156-02 3.459 
156-03 9.080 
156-04 11.242 
156-05 94.689 
156-06 75.665 
157 
157-01 11.070 
157-02 7.073 
157-03 1.230 
157-04 7.585 
157-05 1.845 
157-06 1.435 
day 7 sham ipsi 114 
114-01 3.045 
114-02 3.426 
114-03 4.377 
114-04 2.331 
114-05 4.520 
114-06 4.948 
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115 
115-01 2.189 
115-03 3.188 
115-04 1.856 
115-05 2.998 
84 
84-01 2.432 
84-02 0.000 
84-03 0.187 
84-04 1.871 
84-05 0.561 
159 
159-01 0.000 
159-02 0.000 
159-03 0.000 
159-04 0.462 
159-05 1.385 
159-06 2.769 
con 
114 
114-01 0.476 
114-02 1.380 
114-03 0.285 
114-04 0.095 
114-05 2.855 
114-06 0.952 
115 
115-01 5.757 
115-03 0.904 
115-04 6.328 
115-05 5.377 
84 
84-01 0.374 
84-02 0.000 
84-03 0.000 
84-04 4.304 
84-05 0.561 
159 
159-01 5.077 
159-02 3.231 
159-03 1.846 
159-04 0.923 
159-05 0.462 
159-06 0.923 
3min ipsi 
111 
111-01 54.433 
111-02 206.075 
111-03 282.395 
111-04 54.576 
111-05 288.485 
111-06 329.929 
113 
113-02 3.616 
113-03 2.807 
113-05 13.418 
83 
83-01 2.458 
83-02 74.799 
83-03 12.993 
85 
85-01 191.388 
85-02 302.007 
85-03 115.886 
85-04 5.268 
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87 
87-01 76.555 
87-02 23.528 
87-03 3.863 
87-04 65.318 
87-05 17.207 
con 
111 
111-01 7.328 
111-02 16.035 
111-03 30.785 
111-04 7.232 
111-05 28.406 
111-06 21.554 
113 
113-02 3.378 
113-03 1.761 
113-05 2.331 
83 
83-01 0.351 
83-02 4.565 
83-03 0.351 
85 
85-01 9.833 
85-02 2.809 
85-03 3.512 
87 
87-01 5.268 
87-02 4.916 
87-03 1.405 
87-04 5.970 
87-05 5.970 
15min ipsi 
109 
109-01 2.902 
109-02 17.605 
109-03 47.296 
109-04 4.377 
109-05 260.698 
109-06 206.360 
110 
110-01 138.795 
110-02 191.610 
110-03 136.178 
110-04 82.982 
110-05 38.874 
112 
112-01 78.795 
112-02 16.368 
112-03 197.415 
112-04 125.805 
86 
86-01 28.445 
86-02 134.849 
86-03 54.783 
86-04 12.642 
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158 
158-01 3.692 
158-02 1.385 
158-03 6.923 
158-04 0.462 
con 
109 
109-01 4.377 
109-02 22.744 
109-03 32.260 
109-04 4.806 
109-05 18.604 
109-06 32.784 
110 
110-01 212.070 
110-02 263.505 
110-03 243.188 
110-04 129.754 
110-05 102.205 
112 
112-01 0.952 
112-02 1.951 
112-03 2.855 
112-04 1.427 
86 
86-01 4.214 
86-02 4.916 
86-03 2.458 
86-04 0.702 
158 
158-01 0.000 
158-03 0.000 
158-04 0.462 
Note: Rat ID numbers that begin with a “K” are rats that received surgery by Kristen Nicholson, a former 
member of our lab (K251, K253, and K258). 
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Table B.1.2. Normalized IgG labeling in the ipsilateral (ipsi) and contralateral (con) 
spinal cord at days 1 and 7 after sham, chromic gut insult (chromic), and 15-minute 
compression (15min) (corresponding to studies in Section 3.4.2). 
day group side rat image IgG  (fold over normal) 
day 1 sham 
ipsi 
97 
97-01 201.005 
97-02 52.965 
152 
152-01 1.410 
152-02 2.350 
152-03 31.958 
152-04 28.041 
152-05 2.820 
152-06 19.269 
153 
153-01 2.037 
153-02 9.869 
153-03 17.702 
153-04 15.979 
153-05 0.470 
153-06 1.253 
155 
155-01 12.532 
155-02 59.999 
155-03 33.211 
155-04 64.855 
155-05 18.799 
155-06 37.441 
K258 
K258-01 0.432 
K258-02 36.319 
K258-03 4.756 
K258-04 42.372 
K258-05 10.809 
K258-06 34.590 
con 
97 
97-01 12.830 
97-02 21.055 
152 
152-01 5.170 
152-02 6.423 
152-03 24.282 
152-04 11.906 
152-05 9.399 
152-06 10.183 
153 
153-01 3.603 
153-02 6.423 
153-03 9.086 
153-04 7.206 
153-05 12.219 
153-06 10.026 
155 
155-01 9.086 
155-02 15.196 
155-03 5.483 
155-04 15.822 
155-05 1.723 
155-06 12.689 
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K258 
K258-01 12.539 
K258-02 0.432 
K258-03 11.674 
K258-04 5.188 
K258-05 7.350 
K258-06 15.133 
chromic 
ipsi 
164 
164-01 52.443 
164-02 116.238 
165 
165-01 127.816 
165-02 220.670 
165-03 147.795 
165-04 171.178 
165-05 279.697 
165-06 445.200 
166 
166-01 169.589 
166-02 369.146 
166-03 723.762 
166-04 628.865 
166-05 637.492 
166-06 789.373 
con 
164 164-01 8.400 
164-02 13.622 
165 
165-01 0.454 
165-02 0.000 
165-03 0.227 
165-04 0.227 
165-05 6.811 
165-06 2.951 
166 
166-01 0.000 
166-02 0.227 
166-03 2.497 
166-04 14.984 
166-05 4.086 
166-06 11.351 
15min ipsi 
94 
94-01 1601.132 
94-02 1584.354 
94-03 2628.198 
94-04 2594.972 
100 
100-01 559.731 
100-02 960.300 
100-03 1228.651 
100-05 1347.710 
100-06 1278.938 
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151 
151-01 12.532 
151-02 11.279 
151-03 122.035 
151-04 118.588 
156 
156-01 2080.997 
156-02 2221.949 
156-03 2437.702 
156-04 2036.895 
156-05 1443.683 
156-06 1603.228 
157 
157-01 378.333 
157-02 428.354 
157-05 347.275 
157-06 501.642 
con 
94 
94-01 5.922 
94-02 2.303 
94-03 27.634 
94-04 29.937 
100 
100-02 8.146 
100-03 4.230 
100-05 38.224 
100-06 30.548 
151 
151-01 4.856 
151-02 4.543 
151-03 5.640 
151-04 21.932 
156 
156-01 1.729 
156-02 3.459 
156-03 9.080 
156-04 11.242 
156-05 94.689 
156-06 75.665 
157 
157-01 11.070 
157-02 7.073 
157-03 1.230 
157-04 7.585 
157-05 1.845 
157-06 1.435 
day 7 sham ipsi 114 
114-01 3.045 
114-02 3.426 
114-03 4.377 
114-04 2.331 
114-05 4.520 
114-06 4.948 
  
 288 
 
 
 
 
115 
115-01 2.189 
115-03 3.188 
115-04 1.856 
115-05 2.998 
84 
84-01 2.432 
84-02 0.000 
84-03 0.187 
84-04 1.871 
84-05 0.561 
159 
159-01 0.000 
159-02 0.000 
159-03 0.000 
159-04 0.462 
159-05 1.385 
159-06 2.769 
con 
114 
114-01 0.476 
114-02 1.380 
114-03 0.285 
114-04 0.095 
114-05 2.855 
114-06 0.952 
115 
115-01 5.757 
115-03 0.904 
115-04 6.328 
115-05 5.377 
84 
84-01 0.374 
84-02 0.000 
84-03 0.000 
84-04 4.304 
84-05 0.561 
159 
159-01 5.077 
159-02 3.231 
159-03 1.846 
159-04 0.923 
159-05 0.462 
159-06 0.923 
chromic ipsi 
190 
190-01 10.754 
190-02 4.744 
190-03 5.693 
190-04 43.014 
190-05 2.214 
190-06 1.265 
191 
191-01 14.865 
191-02 4.744 
191-03 2.214 
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192 
192-01 0.949 
192-02 3.795 
192-03 2.530 
192-04 2.530 
192-05 8.856 
193 
193-01 1.581 
193-02 0.633 
193-03 3.479 
193-04 3.479 
193-05 7.274 
193-06 5.377 
con 
190 
190-01 6.958 
190-02 0.000 
190-03 0.000 
190-04 0.316 
190-05 0.316 
190-06 0.633 
191 
191-01 7.907 
191-02 11.702 
191-03 14.233 
192 
192-01 0.000 
192-02 2.530 
192-03 5.060 
192-04 3.795 
192-05 2.530 
193 
193-01 33.209 
193-02 29.730 
193-03 6.642 
193-04 3.479 
193-05 4.428 
193-06 2.847 
15min ipsi 
109 
109-01 2.902 
109-02 17.605 
109-03 47.296 
109-04 4.377 
109-05 260.698 
109-06 206.360 
110 
110-01 138.795 
110-02 191.610 
110-03 136.178 
110-04 82.982 
110-05 38.874 
112 
112-01 78.795 
112-02 16.368 
112-03 197.415 
112-04 125.805 
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86 
86-01 28.445 
86-02 134.849 
86-03 54.783 
86-04 12.642 
158 
158-01 3.692 
158-02 1.385 
158-03 6.923 
158-04 0.462 
con 
109 
109-01 4.377 
109-02 22.744 
109-03 32.260 
109-04 4.806 
109-05 18.604 
109-06 32.784 
110 
110-01 212.070 
110-02 263.505 
110-03 243.188 
110-04 129.754 
110-05 102.205 
112 
112-01 0.952 
112-02 1.951 
112-03 2.855 
112-04 1.427 
86 
86-01 4.214 
86-02 4.916 
86-03 2.458 
86-04 0.702 
158 
158-01 0.000 
158-03 0.000 
158-04 0.462 
Note: Rat ID numbers that begin with a “K” are rats that received surgery by Kristen Nicholson, a former 
member of our lab (K251, K253, and K258). 
 
  
 291 
 
Table B.1.3. Normalized IgG labeling in the ipsilateral (ipsi) and contralateral (con) 
spinal cord at day 1 after a 15-minute compression (15min) and a compression 
treated with APC (15min+APC) (corresponding to studies in Section 3.5.2). 
group side rat image IgG  (fold over normal) 
15min 
ipsi 
156 
156-01 873.818 
156-02 1165.455 
156-03 1367.273 
156-04 1385.636 
156-05 1258.182 
156-06 1300.545 
157 
157-01 378.333 
157-02 428.354 
157-03 347.275 
157-04 501.642 
94 
94-02 415.006 
94-03 340.370 
94-04 417.503 
94-05 327.121 
94-06 280.439 
100 
100-01 479.306 
100-02 564.069 
100-03 593.896 
100-04 481.457 
100-05 595.214 
100-06 586.335 
151 
151-01 17.618 
151-02 24.694 
151-03 7.075 
151-04 17.965 
151-05 44.046 
con 
156 
156-01 2.909 
156-02 0.000 
156-03 9.455 
156-04 3.455 
156-05 21.455 
156-06 49.455 
157 
157-01 11.070 
157-02 7.073 
157-03 1.230 
157-04 7.585 
157-05 1.845 
157-06 1.435 
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94 
94-01 0.139 
94-02 0.763 
94-03 3.954 
94-04 0.832 
94-05 0.347 
94-06 3.052 
100 
100-01 3.191 
100-02 3.468 
100-04 3.468 
100-05 10.960 
100-06 9.919 
151 
151-01 1.457 
151-02 1.387 
151-03 2.775 
151-04 2.220 
151-05 1.665 
15min+APC ipsi 
195 
195-01 7.455 
195-02 98.364 
195-03 7.455 
195-04 99.091 
195-05 1.636 
195-06 53.091 
197 
197-01 147.273 
197-02 648.000 
197-03 682.727 
197-04 1046.000 
197-05 929.455 
197-06 1098.545 
200 
200-01 162.936 
200-02 135.468 
200-03 3.884 
200-04 11.168 
200-05 2.358 
200-06 7.908 
201 
201-01 11.376 
201-02 19.422 
201-03 36.000 
201-04 13.457 
201-05 56.046 
203 
203-01 1.803 
203-02 1.179 
203-03 0.208 
203-04 3.260 
203-05 3.399 
203-06 1.526 
  
 293 
 
 
 
204 
204-01 0.971 
204-02 0.763 
204-03 1.665 
204-04 2.081 
204-05 1.318 
204-06 0.971 
con 
195 
195-01 1.455 
195-02 0.909 
195-03 1.273 
195-04 1.636 
195-05 0.000 
195-06 4.545 
197 
197-01 1.091 
197-02 0.909 
197-03 1.455 
197-04 5.091 
197-05 0.364 
197-06 1.636 
200 
200-01 1.803 
200-02 2.705 
200-03 1.318 
200-04 3.468 
200-05 0.139 
200-06 0.000 
201 
201-01 0.069 
201-02 0.208 
201-03 0.694 
201-04 0.624 
201-05 0.139 
203 
203-01 0.347 
203-02 0.277 
203-03 0.000 
203-04 1.803 
203-05 0.694 
203-06 0.000 
204 
204-01 0.347 
204-02 0.208 
204-03 1.179 
204-04 1.249 
204-05 0.277 
204-06 0.832 
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Table B.2.1. Normalized fibrin(ogen) labeling in the ipsilateral spinal cord at days 1 
and 7 after sham, 3-minute compression (3min), or 15-minute compression (15min) 
(corresponding to studies in Section 4.3.3.1). 
day group rat image fibrin(ogen)  (fold over normal) 
day 1 
sham 
55 
55-01 3.877 
55-02 8.446 
55-03 5.538 
55-04 2.631 
57 
57-01 31.569 
57-03 0.692 
57-04 3.877 
57-05 3.462 
152 
152-01 0.692 
152-02 1.938 
152-03 0.554 
152-04 2.077 
152-05 1.662 
152-06 1.938 
153 
153-01 12.877 
153-02 10.108 
153-03 11.492 
153-04 10.385 
153-05 2.908 
153-06 0.831 
155 
155-01 1.938 
155-02 2.908 
155-03 2.769 
155-04 4.846 
3min 
95 
95-01 4.400 
95-02 7.486 
95-03 7.543 
95-04 5.143 
148 
148-01 0.743 
148-02 0.971 
148-03 3.257 
148-05 4.857 
148-06 5.143 
149 
149-01 72.400 
149-02 17.029 
149-03 18.571 
149-04 11.200 
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150 
150-01 0.571 
150-02 0.171 
150-03 0.229 
150-04 0.343 
150-05 0.171 
154 
154-01 37.257 
154-02 5.543 
154-03 3.657 
154-03 3.257 
15min 
94 
94-01 88.477 
94-02 92.908 
94-03 74.769 
94-04 180.554 
94-05 113.538 
100 
100-01 5.815 
100-02 3.600 
100-03 27.969 
100-04 4.569 
100-05 23.400 
151 
151-01 5.677 
151-02 3.185 
151-03 1.385 
151-04 3.877 
151-05 3.046 
156 
156-01 23.815 
156-02 231.231 
156-03 146.354 
156-04 236.077 
156-05 21.462 
156-06 41.538 
157 
157-01 1.246 
157-02 2.631 
157-03 0.969 
157-04 0.969 
157-05 2.631 
157-06 0.692 
day 7 sham 
J23 
J23-01 0.554 
J23-02 0.000 
J23-03 1.246 
J23-04 1.385 
J28 
J28-01 3.738 
J28-02 2.769 
J28-03 0.277 
J28-04 3.877 
84 
84-01 0.138 
84-03 1.523 
84-04 1.800 
114 
114-01 0.000 
114-02 0.277 
114-03 0.138 
114-04 0.277 
114-05 0.138 
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115 
115-02 1.662 
115-03 0.415 
159 
159-01 0.000 
159-02 1.385 
159-03 0.969 
159-04 0.138 
159-05 0.000 
159-06 0.000 
3min 
83 
83-01 16.114 
83-03 7.314 
85 
85-01 0.343 
85-02 5.143 
85-03 1.486 
85-04 1.086 
85-05 14.971 
87 
87-01 2.343 
87-02 2.571 
87-03 1.257 
87-04 2.114 
111 
111-01 1.314 
111-02 0.743 
111-03 1.086 
111-04 3.829 
111-05 4.629 
113 
113-02 2.743 
113-03 10.686 
113-04 0.229 
113-05 3.771 
113-06 17.886 
15min 
86 
86-01 1.385 
86-02 43.892 
86-03 81.138 
86-04 52.615 
86-05 80.169 
86-06 65.769 
109 
109-01 3.600 
109-02 3.877 
109-03 2.492 
109-04 0.692 
109-05 7.615 
110 
110-01 10.523 
110-02 1.800 
110-03 0.969 
110-04 1.523 
110-05 1.800 
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112 
112-01 1.108 
112-02 1.108 
112-03 1.938 
112-04 3.185 
158 
158-01 0.692 
158-02 0.000 
158-03 1.385 
158-04 0.415 
158-05 0.969 
158-06 0.415 
Note: Rat ID numbers that begin with a “J” are rats that received surgery by Christine Weisshaar, another 
member of the lab (J23, J28). 
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Table B.2.2. Normalized fibrin(ogen) labeling in the ipsilateral spinal cord at days 1 
and 7 after 15-minute compression (15min) and compression pre-treated with 
hirudin (hir+15min) (corresponding to studies in Section 4.3.3.2). 
day group rat image fibrin(ogen)  (fold over normal) 
day 1 
15min 
94 
94-01 88.477 
94-02 92.908 
94-03 74.769 
94-04 180.554 
94-05 113.538 
100 
100-01 5.815 
100-02 3.600 
100-03 27.969 
100-04 4.569 
100-05 23.400 
151 
151-01 5.677 
151-02 3.185 
151-03 1.385 
151-04 3.877 
151-05 3.046 
156 
156-01 23.815 
156-02 231.231 
156-03 146.354 
156-04 236.077 
156-05 21.462 
156-06 41.538 
157 
157-01 1.246 
157-02 2.631 
157-03 0.969 
157-04 0.969 
157-05 2.631 
157-06 0.692 
hir+15min 
172 
172-01 5.314 
172-02 1.486 
172-04 4.343 
172-05 3.143 
172-06 1.029 
173 
173-01 5.486 
173-02 18.743 
173-03 13.543 
173-05 16.000 
174 
174-01 5.429 
174-02 14.057 
174-03 4.000 
174-04 24.743 
175 
175-01 0.686 
175-02 0.914 
175-03 3.429 
175-04 3.714 
175-05 1.486 
175-06 0.914 
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268 
268-01 1.657 
268-02 1.486 
268-03 2.571 
268-04 2.686 
268-05 5.143 
day 7 
15min 
86 
86-01 1.385 
86-02 43.892 
86-03 81.138 
86-04 52.615 
86-05 80.169 
86-06 65.769 
109 
109-01 3.600 
109-02 3.877 
109-03 2.492 
109-04 0.692 
109-05 7.615 
110 
110-01 10.523 
110-02 1.800 
110-03 0.969 
110-04 1.523 
110-05 1.800 
112 
112-01 1.108 
112-02 1.108 
112-03 1.938 
112-04 3.185 
158 
158-01 0.692 
158-02 0.000 
158-03 1.385 
158-04 0.415 
158-05 0.969 
158-06 0.415 
hir+15min 
213 
213-01 2.571 
213-02 3.086 
213-03 0.914 
213-04 0.800 
213-05 2.457 
214 
214-01 1.657 
214-02 0.857 
237 
237-01 7.371 
237-02 14.457 
237-03 0.800 
237-04 1.657 
237-05 0.571 
237-06 0.514 
  
 300 
 
  
238 
238-01 0.743 
238-02 2.114 
238-03 0.971 
238-04 0.857 
238-05 0.400 
238-06 0.514 
239 
239-01 4.686 
239-02 1.200 
239-03 1.486 
239-05 3.029 
239-06 0.800 
240 
240-01 3.257 
240-02 0.800 
240-03 1.143 
240-04 1.429 
240-05 1.143 
240-06 0.400 
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Table B.2.3. Normalized fibrin(ogen) labeling in the ipsilateral spinal cord at days 1 
and 7 after 15-minute compression pre-treated with DMSO (DMSO+15min) or 
SCH79797 (SCH+15min) and at day 7 after DMSO treatment with sham 
(DMSO+sham) (corresponding to studies in Section 4.3.3.4). 
day group rat image fibrin(ogen) 
 (fold over normal) 
day 1 
DMSO+15min 
260 
260-01 12.000 
260-02 1.400 
260-03 15.000 
260-04 6.000 
260-05 2.600 
261 
261-02 28.000 
261-03 25.600 
261-04 37.800 
261-05 41.000 
261-06 53.600 
262 
262-01 39.600 
262-02 19.000 
262-03 15.400 
262-04 11.400 
262-05 13.000 
269 
269-01 0.800 
269-02 2.000 
269-03 4.200 
269-04 3.400 
269-05 2.400 
SCH+15min 
255 
255-01 16.600 
255-02 7.000 
255-03 30.200 
255-04 19.400 
255-05 6.000 
255-06 7.000 
256 
256-01 13.200 
256-02 4.200 
256-03 1.200 
256-04 8.600 
256-05 9.800 
257 
257-01 7.800 
257-02 19.600 
257-03 1.200 
257-04 3.800 
257-05 4.200 
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258 
258-01 33.600 
258-02 22.000 
258-03 9.600 
258-04 15.600 
258-05 27.600 
259 
259-01 11.800 
259-02 54.600 
259-03 10.800 
259-04 12.800 
259-05 81.200 
259-06 26.600 
278 
278-01 2.800 
278-02 2.400 
278-03 3.800 
278-04 7.800 
278-05 2.200 
278-06 2.800 
day 7  
DMSO+sham 
233 
233-01 5.800 
233-02 6.400 
233-03 2.200 
233-04 2.600 
233-05 2.400 
234 
234-01 0.400 
234-02 0.000 
234-03 0.000 
234-04 0.200 
234-05 0.200 
235 
235-01 0.200 
235-02 0.000 
235-03 0.600 
235-05 0.600 
236 
236-01 0.400 
236-02 0.800 
236-03 2.200 
236-04 1.600 
236-05 10.200 
236-06 4.400 
DMSO+15min 
217 
217-01 0.600 
217-02 2.800 
217-03 1.600 
217-04 1.200 
217-05 0.600 
217-06 3.800 
230 
230-01 2.200 
230-02 0.800 
230-03 0.600 
230-04 1.000 
230-05 1.200 
231 
231-02 6.600 
231-03 2.800 
231-04 3.000 
231-05 5.800 
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232 
232-01 1.800 
232-02 3.000 
232-03 0.400 
232-04 0.400 
232-05 1.200 
232-05 1.200 
SCH+15min 
223 
223-01 3.600 
223-02 23.815 
223-03 8.308 
223-04 5.677 
224 
224-01 2.769 
224-02 28.108 
224-03 0.415 
224-05 10.662 
224-06 0.969 
225 
225-01 6.200 
225-02 3.400 
225-03 2.400 
225-04 2.800 
225-05 3.200 
225-06 2.600 
226 
226-01 1.600 
226-02 2.800 
226-03 4.800 
226-04 3.400 
226-05 9.200 
226-06 5.600 
227 
227-01 0.200 
227-02 1.000 
227-03 7.600 
227-04 5.800 
227-05 1.400 
227-06 1.200 
228 
228-01 1.200 
228-02 0.800 
228-03 0.600 
228-04 1.800 
228-05 3.800 
228-06 0.200 
229 
229-01 1.400 
229-02 0.800 
229-03 3.200 
229-04 2.200 
229-05 1.800 
229-06 2.600 
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Table B.2.4. Normalized co-localization of PAR1 and GFAP in the ipsilateral spinal 
cord at days 1 and 7 after sham, 3-minute compression (3min), and 15-minute 
compression (15min) (corresponding to studies in Section 4.4.3.1). 
day group rat image 
PAR1 & GFAP  
co-localization  
(fold over normal) 
day 1 
sham 
97 
97-01 1.825 
97-02 1.121 
152 
152-02 8.942 
152-03 0.896 
152-04 3.136 
152-05 0.581 
153 
153-02 0.000 
152-04 0.017 
155 
155-02 1.062 
155-03 0.365 
155-04 1.095 
155-05 0.033 
155-06 0.133 
3min 
148 
148-01 0.083 
148-02 0.017 
148-03 0.348 
148-04 0.000 
148-05 0.182 
149 
149-01 0.066 
149-02 2.721 
149-03 0.547 
150 
150-01 0.050 
150-02 0.415 
150-03 0.017 
150-04 0.033 
154 
154-02 3.600 
154-03 0.348 
154-04 2.422 
154-05 0.066 
154-06 1.974 
15min 
94 
94-02 4.048 
94-03 4.164 
94-04 15.197 
94-05 0.100 
100 
100-03 2.157 
100-04 0.332 
100-05 0.133 
100-06 13.687 
151 
151-01 0.017 
151-02 0.796 
151-04 0.747 
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156 
156-02 8.644 
156-03 0.133 
156-04 0.863 
156-05 0.066 
156-16 2.422 
157 
157-02 0.946 
157-03 0.249 
157-04 0.382 
157-05 0.000 
157-06 0.116 
day 7  
sham 
84 
84-01 4.430 
84-02 0.066 
84-03 1.427 
84-05 1.377 
159 
159-01 0.000 
159-02 0.000 
159-04 0.000 
159-06 0.000 
J23 
J23-01 0.050 
J23-02 2.804 
J23-03 0.547 
J23-04 0.348 
J28 
J28-01 4.214 
J28-02 2.190 
J28-03 7.880 
J28-04 0.182 
J28-05 0.066 
114 
114-02 2.953 
114-04 0.747 
114-05 1.526 
115 
115-01 0.896 
115-02 0.033 
115-03 0.315 
115-04 0.232 
3min 
111 
111-01 0.066 
111-02 6.553 
111-03 4.795 
111-04 0.133 
111-06 4.844 
113 
113-01 0.398 
113-02 7.698 
113-04 0.979 
113-05 0.182 
82 
85-01 4.098 
85-02 2.074 
85-04 1.858 
87 
87-01 0.630 
87-03 9.904 
87-04 9.589 
87-05 0.033 
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15min 
109 
109-01 0.796 
109-02 4.562 
109-03 7.598 
109-04 9.274 
109-05 8.461 
110 
110-01 9.407 
110-02 12.244 
110-03 8.494 
112 
112-01 0.680 
112-02 2.920 
112-03 12.841 
112-04 5.574 
112-06 3.019 
86 
86-01 0.614 
86-02 4.280 
86-04 1.891 
Note: Rat ID numbers that begin with a “J” are rats that received surgery by Christine Weisshaar, another 
member of the lab (J23, J28). 
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Table B.2.5. Normalized IgG expression in the ipsilateral spinal cord at day 1 after a 
15-minute compression (15min) and compression with hirudin (hir+15min) 
(corresponding to studies in Section 4.4.3.2). 
group rat image IgG  (fold over normal) 
15min 
156 
156-01 534.877 
156-02 661.872 
156-03 445.813 
156-04 372.512 
156-05 546.305 
157 
157-01 76.355 
157-02 286.404 
157-03 194.384 
157-04 96.847 
157-05 132.118 
94 
94-02 1601.132 
94-03 1584.354 
94-04 2628.198 
94-05 2594.972 
100 
100-03 559.731 
100-04 960.300 
100-05 1228.651 
100-06 1278.938 
151 
151-01 12.532 
151-02 11.279 
151-03 122.035 
151-04 118.588 
hir+15min 
172 172-01 45.911 
173 
173-01 10.345 
173-02 31.429 
173-03 15.468 
173-04 19.409 
173-05 89.655 
174 
174-01 78.818 
174-02 258.424 
174-03 157.734 
174-04 130.542 
174-05 151.823 
174-06 100.690 
175 
175-01 100.985 
175-02 114.778 
175-03 120.887 
175-04 196.158 
175-05 241.084 
268 
268-01 204.138 
268-02 241.478 
268-03 60.099 
268-04 115.862 
268-05 302.463 
268-06 135.271 
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Table B.2.6. Normalized GFAP expression in the ipsilateral spinal cord at day 7 
after a 15-minute compression (15min) and compression with hirudin (hir+15min) 
(corresponding to studies in Section 4.4.3.2). 
group rat image GFAP (fold over normal) 
15min 
109 
109-01 1.971 
109-03 1.155 
109-04 1.373 
109-05 1.808 
109-06 2.122 
110 
110-01 1.874 
110-02 1.247 
110-03 3.231 
110-04 1.534 
110-05 1.435 
112 
112-01 1.754 
112-02 1.344 
112-03 3.522 
112-04 0.934 
112-05 1.620 
158 
158-01 0.489 
158-02 0.295 
158-03 0.796 
86 
86-01 1.458 
86-02 2.310 
86-03 3.305 
86-04 1.473 
86-05 2.242 
hir+15min 
213 
213-01 1.260 
213-02 1.076 
213-03 1.063 
213-04 0.737 
213-05 0.577 
213-06 0.439 
214 
214-01 1.484 
214-02 0.295 
214-03 2.036 
214-04 0.142 
214-06 0.998 
237 
237-01 2.479 
237-02 1.454 
237-03 1.043 
237-06 0.888 
238 
238-01 0.837 
238-02 0.157 
238-03 0.900 
238-04 1.159 
239 
239-01 0.223 
239-02 0.387 
239-03 0.696 
239-04 0.383 
239-05 0.739 
240 
240-01 0.415 
240-03 0.933 
240-05 0.467 
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Table B.2.7. Normalized IgG and GFAP expression in the bilateral spinal cord at 
day 1 after intrathecal PBS, rat thrombin (RTh) and SCH79797 pre-treated rat 
thrombin (SCH+RTh) (corresponding to studies in Section 4.4.3.3). 
group rat image IgG (fold over normal) 
GFAP 
(fold over normal) 
PBS 
253 
253-01-L  0.154 1.110 
253-01-R 0.246 0.559 
253-02-L  0.186 0.469 
253-02-R  0.102 0.704 
253-03-L  0.499 1.223 
253-03-R  0.163 0.224 
253-04-L  0.189 0.737 
253-04-R  0.218 0.454 
253-05-L  0.771 1.072 
253-05-R  0.150 0.478 
254 
254-01-L  0.080 0.691 
254-01-R 0.848 2.336 
254-03-L  1.533 2.764 
254-04-L  0.480 1.137 
254-04-R  0.902 2.024 
254-05-L  1.008 1.465 
254-05-R  1.379 1.383 
RTh 
247 
247-01-L  0.490 1.487 
247-02-L  1.546 1.457 
247-02-R  3.373 1.701 
247-03-L  2.887 3.764 
247-03-R  1.322 2.415 
247-04-L  1.635 1.804 
247-04-R  0.595 0.702 
247-05-L  0.989 3.885 
247-06-L  1.645 2.346 
247-06-R  3.712 1.957 
248 
248-02-L 1.139 0.929 
248-03-L 2.842 1.570 
248-03-R 4.826 1.257 
248-04-L 4.698 2.192 
248-04-L 1.232 0.602 
248-05-L 8.228 2.616 
248-05-L 3.079 0.702 
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249 
249-01-L  3.137 1.167 
249-01-R 0.910 0.608 
249-02-L  9.834 3.503 
249-02-R  8.675 3.267 
249-03-L  1.095 0.939 
249-03-R  8.334 4.571 
249-04-L  7.304 4.227 
249-04-R  7.781 3.865 
249-05-L  0.889 2.525 
249-06-L  8.474 5.262 
249-06-R  2.964 3.635 
250 
250-01-L  0.355 1.194 
250-01-R 0.758 1.212 
250-03-L  1.683 2.538 
250-03-R 0.867 0.469 
250-04-L  0.330 0.849 
250-04-R  1.370 0.986 
250-05-L  1.162 2.026 
250-05-R 3.629 1.091 
251 
251-01-L  0.890 1.227 
251-01-R 0.522 0.813 
251-02-L  0.112 0.418 
251-03-L  0.790 0.791 
251-04-L  0.419 0.833 
251-04-R 0.291 0.220 
251-05-L  0.250 0.535 
251-05-R 0.483 0.554 
SCH+RTh 
 
273 
273-01-L 0.742 1.040 
273-03-L 1.360 1.614 
273-04-L 0.228 0.450 
273-05-L 0.412 0.510 
273-06-L 0.255 0.494 
274 
274-01-L 0.493 1.599 
274-01-R 0.623 2.013 
274-02-L 0.076 0.535 
274-02-R 0.114 0.471 
274-04-R 0.591 1.733 
274-05-L 0.293 2.385 
274-05-R 0.282 1.539 
275 
275-01-R 0.222 0.388 
275-02-R 0.574 2.320 
275-03-R 0.266 0.665 
275-04-R 0.477 1.619 
275-05-R 0.374 1.405 
275-06-R 0.352 1.231 
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276 
276-01-L 0.271 0.833 
276-01-R 0.282 2.558 
276-02-L 0.461 1.692 
276-02-R 0.320 2.147 
276-03-L 0.889 1.676 
276-03-R 0.645 2.344 
276-04-L 0.542 1.392 
276-04-R 0.547 2.398 
276-05-L 0.997 1.855 
276-05-R 0.401 1.912 
276-06-L 0.829 1.079 
276-06-R 0.417 1.405 
277 
277-01-L 0.753 1.187 
277-01-R 0.504 0.662 
277-02-R 0.964 2.341 
277-03-L 1.132 2.716 
277-03-R 0.921 1.679 
277-04-L 0.748 1.089 
277-04-R 0.385 0.698 
277-05-L 0.233 0.528 
277-05-R 0.401 0.404 
278 
278-01-L 0.666 0.603 
278-02-R 4.524 2.377 
278-03-L 2.482 4.972 
278-05-L 0.341 0.973 
278-05-R 0.629 1.878 
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Table B.2.8. Normalized IgG expression in the ipsilateral spinal cord at day 1 after a 
15-minute compression pre-treated with DMSO vehicle (DMSO+15min) or 
SCH79797 (SCH+15min) (corresponding to studies in Section 4.4.3.4). 
group rat image IgG (fold over normal) 
DMSO+15min 
260 
260-01 0.165 
260-02 4.673 
260-03 2.419 
260-04 4.041 
260-05 3.408 
260-06 2.144 
261 
261-01 113.219 
261-02 27.789 
261-03 63.605 
261-04 61.323 
261-05 171.463 
261-06 125.560 
262 
262-01 35.183 
262-02 21.632 
262-03 5.223 
262-04 15.145 
262-05 32.819 
262-06 15.200 
269 
269-01 1.264 
269-02 0.990 
269-03 0.577 
269-04 0.137 
269-05 0.825 
269-06 0.357 
SCH+15min 
 
255 255-02 94.115 
256 
256-01 164.372 
256-02 116.654 
256-03 159.781 
256-04 73.005 
256-05 125.230 
256-06 107.226 
257 
257-01 169.017 
257-02 136.005 
257-04 200.407 
257-05 113.136 
257-06 83.615 
258 
258-01 139.029 
258-02 37.602 
258-03 109.563 
258-05 147.825 
259 
259-01 35.458 
259-02 8.823 
259-03 39.829 
259-04 28.999 
259-05 44.584 
270 
270-01 48.982 
270-02 51.236 
270-03 23.556 
270-04 69.707 
270-05 88.041 
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Table B.2.9. Normalized GFAP expression in the ipsilateral spinal cord at day 7 
after a 15-minute compression pre-treated with DMSO vehicle (DMSO+15min) or 
SCH79797 (SCH+15min) (corresponding to studies in Section 4.4.3.4). 
group rat image GFAP (fold over normal) 
DMSO+sham 
233 
233-01 0.964 
233-02 0.837 
233-04 1.516 
234 
234-01 0.552 
234-02 0.419 
234-03 1.714 
234-04 0.477 
234-05 0.237 
235 
235-01 2.202 
235-02 1.181 
235-03 0.886 
235-04 0.837 
235-05 1.122 
235-06 1.249 
236 
236-02 0.792 
236-03 1.806 
236-04 1.099 
236-05 0.130 
236-06 0.875 
DMSO+15min 
217 
217-03 0.737 
217-04 0.427 
217-05 0.836 
217-06 0.663 
230 
230-01 0.927 
230-03 0.476 
230-04 1.793 
231 
231-02 0.814 
231-03 1.116 
231-04 0.978 
232 
232-02 0.866 
232-03 1.147 
232-05 0.634 
232-06 0.409 
SCH+15min 
223 
223-01 0.803 
223-02 1.275 
223-03 0.822 
223-04 0.330 
223-05 1.236 
224 
224-02 0.659 
224-03 1.389 
224-04 1.068 
224-05 2.700 
224-06 2.756 
225 
225-02 0.828 
225-03 0.063 
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226 
226-02 0.576 
226-03 0.821 
226-04 0.680 
226-05 0.355 
226-06 0.303 
227 
227-02 0.868 
227-03 1.143 
227-04 1.227 
228 
228-01 0.827 
228-02 0.748 
228-03 0.780 
228-05 0.788 
229 
229-01 0.339 
229-02 0.904 
229-03 1.187 
229-05 1.597 
229-06 1.057 
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Table B.3.1. Normalized IgG expression in the ipsilateral (ipsi) and contralateral 
(con) spinal cord at day 1 after 15-minute compression treated with vehicle 
(15min+veh), salmon thrombin (15min+STh), or human thrombin (15min+HTh) 
(corresponding to studies in Section 5.3.2). 
side group rat image IgG  (fold over normal) 
ipsi 
15min+veh 
T13 
T13-01 32.865 
T13-03 14.054 
T13-04 7.351 
T13-05 17.514 
T14 
T14-02 10.378 
T14-03 9.297 
T14-04 11.892 
T14-05 56.865 
T14-06 51.243 
T15 
T15-02 136.432 
T15-03 106.811 
T15-04 56.000 
T15-05 154.162 
T15-06 36.541 
T16 
T16-02 4.324 
T16-03 7.351 
T16-04 25.297 
T16-05 39.784 
163 
163-01 496.533 
163-02 349.333 
163-03 648.000 
163-04 992.533 
163-05 698.133 
163-06 314.133 
15min+HTh 
243 
243-01 60.759 
243-02 67.157 
243-03 41.169 
243-04 101.675 
243-05 101.024 
243-06 56.422 
244 
244-01 69.687 
244-02 121.699 
244-03 182.530 
244-04 220.337 
244-05 205.373 
244-06 164.024 
245 
245-01 15.217 
245-02 25.554 
245-04 5.205 
245-06 8.277 
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246 
246-01 273.398 
246-02 261.217 
246-03 240.976 
246-04 275.928 
246-06 267.217 
15min+STh 
T10 
T10-02 38.703 
T10-03 1.946 
T10-04 1.946 
T10-05 0.649 
T10-06 1.730 
T11 
T11-02 0.000 
T11-03 0.000 
T11-04 0.000 
T11-05 0.000 
T11-06 0.649 
T12 
T12-03 9.730 
T12-04 2.162 
T12-05 112.000 
T12-06 3.459 
160 
160-01 10.133 
160-02 4.267 
160-03 22.933 
160-04 35.733 
160-05 28.267 
160-06 65.600 
161 
161-02 53.333 
161-03 116.800 
161-04 154.667 
161-05 2.667 
161-06 38.933 
162 
162-01 0.533 
162-02 0.533 
162-03 5.867 
162-04 8.000 
162-05 1.067 
162-06 20.800 
con 15min+veh 
T13 
T13-03 6.919 
T13-04 3.243 
T13-05 12.757 
T14 
T14-02 19.676 
T14-03 21.189 
T14-04 25.297 
T14-05 206.703 
T14-06 107.676 
T15 
T15-02 55.568 
T15-03 8.000 
T15-04 0.649 
T15-05 22.486 
T15-06 14.919 
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T16 
T16-02 5.838 
T16-03 0.865 
T16-04 16.216 
T16-05 23.568 
163 
163-01 0.000 
163-02 0.533 
163-03 0.000 
163-04 4.267 
163-05 2.133 
163-06 2.667 
T15 
T15-01 1.067 
T15-02 13.867 
T15-03 30.400 
T15-04 27.733 
T16 
T16-03 24.000 
T16-04 8.000 
T16-05 11.200 
T10-02 11.733 
15min+STh 
T10 
T10-03 0.432 
T10-04 0.865 
T10-05 0.000 
T10-06 2.378 
T11-02 0.432 
T11 
T11-03 0.000 
T11-04 0.000 
T11-06 0.000 
T12-02 0.000 
T12 
T12-02 26.378 
T12-03 5.405 
T12-04 8.865 
T12-05 19.243 
T12-06 6.270 
160 
160-01 1.067 
160-02 5.867 
160-03 5.333 
160-04 10.133 
160-05 0.533 
160-06 2.133 
161 
161-02 6.400 
161-03 1.067 
161-04 2.667 
161-05 0.000 
161-06 0.533 
162 
162-01 1.067 
162-02 0.533 
162-03 0.000 
162-04 3.200 
162-05 0.000 
162-06 0.000 
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15min+HTh 
243 
243-01 15.506 
243-02 16.229 
243-03 16.554 
243-04 11.205 
243-05 6.072 
243-06 23.205 
244 
244-01 29.928 
244-02 22.410 
244-03 37.663 
244-04 70.012 
244-05 8.783 
244-06 10.012 
245 
245-01 9.325 
245-02 42.759 
245-03 32.855 
245-04 26.964 
245-05 1.916 
245-06 2.458 
246 
246-01 69.831 
246-02 64.048 
246-03 62.675 
246-04 85.048 
246-05 42.217 
246-06 114.976 
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Table B.3.2. Normalized Iba1 expression in the ipsilateral nerve root at day 7 after 
15-minute compression treated with vehicle (15min+veh), human thrombin 
(15min+HTh), or salmon thrombin (15min+STh)  
(corresponding to findings in Section 5.5). 
group rat image Iba1 (fold over normal) 
15min+veh 
3 
3-03 1.188 
3-04 3.684 
3-05 0.558 
3-06 0.965 
T5 
T5-01 43.365 
T5-02 58.038 
T5-03 55.989 
T5-04 61.308 
T5-06 58.102 
T6 
T6-01 2.209 
T6-03 3.118 
T6-05 1.515 
T6-06 2.249 
T6-07 1.244 
T7 T7-01 1.786 T7-02 2.775 
T8 
T8-04 1.467 
T8-05 3.373 
T8-06 1.427 
15min+HTh 
T19 
T19-01 1.093 
T19-02 1.356 
T19-05 0.821 
T19-06 1.643 
T20 
T20-01 14.131 
T20-02 53.469 
T20-04 48.740 
T20-05 62.982 
T20-06 64.761 
15min+STh 
T1 
T1-02 3.836 
T1-03 1.922 
T1-04 0.774 
T1-05 7.073 
T1-06 1.140 
T3 
T3-03 9.793 
T3-04 2.209 
T3-05 11.707 
T3-06 5.526 
T4 
T4-01 1.300 
T4-02 3.158 
T4-03 3.094 
T4-04 1.332 
T4-05 4.386 
T4-06 7.982 
T17 
T17-01 41.124 
T17-02 46.013 
T17-03 31.890 
T17-04 31.842 
T18 
T18-01 0.510 
T18-02 0.646 
T18-03 0.391 
T18-04 0.423 
T18-05 0.423 
T18-06 0.670 
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Table B.4.1. Normalized vimentin and vimentin co-localized with GFAP in the 
ipsilateral spinal cord at days 1 and 7 after sham, 3-minute compression (3min), and 
15-minute compression (15min) (corresponding to studies in Section 6.3.2). 
day group rat image vimentin  (fold over normal) 
vimentin & GFAP 
co-localization  
(fold over normal) 
day 1 
sham 
97 
97-01 1.810 1.351 
97-04 2.095 5.241 
97-05 1.793 1.870 
97-06 1.414 1.835 
152 
152-01 1.990 2.355 
152-02 0.948 1.016 
152-03 1.741 1.974 
152-04 1.346 1.581 
152-05 1.718 1.974 
152-06 1.350 1.720 
153 
153-01 1.579 0.947 
153-03 1.299 0.219 
153-04 1.009 0.935 
153-05 1.980 0.612 
153-06 0.950 0.300 
155 
155-01 3.182 1.443 
155-02 2.393 1.143 
155-03 3.506 1.443 
155-04 2.720 1.050 
155-05 3.716 0.762 
155-06 1.913 1.131 
3min 
95 
95.2-01 3.727 8.450 
95.2-03 2.130 7.676 
95.2-05 2.462 2.355 
95.2-06 3.259 5.887 
148 
148-01 1.483 0.127 
148-03 1.471 0.381 
148-04 1.364 1.027 
148-05 0.326 0.092 
148-06 1.149 0.358 
149 
149-01 1.783 2.135 
149-03 2.126 2.632 
149-05 1.741 2.574 
149-06 2.211 6.695 
150 
150-01 2.695 0.993 
150-02 1.986 2.378 
150-03 2.381 0.831 
150-04 2.892 1.616 
150-06 3.062 2.574 
154 
154-01 2.588 3.209 
154-02 2.493 3.313 
154-03 2.061 2.713 
154-04 1.196 1.062 
154-05 2.484 1.858 
154-06 1.066 1.778 
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 15min 
151 
151-02 2.916 2.286 
151-03 3.315 1.108 
151-04 2.786 1.097 
151-05 2.006 1.189 
151-06 3.329 1.408 
156 
156-01 1.564 4.040 
156-02 1.611 6.926 
156-03 2.280 10.747 
156-04 1.222 4.144 
156-05 1.303 6.937 
156-06 1.439 7.745 
157 
157-01 1.629 1.524 
157-02 1.076 1.801 
157-03 1.840 0.843 
157-04 1.115 1.304 
157-05 1.110 0.681 
157-06 1.015 0.704 
100 
100-01 4.320 13.540 
100-02 2.786 14.267 
100-03 3.806 5.137 
100-04 2.130 1.154 
100-05 3.496 2.401 
100-06 7.901 7.953 
94 
94-02 5.328 0.935 
94-03 4.245 1.743 
94-04 4.041 0.312 
94-05 4.762 2.643 
271 
271-01 0.898 1.847 
271-02 1.546 4.883 
271-03 1.498 1.743 
271-04 1.216 2.747 
271-05 0.630 1.062 
271-06 1.234 2.516 
272 
272-01 1.735 4.409 
272-02 1.648 5.021 
272-03 1.647 5.194 
272-04 1.836 5.137 
272-05 0.760 0.843 
272-06 1.797 6.002 
day 7  sham 
84 
84-02 2.801 4.179 
84-03 2.280 6.937 
84-06 2.409 6.430 
114 
114-01 2.545 4.363 
114-02 2.134 3.405 
114-04 1.554 1.893 
114-05 2.045 1.951 
114-06 1.870 4.687 
115 
115-01 0.800 0.796 
115-04 1.842 2.089 
115-06 1.416 1.697 
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159 
159-01 0.486 0.104 
159-02 0.334 0.069 
159-03 0.353 0.035 
159-04 0.377 0.046 
159-06 0.547 0.139 
J23 
J23-01 1.299 1.050 
J23-02 1.491 2.216 
J23-03 1.078 0.889 
J23-04 1.084 0.427 
J23-05 1.200 1.420 
J23-06 0.456 0.750 
3min 
85 
85-01 6.746 7.480 
85-02 3.198 7.411 
85-03 4.624 - 
85-04 4.823 - 
85-05 2.563 - 
85-06 3.072 - 
87 
87-01 5.398 3.705 
87-04 4.300 5.691 
87-05 2.576 2.574 
87-06 3.084 5.217 
111 
111-01 4.938 8.138 
111-02 3.998 2.747 
111-03 3.601 1.778 
111-04 7.660 5.414 
111-05 4.576 1.039 
111-06 4.825 4.583 
113 
113-01 3.536 10.874 
113-02 2.349 7.134 
113-04 2.636 12.363 
113-05 2.748 2.493 
113-06 1.688 1.524 
15min 
86 
86-01 6.146 26.976 
86-02 4.491 5.864 
86-03 8.432 - 
86-05 7.425 17.372 
86-06 7.611 21.655 
109 
109-01 1.804 1.466 
109-02 1.877 0.750 
109-03 2.942 2.032 
109-04 3.098 2.863 
109-05 2.835 0.600 
110 
110-01 1.733 1.535 
110-03 1.238 2.055 
110-04 1.429 6.545 
110-05 1.260 4.513 
110-06 1.816 6.129 
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112 
112-04 5.494 3.694 
112-06 5.644 2.216 
158 
158-03 1.648 1.131 
158-04 0.638 0.543 
158-05 1.226 1.847 
Note: Images with artefact in the specified fluorescent channel were not included and are indicated with a 
dash (“-”). 
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Table B.4.2. Normalized vimentin and vimentin co-localized with GFAP in the 
ipsilateral spinal cord at day 7 after 15-minute compression (15min) and 
compression treated with hirudin (hir+15min)  
(corresponding to studies in Section 6.3.2). 
group rat image vimentin  (fold over normal) 
vimentin & GFAP co-localization 
(fold over normal) 
15min 
86 
86-01 6.146 26.976 
86-02 4.491 5.864 
86-03 8.432 - 
86-05 7.425 17.372 
86-06 7.611 21.655 
109 
109-01 1.804 1.466 
109-02 1.877 0.750 
109-03 2.942 2.032 
109-04 3.098 2.863 
109-05 2.835 0.600 
110 
110-02 1.733 1.535 
110-03 1.238 2.055 
110-04 1.429 6.545 
110-05 1.260 4.513 
110-06 1.816 6.129 
112 112-04 5.494 3.694 112-06 5.644 2.216 
158 
158-03 1.648 1.131 
158-04 0.638 0.543 
158-05 1.226 1.847 
hir+15min 
 
213 
213-01 4.342 1.919 
213-02 3.961 2.177 
213-04 5.141 2.207 
213-05 5.069 1.069 
213-06 6.094 2.594 
214 
214-01 8.500 3.625 
214-02 9.522 7.706 
214-05 10.109 3.185 
214-06 8.458 7.660 
237 
237-01 6.131 0.675 
237-02 6.350 1.547 
237-03 8.918 1.062 
237-04 3.905 1.608 
238 
238-01 5.888 1.001 
238-02 7.392 4.702 
238-03 4.779 1.107 
238-04 4.416 2.192 
238-05 7.804 1.570 
239 
239-01 9.107 1.069 
239-02 9.161 1.570 
239-03 9.834 - 
239-04 11.028 4.300 
239-05 10.940 3.944 
240 
240-01 7.352 2.207 
240-02 10.930 - 
240-03 9.984 3.436 
240-04 7.163 2.753 
240-05 6.195 - 
240-06 6.015 1.396 
Note: Images with artefact in the specified fluorescent channel were not included and are indicated with a 
dash (“-”). 
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Table B.4.3. Normalized vimentin and vimentin co-localized with GFAP in the 
ipsilateral spinal cord at day 7 after sham and 15-minute compression treated with 
human thrombin (15min+HTh) or salmon thrombin (15min+STh) 
(corresponding to studies in Section 6.3.2). 
group rat image vimentin  (fold over normal) 
vimentin & GFAP 
co-localization 
(fold over normal) 
sham 
84 
84-02 2.801 4.179 
84-03 2.280 6.937 
84-06 2.409 6.430 
114 
114-01 2.545 4.363 
114-02 2.134 3.405 
114-04 1.554 1.893 
114-05 2.045 1.951 
114-06 1.870 4.687 
115 
115-01 0.800 0.796 
115-04 1.842 2.089 
115-06 1.416 1.697 
159 
159-01 0.486 0.104 
159-02 0.334 0.069 
159-03 0.353 0.035 
159-04 0.377 0.046 
159-06 0.547 0.139 
J23 
J23-01 1.299 1.050 
J23-02 1.491 2.216 
J23-03 1.078 0.889 
J23-04 1.084 0.427 
J23-05 1.200 1.420 
J23-06 0.456 0.750 
15min+HTh 
24 
24-01 2.492 2.090 
24-02 3.418 3.425 
24-05 2.546 3.034 
25 
25-02 6.772 5.145 
25-04 4.991 4.048 
25-05 5.015 3.838 
T19 
T19-01 1.912 1.671 
T19-02 2.895 3.481 
T19-03 2.752 2.468 
T19-04 2.440 2.230 
T19-05 2.116 2.447 
T19-06 2.167 1.524 
T20 
T20-01 6.495 6.501 
T20-02 9.871 20.259 
T20-03 7.011 9.913 
T20-05 7.566 6.781 
15min+STh 65 
65-01 11.822 5.033 
65-03 13.110 7.781 
65-04 12.092 3.446 
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66 
66-01 9.493 6.942 
66-02 13.540 5.390 
66-03 10.222 3.062 
66-05 11.972 5.173 
66-06 9.266 4.481 
67 
67-02 6.662 3.572 
67-03 5.966 3.223 
67-04 4.826 2.132 
67-05 4.698 1.258 
T17 
T17-01 4.580 3.866 
T17-02 4.335 4.320 
T17-03 3.870 2.817 
T17-05 5.755 1.363 
T17-06 6.131 2.237 
T1 
T1-01 2.521 2.650 
T1-03 1.696 0.853 
T1-05 3.222 3.677 
T1-06 2.465 1.335 
T3 
T3-01 4.143 1.720 
T3-02 9.719 10.032 
T3-04 7.261 7.396 
T3-05 8.846 10.200 
T3-06 7.379 8.557 
T4 
T4-01 7.357 1.384 
T4-02 8.411 3.160 
T4-04 5.227 1.105 
T4-06 5.696 1.077 
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Table B.4.4. Normalized vimentin co-localized with VWF in the ipsilateral spinal 
cord at days 1 and 7 after sham, 3-minute compression (3min), and 15-minute 
compression (15min) (corresponding to studies in Section 6.3.3). 
day group rat image 
vimentin & VWF 
co-localization 
(fold over normal) 
day 1 
sham 
152 
152-01 1.330 
152-02 0.986 
152-03 0.676 
152-04 1.463 
152-05 2.222 
155 
155-01 1.330 
155-02 1.047 
155-03 1.269 
155-05 1.275 
155-06 0.898 
97 
97-01 0.909 
97-02 0.660 
97-04 0.294 
97-05 0.920 
97-06 0.637 
55 
55-01 0.549 
55-02 1.341 
55-03 0.759 
55-04 1.718 
3min 
150 
150-01 2.139 
150-02 1.812 
150-03 2.167 
150-04 1.862 
150-05 0.704 
150-06 1.203 
154 
154-01 0.914 
154-02 0.853 
154-03 0.898 
154-04 1.230 
154-05 0.676 
154-06 1.169 
148 
148-01 0.865 
148-02 0.698 
149 
149-02 1.507 
149-03 1.607 
149-04 1.241 
95 
95-01 2.233 
95-02 2.472 
95-03 2.278 
95-04 1.535 
95-05 2.239 
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15min 
271 
271-01 1.092 
271-02 1.114 
271-03 0.720 
271-04 1.313 
271-05 1.258 
272 
272-01 0.521 
272-02 0.948 
272-05 0.560 
272-06 0.632 
199 
199-01 1.275 
199-02 1.934 
199-03 1.424 
199-04 1.042 
199-05 1.812 
151 
151-01 2.028 
151-02 2.971 
151-03 2.256 
151-04 1.602 
151-05 1.241 
156 
156-01 1.114 
156-02 0.986 
156-03 0.826 
156-04 0.765 
157 157-02 0.676 
157-03 0.554 
100 
100-02 0.931 
100-03 1.147 
100-04 2.206 
100-05 2.499 
100-06 1.801 
94 
94-01 2.222 
94-02 2.644 
94-03 4.112 
94-04 4.151 
day 7 sham 
J23 
J23-01 1.075 
J23-03 1.308 
J23-04 1.236 
J28 
J28-01 1.386 
J28-03 1.718 
J28-04 1.502 
159 
159-01 0.593 
159-02 1.064 
159-03 0.992 
159-04 0.798 
159-05 0.565 
114 
114-01 2.189 
114-02 1.264 
114-03 2.450 
114-04 2.211 
115 
115-01 1.286 
115-02 1.125 
115-03 1.036 
115-04 1.718 
115-05 1.258 
 329 
 
 
 
84 
84-01 2.899 
84-02 2.677 
84-03 1.701 
84-04 2.056 
84-05 1.945 
3min 
111 
111-01 2.477 
111-02 3.907 
111-06 2.306 
  
113-02 2.389 
113-03 4.700 
113-04 4.450 
85 
85-01 2.588 
85-02 1.690 
85-04 2.760 
85-05 2.123 
85-06 2.184 
87 
87-01 1.430 
87-02 2.948 
87-03 1.951 
87-04 1.336 
87-05 2.494 
87-06 2.644 
15min 
158 
158-01 1.768 
158-03 1.790 
158-04 2.012 
158-05 1.713 
110 
110-01 1.474 
110-02 1.535 
110-03 1.108 
110-04 1.424 
110-05 1.507 
112 
112-01 3.292 
112-02 3.547 
112-04 4.035 
112-05 4.833 
112-06 2.527 
109 109-04 1.136 
109-05 2.172 
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Table B.4.5. Normalized vimentin co-localized with VWF in the ipsilateral spinal 
cord at day 7 after 15-minute compression (15min) and compression treated with 
hirudin (hir+15min) (corresponding to studies in Section 6.3.3). 
group rat image 
vimentin & VWF 
co-localization 
(fold over normal) 
15min 
158 
158-01 1.768 
158-03 1.790 
158-04 2.012 
158-05 1.713 
110 
110-01 1.474 
110-02 1.535 
110-03 1.108 
110-04 1.424 
110-05 1.507 
112 
112-01 3.292 
112-02 3.547 
112-04 4.035 
112-05 4.833 
112-06 2.527 
109 109-04 1.136 
109-05 2.172 
hir+15min 
213 
213-01 2.656 
213-03 6.434 
213-04 2.254 
213-05 3.077 
213-06 2.506 
214 
214-01 5.536 
214-02 2.300 
214-03 6.097 
214-04 4.077 
214-05 7.855 
214-06 5.059 
239 
239-01 7.248 
239-02 6.434 
239-03 4.592 
239-04 1.926 
239-05 8.136 
237 
237-01 2.993 
237-02 4.442 
237-03 3.750 
237-04 2.497 
238 
238-01 6.013 
238-02 5.190 
238-03 7.117 
238-04 3.610 
238-05 0.776 
240 
240-01 4.479 
240-02 3.151 
240-03 4.853 
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Table B.4.6. Normalized vimentin co-localized with VWF in the ipsilateral spinal 
cord at day 7 after sham and 15-minute compression treated with human thrombin 
(15min+HTh) or salmon thrombin (15min+STh)  
(corresponding to studies in Section 6.3.3). 
group rat image 
vimentin & VWF 
co-localization 
(fold over normal) 
sham 
J23 
J23-01 1.075 
J23-03 1.308 
J23-04 1.236 
J28 
J28-01 1.386 
J28-03 1.718 
J28-04 1.502 
159 
159-01 0.593 
159-02 1.064 
159-03 0.992 
159-04 0.798 
159-05 0.565 
114 
114-01 2.189 
114-02 1.264 
114-03 2.450 
114-04 2.211 
115 
115-01 1.286 
115-02 1.125 
115-03 1.036 
115-04 1.718 
115-05 1.258 
84 
84-01 2.899 
84-02 2.677 
84-03 1.701 
84-04 2.056 
84-05 1.945 
15min+HTh 
T19 
T19-01 1.637 
T19-02 2.123 
T19-03 1.450 
T19-04 1.309 
T20 
T20-01 1.543 
T20-02 2.338 
T20-03 1.983 
T20-04 2.815 
24 
24-01 0.842 
24-02 0.505 
24-03 1.001 
24-04 0.552 
25 
25-01 6.789 
25-02 4.947 
25-03 2.113 
25-04 2.357 
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15min+STh 
T17 
T17-01 1.683 
T17-01 2.890 
T17-03 3.180 
T17-04 1.870 
T17-05 3.011 
T18 
T18-01 0.973 
T18-02 2.478 
T18-04 1.749 
T18-05 2.329 
T18-06 1.150 
T1 
T1-01 3.404 
T1-02 1.169 
T1-04 0.982 
T3 
T3-01 2.852 
T3-02 2.431 
T3-03 3.797 
T3-04 2.076 
T3-05 3.741 
T3-06 2.955 
T4 
T4-01 1.983 
T4-03 3.002 
T4-04 2.562 
65 
65-01 4.554 
65-02 6.827 
65-03 6.883 
65-04 4.498 
66 
66-01 3.469 
66-02 2.422 
66-03 1.262 
66-05 2.852 
67 
67-01 4.012 
67-02 4.161 
67-03 3.339 
67-04 4.311 
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Appendix C 
Correlation of Serum Cytokine/Chemokine 
Concentrations & Mechanical Hyperalgesia  
 
 
This appendix summarizes the concentration of 23 pro- and anti-inflammatory 
cytokines and chemokines in the serum from individual rats at day 1 after a variety of 
nerve root insults (painful compression, non-painful compression, inflammatory insult) as 
described in Chapter 3. Blood samples were collected from rats at day 0 (baseline) prior 
to, and at 1 day after, the insult. Serum was isolated via consecutive centrifugation steps 
and processed using a multiplex bead Luminex assay (#L80-01V11S5; Bio-Rad; 
Hercules, CA). The Luminex assay measures the following analytes: interleukin-1 alpha 
(IL-1α), IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-17, IL-18, monocyte 
chemotactic protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-α), erythropoietin 
(EPO), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-
stimulating factor (GM-CSF), keratinocyte-derived chemokines/growth-related oncogene 
(GRO/KC), interferon-gamma (IFN-γ), macrophage colony-stimulating factor (M-CSF), 
macrophage inflammatory protein-3 alpha (MIP-3α), regulated on activation, normal T 
cell expressed and secreted (RANTES) and vascular endothelial growth factor (VEGF). 
The concentration of each analyte in serum samples at day 1 after surgery was 
normalized to the baseline concentration for each rat. Additionally, the normalized 
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concentration of each cytokine was correlated the corresponding withdrawal thresholds 
for each rat at day 1. Similar to the serum data, the withdrawal threshold (g) at day 1 of 
the forepaw ipsilateral to injury was normalized to the withdrawal threshold at day 0 for 
each rat. Please see Chapter 3 for further details (Smith and Winkelstein 2015).  
Table C.1.1 summarizes the normalized serum expression of the 23 analytes at 
day 1 after a sham surgery, a 3-minute compression (3min), and a 15-minute compression 
(15min) (Section 3.3). For each rat in Table C.1.1, the corresponding normalized 
withdrawal threshold for the ipsilateral forepaw at day 1 are also included. Similarly, 
Table C.1.2 summarizes the concentration of the 23 analytes at day 1 after a chromic gut 
inflammatory insult, with normalized data for the corresponding analytes and withdrawal 
thresholds for each rat detailed (Section 3.4).  
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Table C.1.1. Normalized cytokine and chemokine concentrations in the serum and 
corresponding normalized withdrawal thresholds in the ipsilateral forepaw at day 1 
after sham, 3-minute compression (3min), and 15-minute compression (15min) 
(corresponding to studies in Section 3.3). 
analyte group rat [analyte]                    (fold over baseline) 
withdrawal threshold (fold 
over baseline) 
IL-1α 
sham 
124 1.145 1.39 
141 0.918 1.00 
142 1.034 1.00 
3min 
129 0.889 0.86 
127 1.816 0.29 
139 1.181 0.65 
149 1.502 0.50 
15min 
131 1.320 0.15 
125 1.226 0.48 
104 1.532 0.27 
105 1.724 0.15 
136 1.155 0.55 
137 1.504 0.35 
IL-1β 
sham 
124 1.020 1.39 
141 0.845 1.00 
142 1.012 1.00 
3min 
129 0.829 0.86 
127 2.282 0.29 
139 1.119 0.65 
149 1.650 0.50 
15min 
131 1.173 0.15 
125 1.506 0.48 
104 1.465 0.27 
105 1.658 0.15 
136 1.201 0.55 
137 1.596 0.35 
IL-2 
sham 
124 1.045 1.39 
141 0.918 1.00 
142 1.022 1.00 
3min 
129 0.905 0.86 
127 1.525 0.29 
139 1.146 0.65 
149 1.368 0.50 
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15min 
131 0.923 0.15 
125 1.081 0.48 
104 1.260 0.27 
105 1.827 0.15 
136 1.062 0.55 
137 1.352 0.35 
IL-4 
sham 
124 1.040 1.39 
141 0.925 1.00 
142 0.992 1.00 
3min 
129 0.814 0.86 
127 1.638 0.29 
139 1.121 0.65 
149 1.659 0.50 
15min 
131 0.970 0.15 
125 1.097 0.48 
104 1.429 0.27 
105 1.710 0.15 
136 1.110 0.55 
137 1.505 0.35 
IL-5 
sham 
124 0.991 1.39 
141 0.965 1.00 
142 1.033 1.00 
3min 
129 0.899 0.86 
127 1.175 0.29 
139 1.023 0.65 
149 1.261 0.50 
15min 
131 1.020 0.15 
125 0.998 0.48 
104 1.280 0.27 
105 1.488 0.15 
136 1.026 0.55 
137 1.213 0.35 
IL-6 
sham 
124 1.191 1.39 
141 0.992 1.00 
142 1.079 1.00 
3min 
129 0.937 0.86 
127 1.936 0.29 
139 1.344 0.65 
149 1.837 0.50 
15min 
131 2.119 0.15 
125 1.495 0.48 
104 1.072 0.27 
105 1.314 0.15 
136 1.294 0.55 
137 1.716 0.35 
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IL-7 
sham 
124 0.773 1.39 
141 0.862 1.00 
142 0.581 1.00 
3min 
129 0.646 0.86 
127 1.474 0.29 
139 0.983 0.65 
149 0.765 0.50 
15min 
131 1.139 0.15 
125 1.071 0.48 
104 1.581 0.27 
105 1.627 0.15 
136 1.015 0.55 
137 1.413 0.35 
IL-10 
sham 
124 0.907 1.39 
141 0.843 1.00 
142 0.968 1.00 
3min 
129 0.858 0.86 
127 1.247 0.29 
139 1.065 0.65 
149 1.257 0.50 
15min 
131 0.875 0.15 
125 1.113 0.48 
104 1.330 0.27 
105 1.704 0.15 
136 1.007 0.55 
137 1.309 0.35 
IL-12 
sham 
124 1.032 1.39 
141 0.840 1.00 
142 1.109 1.00 
3min 
129 0.864 0.86 
127 1.910 0.29 
139 1.204 0.65 
149 1.682 0.50 
15min 
131 1.207 0.15 
125 1.329 0.48 
104 1.700 0.27 
105 1.868 0.15 
136 1.304 0.55 
137 1.652 0.35 
IL-13 sham 
124 1.042 1.39 
141 0.868 1.00 
142 1.056 1.00 
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3min 
129 0.876 0.86 
127 2.114 0.29 
139 1.079 0.65 
149 1.485 0.50 
15min 
131 1.174 0.15 
125 1.476 0.48 
104 1.594 0.27 
105 1.748 0.15 
136 1.165 0.55 
137 1.481 0.35 
IL-17 
sham 
124 1.046 1.39 
141 0.859 1.00 
142 0.991 1.00 
3min 
129 0.885 0.86 
127 1.423 0.29 
139 0.984 0.65 
149 1.297 0.50 
15min 
131 1.061 0.15 
125 1.135 0.48 
104 1.346 0.27 
105 1.685 0.15 
136 1.015 0.55 
137 1.322 0.35 
IL-18 
sham 
124 1.177 1.39 
141 0.827 1.00 
142 1.013 1.00 
3min 
129 0.917 0.86 
127 1.589 0.29 
139 0.854 0.65 
149 1.616 0.50 
15min 
131 0.933 0.15 
125 1.211 0.48 
104 1.322 0.27 
105 2.352 0.15 
136 0.967 0.55 
137 1.508 0.35 
MCP-1 
sham 
124 1.376 1.39 
141 1.576 1.00 
142 1.521 1.00 
3min 
129 1.292 0.86 
127 1.661 0.29 
139 1.295 0.65 
149 2.212 0.50 
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15min 
131 1.720 0.15 
125 1.379 0.48 
104 1.323 0.27 
105 1.864 0.15 
136 1.576 0.55 
137 1.962 0.35 
TNF-α 
sham 
124 1.325 1.39 
141 0.943 1.00 
142 1.110 1.00 
3min 
129 0.968 0.86 
127 1.978 0.29 
139 1.206 0.65 
149 1.669 0.50 
15min 
131 1.799 0.15 
125 1.752 0.48 
104 1.235 0.27 
105 2.121 0.15 
136 1.414 0.55 
137 1.674 0.35 
EPO 
sham 
124 1.099 1.39 
141 0.844 1.00 
142 1.017 1.00 
3min 
129 0.911 0.86 
127 1.552 0.29 
139 0.908 0.65 
149 1.525 0.50 
15min 
131 1.010 0.15 
125 1.321 0.48 
104 1.224 0.27 
105 2.207 0.15 
136 1.012 0.55 
137 1.450 0.35 
G-CSF 
sham 
124 1.191 1.39 
141 0.945 1.00 
142 1.018 1.00 
3min 
129 0.918 0.86 
127 1.940 0.29 
139 1.258 0.65 
149 2.059 0.50 
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15min 
131 1.471 0.15 
125 1.521 0.48 
104 1.336 0.27 
105 1.854 0.15 
136 1.216 0.55 
137 1.585 0.35 
GM-CSF 
sham 
124 1.709 1.39 
141 0.856 1.00 
142 0.993 1.00 
3min 
129 0.932 0.86 
127 3.931 0.29 
139 1.076 0.65 
149 1.653 0.50 
15min 
131 1.474 0.15 
125 2.208 0.48 
104 1.583 0.27 
105 1.955 0.15 
136 1.078 0.55 
137 1.599 0.35 
GRO/KC 
sham 
124 0.965 1.39 
141 0.972 1.00 
142 0.767 1.00 
3min 
129 1.064 0.86 
127 1.374 0.29 
139 1.940 0.65 
149 0.771 0.50 
15min 
131 1.072 0.15 
125 1.181 0.48 
104 2.262 0.27 
105 1.302 0.15 
136 1.885 0.55 
137 2.935 0.35 
IFN-γ 
sham 
124 1.137 1.39 
141 0.913 1.00 
142 1.025 1.00 
3min 
129 0.953 0.86 
127 1.852 0.29 
139 1.227 0.65 
149 1.674 0.50 
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15min 
131 1.992 0.15 
125 1.339 0.48 
104 1.035 0.27 
105 1.290 0.15 
136 1.257 0.55 
137 1.494 0.35 
M-CSF 
sham 
124 0.949 1.39 
141 1.059 1.00 
142 1.088 1.00 
3min 
129 0.929 0.86 
127 1.134 0.29 
139 1.037 0.65 
149 1.060 0.50 
15min 
131 1.076 0.15 
125 1.079 0.48 
104 1.237 0.27 
105 1.198 0.15 
136 0.994 0.55 
137 1.454 0.35 
MIP-3α 
sham 
124 1.052 1.39 
141 0.923 1.00 
142 1.022 1.00 
3min 
129 0.888 0.86 
127 1.427 0.29 
139 1.147 0.65 
149 1.395 0.50 
15min 
131 0.994 0.15 
125 1.109 0.48 
104 1.380 0.27 
105 1.560 0.15 
136 1.096 0.55 
137 1.363 0.35 
RANTES 
sham 
124 0.912 1.39 
141 0.961 1.00 
142 0.951 1.00 
3min 
129 1.027 0.86 
127 1.072 0.29 
139 0.842 0.65 
149 1.092 0.50 
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15min 
131 0.975 0.15 
125 1.070 0.48 
104 1.337 0.27 
105 0.669 0.15 
136 1.047 0.55 
137 1.471 0.35 
VEGF 
sham 
124 1.017 1.39 
141 0.950 1.00 
142 1.091 1.00 
3min 
129 0.818 0.86 
127 1.471 0.29 
139 1.084 0.65 
149 1.385 0.50 
15min 
131 1.073 0.15 
125 1.233 0.48 
104 1.361 0.27 
105 1.529 0.15 
136 1.221 0.55 
137 1.567 0.35 
 
 
  
 343 
 
Table C.1.2. Normalized cytokine and chemokine concentrations in the serum and 
corresponding normalized withdrawal thresholds in the ipsilateral forepaw at day 1 
after an inflammatory chromic gut insult (corresponding to studies in Section 3.4). 
analyte rat [analyte]                    (fold over baseline) 
withdrawal threshold  
(fold over baseline) 
IL-1α 
164 0.709 0.41 
165 1.417 0.33 
166 1.414 0.58 
182 0.955 0.79 
183 1.540 0.39 
184 1.338 0.63 
185 2.199 0.59 
IL-1β 
164 0.844 0.41 
165 1.232 0.33 
166 1.773 0.58 
182 1.057 0.79 
183 1.829 0.39 
184 1.615 0.63 
185 2.985 0.59 
IL-2 
164 0.861 0.41 
165 0.884 0.33 
166 1.227 0.58 
182 0.944 0.79 
183 1.343 0.39 
184 1.318 0.63 
185 1.690 0.59 
IL-4 
164 0.825 0.41 
165 1.348 0.33 
166 1.186 0.58 
182 0.915 0.79 
183 1.471 0.39 
184 1.376 0.63 
185 2.459 0.59 
IL-5 
164 1.028 0.41 
165 1.044 0.33 
166 1.250 0.58 
182 0.949 0.79 
183 1.155 0.39 
184 1.105 0.63 
185 1.324 0.59 
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IL-6 
164 0.875 0.41 
165 1.509 0.33 
166 1.730 0.58 
182 1.002 0.79 
183 1.913 0.39 
184 1.428 0.63 
185 3.118 0.59 
IL-7 
164 0.828 0.41 
165 1.223 0.33 
166 1.285 0.58 
182 0.876 0.79 
183 1.434 0.39 
184 1.286 0.63 
185 1.765 0.59 
IL-10 
164 0.990 0.41 
165 1.052 0.33 
166 1.237 0.58 
182 0.928 0.79 
183 1.223 0.39 
184 1.200 0.63 
185 1.830 0.59 
IL-12 
164 0.882 0.41 
165 1.042 0.33 
166 1.095 0.58 
182 1.012 0.79 
183 1.632 0.39 
184 1.408 0.63 
185 2.289 0.59 
IL-13 
164 0.818 0.41 
165 1.413 0.33 
166 1.655 0.58 
182 1.112 0.79 
183 1.829 0.39 
184 1.659 0.63 
185 2.750 0.59 
IL-17 
164 1.046 0.41 
165 1.623 0.33 
166 1.296 0.58 
182 0.966 0.79 
183 1.230 0.39 
184 1.123 0.63 
185 1.662 0.59 
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IL-18 
164 0.692 0.41 
165 1.351 0.33 
166 1.236 0.58 
182 0.953 0.79 
183 1.377 0.39 
184 1.301 0.63 
185 1.671 0.59 
MCP-1 
164 1.163 0.41 
165 1.380 0.33 
166 1.621 0.58 
182 1.368 0.79 
183 1.408 0.39 
184 1.796 0.63 
185 1.694 0.59 
TNF-α 
164 0.639 0.41 
165 1.347 0.33 
166 2.037 0.58 
182 1.235 0.79 
183 1.900 0.39 
184 1.678 0.63 
185 3.076 0.59 
EPO 
164 0.893 0.41 
165 0.832 0.33 
166 1.229 0.58 
182 1.025 0.79 
183 1.493 0.39 
184 1.345 0.63 
185 1.728 0.59 
G-CSF 
164 0.899 0.41 
165 1.204 0.33 
166 1.658 0.58 
182 1.051 0.79 
183 1.905 0.39 
184 1.456 0.63 
185 3.205 0.59 
GM-CSF 
164 - 0.41 
165 - 0.33 
166 - 0.58 
182 1.044 0.79 
183 2.296 0.39 
184 1.934 0.63 
185 3.980 0.59 
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GRO/KC 
164 0.783 0.41 
165 1.367 0.33 
166 1.364 0.58 
182 1.024 0.79 
183 1.332 0.39 
184 1.017 0.63 
185 1.443 0.59 
IFN-γ 
164 0.874 0.41 
165 1.419 0.33 
166 1.385 0.58 
182 0.990 0.79 
183 1.637 0.39 
184 1.334 0.63 
185 2.565 0.59 
M-CSF 
164 1.016 0.41 
165 1.542 0.33 
166 1.723 0.58 
182 1.160 0.79 
183 1.355 0.39 
184 1.295 0.63 
185 1.532 0.59 
MIP-3α 
164 0.992 0.41 
165 1.006 0.33 
166 1.070 0.58 
182 1.047 0.79 
183 1.248 0.39 
184 1.292 0.63 
185 1.609 0.59 
RANTES 
164 1.047 0.41 
165 1.082 0.33 
166 1.364 0.58 
182 0.894 0.79 
183 0.944 0.39 
184 0.949 0.63 
185 1.153 0.59 
VEGF 
164 0.913 0.41 
165 1.119 0.33 
166 1.603 0.58 
182 0.950 0.79 
183 1.496 0.39 
184 1.441 0.63 
185 2.076 0.59 
Note: Serum samples that did not produce a positive reading (were undetected) for an analyte are indicated 
with a dash (“-”). 
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Appendix D 
HUVEC Microchannel Permeability 
 
 
 This appendix contains the data from the human umbilical vein endothelial cell 
(HUVEC) microchannel experiment presented in Chapter 5. HUVECs were seeded in the 
inner lumen (400µm diameter) of a microfluidic device filled with collagen. Those 
luminal HUVEC monolayers form vessels that are impermeable to transluminal flow 
when flow is applied at a rate of 5µl/ml (Galie et al. 2014). In order to determine the 
effects of salmon thrombin on vessel permeability, initially impermeable channels were 
stimulated with TNF-α (100ng/ml) to induce barrier opening. Separate channels were 
treated with TNF-α with salmon thrombin (1U/ml) (TNF-α+STh) or with human 
thrombin (1U/ml) (TNF-α +HTh). In order to track endothelial barrier breakdown, FITC-
labeled dextran was added to the channel flow and its diffusion into the surrounding 
collagen was tracked for 10 minutes, at 1 minute intervals. Detailed methods for the 
microfluidic setup and experiments are provided in Section 5.3.1.3. The diameter of the 
dextran front at each minute was normalized to the diameter of the inner lumen of the 
channel to obtain values for the normalized dextran diameter.  
 Table D.1 contains the normalized dextran diameter for each group in each trail 
(n=3 each). These experiments were performed in conditions containing serum, as well as 
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in serum free conditions, in which the cultures were starved of serum for 4 hours prior to 
testing. Using serum and serum-free conditions was done in order to determine if salmon 
thrombin acts to protect vasculature stability directly through an endothelial receptor or 
indirectly through a serum component. Additionally, the slope of the change in the 
dextran front over time produced by each test group in each of the three trials was then 
normalized to the slope produced by TNF-α alone with serum. The normalized dextran 
flux data are presented in Section 5.3.2 and included in Table D.2 below.  
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Table D.1. Normalized dextran front in HUVEC microchannels exposed to TNF-α 
and TNF-α with salmon thrombin (TNF-α+STh) or human thrombin (TNF-α+HTh) 
in serum containing or serum free conditions  
(corresponding to studies in Section 5.3.2). 
 
  
dextran diameter 
(fold over channel diameter) 
serum group time (minute) trial 1 trail 2 trial 3 
serum 
TNF-α 
1 0.0659 0.0000 0.4304 
2 0.0659 0.1328 0.4683 
3 0.0550 0.3265 0.5151 
4 0.2528 0.4694 0.5385 
5 0.4067 0.6428 0.6187 
6 0.5935 0.7245 0.6388 
7 0.8237 0.8877 0.6889 
8 1.0440 1.0613 0.7090 
9 1.2528 1.1328 0.7592 
10 1.4506 1.1225 0.7859 
TNF-α+STh 
1 0.0326 -0.1353 -0.0269 
2 0.0364 0.0088 -0.0194 
3 0.1087 0.0754 -0.0194 
4 0.1521 0.1197 -0.0222 
5 0.2609 0.1974 -0.0110 
6 0.3478 0.2195 0.0085 
7 0.4574 0.2638 0.0169 
8 0.5000 0.2860 0.0253 
9 0.5869 0.2860 0.0421 
10 0.7501 0.3303 0.0587 
TNF-α+HTh 
1 -0.1958 0.2549 0.0735 
2 -0.0549 0.3739 0.2631 
3 0.0566 0.5006 0.4262 
4 0.1308 0.6521 0.6051 
5 0.2378 0.7471 0.7367 
6 0.3198 0.8503 0.9000 
7 0.3876 0.9592 1.0155 
8 0.4594 1.0177 1.1313 
9 0.5079 1.0774 1.2260 
10 0.5678 1.1582 1.3628 
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serum free 
TNF-α 
1 0.2883 -0.1395 -0.0325 
2 0.4094 0.0657 0.1902 
3 0.5910 0.1945 0.3491 
4 0.8040 0.2542 0.4513 
5 0.8040 0.3303 0.5662 
6 1.0475 0.4058 0.6864 
7 1.1515 0.5329 0.7938 
8 1.2134 0.5676 0.8598 
9 1.4255 0.6833 0.9111 
10 1.5455 0.7056 0.9495 
TNF-α+STh 
1 0.1247 0.1173 -0.1395 
2 0.2565 0.3285 0.0657 
3 0.4040 0.4761 0.1945 
4 0.5172 0.6393 0.2542 
5 0.5818 0.7370 0.3303 
6 0.6745 0.8241 0.4058 
7 0.7757 0.8707 0.5329 
8 0.8332 0.9720 0.5676 
9 0.8709 1.0124 0.6833 
10 - 1.0761 0.7056 
TNF-α+HTh 
1 0.3582 0.3525 1.8541 
2 0.5124 0.4611 2.4107 
3 0.6417 0.6189 2.6414 
4 0.7647 0.7147 2.8820 
5 0.8746 0.8030 3.0611 
6 0.9428 0.8724 3.0752 
7 1.1064 0.8891 - 
8 1.1476 0.9719 - 
9 1.2658 1.0011 - 
10 1.4129 1.0378 - 
Note: Two trials were disrupted due to microchannel failure prior to the 10 minute endpoint. In those cases 
values are represented as a dash (“-”). 
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Table D.2. Slope of the dextran front over time, normalized to the slope produced in 
cultures exposed to serum and TNF-α, in HUVEC channels exposed to TNF-α and 
TNF-α with salmon thrombin (TNF-α+STh) or human thrombin (TNF-α+HTh) in 
serum containing or serum free conditions  
(corresponding to studies in Section 5.3.2). 
serum group trial dextran flux  (fold over TNF-α with serum) 
serum 
TNF-α 
trail 1 1.4835 
trial 2 0.9528 
trial 3 0.5637 
TNF-α+STh 
trail 1 0.4806 
trial 2 0.3454 
trial 3 0.2339 
TNF-α+HTh 
trail 1 1.2665 
trial 2 1.3174 
trial 3 1.8391 
serum 
TNF-α 
trail 1 1.3737 
trial 2 1.2855 
trial 3 1.3273 
TNF-α+STh 
trail 1 0.9898 
trial 2 1.0512 
trial 3 1.2192 
TNF-α+HTh 
trail 1 0.8591 
trial 2 0.8181 
trial 3 1.6377 
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Appendix E 
Fluorogenic Synthetic Peptide Cleavage 
 
 
 This appendix presents data for studies presented in Chapter 5 that measured and 
compared the rate of cleavage of various fluorogenic substrates produced by salmon 
thrombin (STh) and human thrombin (HTh). The ability of salmon and human thrombin 
to produce activated protein C (APC) was investigated using solutions of protein C in its 
zymogen form and the fluorogenic substrate for APC (Leu-Ser-Thr-Arg; Sigma Aldrich; 
St. Louis, MO) with either species of thrombin. The coupled reaction produced in those 
solutions is thrombin activating protein C into APC and then APC activating the 
substrate. Since thrombin is itself an enzyme and may also activate the fluorogenic APC 
substrate, the rates of substrate activation produced by thrombin alone was subtracted 
from the rate produced in solutions containing the respective species of thrombin with 
protein C (see Section 5.3.1.4 for more details on methods). The fluorescent signals 
generated over 290 seconds produced by salmon thrombin, with protein C (STh+PC) or 
without (STh), and human thrombin, with protein C (HTh+PC) or without (HTh), in each 
of three trials are provided in Table E.1. The fluorescent intensity over time was taken as 
the rate of APC substrate cleavage for each trial. Table E.2 provides the rates of APC 
 353 
 
substrate cleavage produces by STh+PC and HTh+PC, as well as those rates corrected by 
subtracting the respective rates of substrate cleavage generated by STh or HTh alone.  
 In order to directly compare the rates of activation by salmon thrombin (STh) and 
human thrombin (HTh) on protease-activated receptor-1 (PAR1), PAR3 and PAR4, three 
fluorogenic peptides were designed (Abden; San Diego, CA) mapping the cleavage sites 
of those receptors (see Section 5.4.1.5). Additionally a fluorescence resonance energy 
transfer (FRET) peptide mapping the PAR1 cleavage site and containing the hirudin-like 
sequence (PAR1-hir) was designed and tested, because mammalian thrombin has the 
highest affinity for PAR1 due to that hirudin-like sequence on the extracellular domain of 
PAR1 (Jaques et al. 2000, Seeley et al. 2003). In all cases, salmon or human thrombin 
(1U/ml) was added to the substrate and fluorescence was measured over time. The slopes 
of the fluorescent signal intensity over time are provided in Table E.3.   
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Table E.1. Fluorescent signal generated in solutions containing a fluorogenic 
substrate for APC with salmon thrombin and protein C (STh+PC), human 
thrombin and protein C (HTh+PC), or either species of thrombin without protein C 
(corresponding to studies in Section 5.3.2). 
 
 
 
fluorescence (generated by APC substrate cleavage) 
trial time (seconds) STh+PC HTh+PC STh HTh 
trial 1 
0 0 0 0 0 
10 395 153 129 152 
20 680 306 231 327 
30 1019 430 325 483 
40 1358 593 458 633 
50 1702 744 544 815 
60 2019 902 665 975 
70 2407 1050 947 1198 
80 2693 1233 868 1379 
90 3015 1330 989 1489 
100 3359 1508 1134 1687 
110 3712 1676 1266 1925 
120 4057 1812 1395 2069 
130 4366 2011 1558 2313 
140 4704 2127 1650 2400 
150 5069 2284 1801 2659 
160 5399 2429 1940 2771 
170 5812 2585 2042 2951 
180 6097 2780 2189 3139 
190 6409 2923 2357 3300 
200 6774 3091 2493 3493 
210 7081 3288 2659 3646 
220 7467 3434 2805 3836 
230 7792 3584 2977 4013 
240 8190 3753 3144 4210 
250 8490 3931 3305 4332 
260 8834 4104 3493 4623 
270 9245 4238 3706 4770 
280 9543 4400 3807 4985 
290 9847 4595 4006 5113 
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trial time (seconds) STh+PC HTh+PC STh HTh 
trial 2 
0 0 0 0 0 
10 378 222 277 166 
20 743 366 485 272 
30 1076 546 786 416 
40 1502 690 1031 537 
50 1889 915 1259 686 
60 2281 1077 1478 821 
70 2649 1272 1714 956 
80 3065 1467 1985 1117 
90 3449 1583 2222 1247 
100 3821 1805 2428 1377 
110 4234 1987 2697 1529 
120 4584 2142 2953 1680 
130 5014 2328 3124 1814 
140 5382 2508 3380 1929 
150 5838 2691 3609 2117 
160 6224 2892 3848 2286 
170 6624 3058 4052 2444 
180 7010 3269 4322 2620 
190 7469 3381 4515 2743 
200 7841 3569 4740 2901 
210 8243 3802 4994 3076 
220 8717 3910 5206 3219 
230 9225 4164 5474 3411 
240 9573 4323 5765 3627 
250 10048 4480 5961 3756 
260 10433 4672 6210 3920 
270 10831 4891 6447 4135 
280 11076 4994 6673 4230 
290 11563 5164 6890 4434 
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trial time (seconds) STh+PC HTh+PC STh HTh 
trial 3  
0 0 0 0 0 
10 323 222 323 222 
20 677 430 677 430 
30 1024 634 1024 634 
40 1358 818 1358 818 
50 1692 937 1692 937 
60 2036 1166 2036 1166 
70 2389 1355 2389 1355 
80 2759 1517 2759 1517 
90 3129 1733 3129 1733 
100 3457 1908 3457 1908 
110 3813 2097 3813 2097 
120 4158 2296 4158 2296 
130 4445 2451 4445 2451 
140 4727 2621 4727 2621 
150 5078 2860 5078 2860 
160 5503 3099 5503 3099 
170 5760 3236 5760 3236 
180 6079 3443 6079 3443 
190 6492 3650 6492 3650 
200 6785 3837 6785 3837 
210 7079 4015 7079 4015 
220 7457 4174 7457 4174 
230 7831 4429 7831 4429 
240 8112 4564 8112 4564 
250 8470 4753 8470 4753 
260 8831 4963 8831 4963 
270 9217 5186 9217 5186 
280 9532 5374 9532 5374 
290 9860 5509 9860 5509 
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Table E.2. APC generation by salmon thrombin (STh) and human thrombin (HTh) 
(corresponding to studies in Section 5.3.2). 
 
group trial 
slope 
(generated by 
thrombin with PC) 
slope  
(slope generated by 
thrombin alone subtracted) 
STh 
trial 1 33.918 18.657 
trial 2 40.796 17.171 
trial 3 34.293 19.032 
HTh 
trial 1 19.004 1.019 
trail 2 17.832 1.990 
trail 3 16.222 -1.764 
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Table E.3. Slope of fluorescence over time produced by salmon thrombin (STh) and 
human thrombin (HTh) using fluorogenic peptides for PAR1, PAR1-hir, PAR3, and 
PAR4 (corresponding to studies in Section 5.4.2). 
 
peptide group trial fluorescence-time slope  
PAR1 
STh trial 1 0.0328 
trial 2 0.0311 
HTh 
trial 1 0.1122 
trial 2 0.1118 
PAR1-hir 
STh 
trial 1 0.0106 
trial 2 0.0101 
trial 3 0.0104 
trial 4 0.0120 
HTh 
trial 1 0.0296 
trial 2 0.0269 
trial 3 0.0295 
trial 4 0.0264 
PAR3 
STh trial 1 0.0001 
trial 2 0.0008 
HTh 
trial 1 0.0001 
trial 2 0.0006 
PAR4 
STh trial 1 -0.0003 
trial 2 -0.0008 
HTh 
trial 1 0.0001 
trial 2 -0.0005 
 
 
  
 359 
 
 
Appendix F 
Mixed Cortical Culture mRNA for  
IL-1β & TNF-α 
 
 
 This appendix contains the gene expression data for the transcription of IL-1β and 
TNF-α by mixed astrocyte and neuron cortical cultures after their stimulation with 
salmon or human thrombin (studies are presented in Chapter 5). Primary cultures of 
dissociated rat brain cortices were treated for 4 hours with human thrombin (HTh, 1U/ml) 
or salmon thrombin (STh, 1U/ml) and RNA was harvested. Four separate trials were run, 
each using cultures from a different brain dissociation; two untreated controls (UT) were 
included from each dissociation for consistency with normalization. Using reverse 
transcriptase real time-polymerase chain reaction (RT-PCR), the expression of the genes 
for IL-1β (Fwd: 5’-CAC CTC TCA AGC AGA GCA CAG-3’, Rev: 5’-GGG TTC CAT 
GGT GAA GTC AAC-3’) and TNF-α (Fwd: 5’-ATC ATC TTC TCA AAA CTC GAG 
TGA CAA-3’, Rev: 5’-CTG CTC CTC TGC TTG GT-3’) were measured and compared 
to levels of the housekeeping gene, cyclophilin-A (Fwd: 5’-TAT CTG CAC TGC CAA 
GAC TGA GTG-3’, Rev: 5’-CTT CTT GCT GGT CTT GCC ATT CC-3’). Expression 
of the respective genes in untreated cultures (UT) using the ∆∆Ct method (Rothman et. 
Al 2009). For more details on RNA harvest, reverse transcription, RT-PCR and 
subsequent analysis, please see Section 5.4.1.4. The normalized increase in IL-1β mRNA 
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is summarized in Table F.1 and data for the normalized increase in TNF-α mRNA is 
presented in Table F.2. 
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Table F.1. Fold increase in IL-1β mRNA produced by mixed cultures treated with 
salmon thrombin (STh) or human thrombin (HTh) normalized to production in 
untreated cultures (UT) (corresponding to studies in Section 5.4.2). 
 
trial group IL-1β mRNA  (fold increase over UT) 
trial 7  
UT 1.509 
0.491 
HTh 7.010 
STh 0.713 
trial 8 
UT 0.949 
1.051 
HTh 5.544 
STh 1.284 
trial 10 
UT 1.092 
0.908 
HTh 5.428 
STh 1.913 
trial 11 
UT 1.145 
0.855 
HTh 
9.270 
7.705 
STh 1.343 
7.556 
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Table F.2. Fold increase in TNF-α mRNA produced by mixed cultures treated with 
salmon thrombin (STh) or human thrombin (HTh) normalized to production in 
untreated cultures (UT) (corresponding to studies in Section 5.4.2). 
 
trial group TNF-α mRNA  (fold increase over UT) 
trial 7  
UT 0.870 
1.130 
HTh 6.954 
STh 1.378 
trial 8 
UT 0.671 
1.329 
HTh 5.085 
STh 1.213 
trial 10 
UT 0.968 
1.032 
HTh 5.892 
STh 1.511 
trial 11 
UT 0.967 
1.033 
HTh 
9.363 
6.918 
STh 1.055 
7.381 
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Appendix G 
Matlab Codes for Densitometry & Co-localization 
 
 
The Matlab code that was used to quantify the percent positive pixels in 
fluorescently labeled tissue sections throughout this thesis and summarized in Appendix 
B is provided here (Section G.1). Prior to running this script, the threshold (0-250) is 
defined and entered as “pos_thresh” in the code. Once the script is finished computing 
the percent positive pixels for all images, typing “Iname” into the command window will 
return a list of all the images that were processed. Entering “percpos” into the command 
window will return the percent positive pixels that were calculated for the corresponding 
images returned by the Iname command.  
Also included in this appendix is the Matlab code that was used to quantify the 
percent of pixels within an image that co-localized between two different fluorescent 
labels. Prior to running that script, a threshold (0-250) is separately defined for each 
fluorescent label and entered as “red_thresh” and “green_thresh” in the code. Once the 
script is finished computing the percent positive pixels for all images, typing “Iname” 
into the command window will return a list of all of the images that were processed. 
Entering “percpos” into the command window returns the percent positive pixels from 
the red channel that were calculated for the corresponding images returned by the Iname 
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command; entering “percpos_green” will do the same for the green channel. Typing 
“perc_co” into the command window will return a list of the percent of co-localized red 
and green positive pixels calculated for the corresponding images returned by the Iname 
command. To run either the densitometry or the co-localization script, the user must save 
the code and the images in the same file directory. 
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Section G.1. Matlab Code for Densitometry 
%% This script was written to calculate and visualize percent positive 
%% pixels per image. To run the file, u want to create an excel file 
that  
%% has the detailed information abt the images to be analyzed, then 
number 
%% those images with a common name that has an ordered numerical (1, 
2...)  
%% ending. NOTE: for the excel file, please have the following columns 
(in 
%% order): rat #, tissue type, injury type, image no., threshold, raw 
%% results, normalized results. Number normals last. 
  
%% requires MATLAB 7.0 (or higher) and imaging toolbox. 
  
%% Written by Ling Dong (modified from K. Quinn) on Feb 2, 2009. 
%% Modified by Kristen Nicholson December 2009 
  
clear all; 
close all; 
  
D = dir('*.tif');%specify which images to analyze (* = wildcard 
character) 
  
for k=1:length(D); 
     
    %reads file in 
    file=D(k).name; 
    
    % Load the image 
    imag_orig = imread(file);  
    % converts to grayscale 
    imag_orig = imag_orig(:,:,1);%grab the red labeled image 
%     imag_orig = imag_orig(:,:,2);%grab the green labeled image 
    imag_orig = rgb2gray(imag_orig; 
    imag = imag_orig; 
    invImag = 255-imag; 
    imag = invImag; 
     
    %calc number of pixels 
    [a b]=size(imag); 
    tsize=a*b;     
    low=double(min(imag(:))); 
    high=double(max(imag(:))); 
    whiteSpace = 0.996*high;  
    pos_thresh = 215; %input based on normal run, remember for DAB 
staining 
    % higher value corresponds to a higher +ive threshold. 
  
    backg=sum(sum(imag>whiteSpace)); 
    posp=sum(sum(imag<pos_thresh)); 
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    %calc percent of positive pixels in tissue 
    percpos(k)=  posp/(tsize-backg); 
    tpost(k) = posp; 
    Iname(k) = {file}; 
  
    %map out pos and neg pixels 
    pmap=(imag<pos_thresh); 
    nmap=(imag>whiteSpace); 
  
    %   make figure for each image, if you are processing a bunch of 
images, you 
    %   may want to comment this part out  
  
    %make positive pixels more green, and background pixels less blue 
    imag1(:,:,1)=double(imag)/255; 
    imag1(:,:,2)=(1-pmap).*double(imag)/255+pmap; 
    imag1(:,:,3)=double(imag)/255.*(1-nmap); 
     
  
    h = figure; 
    subplot(3,1,3); 
    subimage(imag); 
    axis image 
    axis off 
    subplot(3,1,2); 
    subimage(imag1); 
    image(imag1); 
    axis image 
    axis off 
    colormap gray 
    subplot(3,1,1); 
    subimage(imag_orig) 
    axis image 
    axis off 
    drawnow 
     
     
    clear imag imag1 
end 
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Section G.2. Matlab Code for Co-localization 
%% This script was written to calculate and visualize percent positive 
%% pixels per image. To run the file, u want to create an excel file 
that  
%% has the detailed information abt the images to be analyzed, then 
number 
%% those images with a common name that has an ordered numerical (1, 
2...)  
%% ending. NOTE: for the excel file, please have the following columns 
(in 
%% order): rat #, tissue type, injury type, image no., threshold, raw 
%% results, normalized results. Number normals last. 
  
%% requires MATLAB 7.0 (or higher) and imaging toolbox. 
  
%% Written by Ling Dong (modified from K. Quinn) on Feb 2, 2009. 
  
clear all; 
close all; 
clf; 
  
D = dir('*.tif'); %common prefix for all images 
%name the excel output filecl; 
% IPfname = 'PAR1-GFAP_colocalization_8-25-11(2)'; 
% OPfile = strcat(IPfname, '.xls'); 
% fid = fopen(OPfile, 'w'); 
  
red_thresh = 185; %input based on normal run 
green_thresh = 180; 
% higher value corresponds to more positive pixels 
h1 = waitbar(0,'Please wait...'); 
  
for k=1:length(D); 
    %reads file in 
    file=D(k).name; 
    
    % Load the image 
    imag_orig = imread(file);  
    imag_red = imag_orig(:,:,1);%grab the red labeled image 
    imag_green = imag_orig(:,:,2);%grab the green labeled image 
         
    %take the inverse of the image 
    imag_red = uint8(-double(imag_red) + 255); 
    imag_green = uint8(-double(imag_green) + 255); 
         
    %calc number of pixels 
    [a b]=size(imag_red); 
    tsize=a*b;     
    low=double(min(imag_red(:))); 
    high=double(max(imag_red(:))); 
    whiteSpace = 0.99*high;  
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    backg=sum(sum(imag_red > whiteSpace)); 
    posp=sum(sum(imag_red < red_thresh)); 
    %calc percent of positive pixels in tissue for red signal 
    percpos(k)=  posp/(tsize-backg); 
     
    backg_green=sum(sum(imag_green > whiteSpace)); 
    posp_green=sum(sum(imag_green < green_thresh)); 
    %calc percent of positive pixels in tissue for green signal 
    percpos_green(k) = posp_green/(tsize-backg_green); 
  
    %map out pos and neg pixels 
    pmap_red=(imag_red < red_thresh); 
    nmap=(imag_red > whiteSpace); 
  
    pmap_green = (imag_green < green_thresh); 
     
    %make positive pixels  green, and background pixels blue 
    imag1(:,:,1) = zeros(a,b); 
    imag1(:,:,2) = pmap_red; 
    imag1(:,:,3) = zeros(a,b); 
    imag2(:,:,1) = zeros(a,b); 
    imag2(:,:,2) = pmap_green; 
    imag2(:,:,3) = zeros(a,b); 
     
     
    %% set all non-green/red labeled pixels in the green image to zero 
and 
    %% create a new image for the co-localization 
    [R, C] = find(pmap_red == 0);% 
    imag_co = imag2; 
    for ind = 1:length(R) 
        imag_co(R(ind),C(ind),2) = 0; 
    end 
     
    %% caluculate the number of green positive pixels relative to total 
    %% number of pixels that express red(gfap/map2, etc.) 
%     tot_green(k) = length(find(pmap_green == 1)); 
    tot_co(k) = length(find(imag_co(:,:,2) == 1)); 
    col_per_red(k) = tot_co(k)/posp; %amount col per red area 
    perc_co(k) = tot_co(k)/(tsize-backg_green); 
    Iname(k) = {file}; 
     
%     %% calucate the intensity of the green-labeled cells 
%     clear R C ind 
%     [R, C] = find(imag_co(:,:,2) == 1); 
%     for ind = 1:length(R) 
%         ints(ind) = imag_green(R(ind),C(ind)); 
%     end 
%     Ave_ints(k) = mean(ints); 
%     clear ints 
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%     fprintf(fid, '%s \n', D(k).name); 
%     fprintf(fid, 'percent green : \t\t%7.4d\n', percpos_green(k)); 
%     fprintf(fid, 'percent red : \t\t%7.4d\n', percpos(k)); 
%     fprintf(fid, 'percent colocal : \t\t%7.4d\n', perc_co(k)); 
%     fprintf(fid, 'colocal per red area : \t\t%7.4d\n', 
col_per_red(k)); 
%      
    h = figure(k); 
    subplot(3,2,1); 
    subimage(imag_red); 
    axis image; axis off 
    title('RED in gray scale') 
    subplot(3,2,2); 
    subimage(imag_green); 
    axis image; axis off 
    title('GREEN') 
     
    subplot(3,2,3); 
    subimage(imag1); 
    axis image; axis off; 
    title('RED positive') 
    subplot(3,2,4) 
    subimage(imag2); 
    axis image; axis off; 
    title('GREEN positive') 
     
    subplot(3,2,5); 
    blue = zeros(a,b); red = zeros(a,b); 
    imag_orig(:,:,3) = red; imag_orig(:,:,3)=blue; 
    subimage(imag_orig) 
    axis image; axis off 
    title('original image') 
     
    subplot(3,2,6); 
    subimage(imag_co) 
    axis image; axis off 
    title('colocalized pixels') 
    drawnow 
     
    %saveas(h, ['colocalize-' D(k).name], 'jpg') 
    waitbar(k/length(D)) 
    clear imag imag1 imag2 R C 
%      
end 
close(h1) 
status = fclose(fid); 
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